Appendix 17a: Forest plots for clinical evidence reviews on psychological interventions

Psychological vs. Control (OCD)

BT vs. BT (OCD)

Psychological vs. Psychological (OCD)

Psychological vs. Control (BDD)

Psychological vs. Psychological (BDD)

Treatment Intensity Review

Psychological vs. Control (OCD)

Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 01 Leaving the study early

Study or sub-category	Behaviour therapy n/N	Control n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
02 Clinician-quided BT v S	ystematic relaxation			
Greist 2002	4/59	1/66		4.47 [0.51, 38.92]
Subtotal (95% CI)	4/59	1/66		4.47 [0.51, 38.92]
Test for heterogeneity: no	t applicable		_ _ _	
Test for overall effect: Z =	= 1.36 (P = 0.17)			
03 Computer-guided BT v	Systematic relaxation			
Greist 2002	2/57	1/66		2.32 [0.22, 24.88]
Subtotal (95% CI)	2/57	1/66		2.32 [0.22, 24.88]
Test for heterogeneity: no	t applicable			,
Test for overall effect: Z =	= 0.69 (P = 0.49)			
		0.0	n 0.1 1 10 1	100
			Favours BT Favours control	

Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 02 Non-responders (CGI)

Study or sub-category	Behaviour therapy n/N	Control n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clinician-guided BT v Sys	stematic relaxation			
Greist 2002	26/59	57/66		0.51 [0.38, 0.69]
Subtotal (95% CI)	26/59	57/66	•	0.51 [0.38, 0.69]
Test for heterogeneity: not a	applicable		-	
Test for overall effect: $Z = 4$	4.35 (P < 0.0001)			
02 Computer-guided BT vs :	Systematic relaxation			
Greist 2002	36/57	57/66		0.73 [0.59, 0.91]
Subtotal (95% CI)	36/57	57/66	-	0.73 [0.59, 0.91]
Test for heterogeneity: not a	applicable			
Test for overall effect: Z = 2	2.78 (P = 0.005)			
		(0.1 0.2 0.5 1 2 5	10

Favours BT Favours control

Favours BT Favours control

Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 03 Y-BOCS

SMD (fixed) SMD (fixed) Study Behaviour therapy Control Mean (SD) or sub-category Mean (SD) 01 ERP v Anxiety management Lindsay 1997 -2.89 [-4.30, -1.48] -2.89 [-4.30, -1.48] 11.00(3.81) 25.89(5.80) Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 4.01 (P < 0.0001) 03 Clinician-guided BT v Systematic relaxation -1.10 [-1.49, -0.72] -1.10 [-1.49, -0.72] Greist 2002 -8.00(6.60) -1.70(4.80) Subtotal (95% CI) 66 Test for heterogeneity: not applicable
Test for overall effect: Z = 5.61 (P < 0.00001) 04 Computer-guided BT v Systematic relaxation -0.68 [-1.05, -0.31] -0.68 [-1.05, -0.31] Greist 2002 55 -5.60(6.60) 66 -1.70(4.80) Subtotal (95% CI) 55 66 Test for heterogeneity: not applicable Test for overall effect: Z = 3.63 (P = 0.0003) -10

Review: OCD: psychological interventions Comparison: 01 Behaviour therapy v Control Outcome: 04 Padua Inventory SMD (fixed) SMD (fixed) Study Behaviour therapy or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP v Anxiety management Lindsay 1997 41.44(22.54) 81.22(35.15) -1.28 [-2.32, -0.24] Subtotal (95% CI) -1.28 [-2.32, -0.24] Test for heterogeneity: not applicable Test for overall effect: Z = 2.42 (P = 0.02) Total (95% CI) -1.28 [-2.32, -0.24] Test for heterogeneity: not applicable Test for overall effect: Z = 2.42 (P = 0.02) -10 10 -5 Favours BT Favours control OCD: psychological interventions Review: Comparison: 01 Behaviour therapy v Control Outcome: 05 Depression: BDI or HAM-D Study Behaviour therapy Control SMD (fixed) SMD (fixed) orsub-category N Mean (SD) Ν Mean (SD) 95% CI 01 ERP v Anxiety management Lindsay 1997 -0.55 [-1.50, 0.39] 13.11(8.30) 9 18.33(9.66) Subtotal (95% CI) -0.55 [-1.50, 0.39] Test for heterogeneity: not applicable Test for overall effect: Z = 1.14 (P = 0.25) 03 Clinician-guided BT v Systematic relaxation Greist 2002 -2.00(9.40) 66 0.30(7.00) -0.28 [-0.64, 0.08] Subtotal (95% CI) 55 66 -0.28 [-0.64, 0.08] Test for heterogeneity: not applicable Test for overall effect: Z = 1.52 (P = 0.13) 04 Computer-guided BT v Systematic relaxation -0.04 [-0.40, 0.31] Greist 2002 55 0.00(6.80) 66 0.30(7.00) Subtotal (95% CI) 66 -0.04 [-0.40, 0.31] 55 Test for heterogeneity: not applicable Test for overall effect: Z = 0.24 (P = 0.81) -10 Favours BT Favours control Review: OCD: psychological interventions 01 Behaviour therapy v Control Comparison: 06 Maudsley Obsessive-Compulsive Inventory Outcome: Rehaviour therapy Study Control SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP v Anxiety management -1.80 [-2.94, -0.66] -1.80 [-2.94, -0.66] Lindsay 1997 9.56(4.59) 9 17.89(4.23) Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 3.10 (P = 0.002) -10 Π 10 Favours BT Favours control Review: OCD: psychological interventions Comparison: 01 Behaviour therapy v Control Outcome: 07 STAI: Trait SMD (fixed) SMD (fixed) Study Behaviour therapy Control N Mean (SD) N Mean (SD) 95% CI 95% CI or sub-category 01 ERP v Anxiety management Lindsay 1997 9 55.89(12.89) -0.52 [-1.46, 0.42] 49.89(8.71) Subtotal (95% CI) -0.52 [-1.46, 0.42] Test for heterogeneity: not applicable Test for overall effect: Z = 1.08 (P = 0.28) 10 -10 Favours BT Favours control OCD: psychological interventions Review: 01 Behaviour therapy v Control Comparison: 08 STAI: State Outcome: Study Behaviour therapy Control SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) N Mean (SD) 95% CI 95% CI

44.33(8.97)

9

52.11(13.77)

-10

-5

Ó Favours BT Favours control -0.64 [-1.59, 0.32]

-0.64 [-1.59, 0.32]

10

01 ERP v Anxiety management

Test for heterogeneity: not applicable Test for overall effect: Z = 1.31 (P = 0.19)

Lindsay 1997

Subtotal (95% CI)

Review: OCD: psychological interventions Comparison: 01 Behaviour therapy v Control Outcome: 12 Work and Social Adjustment Scale Study or sub-category N 01 Clinician-guided BT v Systematic relaxation

SMD (fixed) SMD (fixed) Behaviour therapy Control Mean (SD) Ν Mean (SD) 95% CI 95% CI -0.60 [-0.96, -0.23] -0.60 [-0.96, -0.23] Greist 2002 55 -6.80(8.30) 66 -2.00(7.70) Subtotal (95% CI) 55 66 Test for heterogeneity: not applicable Test for overall effect: Z = 3.20 (P = 0.001) 02 Computer-guided BT v Systematic relaxation Greist 2002 55 -5.00(7.20) 66 -2.00(7.70) -0.40 [-0.76, -0.04] Subtotal (95% CI) -0.40 [-0.76, -0.04] 55 66 Test for heterogeneity; not applicable Test for overall effect: Z = 2.16 (P = 0.03) 0.5 -0.5 Ó Favours BT Favours control

Review: OCD: psychological interventions Comparison: 01 Behaviour therapy v Control

13 Interference Outcome:

Behaviour therapy Control SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP v Anxiety management Lindsay 1997 -3.16 [-4.64, -1.67] -3.16 [-4.64, -1.67] 3.40(0.88) 6.30(0.87) Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 4.16 (P < 0.0001) -10

Favours BT Favours control

Favours CBT Favours control

Favours CBT Favours control

OCD: psychological interventions 02 CBT v Control Review:

Comparison: Outcome: 01 Y-BOCS

Study or sub-category	N	CBT Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 CBT v Wait-list control (r	patients with obs	essions only)				
Freeston 1997	15	12.20(9.60)	14	22.00(6.00)		-1.18 [-1.98, -0.38]
Subtotal (95% CI)	15		14		-	-1.18 [-1.98, -0.38]
Test for heterogeneity: not	applicable				*	
Test for overall effect: Z = :	2.90 (P = 0.004)					
03 CBT vs Wait-list control	(Group format)					
Cordioli 2003	23	15.10(7.80)	24	23.20(5.50)	=	-1.18 [-1.81, -0.56]
Subtotal (95% CI)	23		24		•	-1.18 [-1.81, -0.56]
Test for heterogeneity: not	applicable				*	·
Test for overall effect: Z = :	3.72 (P = 0.0002)	l				
					+ + + + + + + + + + + + + + + + + + +	10

OCD: psychological interventions Review: 02 CBT v Control Comparison:

Outcome: 02 Padua Inventory

Study or sub-category	N	CBT Mean (SD)	N	Control Mean (SD)		S	MD (fixed) 95% CI)		SMD (fixed) 95% Cl
01 CBT v Wait-list control Freeston 1997 Subtotal (95% CI)	15 15	54.70(32.90)	14 14	83.90(35.60)			<u> </u>			-0.83 [-1.59, -0.07] -0.83 [-1.59, -0.07]
Test for heterogeneity: not ap Test for overall effect: Z = 2.1	plicable		14							-0.03 [-1.39, -0.07]
					-10	-5	ö	5	10	

Review: OCD: psychological interventions

Comparison: 02 CBT v Control


03 Current Functioning Assessment Outcome:

Study or sub-category	N	CBT Mean (SD)	N	Control Mean (SD)		SMD (fixe 95% CI		SMD (fixed) 95% Cl
01 CBT v Wait-list control Freeston 1997 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		-4.70(2.50)	14 14	-5.70(1.60)		•		0.46 [-0.28, 1.20] 0.46 [-0.28, 1.20]
					-10	-5 0	5 evours com	10

Review: OCD: psychological interventions Comparison: 02 CBT v Control Outcome: 04 Beck Anxiety Inventory CBT Control SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 CBT v Wait-list control Freeston 1997 12.80(7.10) 21.60(12.10) -0.87 [-1.64, -0.10] 15 14 Subtotal (95% CI) 15 -0.87 [-1.64, -0.10] Test for heterogeneity: not applicable Test for overall effect: Z = 2.22 (P = 0.03) 10 Favours CBT Favours control Review: OCD: psychological interventions 02 CBT v Control Comparison: Outcome: 05 Beck Depression Inventory CBT SMD (fixed) SMD (fixed) Study Control Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category Ν 01 CBT v Wait-list control Freeston 1997 1.5 15.80(14.30) 14 15.10(8.40) 0.06 [-0.67, 0.79] Subtotal (95% CI) 0.06 [-0.67, 0.79] 15 14 Test for heterogeneity: not applicable Test for overall effect: Z = 0.15 (P = 0.88) -10 10 Favours CBT Favours control OCD: psychological interventions Review: Comparison: 02 CBT v Control 06 NIMH-OC Outcome: СВТ SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 02 CBGT vs Wait-list control 23 5.20(2.60) 24 8.00(1.80) -1.24 [-1.86, -0.61] Subtotal (95% CI) -1.24 [-1.86, -0.61] Test for heterogeneity: not applicable Test for overall effect: Z = 3.85 (P = 0.0001)-10 -5 5 10 Favours CBT Favours control OCD: psychological interventions Review: Comparison: 02 CBT v Control Outcome: 10 Overvalued Ideas Scale СВТ SMD (fixed) SMD (fixed) Study Control Mean (SD) Mean (SD) 95% CI 95% CI or sub-category 01 CBGT vs Wait-list control Cordioli 2003 23 3.60(16.80) 24 5.10(15.30) -0.09 [-0.66, 0.48] Subtotal (95% CI) 23 24 -0.09 [-0.66, 0.48] Test for heterogeneity: not applicable Test for overall effect: Z = 0.31 (P = 0.75) 10 -10 Favours CBT Favours control Review: OCD: psychological interventions Comparison: 02 CBT v Control 11 WHOQOL-BREF: physical Outcome: Study CBT Control SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CL 95% CI 01 CBGT vs Wait-list control Cordioli 2003 -67.50(12.80) -58.90(16.50) -0.57 [-1.16, 0.01] Subtotal (95% CI) 23 24 -0.57 [-1.16, 0.01] Test for heterogeneity: not applicable Test for overall effect: Z = 1.91 (P = 0.06) -10 10 Favours CBT Favours control OCD: psychological interventions Review: Comparison: 02 CBT v Control Outcome: 12 WHOQOL-BREF: psychological SMD (fixed) SMD (fixed) Study Control orsub-category N Mean (SD) Ν Mean (SD) 95% CI 01 CBGT vs Wait-list control -0.59 [-1.18, -0.01] -0.59 [-1.18, -0.01] Cordioli 2003 23 -64.30(19.10) 24 -53.80(15.70) Subtotal (95% CI) 23 Test for heterogeneity: not applicable Test for overall effect: Z = 1.98 (P = 0.05)

Favours CBT Favours control

Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 13 WHOQOL-BREF: social



Review: OCD: psychological interventions

Comparison: 02 CBT v Control

Outcome: 14 WHOQOL-BREF: environmental

Study or sub-category	N	CBT Mean (SD)	N	Control Mean (SD)		S	MD (fixed) 95% CI			SMD (fixed) 95% CI
01 CBGT vs Wait-list contro Cordioli 2003 Subtotal (95% CI)	ol 23 23	-69.60(13.50)	24 24	-54.70(14.40)			=			-1.05 [-1.66, -0.44] -1.05 [-1.66, -0.44]
Test for heterogeneity: not Test for overall effect: Z =		ı								
					-10	-5	Ö	5	10	

Favours CBT Favours control

Favours CBT Favours control

Review: OCD: psychological interventions

Comparison: 02 CBT v Control

Outcome: 15 Non-responders (35% Y-BOCS)

Study or sub-category	CBT n/N	Control n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
01 CBGT vs Wait-list control	B.(00	00.404	_	0.00 10 10 0.00
Cordioli 2003	7/23	23/24		0.32 [0.17, 0.59]
Subtotal (95% CI) Test for heterogeneity: not applica Test for overall effect: Z = 3.61 (P		23/24		0.32 [0.17, 0.59]
Test for overall effect. Z = 5.61 (P	= 0.0003)		0.1 0.2 0.5 1 2	5 10

Review: OCD: psychological interventions

Comparison: 02 CBT v Control

Outcome: 16 Leaving the study early

Study or sub-category	CBT n/N	Control n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 CBT v Wait-list control				
Freeston 1997	3/15	4/14		0.70 [0.19, 2.59]
Subtotal (95% CI)	3/15	4/14	_	0.70 [0.19, 2.59]
Test for heterogeneity: not app	olicable			
Test for overall effect: Z = 0.5				
02 CBGT vs Wait-list control				
Cordioli 2003	1/23	1/24		1.04 [0.07, 15.72]
Subtotal (95% CI)	1/23	1/24		1.04 [0.07, 15.72]
Test for heterogeneity: not app	olicable			
Test for overall effect: Z = 0.0	3 (P = 0.98)			
		0.0	1 0.1 1 10	100
			Favours CBT Favours contro	ol .

Review: OCD: psychological interventions

Comparison: 12 Anxiogenic exposure v Neutral thoughts


Outcome: 01 Non-responders (multiple outcomes "much improved")

Study or sub-category			RR (fixed) 95% Cl	RR (fixed) 95% Cl
Lovell 1994	2/7	0/9		6.25 [0.35, 112.52]
Total (95% CI) Total events: 2 (Anxiogen Test for heterogeneity: no Test for overall effect: Z	• •	9		6.25 [0.35, 112.52]
		0.0	01 0.01 0.1 1 10 100 100 Favours Exposure Favours Neutral	0

Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 02 Leaving the study early

Study Anxiogenic exposure
or sub-category n/N

Lovell 1994 1/7



Favours Exposure Favours Neutral

Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts

Outcome: 03 Compulsions checklist

Study or sub-category	An N	xiogenic exposure Mean (SD)	N N	leutral thoughts Mean (SD)		S	MD (fixed 95% CI)		SMD (fixed) 95% Cl
Lovell 1994	6	16.60(16.00)	6	9.50(6.70)			•			0.53 [-0.63, 1.70]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			6		,	,				0.53 [-0.63, 1.70]
					-100	-50	ó	50	100	

Review: OCD: psychological interventions

Comparison: 12 Anxiogenic exposure v Neutral thoughts

Outcome: 04 Obsessions - time

Study or sub-category	An: N	xiogenic exposure Mean (SD)	N N	eutral thoughts Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
Lovell 1994	6	2.50(2.50)	6	3.70(1.90)	-	-0.50 [-1.66, 0.66]
Total (95% CI) Test for heterogeneity: not app Test for overall effect: Z = 0.8-			6		+	-0.50 [-1.66, 0.66]

Favours treatment Favours control

Favours treatment Favours control

Review: OCD: psychological interventions

Comparison: 12 Anxiogenic exposure v Neutral thoughts


Outcome: 05 Obsessions - discomfort

Study or sub-category	Anx N	iogenic exposure Mean (SD)	N N	eutral thoughts Mean (SD)		5	SMD (fixed 95% Cl)		SMD (fixed) 95% Cl
Lovell 1994	6	3.80(2.20)	6	3.90(1.70)			+			-0.05 [-1.18, 1.08]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			6				+			-0.05 [-1.18, 1.08]
					-10	-5	ó	5	10	
					Favo	urs treatm	ent Fav	ours cont	rol	

Review: OCD: psychological interventions

Comparison: 12 Anxiogenic exposure v Neutral thoughts

Outcome: 06 Main target




Review: OCD: psychological interventions Comparison: 12 Anxiogenic exposure v Neutral thoughts Outcome: 07 Beck Depression Inventory Neutral thoughts SMD (fixed) SMD (fixed) Study Anxiogenic exposure orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Lovell 1994 6 14.00(7.80) 0.10 [-1.04, 1.23] 14.80(7.50) 6 Total (95% CI) 0.10 [-1.04, 1.23] Test for heterogeneity: not applicable Test for overall effect: Z = 0.17 (P = 0.87) 10 Favours treatment Favours control Review: OCD: psychological interventions Comparison: 12 Anxiogenic exposure v Neutral thoughts Outcome 08 Work adjustment SMD (fixed) SMD (fixed) Study Anxiogenic exposure Neutral thoughts N Ν 95% CI 95% CI or sub-category Mean (SD) Mean (SD) Lovell 1994 6 3.50(2.30) 3.20(1.80) 0.13 [-1.00, 1.27] Total (95% CI) 0.13 [-1.00, 1.27] Test for heterogeneity: not applicable Test for overall effect: Z = 0.23 (P = 0.82) -10 10 Favours treatment Favours control OCD: psychological interventions Review Comparison: 12 Anxiogenic exposure v Neutral thoughts Outcome: 09 Home adjustment SMD (fixed) SMD (fixed) Anxiogenic exposure Neutral thoughts or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Lovell 1994 -0.59 [-1.75, 0.58] 6 2.20(2.00) 6 3.50(2.10) Total (95% CI) 6 -0.59 [-1.75, 0.58] Test for heterogeneity: not applicable Test for overall effect: Z = 0.98 (P = 0.33)-10 -5 10 Favours treatment Favours control OCD: psychological interventions Review: Comparison: 12 Anxiogenic exposure v Neutral thoughts Outcome SMD (fixed) Study Anxiogenic exposure Neutral thoughts SMD (fixed) 95% CI 95% CI or sub-category Mean (SD) Mean (SD) Lovell 1994 6 3.50(1.40) 6 3.00(2.20) 0.25 [-0.89, 1.39] Total (95% CI) 6 0.25 [-0.89, 1.39] Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67) -10 10 Favours treatment Favours control Review: OCD: psychological interventions Comparison 12 Anxiogenic exposure v Neutral thoughts 11 Private adjustment Outcome: Study Neutral thoughts SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CL 95% CL Lovell 1994 6 2.50(1.50) 6 2.50(0.80) 0.00 [-1.13, 1.13] Total (95% CI) 6 0.00 [-1.13, 1.13] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)-10 10 Favours treatment Favours control OCD: psychological interventions Review: Comparison: 15 Children: Individual CBFT v Wait-list control Outcome: 01 CY-BOCS Individual CBFT Wait-list control SMD (fixed) SMD (fixed) Study or sub-category N Ν Mean (SD) Mean (SD) Barrett 2004 24.02(4.14) -2.73 [-3.55, -1.90] 22 8.36(6.93) 24 Total (95% CI) -2.73 [-3.55, -1.90] Test for heterogeneity: not applicable Test for overall effect: Z = 6.51 (P < 0.00001)10

Favours Ind-CBFT Favours WLC

OCD: psychological interventions Review:

Comparison: 15 Children: Individual CBFT v Wait-list control

Outcome: 02 NIMH-GOCS



Review: OCD: psychological interventions

15 Children: Individual CBFT v Wait-list control Comparison: Outcome: 03 Multidimensional Anxiety Scale for Children

Study or sub-category	N	Individual CBFT Mean (SD)	N	Wait-list control Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
Barrett 2004	19	50.37(15.31)	15	49.47(15.78)			+			0.06 [-0.62, 0.73]
Total (95% CI) Test for heterogeneity: no			15				†			0.06 [-0.62, 0.73]
Test for overall effect: Z =	= 0.16 (P = 0.87)				-10	-5		5	10	

Review: OCD: psychological interventions

Comparison: 15 Children: Individual CBFT v Wait-list control 04 Children's Depression Inventory Outcome:

Individual CBFT Wait-list control SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 19 6.26(6.59) 15 8.07(7.26) -0.26 [-0.94, 0.42] Total (95% CI) 15 -0.26 [-0.94, 0.42] Test for heterogeneity: not applicable Test for overall effect: Z = 0.74 (P = 0.46) -10 -5 10

Review: OCD: psychological interventions

15 Children: Individual CBFT v Wait-list control Comparison:

Outcome: 05 McMaster Family Assessment Device - Mother's rating

Study or sub-category	N I	ndividual CBFT Mean (SD)	N V	Vait-list control Mean (SD)		SMD (fix 95% 0			SMD (fixed) 95% Cl
Barrett 2004	18	2.16(0.30)	14	2.45(0.31)		=		-(0.93 [-1.67, -0.19]
Total (95% CI)	18		14			•		-0	0.93 [-1.67, -0.19]
Test for heterogeneity: not	applicable								
Test for overall effect: Z =	2.46 (P = 0.01)								
					-10	-5 0	5	10	

Review: OCD: psychological interventions

15 Children: Individual CBFT v Wait-list control Comparison: Outcome: 06 McMaster Family Assessment Device - Father's rating

Study or sub-category	lı N	ndividual CBFT Mean (SD)	N V	/ait-list control Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
Barrett 2004	9	2.12(0.37)	10	2.33(0.23)	=	-0.66 [-1.59, 0.27]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.			10			-0.66 [-1.59, 0.27]

-10

Ó Favours Ind-CBFT Favours WLC 10

Favours Ind-CBFT Favours WLC

Favours Ind-CBFT Favours WLC

Favours Ind-CBFT Favours WLC

Review: OCD: psychological interventions Comparison:

15 Children: Individual CBFT v Wait-list control Outcome: 07 Depression Anxiety Stress Scale: Mother depression

SMD (fixed) SMD (fixed) Individual CBFT Wait-list control Study or sub-category N Ν 95% CI Barrett 2004 18 4.44(6.12) 15 7.73(9.41) -0.41 [-1.11, 0.28] Total (95% CI) 15 -0.41 [-1.11, 0.28] Test for heterogeneity: not applicable Test for overall effect: Z = 1.17 (P = 0.24) 10 Favours Ind-CBFT Favours WLC

Review: OCD: psychological interventions Comparison: 15 Children: Individual CBFT v Wait-list control Outcome: 08 Depression Anxiety Stress Scale: Mother anxiety Individual CBFT Wait-list control SMD (fixed) SMD (fixed) Study orsub-category N Ν Mean (SD) 95% CI 95% CI Mean (SD) Barrett 2004 18 2.83(4.20) 15 7,73(9,88) -0.65 [-1.36, 0.05] Total (95% CI) 18 -0.65 [-1.36, 0.05] Test for heterogeneity: not applicable Test for overall effect: Z = 1.81 (P = 0.07)10 Favours Ind-CBFT Favours WLC Review: OCD: psychological interventions Comparison: 15 Children: Individual CBFT v Wait-list control Outcome 09 Depression Anxiety Stress Scale: Mother stress Individual CBFT SMD (fixed) SMD (fixed) Study Wait-list control Ν 95% CI 95% CI or sub-category Ν Mean (SD) Mean (SD) Barrett 2004 18 10.06(7.67) 15 13.73(9.00) -0.43 [-1.13, 0.26] Total (95% CI) 15 -0.43 [-1.13, 0.26] 18 Test for heterogeneity: not applicable Test for overall effect: Z = 1.22 (P = 0.22) 10 -10 Favours Ind-CBFT Favours WLC OCD: psychological interventions Review Comparison: 15 Children: Individual CBFT v Wait-list control Outcome: 10 Depression Anxiety Stress Scale: Father depression Individual CBFT SMD (fixed) SMD (fixed) Wait-list control or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 11 5.55(6.77) 5.56(7.33) 0.00 [-0.88, 0.88] 9 Total (95% CI) 9 0.00 [-0.88, 0.88] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)-10 -5 10 Favours Ind-CBFT Favours WLC OCD: psychological interventions Review: 15 Children: Individual CBFT v Wait-list control Comparison: Outcome 11 Depression Anxiety Stress Scale: Father anxiety SMD (fixed) Study Individual CBFT Wait-list control SMD (fixed) 95% CI 95% CI or sub-category Mean (SD) Mean (SD) Barrett 2004 11 4.82(7.44) 9 3.56(4.10) 0.20 [-0.69, 1.08] Total (95% CI) 0.20 [-0.69, 1.08] 11 Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67) -10 10 Favours Ind-CBFT Favours WLC Review: OCD: psychological interventions Comparison 15 Children: Individual CBFT v Wait-list control 12 Depression Anxiety Stress Scale: Father stress Outcome: Study Individual CBFT Wait-list control SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) N Mean (SD) 95% CL 95% CL Barrett 2004 11 11.64(9.83) 9 9.78(9.77) 0.18 [-0.70, 1.06] Total (95% CI) q 0.18 [-0.70, 1.06] Test for heterogeneity: not applicable Test for overall effect: Z = 0.40 (P = 0.69) -10 10 Favours Ind-CBFT Favours WLC OCD: psychological interventions Review: Comparison: 15 Children: Individual CBFT v Wait-list control Outcome: 13 Children's Depression Inventory: sibling's rating Individual CBFT Wait-list control SMD (fixed) SMD (fixed) Study or sub-category N Ν Mean (SD) Barrett 2004 1.92(2.11) 7.00(4.92) -1.36 [-2.34, -0.39] 12 9 Total (95% CI) -1.36 [-2.34, -0.39] Test for heterogeneity: not applicable Test for overall effect: Z = 2.73 (P = 0.006)

10

Favours Ind-CBFT Favours WLC

Review: OCD: psychological interventions Comparison: 15 Children: Individual CBFT v Wait-list control Outcome: 14 Multidimensional Anxiety Scale for Children - sibling's ratings Individual CBFT Wait-list control SMD (fixed) SMD (fixed) Study orsub-category N N Mean (SD) 95% CI 95% CI Mean (SD) Barrett 2004 13 34.08(11.30) 9 57.56(15.66) -1.71 [-2.73, -0.69] Total (95% CI) 13 -1.71 [-2.73, -0.69] Test for heterogeneity: not applicable Test for overall effect: Z = 3.30 (P = 0.0010)10 Favours Ind-CBFT Favours WLC Review: OCD: psychological interventions Comparison: 15 Children: Individual CBFT v Wait-list control Outcome: 15 Sibling Accomodation Scale Individual CBFT SMD (fixed) SMD (fixed) Study Wait-list control Ν 95% CI 95% CI or sub-category Ν Mean (SD) Mean (SD) Barrett 2004 9 6.11(5.01) 12.67(8.41) -0.90 [-1.88, 0.08] Total (95% CI) -0.90 [-1.88. 0.08] Test for heterogeneity: not applicable Test for overall effect: Z = 1.80 (P = 0.07)-10 10 Favours Ind-CBFT Favours WLC OCD: psychological interventions Review Comparison: 16 Children: Group CBFT v Wait-list control Outcome: 01 CY-BOCS Group CBFT Wait-list control SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 8.28(7.33) -2.54 [-3.28, -1.81] 29 24 24.04(4.14) Total (95% CI) 24 -2.54 [-3.28, -1.81] Test for heterogeneity: not applicable Test for overall effect: Z = 6.75 (P < 0.00001)-10 -5 5 10 Favours Group CBFT Favours WLC OCD: psychological interventions Review: 16 Children: Group CBFT v Wait-list control Comparison: Outcome 02 NIMH-GOCS Group CBFT SMD (fixed) Study Wait-list control SMD (fixed) 95% CI 95% CI or sub-category Mean (SD) Mean (SD) Barrett 2004 29 3.31(2.16) 24 9.00(2.00) -2.68 [-3.44, -1.93] Total (95% CI) 29 24 -2.68 [-3.44, -1.93] Test for heterogeneity: not applicable Test for overall effect: Z = 6.94 (P < 0.00001)-10 10 Favours Group CBFT Favours WLC Review: OCD: psychological interventions 16 Children: Group CBFT v Wait-list control Comparison 03 Multidimensional Anxiety Scale for Children Outcome: Study Group CBFT Wait-list control SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) N Mean (SD) 95% CL 95% CL Barrett 2004 39.09(18.00) 15 49.47(15.78) -0.59 [-1.26, 0.07] Total (95% CI) 15 -0.59 [-1.26, 0.07] Test for heterogeneity: not applicable Test for overall effect: Z = 1.74 (P = 0.08) -10 10 Favours Group CBFT Favours WLC OCD: psychological interventions Review: Comparison: 16 Children: Group CBFT v Wait-list control Outcome: 04 Children's Depression Inventory Group CBFT Wait-list control SMD (fixed) SMD (fixed) Study or sub-category N Mean (SD) N 95% CI Mean (SD) Barrett 2004 8.07(7.26) -0.78 [-1.46, -0.11] 23 3.35(4.82) 15 Total (95% CI) 23 15 -0.78 [-1.46, -0.11] Test for heterogeneity: not applicable Test for overall effect: Z = 2.27 (P = 0.02) 10

Favours Group CBFT Favours WLC

Review: OCD: psychological interventions Comparison: 16 Children: Group CBFT v Wait-list control Outcome: 05 McMaster Family Assessment Device - Mother's rating Group CBFT Wait-list control SMD (fixed) SMD (fixed) Study orsub-category N Ν Mean (SD) 95% CI 95% CI Mean (SD) Barrett 2004 26 2.45(0.31) -0.78 [-1.45, -0.11] 2.16(0.39) 14 Total (95% CI) 26 -0.78 [-1.45, -0.11] Test for heterogeneity: not applicable Test for overall effect: Z = 2.27 (P = 0.02) 10 Favours Group CBFT Favours WLC Review: OCD: psychological interventions Comparison: 16 Children: Group CBFT v Wait-list control 06 McMaster Family Assessment Device - Father's rating Outcome Group CBFT SMD (fixed) SMD (fixed) Study Wait-list control Ν 95% CI 95% CI or sub-category Ν Mean (SD) Mean (SD) Barrett 2004 13 2.13(0.45) 10 2.33(0.23) -0.52 [-1.36, 0.32] Total (95% CI) -0.52 [-1.36, 0.32] 10 13 Test for heterogeneity: not applicable Test for overall effect: Z = 1.21 (P = 0.23) 10 Favours Group CBFT Favours WLC OCD: psychological interventions Review Comparison: 16 Children: Group CBFT v Wait-list control Outcome: 07 Depression Anxiety Stress Scale: Mother depression Group CBFT SMD (fixed) SMD (fixed) Wait-list control or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 27 7.73(9.41) 5.33(7.23) 15 -0.29 [-0.93, 0.34] Total (95% CI) 15 -0.29 [-0.93, 0.34] Test for heterogeneity: not applicable Test for overall effect: Z = 0.90 (P = 0.37)-10 -5 10 Favours Group CBFT Favours WLC OCD: psychological interventions Review: 16 Children: Group CBFT v Wait-list control Comparison: Outcome 08 Depression Anxiety Stress Scale: Mother anxiety SMD (fixed) Study Group CBFT Wait-list control SMD (fixed) 95% CI 95% CI or sub-category Mean (SD) Mean (SD) Barrett 2004 27 4.30(7.10) 15 7.73(9.88) -0.41 [-1.05, 0.23] Total (95% CI) 15 -0.41 [-1.05, 0.23] Test for heterogeneity: not applicable Test for overall effect: Z = 1.26 (P = 0.21) -10 10 Favours Group CBFT Favours WLC Review: OCD: psychological interventions 16 Children: Group CBFT v Wait-list control Comparison 09 Depression Anxiety Stress Scale: Mother stress Outcome: Study Group CBFT Wait-list control SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CL 95% CL Barrett 2004 8.85(9.00) 25 13.73(9.00) -0.53 [-1.09, 0.02] Total (95% CI) 25 -0.53 [-1.09, 0.02] Test for heterogeneity: not applicable Test for overall effect: Z = 1.89 (P = 0.06)-10 10 Favours Group CBFT Favours WLC OCD: psychological interventions Review: Comparison: 16 Children: Group CBFT v Wait-list control Outcome: 10 Depression Anxiety Stress Scale: Father depression

Wait-list control

Mean (SD)

5.56(7.33)

Ν

9

SMD (fixed)

95% CI

Favours Group CBFT Favours WLC

SMD (fixed)

-0.39 [-1.24, 0.46]

-0.39 [-1.24, 0.46]

10

N

14

Study

or sub-category

Barrett 2004

Total (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.91 (P = 0.37) Group CBFT

Mean (SD)

3.14(4.94)

Comparison: 16 Children: Group CBFT v Wait-list control Outcome: 11 Depression Anxiety Stress Scale: Father anxiety SMD (fixed) SMD (fixed) Study Group CBFT Wait-list control orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 14 3.36(4.36) 9 3.56(4.10) -0.05 [-0.88, 0.79] Total (95% CI) -0.05 [-0.88, 0.79] 14 Test for heterogeneity: not applicable Test for overall effect: Z = 0.11 (P = 0.92) 10 Favours Group CBFT Favours WLC Review: OCD: psychological interventions 16 Children: Group CBFT v Wait-list control Comparison: Outcome: 12 Depression Anxiety Stress Scale: Father stress SMD (fixed) SMD (fixed) Group CBFT Wait-list control Study Mean (SD) Ν 95% CI 95% CI or sub-category Ν Mean (SD) Barrett 2004 7.43(6.77) 9 9.78(9.77) -0.28 [-1.12, 0.56] Total (95% CI) -0.28 [-1.12. 0.56] Test for heterogeneity: not applicable Test for overall effect: Z = 0.66 (P = 0.51) 10 Favours Group CBFT Favours WLC Review: OCD: psychological interventions Comparison: 16 Children: Group CBFT v Wait-list control 13 Children's Depression Inventory: sibling's rating Outcome: Group CBFT Wait-list control SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 10 3.20(3.94) 9 7.00(4.92) -0.82 [-1.77, 0.13] Total (95% CI) 10 9 -0.82 [-1.77, 0.13] Test for heterogeneity: not applicable Test for overall effect: Z = 1.70 (P = 0.09)-10 -5 10 Favours Group CBFT Favours WLC Review: OCD: psychological interventions 16 Children: Group CBFT v Wait-list control Comparison: Outcome: 14 Multidimensional Anxiety Scale for Children - sibling's ratings Group CBFT SMD (fixed) SMD (fixed) Study Wait-list control or sub-category Mean (SD) 95% CI 95% CI Mean (SD) Barrett 2004 10 30.50(10.16) 9 57.56(15.66) -1.98 [-3.13, -0.84] Total (95% CI) -1.98 [-3.13, -0.84] 10 Test for heterogeneity: not applicable Test for overall effect: Z = 3.39 (P = 0.0007) -10 10 Favours Group CBFT Favours WLC Review: OCD: psychological interventions 16 Children: Group CBFT v Wait-list control Comparison 15 Sibling Accomodation Scale Outcome: Study Group CBFT Wait-list control SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CL 95% CL Barrett 2004 9 12.67(8.41) 10 6.30(5.46) -0.87 [-1.82, 0.08] Total (95% CI) 10 9 -0.87 [-1.82, 0.08] Test for heterogeneity: not applicable Test for overall effect: Z = 1.79 (P = 0.07)

-10

Favours Group CBFT Favours WLC

10

Review:


OCD: psychological interventions

BT vs. BT (OCD)

Review: OCD: psychological interventions

Comparison: 13 Self-exposure v Partner-assisted exposure

01 Anxiety/discomfort - Main compulsion (assessor rated) Outcome:



Review: OCD: psychological interventions

Comparison: 13 Self-exposure v Partner-assisted exposure

Outcome: 02 Anxiety/discomfort - Other compulsions (assessor rated)

Study or sub-category	Se N	elf-controlled exp Mean (SD)	Parti N	ner-assisted exp Mean (SD)		,	random) % Cl		WMD (random) 95% CI
Emmelkamp 1983	6	3.30(1.25)	6	2.30(1.76)		-	-		1.00 [-0.73, 2.73]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1			6				•		1.00 [-0.73, 2.73]
					-10	-5	0 5	10	

Favours Self-exp Favours Couple-exp

Favours Self-exp Favours Couple-exp

Favours Self-exp Favours Couple-exp

Favours Self-exp Favours Couple-exp

Review: OCD: psychological interventions

13 Self-exposure v Partner-assisted exposure Comparison: Outcome: 03 Maudsley Obsessive-compulsive inventory

Emmelkamp 1983 6 8.00 (4.03) 6 8.00 (3.16) —	95% CI
	0.00 [-4.10, 4.10]
Total (95% CI) 6 6 Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)	0.00 [-4.10, 4.10]

Review: OCD: psychological interventions

Comparison: 13 Self-exposure v Partner-assisted exposure Outcome: 04 Social and Marital Adjustment: Marital

Study or sub-category	Se N	elf-controlled exp Mean (SD)	Par N	tner-assisted exp Mean (SD)		W	MD (randoi 95% Cl	m)		WMD (random) 95% Cl
Emmelkamp 1983	6	9.70(5.78)	6	14.70(8.21)			=			-5.00 [-13.03, 3.03]
Fotal (95% CI) Fest for heterogeneity: not a Fest for overall effect: Z = 1			6				•			-5.00 [-13.03, 3.03]
					-100	-50	ó	50	100	

Review:

OCD: psychological interventions 13 Self-exposure v Partner-assisted exposure Comparison: Outcome: 05 Social and Marital Adjustment: Sexual

Study or sub-category	Se N	elf-controlled exp Mean (SD)	Parti N	ner-assisted exp Mean (SD)		W	MD (random 95% Cl)		VVMD (random) 95% Cl
Emmelkamp 1983	6	10.30(1.93)	6	8.70(1.61)			-	_		1.60 [-0.41, 3.61]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1			6				-	•		1.60 [-0.41, 3.61]
•					-10	-5	- 6	5	10	

Review: OCD: psychological interventions

Comparison: 13 Self-exposure v Partner-assisted exposure


06 Social and Marital Adjustment: Social Outcome:

Study or sub-category	N S	elf-controlled exp Mean (SD)	Pa N	rtner-assisted exp Mean (SD)		W	MD (rando 95% Cl	m)		WMD (random) 95% Cl
Emmelkamp 1983	6	12.70(2.52)	6	10.30(5.91)		-	-		-	2.40 [-2.74, 7.54]
Total (95% CI) Test for heterogeneity: not applical Test for overall effect: Z = 0.92 (P			6			-			-	2.40 [-2.74, 7.54]
					-10	-5	Ó	5	10	
					Fav	ours Self-	exp Fav	vours Cou	ple-exp	

Review: OCD: psychological interventions

Comparison: 13 Self-exposure v Partner-assisted exposure

Outcome: 07 Anxious mood (assessor-rated)



Review: OCD: psychological interventions

Comparison: 13 Self-exposure v Partner-assisted exposure

Outcome: 08 Self-rating Depression scale

Study or sub-category	Se N	elf-controlled exp Mean (SD)	Par N	tner-assisted exp Mean (SD)		W	MD (randor 95% Cl	n)		VVMD (random) 95% Cl
Emmelkamp 1983	6	49.00(9.69)	6	43.30(7.50)			-			5.70 [-4.10, 15.50]
Total (95% CI) Test for heterogeneity: not a			6				•			5.70 [-4.10, 15.50]
Test for overall effect: Z = 1	.14 (P = 0.25)				-100	-50		50	100	
					Favo	urs Self-e	exp Fav	ours Cou	ole-exp	

Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 01 Leaving the study early

Study or sub-category	lmagined + live ERP n <i>l</i> N	Live ERP n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
De Araujo1995	5/28	5/28		1.00 [0.33, 3.08]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =	• •	5/28		1.00 [0.33, 3.08]
		0	1 0.2 0.5 1 2 5	10

Favours Img/Live ERP Favours Live ERP

Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 02 Relapse (multiple outcomes)

Study or sub-category	lmagined + live ERP n/N	Live ERP n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 At 20 weeks follow-up				
De Araujo1995	8/28	5/28		1.60 [0.60, 4.29]
Subtotal (95% CI)	8/28	5/28		1.60 [0.60, 4.29]
Test for heterogeneity: not ap-	plicable			
Test for overall effect: $Z = 0.9$	3 (P = 0.35)			
02 At 32 weeks follow-up				
De Araujo1995	2/28	4/28		0.50 [0.10, 2.51]
Subtotal (95% CI)	2/28	4/28		0.50 [0.10, 2.51]
Test for heterogeneity: not ap-	plicable		_ _ _	
Test for overall effect: $Z = 0.8$	4 (P = 0.40)			
			0.1 0.2 0.5 1 2 5 10	
			Favours Img/Live ERP Favours Live ERP	

OCD: psychological interventions 14 Imaginal + live ERP v Live ERP 03 Y-BOCS obsessions Review: Comparison: Outcome:

Study or sub-category	lrt N	nagined + live ERP Mean (SD)	N	Live ERP Mean (SD)	WMD (random) 95% Cl	WMD (random) 95% CI
01 At 9 weeks (post treatment)						
De Araujo1995	23	7.50(3.20)	23	7.90(3.90)	_ 	-0.40 [-2.46, 1.66]
Subtotal (95% CI)	23		23		•	-0.40 [-2.46, 1.66]
Test for heterogeneity: not applicable	е				7	
Test for overall effect: Z = 0.38 (P =	0.70)					
02 At 20 weeks (post treatment)						
De Araujo1995	23	8.00(4.00)	23	8.80(5.40)		-0.80 [-3.55, 1.95]
Subtotal (95% CI)	23		23			-0.80 [-3.55, 1.95]
Test for heterogeneity: not applicable	е				-	
Test for overall effect: $Z = 0.57$ (P =	0.57)					
03 At 32 weeks (post treatment)						
De Araujo1995	20	7.00(2.90)	21	8.00(5.90)		-1.00 [-3.83, 1.83]
Subtotal (95% CI)	20		21			-1.00 [-3.83, 1.83]
Test for heterogeneity: not applicable	е					
Test for overall effect: Z = 0.69 (P =						
				-1		10

Favours Img/live ERP Favours Live ERP

Favours Img/live ERP Favours Live ERP

OCD: psychological interventions 14 Imaginal + live ERP v Live ERP 04 Y-BOCS rituals Review: Comparison:

Outcome:

Study or sub-category	lm: N	agined + live ERP Mean (SD)	N	Live ERP Mean (SD)	WMD (random) 95% Cl	VVMD (random) 95% CI
01 At 9 weeks (post treatment)						
De Araujo1995	23	6.80(3.60)	23	7.60(4.90)		-0.80 [-3.28, 1.68]
Subtotal (95% CI)	23		23			-0.80 [-3.28, 1.68]
Test for heterogeneity: not applicate	ole				7	,
Test for overall effect: Z = 0.63 (P	= 0.53)					
02 At 20 weeks (post treatment)						
De Araujo1995	20	7.60(4.40)	21	9.00(6.40)		-1.40 [-4.75, 1.95]
Subtotal (95% CI)	20		21			-1.40 [-4.75, 1.95]
Test for heterogeneity; not applicate	ole				_	
Test for overall effect: Z = 0.82 (P	= 0.41)					
03 At 32 weeks (post treatment)						
De Araujo1995	20	7.00(3.00)	21	8.60(5.90)		-1.60 [-4.45, 1.25]
Subtotal (95% CI)	20		21			-1.60 [-4.45, 1.25]
Test for heterogeneity: not applicate	ole					•
Test for overall effect: Z = 1.10 (P	= 0.27)					
-				-10		10

OCD: psychological interventions 14 Imaginal + live ERP v Live ERP 05 Compulsions checklist Review: Comparison: Outcome:

Study or sub-category	lm N	agined + live ERP Mean (SD)	N	Live ERP Mean (SD)		W	MD (randor 95% Cl	1)		VVMD (random) 95% Cl
01 At 9 weeks (post treatment)										
De Araujo1995	23	2.00(1.60)	23	2.20(1.70)			-			-0.20 [-1.15, 0.75]
Subtotal (95% CI)	23		23				-			-0.20 [-1.15, 0.75]
Test for heterogeneity: not applica	able						Ţ			, ,
Test for overall effect: $Z = 0.41$ (F										
02 At 20 weeks (post treatment)										
De Araujo1995	20	2.00(1.70)	21	2.20(2.00)			-			-0.20 [-1.33, 0.93]
Subtotal (95% CI)	20		21				•			-0.20 [-1.33, 0.93]
Test for heterogeneity: not applica	able						T			
Fest for overall effect: $Z = 0.35$ (F										
03 At 32 weeks (post treatment)										
De Araujo1995	20	1.90(1.60)	21	2.40(1.20)			=			-0.50 [-1.37, 0.37]
Subtotal (95% CI)	20		21				4			-0.50 [-1.37, 0.37]
Fest for heterogeneity: not applica	able						٦			•
Test for overall effect: $Z = 1.13$ (F										
					-10	-5	-	5	10	
					Favours	lmg/live	ERP Fav	ours Live I	ERP	


Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 06 Beck Depression Inventory

Study or sub-category	lm N	agined + live ERP Mean (SD)	N	Live ERP Mean (SD)	VVMD (random) 95% Cl	VVMD (random) 95% Cl
01 At 9 weeks (post treatment)						
De Araujo1995	23	15.00(13.10)	23	19.00(13.20)	=	-4.00 [-11.60, 3.60]
Subtotal (95% CI)	23		23		₩	-4.00 [-11.60, 3.60]
Test for heterogeneity: not applic	able				1	
Test for overall effect: Z = 1.03 (P = 0.30)					
02 At 20 weeks (post treatment)						
De Araujo1995	20	14.00(15.20)	21	22.00(19.10)	-	-8.00 [-18.54, 2.54]
Subtotal (95% CI)	20		21		•	-8.00 [-18.54, 2.54]
Test for heterogeneity: not applic	able					
Test for overall effect: Z = 1.49 (P = 0.14)					
03 At 32 weeks (post treatment)						
De Araujo1995	20	12.00(14.00)	21	17.00(17.60)	-	-5.00 [-14.71, 4.71]
Subtotal (95% CI)	20		21		-	-5.00 [-14.71, 4.71]
Test for heterogeneity: not applic	able					
Test for overall effect: Z = 1.01 (P = 0.31)					
					-100 -50 0 5	0 100
					Favours Img/live ERP Favours	Live ERP

Review: OCD: psychological interventions

Comparison: 15 ERP + response prevention v ERP + associative therapy


Outcome: 01 Non-responders (Y-BOCS 50%)



Review: OCD: psychological interventions

Comparison: 15 ERP + response prevention v ERP + associative therapy

Outcome: 02 Leaving the study early



Review:

OCD: psychological interventions 15 ERP + response prevention v ERP + associative therapy 03 Y-BOCS Comparison:

Outcome:

Review:

Study or sub-category	ERF N	P + resp. prevent Mean (SD)	ER N	P + assn. therapy Mean (SD)		W	MD (random) 95% Cl		WMD (random) 95% Cl
O1 Post treatment									
Hiss 1994	8	8.75(4.53)	10	9.80(7.24)			<u> </u>		-1.05 [-6.53, 4.43]
Subtotal (95% CI)	8		10				•		-1.05 [-6.53, 4.43]
Test for heterogeneity: not applic	able						Ī		•
Test for overall effect: Z = 0.38 (P = 0.71)								
02 At 6-month follow-up									
Hiss 1994	8	8.13(7.10)	10	13.44(8.78)			- - 		-5.31 [-12.65, 2.03]
Subtotal (95% CI)	8		10				→		-5.31 [-12.65, 2.03]
Test for heterogeneity: not applic	able						1		
Test for overall effect: Z = 1.42 (
					-100	-50	0 50	100	

OCD: psychological interventions 15 ERP + response prevention v ERP + associative therapy Comparison: Outcome: 04 Obessive-compulsive symptoms (assessor-rated)

Study	ERI	P + resp. prevent	ER	P + assn. therapy	WMD (random)	WMD (random)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Post treatment						
Hiss 1994	8	2.75(2.25)	10	5.00(4.57)	=	-2.25 [-5.48, 0.98]
Subtotal (95% CI)	8		10		₹	-2.25 [-5.48, 0.98]
Test for heterogeneity: not ap	oplicable				1	
Test for overall effect: $Z = 1$.	36 (P = 0.17)					
02 At 6-month follow-up						
Hiss 1994	8	4.50(4.66)	10	11.80(7.55)	=	-7.30 [-12.99, -1.61]
Subtotal (95% CI)	8		10		•	-7.30 [-12.99, -1.61]
Test for heterogeneity: not ap	oplicable				•	•
Test for overall effect: $Z = 2$.	52 (P = 0.01)					

Favours ERP+RP Favours ERP+assn.the

Favours ERP+RP Favours ERP+assn.the

OCD: psychological interventions

15 ERP + response prevention v ERP + associative therapy 05 Hamilton Depression Scale Comparison:

Outcome:

Study or sub-category	ERI N	ERP + resp. prevent N Mean (SD)		+ assn. therapy Mean (SD)	VVMD (random) 95% Cl	VVMD (random) 95% CI
01 Post treatment						
Hiss 1994	8	7.71(4.92)	10	5.70(3.74)		2.01 [-2.11, 6.13]
		7.71(4.32)		5.70(5.74)	<u></u>	
Subtotal (95% CI)	8		10			2.01 [-2.11, 6.13]
Test for heterogeneity: not ag	plicable					
Test for overall effect: $Z = 0.9$	96 (P = 0.34)					
02 At 6-month follow-up						
Hiss 1994	8	3.75(2.38)	10	7.89(7.64)		-4.14 [-9.15, 0.87]
Subtotal (95% CI)	8		10			-4.14 [-9.15, 0.87]
Test for heterogeneity; not as	plicable					
Test for overall effect: Z = 1.						
					-10 -5 0 5	10

Favours ERP+RP Favours ERP+assn.the OCD: psychological interventions

Review:

15 ERP + response prevention v ERP + associative therapy 06 Beck Depression Inventory Comparison:

Outcome:


Study		P + resp. prevent		P + assn. therapy		WMD (rando	n)		WMD (random)
r sub-category	N	Mean (SD)	N	Mean (SD)		95% CI			95% CI
01 Post treatment									
Hiss 1994	8	6.13(5.84)	10	5.56(8.63)		=			0.57 [-6.14, 7.28]
Subtotal (95% CI)	8		10			•			0.57 [-6.14, 7.28]
Test for heterogeneity: not app	olicable								
Test for overall effect: $Z = 0.17$	7 (P = 0.87)								
02 At 6-month follow-up									
Hiss 1994	8	6.33(8.26)	10	10.00(16.10)		-			-3.67 [-15.17, 7.83]
Subtotal (95% CI)	8		10			•			-3.67 [-15.17, 7.83]
Test for heterogeneity: not app	olicable								
Test for overall effect: $Z = 0.63$	3 (P = 0.53)								
					-100	-50 0	50	100	

Favours ERP+RP Favours ERP+assn.the

Review: OCD: psychological interventions

Comparison: 15 ERP + response prevention v ERP + associative therapy

Outcome: 07 State-Trait Anxiety Inventory - State



Favours ERP+RP Favours ERP+assn.the

Review: OCD: psychological interventions

Comparison: 16 Anxiogenic exposure v Neutral thoughts

Outcome: 01 Non-responders (multiple outcomes "much improved")

Study or sub-category	Anxiogenic exposure n/N	Neutral thoughts n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
Lovell 1994	2/7	0/9	-	6.25 [0.35, 112.52]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1		0/9		6.25 [0.35, 112.52]
		0.001	0.01 0.1 1 10 100 10	000

Favours Exposure Favours Neutral

Review: OCD: psychological interventions

Comparison: 16 Anxiogenic exposure v Neutral thoughts

Outcome: 02 Leaving the study early

Study or sub-category	Anxiogenic exposure n/N	Neutral thoughts n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
Lovell 1994	1/7	3/9		0.43 [0.06, 3.28]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z :	• •	3/9		0.43 [0.06, 3.28]
		0.0	1 0.1 1	10 100

Favours Exposure Favours Neutral

Review: OCD: psychological interventions

Comparison: 16 Anxiogenic exposure v Neutral thoughts


Outcome: 03 Compulsions checklist

Study or sub-category	An: N	kiogenic exposure Mean (SD)	N N	eutral thoughts Mean (SD)		WN	1D (rando 95% Cl	m)		VMMD (random) 95% Cl
Lovell 1994	6	16.60(16.00)	6	9.50(6.70)			-			7.10 [-6.78, 20.98]
Total (95% Cl) Test for heterogeneity: not Test for overall effect: Z =			6				•			7.10 [-6.78, 20.98]
					-100 Eave	-50 ours treatme	0 ent Fes	50 ours cont	100	

Review: OCD: psychological interventions


Comparison: 16 Anxiogenic exposure v Neutral thoughts

Outcome: 04 Obsessions - time



Review: OCD: psychological interventions Comparison: 16 Anxiogenic exposure v Neutral thoughts 05 Obsessions - discomfort

Outcome:



OCD: psychological interventions Review:

Comparison: 16 Anxiogenic exposure v Neutral thoughts

Outcome: 06 Main target

Study or sub-category	An> N	kiogenic exposure Mean (SD)	N N	eutral thoughts Mean (SD)		W	MD (random) 95% Cl			WMD (random) 95% Cl
Lovell 1994	6	4.80(2.60)	6	4.00(1.40)			-			0.80 [-1.56, 3.16]
Total (95% CI)	6		6				-			0.80 [-1.56, 3.16]
Test for heterogeneity: not Test for overall effect: Z =										
					-10	-5	ó	5	10	

Favours treatment Favours control

Favours treatment Favours control

Favours treatment Favours control

Review: OCD: psychological interventions 16 Anxiogenic exposure v Neutral thoughts Comparison:

Outcome: 07 Beck Depression Inventory

Study or sub-category	An N	xiogenic exposure Mean (SD)	N N	leutral thoughts Mean (SD)		VVMD (random) 95% Cl			VVMD (random) 95% Cl	
Lovell 1994	6	14.80(7.50)	6	14.00(7.80)	_		-		_	0.80 [-7.86, 9.46]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6		-				_	0.80 [-7.86, 9.46]
					-10	-5	-	5	10	

Review: OCD: psychological interventions

Comparison: 16 Anxiogenic exposure v Neutral thoughts

Outcome: 08 Work adjustment

Study or sub-category	An> N	iogenic exposure Mean (SD)	N	eutral thoughts Mean (SD)			D (random 95% Cl)		WMD (random) 95% Cl
Lovell 1994	6	3.50(2.30)	6	3.20(1.80)		-	-			0.30 [-2.04, 2.64]
Total (95% CI) Test for heterogeneity: not	6 t applicable		6			-	-			0.30 [-2.04, 2.64]
Test for overall effect: Z =					-10	-5		<u> </u>	10	

OCD: psychological interventions Review:

16 Anxiogenic exposure v Neutral thoughts 09 Home adjustment Comparison:


Outcome:

Study or sub-category	Anx N	kiogenic exposure Mean (SD)	N N	eutral thoughts Mean (SD)			D (randor 95% Cl	n)		WMD (random) 95% Cl
Lovell 1994	6	2.20(2.00)	6	3.50(2.10)		-	-			-1.30 [-3.62, 1.02]
Total (95% CI) Test for heterogeneity: not	6 t applicable		6			-	-			-1.30 [-3.62, 1.02]
Test for overall effect: Z =	• •									
					-10	-5	Ö	5	10	
					Favo	urs treatme	nt Fav	ours conti	rol	

Review: OCD: psychological interventions

Comparison: 16 Anxiogenic exposure v Neutral thoughts


Outcome: 10 Social adjustment



Review: OCD: psychological interventions

Comparison: 16 Anxiogenic exposure v Neutral thoughts

Outcome: 11 Private adjustment




Psychological vs. Psychological (OCD)

Review: OCD: psychological interventions

Comparison: 03 Behaviour therapy: Computer-guided v Clinician-guided


Outcome: 01 Non-responders (CGI)



Review: OCD: psychological interventions

Comparison: 03 Behaviour therapy: Computer-guided v Clinician-guided

Outcome: 02 Y-BOCS



Favours treatment Favours control

Favours treatment Favours control

Review: OCD: psychological interventions

Comparison: 03 Behaviour therapy: Computer-guided v Clinician-guided


Outcome: 03 Hamilton Depression Rating Scale

Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
Greist 2002	55	0.00(6.80)	55	-2.00(9.40)		-	0.24 [-0.13, 0.62]
Total (95% Cl) Test for heterogeneity: not Test for overall effect: Z =			55				0.24 [-0.13, 0.62]
					-1 .	05 0 05	1

Review: OCD: psychological interventions

Comparison: 03 Behaviour therapy: Computer-guided v Clinician-guided

Outcome: 04 Work and Social Adjustment Scale



Review: OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 01 Leaving the study early Comparison:

Outcome:

Study or sub-category	Behaviour therapy n/N	Cognitive therapy n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Cottraux 2001	3/33	2/32		1.45 [0.26, 8.14]
Van Oppen 1995	7/36	7/35	-	0.97 [0.38, 2.49]
Whittal(under review	10/39	7/37		1.36 [0.58, 3.19]
Subtotal (95% CI)	108	104	•	1.20 [0.66, 2.17]
	therapy), 16 (Cognitive therapy) = 0.32, df = 2 (P = 0.85), I² = 0% .61 (P = 0.54)			
02 Group format				
McLean 2001	12/44	18/49	-	0.74 [0.40, 1.36]
Subtotal (95% CI)	44	49	•	0.74 [0.40, 1.36]
Total events: 12 (Behaviour t Test for heterogeneity: not a Test for overall effect: Z = 0				
•	152 therapy), 34 (Cognitive therapy) = 1.54, df = 3 (P = 0.67), l² = 0% .16 (P = 0.88)		•	0.97 [0.63, 1.47]
		0.0	01 0.01 0.1 1 10 100	1000
			Favours BT Favours CT	

Review: OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 02 Leaving the study early at 26 weeks follow-up Comparison: Outcome:

Study or sub-category	Behaviour therapy n/N	Cognitive therapy n/N	RR (f 95%	,	RR (fixed) 95% Cl
01 At 26 weeks follow-up					
Cottraux 2001	8/33	4/32	4	-	1.94 [0.65, 5.81]
Subtotal (95% CI)	33	32	4	•	1.94 [0.65, 5.81]
Total events: 8 (Behaviour	therapy), 4 (Cognitive therapy)			-	
Test for heterogeneity: not	applicable				
Test for overall effect: Z =	1.18 (P = 0.24)				
		0.001	0.01 0.1 1	10 100	1000

Favours BT Favours CT

OCD: psychological interventions Review: 04 Behaviour therapy v Cognitive therapy Comparison: Outcome: 03 Leaving the study early at 52 weeks follow-up

Study or sub-category	Behaviour therapy n/N	Cognitive therapy n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 At 52 weeks follow-up				
Cottraux 2001	10/33	7/32		1.39 [0.60, 3.19]
Subtotal (95% CI)	33	32	•	1.39 [0.60, 3.19]
Total events: 10 (Behaviou	r therapy), 7 (Cognitive therapy)			
Test for heterogeneity: not	applicable			
Test for overall effect: Z =	• •			
			0.001 0.01 0.1 1 10 100 1	000
			Favours BT Favours CT	

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 04 Not recovered (Y-BOCS) post treatment

Study or sub-category	Behaviour therapy n/N	Cognitive therapy n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 Individual format						
Van Oppen 1995	24/36	21/35	 	1.11 [0.78, 1.59]		
Subtotal (95% CI)	36	35		1.11 [0.78, 1.59]		
Total events: 24 (Behaviou Test for heterogeneity: not Test for overall effect: Z =	• •					
02 Group format						
McLean 2001	32/44	44/49		0.81 [0.66, 0.99]		
Subtotal (95% CI)	44	49		0.81 [0.66, 0.99]		
Total events: 32 (Behaviou Test for heterogeneity: not Test for overall effect: Z =						
,	80 ir therapy), 65 (Cognitive therapy) ² = 2.48, df = 1 (P = 0.12), l ² = 59.7° 0.98 (P = 0.33)	84		0.91 [0.76, 1.10]		
			0.5 0.7 1 1.5	2		
			Favours BT Favours CT			

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 05 Not reliable change (Y-BOCS) post treatment

Study or sub-category	Behaviour therapy n/N	Cognitive therapy n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 Individual format						
Van Oppen 1995	17/36	14/35	- - 	1.18 [0.69, 2.01]		
Subtotal (95% CI)	36	35		1.18 [0.69, 2.01]		
Total events: 17 (Behaviou Test for heterogeneity: not Test for overall effect: Z =						
02 Group format						
McLean 2001	7/19	6/16		0.98 [0.41, 2.33]		
Subtotal (95% CI)	19	16		0.98 [0.41, 2.33]		
Total events: 7 (Behaviour Test for heterogeneity: not Test for overall effect: Z =						
	55 r therapy), 20 (Cognitive therapy) ² = 0.13, df = 1 (P = 0.72), l ² = 0% 0.48 (P = 0.63)	51		1.12 [0.71, 1.76]		
			0.2 0.5 1 2	5		
			Favours BT Favours CT			

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy

Outcome: 06 Not recovered (Y-BOCS) at 12 weeks follow-up

Study or sub-category	Behaviour therapy Cognitive therapy n/N n/N		RR (fixed) 95% Cl	RR (fixed) 95% CI
01 Group format				
McLean 2001	30/44	45/49		0.74 [0.60, 0.92]
Subtotal (95% CI)	44	49		0.74 [0.60, 0.92]
Total events: 30 (Behaviou	ır therapy), 45 (Cognitive therapy	')	-	
Test for heterogeneity: not	applicable			
Test for overall effect: Z =	2.67 (P = 0.008)			
			0.5 0.7 1 1.5	2
			Favoure BT Favoure CT	

OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 07 Non-responder (Y-BOCS 25%) Review: Comparison: Outcome:

Study or sub-category	Behaviour therapy n/N	Cognitive therapy n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Individual format post-tr	reatment			
Cottraux 2001	12/33	9/32		1.29 [0.63, 2.64]
Subtotal (95% CI)	33	32		1.29 [0.63, 2.64]
Total events: 12 (Behaviou	ır therapy), 9 (Cognitive therapy)			
Test for heterogeneity: not				
Test for overall effect: Z =	0.70 (P = 0.48)			
02 Individual format at 26 v	veeks follow-up			
Cottraux 2001	13/33	10/32		1.26 [0.65, 2.45]
Subtotal (95% CI)	33	32		1.26 [0.65, 2.45]
Total events: 13 (Behaviou	ır therapγ), 10 (Cognitive therapγ)		•
Test for heterogeneity: not	applicable			
Test for overall effect: Z =	0.68 (P = 0.50)			
03 Individual format at 52	weeks follow-up			
Cottraux 2001	13/33	13/32		0.97 [0.53, 1.76]
Subtotal (95% CI)	33	32		0.97 [0.53, 1.76]
Total events: 13 (Behaviou	ır therapγ), 13 (Cognitive therapγ)	T	•
Test for heterogeneity; not	applicable			
Test for overall effect: Z =				
		0.	2 0.5 1 2	5
			Favours BT Favours CT	
			1410410 21 1410410 01	

OCD: psychological interventions Comparison: Outcome: 04 Behaviour therapy v Cognitive therapy 08 Y-BOCS post treatment

Study	E	Behaviour therapy	1	Cognitive therapy	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Individual format						
Cottraux 2001	30	-12.10(7.80)	30	-12.50(8.20)		0.05 [-0.46, 0.56]
Van Oppen 1995	29	17.30(8.30)	28	13.30(8.50)	 -	0.47 [-0.06, 1.00]
Whittal(under review	37	13.57(9.27)	34	11.94(8.21)	 -	0.18 [-0.28, 0.65]
Subtotal (95% CI)	96		92		•	0.23 [-0.06, 0.51]
est for heterogeneity: Chi² =	1.32, df = 2 (F	P = 0.52), I ² = 0%			'	
est for overall effect: Z = 1.5	54 (P = 0.12)					
2 Group format						
McLean 2001	40	16.40(9.28)	33	16.52(6.93)	-	-0.01 [-0.48, 0.45]
ubtotal (95% CI)	40		33		•	-0.01 [-0.48, 0.45]
est for heterogeneity: not ap	plicable					
est for overall effect: Z = 0.0	06 (P = 0.95)					
otal (95% CI)	136		125		•	0.16 [-0.09, 0.40]
est for heterogeneity: Chi² =	2.07, df = 3 (F	P = 0.56), I ² = 0%			ľ	·
est for overall effect: Z = 1.2	27 (P = 0.20)					
					4 -2 0 2	4

Favours BT Favours CT

OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 09 Y-BOCS at 12 weeks follow-up Review: Comparison: Outcome:

Study or sub-category	N B	ehaviour therapy Mean (SD)	N	CBT Mean (SD)) (fixed) 5% Cl			SMD (fixed) 95% Cl
01 Individual										
Whittal(under review	37	14.43(9.41)	34	11.59(7.80)			+			0.32 [-0.15, 0.79]
Subtotal (95% CI)	37		34							0.32 [-0.15, 0.79]
Test for heterogeneity: not	applicable						-			
Test for overall effect: Z =										
02 Group format										
McLean 2001	40	16.35(9.34)	33	17.91(8.43)		-	_			-0.17 [-0.63, 0.29]
Subtotal (95% CI)	40		33			•	•			-0.17 [-0.63, 0.29]
Test for heterogeneity: not	applicable									
Test for overall effect: Z =	0.73 (P = 0.46)									
Total (95% CI)	77		67				•			0.07 [-0.26, 0.40]
Test for heterogeneity: Chi ²	² = 2.19, df = 1 (P	= 0.14), I ² = 54.2%					Γ			
Test for overall effect: Z =	0.43 (P = 0.67)									
					-4	-2	ò	2	4	
						Favours BT	Favo	urs CBT		

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 10 Y-BOCS at 26 weeks follow-up

Study or sub-category	N E	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)		SMD (fixed) 95% Cl				SMD (fixed) 95% Cl
02 Individual format										
Cottraux 2001	25	-15.30(10.20)	28	-13.90(8.00)			-			-0.15 [-0.69, 0.39]
Subtotal (95% CI)	25		28				•			-0.15 [-0.69, 0.39]
Test for heterogeneity: not	applicable						٦			•
Test for overall effect: Z =	0.55 (P = 0.58)									
					-4	-2	-	2	4	
						Favours	BT Fav	ours CT		

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 11 Y-BOCS at 52 weeks follow-up

Study or sub-category	N E	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)			MD (fixed) 95% CI	ı		SMD (fixed) 95% Cl
03 Individual format Cottraux 2001	23	-17.40(8.50)	25	-13.60(8.80)		_				-0.43 [-1.01, 0.14]
Subtotal (95% CI)	23	2,0,	25	20100,0100,		-				-0.43 [-1.01, 0.14]
Test for heterogeneity: not	applicable						T			
Test for overall effect: Z =	1.48 (P = 0.14)									
					-4	-2	\neg	2	-	1 4

Favours BT Favours CT

Favours BT Favours CT

Favours BT Favours CT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 12 Y-BOCS at 2 years follow-up

Study or sub-category	N B	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Individual format						
Whittal(under review	37	13.92(9.51)	34	11.68(7.68)	 	0.26 [-0.21, 0.72]
Subtotal (95% CI)	37		34		◆	0.26 [-0.21, 0.72]
Test for heterogeneity: not ap	pplicable				-	
Test for overall effect: $Z = 1$.	07 (P = 0.28)					
02 Group format						
McLean 2001	40	17.00(9.91)	33	15.64(8.80)	- <u>+</u>	0.14 [-0.32, 0.60]
Subtotal (95% CI)	40		33		•	0.14 [-0.32, 0.60]
Test for heterogeneity: not as	pplicable					
Test for overall effect: $Z = 0$.	61 (P = 0.54)					
Total (95% CI)	77		67		•	0.20 [-0.13, 0.53]
Test for heterogeneity: Chi ² =	0.11, df = 1 (P	$= 0.74$), $I^2 = 0\%$				
Test for overall effect: $Z = 1$.		**				
				-4	-2 0 2	4


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 13 Beck Depression Inventory post treatment

SMD (fixed) 95% Cl	SMD (fixed) 95% CI	ognitive therapy Mean (SD)	Co N	ehaviour therapy Mean (SD)	Be N	Study or sub-category
						01 Individual format
0.77 [0.24, 1.30]	-	-8.40(7.20)	30	-3.40(5.50)	30	Cottraux 2001
0.18 [-0.34, 0.71]	 -	11.30(8.70)	27	12.90(8.50)	29	Van Oppen 1995
-0.11 [-0.58, 0.36]	-	13.47(9.00)	34	12.32(11.33)	37	Whittal(under review
0.25 [-0.04, 0.54]	•		91		96	Subtotal (95% CI)
				= 0.05), i* = 67.3%		Test for heterogeneity: $Chi^2 = 6.12$ Test for overall effect: $Z = 1.68$ (F
						02 Group format
-0.06 [-0.52, 0.40]	- -	16.15(13.44)	33	15.38(13.21)	40	McLean 2001
-0.06 [-0.52, 0.40]	•		33		40	Subtotal (95% CI)
					able	Test for heterogeneity: not applica
					P = 0.81)	Test for overall effect: $Z = 0.24$ (F
0.16 [-0.08, 0.41]	•		124		136	Total (95% CI)
	ſ			= 0.06), I² = 59.1%	3, df = 3 (P :	Test for heterogeneity: Chi² = 7.33
					P = 0.20)	Test for overall effect: $Z = 1.29$ (F
	-2 0 2	-4	124	= 0.06), I ^z = 59.1%	3, df = 3 (P :	Test for heterogeneity: Chi² = 7.33 Test for overall effect: Z = 1.29 (F

Review: OCD: psychological interventions

Comparison: 04 Behaviour therapy v Cognitive therapy

14 Beck Depression Inventory at 12 weeks follow-up Outcome:



Review: OCD: psychological interventions

Comparison: 04 Behaviour therapy v Cognitive therapy Outcome:

15 Beck Depression Inventory at 26 weeks follow-up

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)		(fixed) % Cl	SMD (fixed) 95% CI
O1 Individual format Cottraux 2001 Subtotal (95% CI) Test for heterogeneity: not a	25 25	-5.40(8.50)	28 28	-8.00(6.40)		.	0.34 [-0.20, 0.89] 0.34 [-0.20, 0.89]
Test for overall effect: Z = 1							

Favours BT Favours CT

OCD: psychological interventions Review:

Comparison: 04 Behaviour therapy v Cognitive therapy

Outcome: 16 Beck Depression Inventory at 52 weeks follow-up

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)	S	MD (fixed) 95% Cl		SMD (fixed) 95% Cl	
02 Individual format Cottraux 2001 Subtotal (95% CI)	23 23	-5.20(5.50)	25	-7.10(7.40)		•		0.28 [-0.28, 0.85]	
Test for heterogeneity: not a Test for overall effect: Z = 0	pplicable		25		 			0.28 [-0.28, 0.85]	

Favours BT Favours CT

Favours BT Favours CT

Review: OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 17 Beck Depression Inventory at 2 years follow-up Comparison:

Outcome:

Study or sub-category	N B	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Individual format						
Whittal(under review	37	11.21(10.32)	34	13.73(9.79)	- =	-0.25 [-0.72, 0.22]
Subtotal (95% CI)	37		34		•	-0.25 [-0.72, 0.22]
Test for heterogeneity: not ag	oplicable				7	
Test for overall effect: Z = 1.	04 (P = 0.30)					
02 Group format						
McLean 2001	40	15.33(13.65)	33	14.94(14.22)		0.03 [-0.43, 0.49]
Subtotal (95% CI)	40		33		•	0.03 [-0.43, 0.49]
Test for heterogeneity: not as	oplicable				ľ	
Test for overall effect: $Z = 0$.	12 (P = 0.91)					
Total (95% CI)	77		67		•	-0.11 [-0.44, 0.22]
Test for heterogeneity: Chi2 =	0.68, df = 1 (P	= 0.41), I ² = 0%			7	,
Test for overall effect: Z = 0.		**				
				-4	-2 0 2	4

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 18 NIMH-OCS

Cognitive therapy SMD (fixed) SMD (fixed) Study Behaviour therapy or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Post treatment Cottraux 2001 0.15 [-0.36, 0.66] 30 -3.40(2.50) 30 -3.80(2.70) Subtotal (95% CI) 30 30 0.15 [-0.36, 0.66] Test for heterogeneity: not applicable Test for overall effect: Z = 0.59 (P = 0.56) 02 At 26 weeks follow-up Cottraux 2001 25 -4.60(2.80) 28 -4.40(2.40) -0.08 [-0.62, 0.46] Subtotal (95% CI) -0.08 [-0.62, 0.46] 25 28 Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) 03 At 52 weeks follow-up -0.18 [-0.75, 0.39] -0.18 [-0.75, 0.39] Cottraux 2001 -4.60(2.60) 23 -5.10(2.90) 25 Subtotal (95% CI) 23 Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) 0.5 Favours BT Favours CT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 19 Padua Inventory post treatment

Study or sub-category	В N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)	SMD (fix 95% C	
or sub-category		mean (ob)	14 Modif (OD)			
01 Individual format						
Van Oppen 1995	29	58.10(23.50)	28	51.50(27.80)		0.25 [-0.27, 0.77]
Whittal(under review	37	28.98(27.28)	34	28.58(16.70)		0.02 [-0.45, 0.48]
Subtotal (95% CI)	66		62			0.12 [-0.23, 0.47]
est for heterogeneity: Chi² =	= 0.44, df = 1 (P	= 0.51), I ² = 0%				
Test for overall effect: $Z = 0$.	.69 (P = 0.49)					
14 Group format						
McLean 2001	40	33.76(20.25)	33	35.58(22.74)		-0.08 [-0.55, 0.38]
ubtotal (95% CI)	40		33			-0.08 [-0.55, 0.38]
est for heterogeneity: not a	pplicable					
est for overall effect: $Z = 0$.	36 (P = 0.72)					
Fotal (95% CI)	106		95		-	0.05 [-0.23, 0.32]
est for heterogeneity: Chi² =	= 0.93, df = 2 (P	= 0.63), I ² = 0%			_	
est for overall effect: Z = 0.	33 (P = 0.74)					
					-1 -0.5 0	0.5 1

Favours BT Favours CT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 20 Padua Inventory at 12 weeks follow-up

Behaviour therapy N Mean (SD)		Cognitive therapy N Mean (SD)			SMD (fixed)				SMD (fixed)	
						95% CI			95% CI	
37	28.87(27.05)	34	28.82(16.69)			-			0.00 [-0.46, 0.47]	
37		34					_		0.00 [-0.46, 0.47]	
able						T				
9 = 0.99)										
40	34.29(22.32)	33	35.36(24.42)			_			-0.05 [-0.51, 0.42]	
40		33					_		-0.05 [-0.51, 0.42]	
able										
9 = 0.85)										
77		67				-	-		-0.02 [-0.35, 0.31]	
2, df = 1 (P	= 0.89), I ² = 0%					1				
P = 0.90										
				-1	-0.5	-	0.5	1		
					Favours I	BT Fav	vours CT			
	37 37 able = 0.99) 40 40 40 = 0.85) 77 2, df = 1 (P	N Mean (SD) 37 28.87 (27.05) 37 ible 1= 0.99) 40 34.29 (22.32) 40 ible 1= 0.85) 77 2, df = 1 (P = 0.89), I ² = 0%	N Mean (SD) N 37 28.87(27.05) 34 37 34 bible 1= 0.99) 40 34.29(22.32) 33 40 33 bible 1= 0.85) 77 2, df = 1 (P = 0.89), P = 0%	N Mean (SD) N Mean (SD) 37 28.87 (27.05) 34 28.82 (16.69) 37 34 bible 1= 0.99) 40 34.29 (22.32) 33 35.36 (24.42) 40 33 bible 1= 0.85) 77 2, df = 1 (P = 0.89), P = 0%	N Mean (SD) N Mean (SD) 37 28.87 (27.05) 34 28.82 (16.69) 37 34 able = 0.99) 40 34.29 (22.32) 33 35.36 (24.42) 40 33 able = 0.85) 77 67 c, df = 1 (P = 0.89), P = 0% = 0.90)	N Mean (SD) N Mean (SD) 37 28.87 (27.05) 34 28.82 (16.69) 37 34 34 28.82 (16.69) 40 34.29 (22.32) 33 35.36 (24.42) 40 33 able 1= 0.85) 77 67 2, df = 1 (P = 0.89), P = 0% 1= 0.90)	N Mean (SD) N Mean (SD) 95% CI 37 28.87(27.05) 34 28.82(16.69) 37 34 able = 0.99) 40 34.29(22.32) 33 35.36(24.42) 40 33 able = 0.85) 77 67 2, df = 1 (P = 0.89), P = 0% = 0.90)	N Mean (SD) N Mean (SD) 95% CI 37 28.87(27.05) 34 28.82(16.69) 37 34 sble 1= 0.99) 40 34.29(22.32) 33 35.36(24.42) 40 38 10 10 10 10 10 10 10 10 10 10 10 10 10	N Mean (SD) N Mean (SD) 95% CI 37	

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 21 Padua Inventory at 2 years follow-up

Study or sub-category	В N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)		SMD (fix 95% (SMD (fixed) 95% Cl
01 Individual format									
Whittal(under review	40	34.46(21.40)	33	34.45(24.31)				0	.00 [-0.46, 0.46]
Subtotal (95% CI)	40		33					0	.00 [-0.46, 0.46]
Test for heterogeneity: not	applicable					T			
Test for overall effect: Z =	0.00 (P = 1.00)								
02 Group format									
McLean 2001	37	27.74(25.03)	34	28.29(17.38)				-0	.03 [-0.49, 0.44]
Subtotal (95% CI)	37		34					-0	.03 [-0.49, 0.44]
Test for heterogeneity: not	applicable					T			
Test for overall effect: Z =	0.11 (P = 0.92)								
Total (95% CI)	77		67			-		-0	.01 [-0.34, 0.32]
Test for heterogeneity: Chi-	$^{2} = 0.01$, df = 1 (P	= 0.94), I ² = 0%				T			
Test for overall effect: Z =	0.07 (P = 0.94)								
					-1	-0.5 0	0.5	i -	
						Favours BT F	avours CT		

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 22 Beck Anixety Inventory post treatment


Study or sub-category	Be N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)	SMD (fixed) 95% CI)	SMD (fixed) 95% Cl
01 Individual format							
Whittal(under review	37	11.99(10.66)	34	13.55(9.66)			-0.15 [-0.62, 0.31]
Subtotal (95% CI)	37		34		•		-0.15 [-0.62, 0.31]
Test for heterogeneity: not a	pplicable				1		
Test for overall effect: $Z = 0$.64 (P = 0.52)						
02 Group format							
McLean 2001	40	13.23(11.98)	33	14.88(10.99)	-		-0.14 [-0.60, 0.32]
Subtotal (95% Cl)	40		33		•		-0.14 [-0.60, 0.32]
Fest for heterogeneity: not a	pplicable				7		
Test for overall effect: Z = 0	.60 (P = 0.55)						
Total (95% CI)	77		67		•		-0.15 [-0.47, 0.18]
Test for heterogeneity: Chi ² :	= 0.00, df = 1 (P	= 0.98), I ² = 0%			٦		•
Test for overall effect: Z = 0.							
	. ,				 		
				-	4 -2 0	2 4	

Favours BT Favours CT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 23 Beck Anxiety Inventory at 12 weeks follow-up

Study or sub-category	В N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)		:	SMD (fixed 95% CI)		SMD (fixed) 95% Cl
01 Individual format										
Whittal(under review	37	11.31(10.75)	34	11.46(9.44)			-			-0.01 [-0.48, 0.45]
Subtotal (95% CI)	37		34				•			-0.01 [-0.48, 0.45]
Test for heterogeneity: not a	applicable						T			
Test for overall effect: Z = 0	0.06 (P = 0.95)									
03 Group format										
McLean 2001	40	13.40(11.06)	33	15.39(11.21)			-			-0.18 [-0.64, 0.28]
Subtotal (95% CI)	40		33				•			-0.18 [-0.64, 0.28]
Test for heterogeneity: not a	applicable									
Test for overall effect: Z = 0	0.75 (P = 0.45)									
Total (95% CI)	77		67				•			-0.10 [-0.42, 0.23]
Test for heterogeneity: Chi ²	= 0.24, df $= 1$ (P	= 0.63), I ² = 0%					1			
Test for overall effect: $Z = 0$	0.58 (P = 0.56)									
					-4	-2	ó	2	4	
						Favours	BT Fav	ours CT		

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 24 Beck Anxiety Inventory at 2 years follow-up



Review: OCD: psychological interventions

Comparison: 04 Behaviour therapy v Cognitive therapy

Outcome: 25 Symptom Checklist-90

Study or sub-category	N E	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)			(fixed) % Cl	SMD (fixed) 95% Cl
01 Post treatment Van Oppen 1995 Subtotal (95% CI)	29 29	178.30(48.70)	28 28	166.30(58.80)				0.22 [-0.30, 0.74] 0.22 [-0.30, 0.74]
Test for heterogeneity: not Test for overall effect: Z =	applicable							,,
					-1	-0.5	0 0.5 1	

Favours BT Favours CT

Favours BT Favours CT

Review: OCD: psychological interventions

Comparison: 04 Behaviour therapy v Cognitive therapy


Outcome: 26 Anxiety Discomfort Scale: mean of patient, therapist and assessor ratings

Study or sub-category	N B	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)			D (fixed) 5% Cl		SMD (fixed) 95% Cl
01 Post treatment									
Van Oppen 1995	29	17.90(9.00)	28	13.40(9.40)			-		0.48 [-0.04, 1.01]
Subtotal (95% CI)	29		28				•		0.48 [-0.04, 1.01]
Test for heterogeneity: not	applicable						-		•
Test for overall effect: Z =	1.79 (P = 0.07)								
					-4	-2	<u> </u>	2	4

Review: OCD: psychological interventions

Comparison: 04 Behaviour therapy v Cognitive therapy

Outcome: 27 Irrational Belief Inventory



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 28 Behavioural Avoidance Test: Avoidance

Study or sub-category	В N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Post treatment									
Cottraux 2001	30	-2.40(1.50)	30	-2.90(1.40)				_	0.34 [-0.17, 0.85]
Subtotal (95% CI)	30		30					_	0.34 [-0.17, 0.85]
est for heterogeneity; not ap	plicable								
est for overall effect: Z = 1.3									
02 At 26 weeks follow-up									
Cottraux 2001	25	-2.80(1.70)	28	-3.10(1.30)			_		0.20 [-0.34, 0.74]
Subtotal (95% CI)	25		28						0.20 [-0.34, 0.74]
Fest for heterogeneity: not ap	plicable						_		
Test for overall effect: $Z = 0.7$	71 (P = 0.48)								
03 At 52 weeks follow-up									
Cottraux 2001	23	-2.90(1.60)	25	-3.10(1.20)			_		0.14 [-0.43, 0.71]
Subtotal (95% CI)	23		25						0.14 [-0.43, 0.71]
Test for heterogeneity: not ap	plicable						_ _ _		
Test for overall effect: $Z = 0.4$	48 (P = 0.63)								
					-1	-0.5 (0.5	i	
						Favours BT	Favours CT		

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 29 Behavioural Avoidance Test: Discomfort

Study or sub-category	N E	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl		
01 Post treatment								
Cottraux 2001	30	-16.90(9.70)	30	-17.60(9.60)		0.07 [-0.43, 0.58]		
Subtotal (95% CI)	30		30			0.07 [-0.43, 0.58]		
Test for heterogeneity: not a	pplicable				T-	·		
Test for overall effect: $Z = 0$.28 (P = 0.78)							
02 At 26 weeks follow-up								
Cottraux 2001	25	-21.40(8.80)	28	-21.00(7.70)		-0.05 [-0.59, 0.49]		
Subtotal (95% CI)	25		28			-0.05 [-0.59, 0.49]		
Test for heterogeneity: not a	pplicable							
Test for overall effect: Z = 0	.17 (P = 0.86)							
03 At 52 weeks follow-up								
Cottraux 2001	23	-21.90(8.40)	25	-20.80(6.80)		-0.14 [-0.71, 0.42]		
Subtotal (95% CI)	23		25			-0.14 [-0.71, 0.42]		
Test for heterogeneity: not a	pplicable					•		
Test for overall effect: $Z = 0$								

Favours BT Favours CT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 30 Obsessive Thoughts Checklist: total

Study or sub-category	N E	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment							
Cottraux 2001	30	-13.60(14.30)	30	-17.30(17.00)		- - 	0.23 [-0.28, 0.74]
Subtotal (95% CI)	30		30				0.23 [-0.28, 0.74]
Test for heterogeneity: not applical	ble						
Test for overall effect: Z = 0.90 (P	= 0.37)						
02 At 26 weeks follow-up							
Cottraux 2001	25	-19.80(19.70)	28	-23.00(11.50)			0.20 [-0.34, 0.74]
Subtotal (95% CI)	25		28				0.20 [-0.34, 0.74]
Test for heterogeneity: not applical	ble						
Test for overall effect: Z = 0.72 (P	= 0.47)						
03 At 52 weeks follow-up							
Cottraux 2001	23	-17.70(14.30)	25	-22.40(17.20)			- 0.29 [-0.28, 0.86]
Subtotal (95% CI)	23		25				0.29 [-0.28, 0.86]
Test for heterogeneity: not applical	ble					- -	
Test for overall effect: $Z = 1.00$ (P							
					-1	-0.5 0 0.5	1
						Favours BT Favours CT	

Review: OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 31 ITIQ - intrusive thoughts Comparison:

Outcome:

Study or sub-category I	B N	ehaviour therapy Mean (SD)	N	ognitive therapy Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Post treatment						
Cottraux 2001	30	-7.10(8.50)	30	-9.50(7.90)		0.29 [-0.22, 0.80]
Subtotal (95% CI)	30		30			0.29 [-0.22, 0.80]
Fest for heterogeneity: not applicable	е					
Fest for overall effect: Z = 1.11 (P =	0.27)					
02 At 26 weeks follow-up						
Cottraux 2001	25	-9.30(8.60)	28	-9.70(8.50)		0.05 [-0.49, 0.59]
Subtotal (95% CI)	25		28			0.05 [-0.49, 0.59]
est for heterogeneity; not applicable	е					
est for overall effect: Z = 0.17 (P =	0.87)					
03 At 52 weeks follow-up						
Cottraux 2001	23	-8.30(8.60)	25	-10.60(8.90)		0.26 [-0.31, 0.83]
Subtotal (95% CI)	23		25			0.26 [-0.31, 0.83]
est for heterogeneity; not applicable	е					
est for overall effect: Z = 0.89 (P =	0.37)					
					-1 -0.5 0 0.5	1

Favours BT Favours CT

Favours BT Favours CT

OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 32 ITIQ - interpretation/intrusion Review: Comparison:

Study or sub-category I	N E	lehaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Cottraux 2001	30	-24.40(33.20)	30	-25.10(28.30)	<u>-</u>	0.02 [-0.48, 0.53]
Subtotal (95% CI)	30		30			0.02 [-0.48, 0.53]
est for heterogeneity: not applicable	е				<u> </u>	
est for overall effect: Z = 0.09 (P =	0.93)					
2 At 26 weeks follow-up						
Cottraux 2001	25	-40.00(30.80)	28	-29.20(27.10)		-0.37 [-0.91, 0.18]
ubtotal (95% CI)	25		28			-0.37 [-0.91, 0.18]
est for heterogeneity: not applicable	е					
est for overall effect: Z = 1.33 (P =	0.18)					
3 At 52 weeks follow-up						
Cottraux 2001	23	-32.30(30.70)	25	-28.70(26.50)		-0.12 [-0.69, 0.44]
ubtotal (95% CI)	23		25			-0.12 [-0.69, 0.44]
est for heterogeneity: not applicable	е				_ _ _	•
est for overall effect: Z = 0.43 (P =	0.67)					
					-1 -0.5 0 0.5	<u>i</u>

Review: OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 33 ITIQ - responsibility Comparison:

Outcome:

Study or sub-category	N	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% Cl	
01 Post treatment										
Cottraux 2001	30	-8.10(11.90)	30	-9.30(10.40)					0.	11 [-0.40, 0.61]
Subtotal (95% CI)	30		30							11 [-0.40, 0.61]
est for heterogeneity; not applicable	е									
Test for overall effect: Z = 0.41 (P =										
02 At 26 weeks follow-up										
Cottraux 2001	25	-14.30(11.00)	28	-10.30(10.50)	_				-0.	37 [-0.91, 0.18]
Subtotal (95% CI)	25		28		-					37 [-0.91, 0.18]
est for heterogeneity; not applicable	е						_			,
est for overall effect: Z = 1.32 (P =										
03 At 52 weeks follow-up										
Cottraux 2001	23	-11.00(10.50)	25	-10.80(8.90)			_		-0.	02 [-0.59, 0.55]
Subtotal (95% CI)	23		25				-			02 [-0.59, 0.55]
est for heterogeneity; not applicable	е						$\neg \top$			•
Fest for overall effect: Z = 0.07 (P =										
					-1	-0.5	-	0.5	1	
						Favours	BT Fa	ours CT		

Review: OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 34 ITIQ - guilt Comparison:

Outcome:

Study	Behaviour therapy		Cognitive therapy		SMD (fixed)	SMD (fixed)	
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI	
11 Post treatment							
Cottraux 2001	30	-9.50(12.80)	30	-8.30(13.90)		-0.09 [-0.59, 0.42]	
ubtotal (95% CI)	30		30			-0.09 [-0.59, 0.42]	
est for heterogeneity: not applicabl	е						
est for overall effect: Z = 0.34 (P =	0.73)						
2 At 26 weeks follow-up							
Cottraux 2001	25	-13.80(12.20)	28	-10.50(12.10)		-0.27 [-0.81, 0.27]	
ubtotal (95% CI)	25		28			-0.27 [-0.81, 0.27]	
est for heterogeneity: not applicabl	е				- - -		
est for overall effect: Z = 0.97 (P =	0.33)						
3 At 52 weeks follow-up							
Cottraux 2001	23	-11.70(10.90)	25	-10.60(12.40)		-0.09 [-0.66, 0.47]	
ubtotal (95% CI)	23		25			-0.09 [-0.66, 0.47]	
est for heterogeneity: not applicabl	е					·	
est for overall effect: $Z = 0.32$ (P =	0.75)						
					-1 -0.5 0 0.5	i	

Favours BT Favours CT

Favours BT Favours CT

OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 35 ITIQ - inferiority Review: Comparison: Outcome:

Study or sub-category	N E	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl		
01 Post treatment								
Cottraux 2001	30	-6.80(11.30)	30	-7.50(10.30)		0.06 [-0.44, 0.57]		
ubtotal (95% CI)	30		30			0.06 [-0.44, 0.57]		
est for heterogeneity: not ap	plicable				_	·		
est for overall effect: $Z = 0.2$	25 (P = 0.80)							
2 At 26 weeks follow-up								
Cottraux 2001	25	-11.90(10.90)	28	-8.40(10.10)		-0.33 [-0.87, 0.21]		
ubtotal (95% CI)	25		28			-0.33 [-0.87, 0.21]		
est for heterogeneity: not ap	plicable							
est for overall effect: $Z = 1.1$	9 (P = 0.24)							
3 At 52 weeks follow-up								
Cottraux 2001	23	-9.60(11.70)	25	-7.40(10.50)		-0.20 [-0.76, 0.37]		
ubtotal (95% CI)	23		25			-0.20 [-0.76, 0.37]		
est for heterogeneity: not ap	plicable				 -			
est for overall effect: Z = 0.6	87 (P = 0.50)							

OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 36 Salkovskis Responsibility Scale Review: Comparison: Outcome:

Study or sub-category	N E	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% Cl	
01 Post treatment										
Cottraux 2001	30	-12.80(19.20)	30	-16.30(18.30)		_				0.18 [-0.32, 0.69]
Subtotal (95% CI)	30		30				-			0.18 [-0.32, 0.69]
Test for heterogeneity: not applica	ble						_			
Test for overall effect: $Z = 0.71$ (P	= 0.48)									
02 At 26 weeks follow-up										
Cottraux 2001	25	-17.90(20.00)	28	-20.40(18.40)						0.13 [-0.41, 0.67]
Subtotal (95% CI)	25		28							0.13 [-0.41, 0.67]
Test for heterogeneity: not applica	ble									
Test for overall effect: $Z = 0.47$ (P	= 0.64)									
03 At 52 weeks follow-up										
Cottraux 2001	23	-17.30(20.90)	25	-15.50(17.20)			-			-0.09 [-0.66, 0.47]
Subtotal (95% CI)	23		25					_		-0.09 [-0.66, 0.47]
Test for heterogeneity: not applica	ble						_			
Test for overall effect: $Z = 0.32$ (P	= 0.75)									
					-1	-0.5	ò	0.5	1	
						Favours E	3T Fav	ours CT		

Review: OCD: psychological interventions Comparison: 04 Behaviour therapy v Cognitive therapy

Outcome: 37 Quality of life

Study or sub-category	N E	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% CI
01 Post treatment									
Cottraux 2001	30	-7.20(9.70)	30	-10.30(9.00)				_	0.33 [-0.18, 0.84]
Subtotal (95% CI)	30		30					-	0.33 [-0.18, 0.84]
Test for heterogeneity: not applic	able								
Test for overall effect: Z = 1.26 (
02 At 26 weeks follow-up									
Cottraux 2001	25	-11.10(10.60)	28	-11.50(9.00)					0.04 [-0.50, 0.58]
Subtotal (95% CI)	25		28						0.04 [-0.50, 0.58]
Test for heterogeneity: not applic	able						_		
Test for overall effect: $Z = 0.15$ (P = 0.88)								
03 At 52 weeks follow-up									
Cottraux 2001	23	-10.50(10.90)	25	-12.00(9.20)					0.15 [-0.42, 0.71]
Subtotal (95% CI)	23		25				<u> </u>		0.15 [-0.42, 0.71]
Test for heterogeneity: not applic	able								
Test for overall effect: Z = 0.51 (P = 0.61)								
					-1	-0.5	0.5	i	
						Favours BT	Favours CT		

OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy Review: Comparison: Outcome: 38 Thought Action Fusion Scale: Moral

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N	CBT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
McLean 2001	32	15.10(11.70)	31	15.20(14.50)		-0.01 [-0.50, 0.49]
Subtotal (95% CI)	32		31			-0.01 [-0.50, 0.49]
Test for heterogeneity: not a	pplicable				T	
Test for overall effect: Z = 0	.03 (P = 0.98)					
02 At 3-months follow-up						
McLean 2001	31	17.00(14.20)	30	14.20(15.10)		0.19 [-0.31, 0.69]
Subtotal (95% CI)	31		30			0.19 [-0.31, 0.69]
Test for heterogeneity: not a	pplicable				-	
Test for overall effect: Z = 0	.74 (P = 0.46)					
					-1 -0.5 0 0.5	1

Favours BT Favours CBT

Favours BT Favours CBT

Review: Comparison:

OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 39 Thought Action Fusion Scale: Likelihood for Others Outcome:

Study or sub-category	N	BT Mean (SD)	N	CBT Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
01 Post treatment						
McLean 2001	32	2.40(3.20)	31	3.00(4.60)	<u>=</u>	-0.15 [-0.64, 0.34]
Subtotal (95% CI)	32		31		∓	-0.15 [-0.64, 0.34]
Test for heterogeneity: not a	pplicable]	
Test for overall effect: Z = 0	.59 (P = 0.55)					
02 At 3-months follow-up						
McLean 2001	31	3.00(3.70)	30	3.00(4.90)	<u> </u>	0.00 [-0.50, 0.50]
Subtotal (95% CI)	31		30			0.00 [-0.50, 0.50]
Test for heterogeneity: not a	pplicable					
Test for overall effect: Z = 0	.00 (P = 1.00)					

Review: Comparison: Outcome: OCD: psychological interventions 04 Behaviour therapy v Cognitive therapy 40 Thought Action Fusion Scale: Likelihood for Self

Study or sub-category	N	BT Mean (SD)	N	CBT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
McLean 2001	32	2.90(2.90)	31	3.00(4.10)	<u>=</u>	-0.03 [-0.52, 0.47]
Subtotal (95% CI)	32		31			-0.03 [-0.52, 0.47]
Test for heterogeneity: not a	applicable				Ĭ	
Test for overall effect: $Z = 0$).11 (P = 0.91)					
02 At 3-months follow-up						
McLean 2001	31	2.90(2.80)	30	3.20(4.10)	<u>=</u>	-0.08 [-0.59, 0.42]
Subtotal (95% CI)	31		30		•	-0.08 [-0.59, 0.42]
Test for heterogeneity: not a	applicable				Ī	·
Test for overall effect: Z = 0).33 (P = 0.74)					
					-10 -5 0 :	, , 5 10
					Favours BT Favours	CRT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 41 IBRO: inflated responsibility

Study СВТ SMD (fixed) SMD (fixed) Behaviour therapy or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Post treatment McLean 2001 40.80(11.90) -0.25 [-0.74, 0.25] 32 38.10(9.60) 31 Subtotal (95% CI) 32 31 -0.25 [-0.74, 0.25] Test for heterogeneity: not applicable Test for overall effect: Z = 0.98 (P = 0.33) 02 At 3-months follow-up McLean 2001 Subtotal (95% CI) 31 38.50(9.90) 30 38.90(11.20) -0.04 [-0.54, 0.46] -0.04 [-0.54, 0.46] 30 31 Test for heterogeneity: not applicable Test for overall effect: Z = 0.15 (P = 0.88) -1 -0.5 0 0.5

Favours BT Favours CBT

Favours BT Favours CBT

Favours BT Favours CBT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 42 IBRO: overestimation of threat

Study	Be	ehaviour therapy		CBT	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Post treatment						
McLean 2001	32	15.20(4.90)	31	15.40(6.40)		-0.03 [-0.53, 0.46]
Subtotal (95% CI)	32		31			-0.03 [-0.53, 0.46]
Test for heterogeneity: not app	licable				Т	
Test for overall effect: $Z = 0.14$	l (P = 0.89)					
02 At 3-months follow-up						
McLean 2001	31	15.50(5.80)	30	15.30(6.20)		0.03 [-0.47, 0.53]
Subtotal (95% CI)	31		30			0.03 [-0.47, 0.53]
Test for heterogeneity: not app	licable					
Test for overall effect: Z = 0.13	3 (P = 0.90)					
					-0.5 0 0.5	-:

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 43 IBRO: intolerance of uncertainty

Study	Ве	ehaviour therapy		СВТ	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Post treatment						
McLean 2001	32	19.90(4.80)	31	21.90(5.60)		-0.38 [-0.88, 0.12]
Subtotal (95% CI)	32		31			-0.38 [-0.88, 0.12]
Test for heterogeneity: not app	olicable					
Test for overall effect: $Z = 1.4$	9 (P = 0.14)					
02 At 3-months follow-up						
McLean 2001	31	19.70(5.50)	30	20.40(6.80)		-0.11 [-0.61, 0.39]
Subtotal (95% CI)	31		30			-0.11 [-0.61, 0.39]
Test for heterogeneity: not app	olicable					
Test for overall effect: $Z = 0.4$	4 (P = 0.66)					
					-1 -0.5 0 0.5	1

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 44 Responsibility Attitude Scale

Study	Ве	ehaviour therapy		СВТ		SMD (fixed)	SMD (fixed)
or sub-category	N	N Mean (SD)		Mean (SD)	95% CI		95% CI
01 Post treatment							
McLean 2001	32	63.70(29.70)	31	68.90(33.80)			-0.16 [-0.66, 0.33]
Subtotal (95% CI)	32		31				-0.16 [-0.66, 0.33]
Test for heterogeneity: not a	pplicable					_	
Test for overall effect: Z = 0	.64 (P = 0.52)						
02 At 3-months follow-up							
McLean 2001	31	68.00(34.00)	30	66.80(35.20)	-		0.03 [-0.47, 0.54]
Subtotal (95% CI)	31		30		-		0.03 [-0.47, 0.54]
Test for heterogeneity: not a	pplicable					T	
Test for overall effect: Z = 0	.13 (P = 0.89)						
					-1 -0.5	5 0 0.5	1
					Favo	ours BT Favours CE	эт

Review: OCD: psychological interventions

05 Behaviour therapy v Rational emotive therapy 01 Non-responders (ADS 70%) Comparison:

Outcome:

Study or sub-category	Behaviour therapy n/N	RET n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Post treatment				
Emmelkamp 1988	7/9	9/9		0.78 [0.55, 1.10]
Subtotal (95% CI)	9	9		0.78 [0.55, 1.10]
Total events: 7 (Behaviour	therapy), 9 (RET)			
Test for heterogeneity: not	applicable			
Test for overall effect: Z =	1.41 (P = 0.16)			
02 At 1-month follow-up				
Emmelkamp 1988	7/9	7/9		1.00 [0.61, 1.64]
Subtotal (95% CI)	9	9		1.00 [0.61, 1.64]
Total events: 7 (Behaviour	therapy), 7 (RET)		T	
Test for heterogeneity: not	applicable			
Test for overall effect: Z =	0.00 (P = 1.00)			
			0.5 0.7 1 1.5	2
			Favours BT Favours RET	

OCD: psychological interventions 05 Behaviour therapy v Rational emotive therapy 02 Maudsley Obsessive-Compulsive Inventory Review: Comparison: Outcome:

Study	В	ehaviour therapy		RET	SMD (fixed)	SMD (fixed)	
or sub-category	N	Mean (SD)	N Mean (SD)		95% CI	95% CI	
01 Post treatment							
Emmelkamp 1988	9	12.60(5.40)	9	11.30(1.70)	- = -	0.31 [-0.62, 1.24]	
Emmelkamp 1991	11	13.70(6.10)	10	12.30(7.30)		0.20 [-0.66, 1.06]	
Subtotal (95% CI)	20		19		-	0.25 [-0.38, 0.88]	
Test for heterogeneity: Chi ²	= 0.03, df $= 1$ (P)	= 0.87), I ² = 0%			-	•	
		~					
est for overall effect: Z = 0							
est for overall effect: Z = 0 02 At 1-month follow-up		11.40(4.70)	9	9.80(5.40)		0.30 [-0.63, 1.23]	
est for overall effect: Z = 0 02 At 1-month follow-up Emmelkamp 1988).78 (P = 0.44)	,	9 9	9.80(5.40)	_	0.30 [-0.63, 1.23] 0.30 [-0.63, 1.23]	
Test for overall effect: Z = 0 02 At 1-month follow-up Emmelkamp 1988 Subtotal (95% CI) Test for heterogeneity: not a	9 9	,	9 9	9.80(5.40)	-		

Favours BT Favours RET

Favours BT Favours RET

Review:

OCD: psychological interventions 05 Behaviour therapy v Rational emotive therapy 03 Anxiety Discomfort Scale Comparison:

Outcome:

itudy r sub-category	Be N	ehaviour therapy Mean (SD)	N	RET Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Post treatment						
Emmelkamp 1988	9	26.00(15.70)	9	29.10(10.00)	_ _	-0.22 [-1.15, 0.70]
Subtotal (95% CI)	9		9		<u> </u>	-0.22 [-1.15, 0.70]
Test for heterogeneity: not a	pplicable				7	
Test for overall effect: Z = 0	.47 (P = 0.64)					
02 At 1-month follow-up						
Emmelkamp 1988	9	23.30(10.20)	9	25.70(14.70)		-0.18 [-1.11, 0.75]
Subtotal (95% CI)	9		9			-0.18 [-1.11, 0.75]
Test for heterogeneity: not a	pplicable				T	,
Test for overall effect: Z = 0						

Review:

OCD: psychological interventions 05 Behaviour therapy v Rational emotive therapy Comparison:

Outcome: 04 Irrational Beliefs Test

Study		Behaviour therapy		RET (CD)		:	SMD (fixed))		SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)			95% CI			95% CI
01 Post treatment										
Emmelkamp 1988	9	164.30(16.90)	9	164.00(12.50)			-			0.02 [-0.90, 0.94]
Emmelkamp 1991	11	104.60(11.00)	10	97.50(16.60)			+-	_		0.49 [-0.38, 1.36]
Subtotal (95% CI)	20		19							0.27 [-0.37, 0.90]
Test for heterogeneity: Chi ² =	0.53, df = 1 (F	P = 0.47), I ² = 0%								
Test for overall effect: Z = 0.	83 (P = 0.41)									
02 At 1-month follow-up										
Emmelkamp 1988	9	163.90(16.90)	9	155.80(17.10)			_	_		0.45 [-0.49, 1.39]
Subtotal (95% CI)	9		9				-	-		0.45 [-0.49, 1.39]
Test for heterogeneity: not ap	pplicable						-			
Test for overall effect: $Z = 0$.	95 (P = 0.34)									
					-4	-2	ó	2	4	
						Favours	BT Fav	ours RET		

Review: OCD: psychological interventions

Comparison: 05 Behaviour therapy v Rational emotive therapy

Outcome: 05 Self-rating Depression Scale

Study or sub-category	В N	ehaviour therapy Mean (SD)	N	RET Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment							
Emmelkamp 1988	9	47.90(6.20)	9	45.60(7.30)			0.32 [-0.61, 1.26]
Emmelkamp 1991	11	52.10(8.10)	10	47.80(9.40)			0.47 [-0.40, 1.34]
Subtotal (95% CI)	20	02.10(0.10)	19	11.00 (5.10)			0.40 [-0.23, 1.04]
Test for heterogeneity: Chi ² =		= 0.82), I ² = 0%					0.10 (0.20, 2.01,
Test for overall effect: $Z = 1$.							
02 At 1-month follow-up							
Emmelkamp 1988	9	48.70(10.40)	9	43.40(9.50)		_	0.51 [-0.44, 1.45]
Subtotal (95% CI)	9		9				0.51 [-0.44, 1.45]
Test for heterogeneity: not as	plicable						•
Test for overall effect: Z = 1.	05 (P = 0.29)						
					-4	-2 0 2	4

Favours BT Favours RET

Favours BT Favours RET

Favours BT Favours RET

Review:

OCD: psychological interventions 05 Behaviour therapy v Rational emotive therapy 06 Social Anxiety scale Comparison: Outcome:

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N	RET Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
01 Post treatment						
Emmelkamp 1988	9	48.30(18.80)	9	48.10(14.20)	<u>-</u>	0.01 [-0.91, 0.94]
Subtotal (95% CI)	9		9			0.01 [-0.91, 0.94]
est for heterogeneity: not ap	oplicable					
est for overall effect: Z = 0.						
2 At 1-month follow-up						
Emmelkamp 1988	9	44.30(23.30)	9	44.30(17.20)		0.00 [-0.92, 0.92]
ubtotal (95% CI)	9		9			0.00 [-0.92, 0.92]
est for heterogeneity: not ap	oplicable				_ _	•
est for overall effect: Z = 0.	00 (P = 1.00)					

Review:

Comparison: Outcome:

OCD: psychological interventions 05 Behaviour therapy v Rational emotive therapy 07 Hostility and Direction of Hostility Questionnaire: Intrapunitivity

35% CI	SMD (fixe 95% CI	SMD (fixed) 95% Cl	RET Mean (SD)	N	ehaviour therapy Mean (SD)	B∈ N	Study or sub-category
							D1 Post treatment
.95, 0.90]	-0.03 [-0.95,		17.30(7.20)	9	17.10(7.70)	9	Emmelkamp 1988
.95, 0.901	-0.03 [-0.95]	•		9		9	Subtotal (95% CI)
		T				olicable	est for heterogeneity; not app
							est for overall effect: Z = 0.0
							2 At 1-month follow-up
.82, 1.03]	0.10 [-0.82,	_ 	16.10(8.20)	9	17.10(10.00)	9	Emmelkamp 1988
.82, 1.031	0.10 [-0.82,			9		9	ubtotal (95% CI)
,		T-				olicable	est for heterogeneity; not app
		-2 0 2	16.10(8.20)		17.10(10.00)	9 olicable	Emmelkamp 1988 Subtotal (95% CI) Test for heterogeneity: not app Test for overall effect: Z = 0.2

Review: Comparison: Outcome:

OCD: psychological interventions 05 Behaviour therapy v Rational emotive therapy 08 Hostility and Direction of Hostility Questionnaire: Extrapunitivity

Study or sub-category	N B	ehaviour therapy Mean (SD)	N	RET Mean (SD)		SMD (fix 95% (SMD (fixed) 95% Cl	
01 Post treatment										
Emmelkamp 1988	9	16.80(6.00)	9	16.30(7.20)					0.07 [-0.85, 1.00]	
Subtotal (95% CI)	9		9			-			0.07 [-0.85, 1.00]	
Test for heterogeneity: not applic	able									
Test for overall effect: Z = 0.15 (P = 0.88)									
02 At 1-month follow-up										
Emmelkamp 1988	9	14.80(5.90)	9	15.80(9.50)		_	_	-	-0.12 [-1.05, 0.80]	
Subtotal (95% CI)	9		9			-	-	-	-0.12 [-1.05, 0.80]	
Test for heterogeneity; not applic	able					T			•	
Test for overall effect: Z = 0.26 (
					-4	-2 0	2	4		
						Favours BT Favours RET				

05 Behaviour therapy v Rational emotive therapy 09 Dutch Obsessive-Compulsive Questionnaire Comparison: Outcome:

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N	RET Mean (SD)			D (fixed) 15% Cl			SMD (fixed) 95% Cl
O1 Post treatment Emmelkamp 1991 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		84.80(24.40)	10 10	80.50(23.20)	=		-	 -	-	0.17 [-0.69, 1.03] 0.17 [-0.69, 1.03]
						-0.5 Favours B1	0 T Favo	0.5 urs RET	1	

Review:

OCD: psychological interventions 05 Behaviour therapy v Rational emotive therapy Comparison:

Outcome: 10 Anxiety Discomfort Scale: main OC symptoms (Assessor)

Study or sub-category	Be N	haviour therapy Mean (SD)	N	RET Mean (SD)		SMD (fixed) 95% CI		SMD (fixed) 95% Cl
01 Post treatment								
Emmelkamp 1991	11	4.30(2.10)	10	4.10(2.90)				0.08 [-0.78, 0.93]
Subtotal (95% CI)	11		10					0.08 [-0.78, 0.93]
Test for heterogeneity: not	applicable							
Test for overall effect: Z =	0.17 (P = 0.86)							
					-1	-0.5	0 0.5 1	

Favours BT Favours RET

Review:

OCD: psychological interventions 06 BT v RET + exposure in vivo (post RET alone) 01 Maudsley Obsessive-Compulsive Inventory Comparison: Outcome:

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N R	ET + exposure Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Emmelkamp 1991	11	11.70(6.10)	10	9.60(6.90)	_ 	0.31 [-0.55, 1.17]
Subtotal (95% CI)	11		10			0.31 [-0.55, 1.17]
Test for heterogeneity: not	applicable				_	
Test for overall effect: Z =	0.71 (P = 0.48)					
02 At follow-up						
Emmelkamp 1991	11	12.20(5.90)	10	9.60(7.20)		0.38 [-0.48, 1.25]
Subtotal (95% CI)	11		10		-	0.38 [-0.48, 1.25]
Test for heterogeneity: not	applicable				_	
Test for overall effect: Z =	0.86 (P = 0.39)					
						<u>;</u>

Favours BT Favours RET + exp

OCD: psychological interventions

06 BT v RET + exposure in vivo (post RET alone)
02 Dutch Obsessive-Compulsive Questionnaire Comparison: Outcome:

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N F	RET + exposure Mean (SD)		SMD (fixed 95% Cl)	SMD (fixed) 95% Cl
01 Post treatment								
Emmelkamp 1991	11	80.80(25.90)	10	73.80(15.90)			-	0.31 [-0.55, 1.17]
Subtotal (95% CI)	11		10			•		0.31 [-0.55, 1.17]
Test for heterogeneity: not a	pplicable					_		
Test for overall effect: $Z = 0$.70 (P = 0.48)							
02 At follow-up								
Emmelkamp 1991	11	83.40(26.60)	10	76.60(20.20)		_	-	0.27 [-0.59, 1.14]
Subtotal (95% CI)	11		10			•		0.27 [-0.59, 1.14]
Test for heterogeneity: not a	pplicable					_		
Test for overall effect: Z = 0	.62 (P = 0.53)							
					-4	-2 0	2	4
					F8	avours BT Fav	ours RET + exp)

05 Behaviour therapy v Rational emotive therapy 03 Anxiety Discomfort Scale Comparison:

Outcome:

Study or sub-category	N B	ehaviour therapy Mean (SD)	N	RET Mean (SD)		SMD (fi: 95% (,	SMD (fixed) 95% Cl
01 Post treatment								
Emmelkamp 1988	9	26.00(15.70)	9	29.10(10.00)			_	-0.22 [-1.15, 0.70]
Subtotal (95% CI)	9		9				-	-0.22 [-1.15, 0.70]
Test for heterogeneity: not applic	cable							
Test for overall effect: $Z = 0.47$	(P = 0.64)							
02 At 1-month follow-up								
Emmelkamp 1988	9	23.30(10.20)	9	25.70(14.70)		_	_	-0.18 [-1.11, 0.75]
Subtotal (95% CI)	9		9			-	-	-0.18 [-1.11, 0.75]
Test for heterogeneity: not applic	cable					٦		•
Test for overall effect: Z = 0.38								
					-4	-2 0	2	4
						Favours BT	Favours RET	

Review: OCD: psychological interventions

05 Behaviour therapy v Rational emotive therapy 04 Irrational Beliefs Test Comparison:

Outcome:

tudy		Behaviour therapy		RET	SMD (fixed)	SMD (fixed)
r sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
1 Post treatment						
Emmelkamp 1988	9	164.30(16.90)	9	164.00(12.50)		0.02 [-0.90, 0.94]
Emmelkamp 1991	11	104.60(11.00)	10	97.50(16.60)	 -	0.49 [-0.38, 1.36]
ubtotal (95% CI)	20		19		-	0.27 [-0.37, 0.90]
est for heterogeneity: Chi² =	0.53, df = 1 (F	P = 0.47), I ² = 0%				
est for overall effect: $Z = 0.8$	3 (P = 0.41)					
2 At 1-month follow-up						
Emmelkamp 1988	9	163.90(16.90)	9	155.80(17.10)	- 	0.45 [-0.49, 1.39]
ubtotal (95% CI)	9		9		-	0.45 [-0.49, 1.39]
est for heterogeneity: not app	olicable					
est for overall effect: Z = 0.9	5 (P = 0.34)					

Favours BT Favours RET

Favours BT Favours RET

Review:

OCD: psychological interventions 05 Behaviour therapy v Rational emotive therapy 05 Self-rating Depression Scale Comparison: Outcome:

Study	В	ehaviour therapy		RET	SMD (fixed)	SMD (fixed)	
r sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI	
11 Post treatment							
Emmelkamp 1988	9	47.90(6.20)	9	45.60(7.30)	- = -	0.32 [-0.61, 1.26]	
Emmelkamp 1991	11	52.10(8.10)	10	47.80(9.40)	 - 	0.47 [-0.40, 1.34]	
Subtotal (95% CI)	20		19		-	0.40 [-0.23, 1.04]	
est for heterogeneity: Chi² =	0.05, df = 1 (P	= 0.82), I ² = 0%			•		
est for overall effect: $Z = 1$.	24 (P = 0.21)						
2 At 1-month follow-up							
Emmelkamp 1988	9	48.70(10.40)	9	43.40(9.50)	- 	0.51 [-0.44, 1.45]	
Subtotal (95% CI)	9		9			0.51 [-0.44, 1.45]	
est for heterogeneity: not ap	oplicable						
est for overall effect: $Z = 1$.	05 (P = 0.29)						

OCD: psychological interventions Review:


Comparison: 05 Behaviour therapy v Rational emotive therapy

Outcome: 06 Social Anxiety scale

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N	RET Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Emmelkamp 1988	9	48.30(18.80)	9	48.10(14.20)		— 0.01 [-0.91, 0.94]
Subtotal (95% CI)	9		9			0.01 [-0.91, 0.94]
Test for heterogeneity: not appli	cable					
Test for overall effect: $Z = 0.02$	(P = 0.98)					
02 At 1-month follow-up						
Emmelkamp 1988	9	44.30(23.30)	9	44.30(17.20)		— 0.00 [-0.92, 0.92]
Subtotal (95% CI)	9		9			- 0.00 [-0.92, 0.92]
Test for heterogeneity: not appli	cable					
Test for overall effect: Z = 0.00						
					-1 -0.5 0 0.5	i
					Favours BT Favours RET	

Comparison: 05 Behaviour therapy v Rational emotive therapy

07 Hostility and Direction of Hostility Questionnaire: Intrapunitivity Outcome:



OCD: psychological interventions

Review: Comparison: 05 Behaviour therapy v Rational emotive therapy

Outcome: 08 Hostility and Direction of Hostility Questionnaire: Extrapunitivity

Study or sub-category	B _i N	ehaviour therapy Mean (SD)	N	RET Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
or sub-category	14	Mean (SD)	14	Mean (SD)	33.60	33 % CI
D1 Post treatment						
Emmelkamp 1988	9	16.80(6.00)	9	16.30(7.20)		0.07 [-0.85, 1.00]
Subtotal (95% CI)	9		9		•	0.07 [-0.85, 1.00]
Test for heterogeneity: not a	pplicable				Γ	·
「est for overall effect: Z = 0	.15 (P = 0.88)					
02 At 1-month follow-up						
Emmelkamp 1988	9	14.80(5.90)	9	15.80(9.50)	 _	-0.12 [-1.05, 0.80]
Subtotal (95% CI)	9		9		•	-0.12 [-1.05, 0.80]
Test for heterogeneity: not a	pplicable				T	·
Test for overall effect: Z = 0	26 (P = 0.80)					

Favours BT Favours RET

Favours BT Favours RET

Review: OCD: psychological interventions

Comparison: 05 Behaviour therapy v Rational emotive therapy 09 Dutch Obsessive-Compulsive Questionnaire Outcome:

Study or sub-category	В N	lehaviour therapy Mean (SD)	N	RET Mean (SD)		S	SMD (fixed 95% CI	1)		SMD (fixed) 95% Cl
01 Post treatment Emmelkamp 1991 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		84.80(24.40)	10 10	80.50(23.20)			-		<u></u>	0.17 [-0.69, 1.03] 0.17 [-0.69, 1.03]
					-1	-0.5	ó	0.5	1	

OCD: psychological interventions Review:

05 Behaviour therapy v Rational emotive therapy Comparison:

Outcome: 10 Anxiety Discomfort Scale: main OC symptoms (Assessor)

Study or sub-category	Be N	ehaviour therapy Mean (SD)	N	RET Mean (SD)		D (fixed) 5% Cl	SMD (fixed) 95% Cl
O1 Post treatment Emmelkamp 1991 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		4.30(2.10)	10 10	4.10(2.90)			0.08 [-0.78, 0.93] 0.08 [-0.78, 0.93]
					-1 -0.5	0 0.5 1	
					Favours B	Γ Favours RET	

06 BT v RET + exposure in vivo (post RET alone) 01 Maudsley Obsessive-Compulsive Inventory Comparison: Outcome:

Study or sub-category	Bi N	ehaviour therapy Mean (SD)	N R	ET + exposure Mean (SD)		SMD (fixed) 95% Cl		SMD (fixed) 95% CI
01 Post treatment								
Emmelkamp 1991	11	11.70(6.10)	10	9.60(6.90)				0.31 [-0.55, 1.17]
Subtotal (95% CI)	11		10	,		-		0.31 [-0.55, 1.17]
Test for heterogeneity: not								
Test for overall effect: Z = I	0.71 (P = 0.48)							
02 At follow-up								
Emmelkamp 1991	11	12.20(5.90)	10	9.60(7.20)			-	0.38 [-0.48, 1.25]
Subtotal (95% CI)	11		10			•	•	0.38 [-0.48, 1.25]
Test for heterogeneity: not	applicable					-		
Test for overall effect: Z = I	0.86 (P = 0.39)							
					-4	-2 0	2	. 4

Favours BT Favours RET + exp

Favours BT Favours RET + exp

Favours BT Favours RET + exp

OCD: psychological interventions

06 BT v RET + exposure in vivo (post RET alone) Comparison: Outcome: 02 Dutch Obsessive-Compulsive Questionnaire

Review:

Study	В	ehaviour therapy	F	RET + exposure	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Post treatment						
Emmelkamp 1991	11	80.80(25.90)	10	73.80(15.90)	- - -	0.31 [-0.55, 1.17]
Subtotal (95% CI)	11		10		-	0.31 [-0.55, 1.17]
Test for heterogeneity: not a	oplicable					
Test for overall effect: $Z = 0$.	70 (P = 0.48)					
02 At follow-up						
Emmelkamp 1991	11	83.40(26.60)	10	76.60(20.20)	_	0.27 [-0.59, 1.14]
Subtotal (95% CI)	11		10		-	0.27 [-0.59, 1.14]
Test for heterogeneity: not a	oplicable					
Test for overall effect: $Z = 0$	62 (P = 0.53)					

OCD: psychological interventions

06 BT v RET + exposure in vivo (post RET alone) Comparison:

Outcome: 03 Anxiety Discomfort Scale: main OC symptoms (assessor)

Study or sub-category	Be N	haviour therapy Mean (SD)	N F	ET + exposure Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Post treatment										
Emmelkamp 1991	11	2.30(1.70)	10	3.50(3.00)		_	-			-0.48 [-1.35, 0.39]
Subtotal (95% CI)	11		10				-			-0.48 [-1.35, 0.39]
Test for heterogeneity: not	applicable						-			•
Test for overall effect: Z =	1.08 (P = 0.28)									
					-4	-2	-	2	4	

Review:

OCD: psychological interventions 06 BT v RET + exposure in vivo (post RET alone) Comparison:

04 Irrational Beliefs Test Outcome:

Study or sub-category	N E	Behaviour therapy Mean (SD)	N F	RET + exposure Mean (SD)			(fixed) i% Cl		SMD (fixed) 95% Cl
01 Post treatment									
Emmelkamp 1991	11	100.80(21.10)	10	88.80(18.30)			-		0.58 [-0.30, 1.46]
Subtotal (95% CI)	11		10				-		0.58 [-0.30, 1.46]
Test for heterogeneity: not ap	plicable						-		
Test for overall effect: $Z = 1.3$	30 (P = 0.19)								
02 At follow-up									
Emmelkamp 1991	11	103.50(17.80)	10	88.90(24.70)			-		0.66 [-0.23, 1.54]
Subtotal (95% CI)	11		10				-		0.66 [-0.23, 1.54]
Test for heterogeneity: not ap	plicable						-		
Test for overall effect: $Z = 1.4$	46 (P = 0.15)								
					-4	-2	0	2	4
						Favours BT	Favou	rs RET +	ехр

Review:

OCD: psychological interventions 06 BT v RET + exposure in vivo (post RET alone) 05 Self-rating Depression Scale Comparison:

Outcome:

Study		ehaviour therapy		RET + exposure			4D (fixed)			SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)			95% CI			95% CI
01 Post treatment										
Emmelkamp 1991	11	49.50(10.80)	10	43.70(10.40)			+	_		0.52 [-0.35, 1.40]
Subtotal (95% CI)	11		10					-		0.52 [-0.35, 1.40]
Test for heterogeneity: not	applicable						-			
Test for overall effect: Z =	1.18 (P = 0.24)									
02 At follow-up										
Emmelkamp 1991	11	49.90(11.80)	10	49.60(16.40)		_	_			0.02 [-0.84, 0.88]
Subtotal (95% CI)	11		10			-	•			0.02 [-0.84, 0.88]
Test for heterogeneity: not	applicable						T			
Test for overall effect: Z =	0.05 (P = 0.96)									
					-4	-2	ó	2	4	

Favours BT Favours RET + exp

Favours BT Favours CBT

Review: OCD: psychological interventions
Comparison: 07 BT v CBT

01 Leaving the study early Outcome:

Study or sub-category	Behaviour therapy n/N	CBT n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Vogel 2004	8/19	1/16		6.74 [0.94, 48.29]
Total (95% CI) Total events: 8 (Behaviour Test for heterogeneity: no Test for overall effect: Z =	t applicable	16		6.74 [0.94, 48.29]
		0	.01 0.1 1 10 10	00

OCD: psychological interventions 07 BT v CBT Review:

Comparison:

02 Non-remission (Y-BOCS) Outcome:

Study or sub-category	Behaviour therapy n/N	CBT n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Post treatment				
Vogel 2004	9/19	10/16		0.76 [0.41, 1.39]
Subtotal (95% CI)	19	16		0.76 [0.41, 1.39]
Total events: 9 (Behaviour t Test for heterogeneity: not Test for overall effect: Z = 1	applicable			
00 At 2 months follows up				
02 At 3 months follow-up Vogel 2004	9/19	10/16		0.76 (0.41 1.20)
Subtotal (95% CI)	19	16/16		0.76 [0.41, 1.39] 0.76 [0.41, 1.39]
Total events: 9 (Behaviour) Test for heterogeneity: not Test for overall effect: Z = 1	therapy), 10 (CBT) applicable	16		0.70 [0.41, 1.35]
Total (95% CI) Total events: 18 (Behaviour Test for heterogeneity: Chi ^a Test for overall effect: Z =	= 0.00, df = 1 (P = 1.00), I ² = 0%	32		0.76 [0.49, 1.16]
			0.2 0.5 1 2	5
			Favours BT Favours CBT	

OCD: psychological interventions 07 BT v CBT 03 Y-BOCS Review:

Comparison: Outcome:

Study or sub-category	N B	ehaviour therapy Mean (SD)	N	CBT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Post treatment						
Vogel 2004	19	16.10(7.30)	16	16.70(7.20)	- + -	-0.08 [-0.75, 0.58]
Subtotal (95% CI)	19		16		•	-0.08 [-0.75, 0.58]
Test for heterogeneity: not app						
est for overall effect: Z = 0.2	4 (P = 0.81)					
02 At 3 months follow-up						
Vogel 2004	19	17.30(7.10)	16	14.40(7.00)	+=-	0.40 [-0.27, 1.07]
Subtotal (95% CI)	19		16		-	0.40 [-0.27, 1.07]
est for heterogeneity: not app						
est for overall effect: Z = 1.1	7 (P = 0.24)					
3 At 6 months follow-up						
Vogel 2004	19	17.80(5.70)	16	12.70(5.90)	_ -	0.86 [0.16, 1.56]
ubtotal (95% CI)	19		16		•	0.86 [0.16, 1.56]
est for heterogeneity: not app						
est for overall effect: Z = 2.4	1 (P = 0.02)					
4 At 12 months follow-up						
Vogel 2004	19	15.40(8.10)	16	14.80(8.30)	- -	0.07 [-0.59, 0.74]
ubtotal (95% Cl)	19		16		•	0.07 [-0.59, 0.74]
est for heterogeneity: not app est for overall effect: Z = 0.2						
est for overall effect. Z = 0.2	T (F = 0.03)					
otal (95% CI)	76		64		•	0.30 [-0.04, 0.64]
est for heterogeneity: Chi² = 4		= 0.23), l ² = 29.8%			1	
est for overall effect: Z = 1.7	4 (P = 0.08)					
					-4 -2 0 2	4
					Favours BT Favours CBT	

OCD: psychological interventions 07 BT v CBT 08 BDI

Review: Comparison: Outcome:

Study or sub-category	N B	ehaviour therapy Mean (SD)	N	CBT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
D1 Post treatment						
Vogel 2004	18	9.70(8.30)	16	10.60(9.20)		-0.10 [-0.77, 0.57]
Subtotal (95% CI)	18	3.10,0.007	16	10:00(3:20)		-0.10 [-0.77, 0.57]
Test for heterogeneity: not app						0.20 (0, 0.0.,
Test for overall effect: Z = 0.29						
02 At 3 months follow-up						
Vogel 2004	18	10.80(6.00)	16	9.40(9.30)		- 0.18 [-0.50, 0.85]
Subtotal (95% CI)	18		16			→ 0.18 [-0.50, 0.85]
Test for heterogeneity: not app	licable				_	
Test for overall effect: $Z = 0.51$	(P = 0.61)					
03 At 6 months follow-up						
Vogel 2004	18	10.70(8.10)	16	10.40(10.40)		0.03 [-0.64, 0.71]
Subtotal (95% CI)	18		16			0.03 [-0.64, 0.71]
Test for heterogeneity: not app	licable					
Test for overall effect: $Z = 0.09$	9 (P = 0.93)					
04 At 12 months follow-up						
Vogel 2004	18	9.20(8.80)	16	11.20(9.70)		-0.21 [-0.89, 0.46]
Subtotal (95% CI)	18		16			-0.21 [-0.89, 0.46]
Test for heterogeneity: not app	licable				_	
Test for overall effect: Z = 0.61	(P = 0.54)					
Total (95% CI)	72		64			-0.03 [-0.36, 0.31]
Test for heterogeneity: Chi² = 0 Test for overall effect: Z = 0.15		= 0.87), I ² = 0%			T	

Review:

OCD: psychological interventions 08 Kundalini yoga v Relaxation response + mindfulness meditation 01 Leaving the study early Comparison:


Outcome:

Study or sub-category	Kundalini yoga n/N	RR+MM n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Shannahoff-Khalsa99	5/12	3/10		1.39 [0.44, 4.43]
Total (95% CI) Total events: 5 (Kundalini yoga Test for heterogeneity: not app Test for overall effect: Z = 0.5	olicable	10		1.39 [0.44, 4.43]
			0.1 0.2 0.5 1 2 5 1 Favours K-yoga Favours RR+MM	0

Favours BT Favours CBT

Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation

Outcome: 02 Y-BOCS (ITT)



Review: OCD: psychological interventions

Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation

Outcome: 03 Profile of Moods scale

Study or sub-category	N	Kundalini yoga Mean (SD)	N	RR+MM Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
Shannahoff-Khalsa99	7	-27.29(21.52)	7	1.71(26.91)	-	-1.11 [-2.27, 0.04]
Total (95% CI) Test for heterogeneity: not appl Test for overall effect: Z = 1.89			7			-1.11 [-2.27, 0.04]

Favours RR+MM

Favours K-yoga Favours RR+MM

Favours K-yoga Favours RR+MM

Favours K-yoga Favours RR+MM

Favours K-yoga

Review: OCD: psychological interventions

Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation

Outcome: 04 Perceived Stress scale

Study or sub-category	N	Kundalini yoga Mean (SD)	N	RR+MM Mean (SD)			D (fixed) 15% Cl			SMD (fixed) 95% Cl
Shannahoff-Khalsa99	7	-6.14(5.96)	7	-2.14(5.24)		-	+			-0.67 [-1.75, 0.42]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.2			7			-				-0.67 [-1.75, 0.42]
					-4	-2	ò	2	4	

Review: OCD: psychological interventions

Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation

Outcome: 05 Purpose in Life scale

Study or sub-category	N	Kundalini yoga Mean (SD)	N	RR+MM Mean (SD)			MD (fixed) 95% CI)		SMD (fixed) 95% CI
Shannahoff-Khalsa99	7	-10.29(5.91)	7	1.00(10.91)		-				-1.20 [-2.38, -0.03]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 2.0			7			-				-1.20 [-2.38, -0.03]
					-4	-2	ö	2	4	

Review: OCD: psychological interventions

Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation

Outcome: 06 Y-BOCS (PP)

Study or sub-category	N	Kundalini yoga Mean (SD)	N	RR+MM Mean (SD)		\$	SMD (fixed) 95% CI)		SMD (fixed) 95% Cl
Shannahoff-Khalsa99	7	-9.43(7.21)	7	-2.86(3.13)			-			-1.11 [-2.26, 0.05]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.8			7				•			-1.11 [-2.26, 0.05]
					-10	-5	-	5	10	

Review: OCD: psychological interventions

Comparison: 09 Self-exposure v Partner-assisted exposure

Outcome: 01 Anxiety/discomfort - Main compulsion (assessor rated)

Study or sub-category	Se N	lf-controlled exp Mean (SD)	Parti N	ner-assisted exp Mean (SD)		\$	SMD (fixed 95% CI)		SMD (fixed) 95% Cl
Emmelkamp 1983	6	5.00(1.99)	6	4.20(1.95)			-			0.37 [-0.77, 1.52]
Total (95% CI) Test for heterogeneity: not app Test for overall effect: Z = 0.6			6				•			0.37 [-0.77, 1.52]
					-10	-5 ours Self-	0 Fau	5 ours Cou	10	

OCD: psychological interventions Review: Comparison: 09 Self-exposure v Partner-assisted exposure Outcome: 02 Anxiety/discomfort - Other compulsions (assessor rated) Self-controlled exp SMD (fixed) SMD (fixed) Study Partner-assisted exp or sub-category N Ν Mean (SD) 95% CI 95% CI Mean (SD) Emmelkamp 1983 6 0.60 [-0.56, 1.77] 3.30(1.25) 6 2.30(1.76) Total (95% CI) 0.60 [-0.56, 1.77] Test for heterogeneity: not applicable Test for overall effect: Z = 1.01 (P = 0.31) 10 Favours Couple-exp Favours Self-exp Review: OCD: psychological interventions Comparison: 09 Self-exposure v Partner-assisted exposure 03 Maudsley Obsessive-compulsive inventory Outcome SMD (fixed) SMD (fixed) Study Self-controlled exp Partner-assisted exp Ν 95% CI 95% CI or sub-category Ν Mean (SD) Mean (SD) Emmelkamp 1983 8.00(4.03) 8.00(3.16) 0.00 [-1.13, 1.13] Total (95% CI) 0.00 [-1.13, 1.13] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) -10 Favours Self-exp Favours Couple-exp OCD: psychological interventions Comparison: 09 Self-exposure v Partner-assisted exposure 04 Social and Marital Adjustment: Marital Outcome: SMD (fixed) SMD (fixed) Self-controlled exp Partner-assisted exp or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Emmelkamp 1983 14.70(8.21) -0.65 [-1.83, 0.53] 6 9.70(5.78) 6 Total (95% CI) -0.65 [-1.83, 0.53] Test for heterogeneity: not applicable Test for overall effect: Z = 1.08 (P = 0.28)-100 -50 50 100 Favours Self-exp Favours Couple-exp OCD: psychological interventions Review: 09 Self-exposure v Partner-assisted exposure Comparison: Outcome 05 Social and Marital Adjustment: Sexual Study Self-controlled exp Partner-assisted exp SMD (fixed) SMD (fixed) 95% CI 95% CI or sub-category Mean (SD) Mean (SD) Emmelkamp 1983 6 10.30(1.93) 6 8.70(1.61) 0.83 [-0.37, 2.03] Total (95% CI) 6 0.83 [-0.37, 2.03] Test for heterogeneity: not applicable Test for overall effect: Z = 1.35 (P = 0.18) -10 10 Favours Self-exp Favours Couple-exp OCD: psychological interventions 09 Self-exposure v Partner-assisted exposure Review: Comparison 06 Social and Marital Adjustment: Social Outcome: Study Self-controlled exp Partner-assisted exp SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) N Mean (SD) 95% CL 95% CI Emmelkamp 1983 12.70(2.52) 6 10.30(5.91) 0.49 [-0.67, 1.64] Total (95% CI) 6 0.49 [-0.67, 1.64] Test for heterogeneity: not applicable Test for overall effect: Z = 0.83 (P = 0.41) -10 Favours Self-exp Favours Couple-exp Review: OCD: psychological interventions Comparison: 09 Self-exposure v Partner-assisted exposure Outcome: 07 Anxious mood (assessor-rated) SMD (fixed) SMD (fixed) Study Self-controlled exp Partner-assisted exp N Ν 95% CI or sub-category Mean (SD) Mean (SD) -0.62 [-1.79, 0.55] Emmelkamp 1983 6 2.30(1.93) 6 3.30(0.87) Total (95% CI) -0.62 [-1.79, 0.55] Test for heterogeneity: not applicable Test for overall effect: Z = 1.03 (P = 0.30)

Favours Self-exp Favours Couple-exp

Review: OCD: psychological interventions Comparison: 09 Self-exposure v Partner-assisted exposure 08 Self-rating Depression scale Outcome: Self-controlled exp Study or sub-category N Mean (SD) Emmelkamp 1983 6 49.00(9.69) Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 1.02 (P = 0.31)

Partner-assisted exp N Mean (SD) SMD (fixed) SSMD (fixed) 95% CI S

Favours Self-exp Favours Couple-exp

Favours Live ERP

Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 01 Leaving the study early

Study or sub-category	lmagined + live ERP n/N	Live ERP n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
De Araujo1995	5/28	5/28		1.00 [0.33, 3.08]
Total (95% CI) Total events: 5 (Imagined a Test for heterogeneity: no Test for overall effect: Z	t applicable	28		1.00 [0.33, 3.08]
		C	0.1 0.2 0.5 1 2 5	10

Favours Img/Live ERP

Favours Img/Live ERP Favours Live ERP

Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 02 Relapse (multiple outcomes)

Study or sub-category	lmagined + live ERP n/N	Live ERP n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 At 20 weeks follow-up				
De Araujo1995	8/28	5/28	- - - - - - - - - - 	1.60 [0.60, 4.29]
Subtotal (95% CI)	28	28		1.60 [0.60, 4.29]
Total events: 8 (Imagined + li	ve ERP), 5 (Live ERP)			
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 0	.93 (P = 0.35)			
02 At 32 weeks follow-up				
De Araujo1995	2/28	4/28		0.50 [0.10, 2.51]
Subtotal (95% CI)	28	28		0.50 [0.10, 2.51]
Total events: 2 (Imagined + li	ve ERP), 4 (Live ERP)		_	
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 0	.84 (P = 0.40)			
			0.1 0.2 0.5 1 2 5	10

Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 03 Y-BOCS obsessions

Study or sub-category	lma N	agined + live ERP Mean (SD)	N	Live ERP Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 At 9 weeks (post treatment)						
De Araujo1995	23	7.50(3.20)	23	7.90(3.90)	=	-0.11 [-0.69, 0.47]
Subtotal (95% CI)	23		23			-0.11 [-0.69, 0.47]
Test for heterogeneity: not applicate	able]	
Test for overall effect: $Z = 0.37$ (F						
02 At 20 weeks (post treatment)						
De Araujo1995	23	8.00(4.00)	23	8.80(5.40)	=	-0.17 [-0.74, 0.41]
Subtotal (95% CI)	23		23		▼	-0.17 [-0.74, 0.41]
Test for heterogeneity: not applicate	able				Ţ	
Test for overall effect: $Z = 0.56$ (F						
D3 At 32 weeks (post treatment)						
De Araujo1995	20	7.00(2.90)	21	8.00(5.90)	=	-0.21 [-0.82, 0.40]
Subtotal (95% CI)	20		21		∓	-0.21 [-0.82, 0.40]
Test for heterogeneity: not applica	able				1	
Test for overall effect: Z = 0.67 (F						

OCD: psychological interventions 10 Imaginal + live ERP v Live ERP 04 Y-BOCS rituals Review: Comparison:

Outcome:

Study or sub-category	lma N	agined + live ERP Mean (SD)	N	Live ERP Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
D1 At 9 weeks (post treatment)						
De Araujo1995	23	6.80(3.60)	23	7.60(4.90)	<u>=</u>	-0.18 [-0.76, 0.40]
Subtotal (95% CI)	23		23		▼	-0.18 [-0.76, 0.40]
Test for heterogeneity: not applic	able]	
Test for overall effect: $Z = 0.62$ (P = 0.54)					
02 At 20 weeks (post treatment)						
De Araujo1995	20	7.60(4.40)	21	9.00(6.40)	=	-0.25 [-0.86, 0.37]
Subtotal (95% CI)	20		21			-0.25 [-0.86, 0.37]
Test for heterogeneity: not applic	able				1	
Test for overall effect: Z = 0.79 (P = 0.43)					
D3 At 32 weeks (post treatment)						
De Araujo1995	20	7.00(3.00)	21	8.60(5.90)	=	-0.33 [-0.95, 0.28]
Subtotal (95% CI)	20		21			-0.33 [-0.95, 0.28]
Test for heterogeneity: not applic	able				1	
Test for overall effect: $Z = 1.06$ (P = 0.29)					
					-10 -5 0 5	5 10
					Favours Img/live ERP Favours	Live ERP

OCD: psychological interventions 10 Imaginal + live ERP v Live ERP 05 Compulsions checklist Review: Comparison: Outcome:

Study or sub-category	lm: N	agined + live ERP Mean (SD)	N	Live ERP Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 At 9 weeks (post treatment)						
De Araujo1995	23	2.00(1.60)	23	2.20(1.70)	<u>=</u>	-0.12 [-0.70, 0.46]
Subtotal (95% CI)	23		23		▼	-0.12 [-0.70, 0.46]
Test for heterogeneity: not applical	ble				Ţ	•
Test for overall effect: Z = 0.40 (P	= 0.69)					
02 At 20 weeks (post treatment)						
De Araujo1995	20	2.00(1.70)	21	2.20(2.00)	<u>=</u>	-0.11 [-0.72, 0.51]
Subtotal (95% CI)	20		21		•	-0.11 [-0.72, 0.51]
Test for heterogeneity: not applical	ble				Ī	
Test for overall effect: Z = 0.34 (P	= 0.74)					
03 At 32 weeks (post treatment)						
De Araujo1995	20	1.90(1.60)	21	2.40(1.20)	<u>=</u>	-0.35 [-0.97, 0.27]
Subtotal (95% CI)	20		21			-0.35 [-0.97, 0.27]
Test for heterogeneity: not applical	ble				1	•
Test for overall effect: Z = 1.10 (P	= 0.27)					
				-10	-5 0 5	10

Favours Img/live ERP Favours Live ERP


Favours Img/live ERP Favours Live ERP

OCD: psychological interventions 10 Imaginal + live ERP v Live ERP 06 Beck Depression Inventory Review: Comparison: Outcome:

Study or sub-category	lm N	agined + live ERP Mean (SD)	N	Live ERP Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
01 At 9 weeks (post treatment	t)					
De Araujo1995	23	15.00(13.10)	23	19.00(13.20)	e e e e e e e e e e e e e e e e e e e	-0.30 [-0.88, 0.28]
Subtotal (95% CI)	23		23		T	-0.30 [-0.88, 0.28]
Test for heterogeneity: not app	olicable					
Test for overall effect: $Z = 1.0$	1 (P = 0.31)					
02 At 20 weeks (post treatmer	nt)					
De Araujo1995	20	14.00(15.20)	21	22.00(19.10)	in the second se	-0.45 [-1.07, 0.17]
Subtotal (95% CI)	20		21		T	-0.45 [-1.07, 0.17]
Test for heterogeneity: not app	olicable					
Test for overall effect: $Z = 1.4$	3 (P = 0.15)					
03 At 32 weeks (post treatmer	nt)					
De Araujo1995	20	12.00(14.00)	21	17.00(17.60)	e e e e e e e e e e e e e e e e e e e	-0.31 [-0.92, 0.31]
Subtotal (95% CI)	20		21		T	-0.31 [-0.92, 0.31]
Test for heterogeneity: not app	olicable					•
Test for overall effect: Z = 0.9						

11 ERP + relapse prevention v ERP + associative therapy Comparison:


Outcome: 01 Non-responders (Y-BOCS 50%)



Review: OCD: psychological interventions

11 ERP + relapse prevention v ERP + associative therapy Comparison:

02 Leaving the study early Outcome:



Favours ERP+RP Favours ERP+assn.the OCD: psychological interventions

Review:

Comparison: 11 ERP + relapse prevention v ERP + associative therapy

Outcome: 03 Y-BOCS

Study	ERF	o + resp. prevent	ERI	P + assn. therapy		SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)		95% CI	95% CI
01 Post treatment							
Hiss 1994	8	8.75(4.53)	10	9.80(7.24)			-0.16 [-1.09, 0.77]
Subtotal (95% CI)	8		10				-0.16 [-1.09, 0.77]
Fest for heterogeneity: not applicab	le						
Fest for overall effect: Z = 0.34 (P =	0.73)						
02 At 6-month follow-up							
Hiss 1994	8	8.13(7.10)	10	13.44(8.78)			-0.63 [-1.58, 0.33]
Subtotal (95% CI)	8		10			∓	-0.63 [-1.58, 0.33]
est for heterogeneity: not applicab	le						
Fest for overall effect: Z = 1.28 (P =	0.20)						
					-100 -:	. l . 50 0 50	100

OCD: psychological interventions Review:


Comparison: 11 ERP + relapse prevention v ERP + associative therapy Outcome: 04 Obessive-compulsive symptoms (assessor-rated)

Study	ERI	P + resp. prevent	ER	P + assn. therapy	SM	ID (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	9	95% CI	95% CI
01 Post treatment							
Hiss 1994	8	2.75(2.25)	10	5.00(4.57)		•	-0.57 [-1.53, 0.38]
Subtotal (95% CI)	8		10			Ŧ	-0.57 [-1.53, 0.38]
Test for heterogeneity: not appli	cable						
Test for overall effect: $Z = 1.18$	(P = 0.24)						
02 At 6-month follow-up							
Hiss 1994	8	4.50(4.66)	10	11.80(7.55)			-1.08 [-2.09, -0.07]
Subtotal (95% CI)	8		10			T	-1.08 [-2.09, -0.07]
Test for heterogeneity: not appli	cable					1	
Test for overall effect: $Z = 2.09$	(P = 0.04)						
Test for overall effect: Z = 2.09	(P = 0.04)			-1	00 -50	0 50	100

Favours ERP+RP Favours ERP+assn.the

Comparison: 11 ERP + relapse prevention v ERP + associative therapy

Outcome: 05 Hamilton Depression Scale



Review: OCD: psychological interventions

Comparison: 11 ERP + relapse prevention v ERP + associative therapy

Outcome: 06 Beck Depression Inventory

Study or sub-category	ERI N	P + resp. prevent Mean (SD)	ERI N	P + assn. therapy Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
or cab-category		modif (OD)		moun (ob)	3576 31	5570 61
01 Post treatment						
Hiss 1994	8	6.13(5.84)	10	5.56(8.63)	<u> </u>	0.07 [-0.86, 1.00]
Subtotal (95% CI)	8		10		T	0.07 [-0.86, 1.00]
est for heterogeneity: not a	pplicable				ſ	
est for overall effect: Z = 0	.15 (P = 0.88)					
02 At 6-month follow-up						
Hiss 1994	8	6.33(8.26)	10	10.00(16.10)	· ·	-0.26 [-1.20, 0.67]
Subtotal (95% CI)	8		10		T	-0.26 [-1.20, 0.67]
est for heterogeneity: not a	pplicable					•
est for overall effect: Z = 0	66 (D = 0.60)					

Review: OCD: psychological interventions

Comparison: 13 BTSTEPS + scheduled support v BTSTEPS + requested support

Outcome: 04 Leaving the study early

Study or sub-category	Scheduled support n/N	Requested support n/N	RR (fixed) 95% CI	Weight %	RR (fixed) 95% CI
Kenwright 2005	3/22	13/22		100.00	0.23 [0.08, 0.70]
Total (95% CI) Total events: 3 (Schedule Test for heterogeneity: no Test for overall effect: Z =		22 rt)		100.00	0.23 [0.08, 0.70]
		0.0	1 0.1 1	10 100	

Favours sched suppor

Review: OCD: psychological interventions

Comparison: 13 BTSTEPS + scheduled support v BTSTEPS + requested support


Outcome: 01 Y-BOCS

Study or sub-category	N S	Scheduled support Mean (SD)	N	Requested support Mean (SD)		SMD 95%	(fixed) % CI	Weight %	SMD (fixed) 95% CI
Kenwright 2005	20	-6.30(8.92)	16	-2.10(5.12)		-	-	100.00	-0.55 [-1.22, 0.12]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1.			16			•		100.00	-0.55 [-1.22, 0.12]
•					-4	-2 () 2	4	

Review: OCD: psychological interventions

Comparison: 13 BTSTEPS + scheduled support v BTSTEPS + requested support

Outcome: 02 Target triggers discomfort




Favours sched suppor Favours requ support

Favours ERP+RP Favours ERP+assn.the

Favours requ support

13 BTSTEPS + scheduled support v BTSTEPS + requested support 03 Work and Social Adjustment Scale Comparison: Outcome:



Favours sched suppor Favours requ support

Favours ERP+RP Favours ERP+assn.the

Review:

OCD: psychological interventions 11 ERP + relapse prevention v ERP + associative therapy Comparison:

Outcome: 07 State-Trait Anxiety Inventory - State

Study	ER	ERP + resp. prevent		P + assn. therapy	SMD (fixed)	SMD (fixed)	
or sub-category	N Mean (SD)		N Mean (SD)		95% CI	95% CI	
01 Post treatment							
Hiss 1994	8	42.00(9.78)	10	36.00(13.79)	in the second se	0.47 [-0.48, 1.41]	
Subtotal (95% CI)	8		10		T	0.47 [-0.48, 1.41]	
Test for heterogeneity: not a	applicable				[
Test for overall effect: $Z = 0$	0.97 (P = 0.33)						
02 At 6-month follow-up							
Hiss 1994	8	34.67(10.23)	10	37.38(10.39)	•	-0.25 [-1.18, 0.68]	
Subtotal (95% CI)	8		10		T	-0.25 [-1.18, 0.68]	
Test for heterogeneity: not a	applicable						
Test for overall effect: Z = 0	0.52 (P = 0.60)						

OCD: psychological interventions Review: Comparison: 14 Family-based BT v Patient-based BT

Outcome: 01 MOCI

Study	F	amily-based BT	Р	atient-based BT	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Post-treatment						
Mehta 1990	15	8.00(2.70)	15	10.71(3.20)	=	-0.89 [-1.65, -0.14]
Subtotal (95% CI)	15		15		•	-0.89 [-1.65, -0.14]
Test for heterogeneity: not ap	pplicable				·	
Test for overall effect: $Z = 2$.	31 (P = 0.02)					
02 Follow-up at 6 months						
Mehta 1990	15	7.20(2.90)	15	12.44(4.10)		-1.44 [-2.25, -0.62]
Subtotal (95% CI)	15		15		•	-1.44 [-2.25, -0.62]
est for heterogeneity: not ap	pplicable				·	
Test for overall effect: $Z = 3$.	45 (P = 0.0006)					
					-10 -5 0 5	10

Favours family BT Favours patient BT OCD: psychological interventions Review:

Comparison: 14 Family-based BT v Patient-based BT Outcome: 02 Zung Self-rating Depression Scale

Study or sub-category	F N	amily-based BT Mean (SD)	Pi N	atient-based BT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
M Double of the control of the contr						
01 Post-treatment						
Mehta 1990	15	40.70(4.80)	15	48.20(5.70)	· ·	-1.38 [-2.19, -0.58]
Subtotal (95% CI)	15		15		(-1.38 [-2.19, -0.58]
est for heterogeneity; not ap	oplicable]	
rest for overall effect: Z = 3.						
02 Follow-up at 6 months						
Mehta 1990	15	37.50(4.20)	15	47.00(5.90)	e e e e e e e e e e e e e e e e e e e	-1.80 [-2.67, -0.94]
Subtotal (95% CI)	15		15		Τ	-1.80 [-2.67, -0.94]
Test for heterogeneity: not ap	oplicable				1	·
Test for overall effect: Z = 4.	0970 ~ 0.00043					

Favours family BT Favours patient BT

Review: OCD: psychological interventions 14 Family-based BT v Patient-based BT Comparison: Outcome: 03 Social adjustment: Occupation

Study or sub-category	F N	Family-based BT N Mean (SD)		atient-based BT Mean (SD)		SMD (fixed) SMD (fixe 95% Cl 95% Cl		
01 Post-treatment								
Mehta 1990	15	2.30(0.90)	15	3.10(0.80)			-n s	1 [-1.67, -0.16]
Subtotal (95% CI)	15	2.00(0.50)	15	3.10(0.00)				1 [-1.67, -0.16]
Test for heterogeneity: not Test for overall effect: Z = :	• •							- ,,
02 Follow-up at 6 months								
Mehta 1990	15	1.80(0.60)	15	2.70(0.70)		_	-1.3	4 [-2.15, -0.54]
Subtotal (95% CI)	15		15			•	-1.3	4 [-2.15, -0.54]
Test for heterogeneity: not	applicable					_		•
Test for overall effect: Z = :	3.28 (P = 0.001)							
					-4	-2 0	2 4	

OCD: psychological interventions

Review: 14 Family-based BT v Patient-based BT 04 Social adjustment: family Comparison: Outcome:

Study	Family-based BT		Patient-based BT		SMD (fixed)	SMD (fixed)	
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI	
01 Post-treatment							
Mehta 1990	15	2.60(0.70)	15	3.20(0.80)		-0.78 [-1.52, -0.03]	
Subtotal (95% CI)	15		15		•	-0.78 [-1.52, -0.03]	
Test for heterogeneity: not a	pplicable				-		
est for overall effect: Z = 2	.04 (P = 0.04)						
12 Follow-up at 6 months							
Mehta 1990	15	1.60(1.10)	15	2.30(0.40)	 -	-0.82 [-1.57, -0.07]	
Subtotal (95% CI)	15		15		•	-0.82 [-1.57, -0.07]	
est for heterogeneity; not a	pplicable				-		
Test for overall effect: Z = 2	15 (P = 0.03)						

Review: OCD: psychological interventions 14 Family-based BT v Patient-based BT Comparison: 05 Social adjustment: household responsibilities Outcome:

Study		amily-based BT		atient-based BT	SMD (fix	,	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% (95% CI
01 Post-treatment							
Mehta 1990	15	2.20(1.00)	15	2.80(1.10)			-0.56 [-1.29, 0.18]
Subtotal (95% CI)	15		15		-		-0.56 [-1.29, 0.18]
Test for heterogeneity: not	applicable				-		
Test for overall effect: Z =	1.49 (P = 0.14)						
02 Follow-up at 6 months							
Mehta 1990	15	1.80(1.00)	15	2.30(0.90)			-0.51 [-1.24, 0.22]
Subtotal (95% CI)	15		15		-		-0.51 [-1.24, 0.22]
Test for heterogeneity: not	applicable				-		
Test for overall effect: Z =	1.37 (P = 0.17)						
					-4 -2 0	2 4	

Review: OCD: psychological interventions 14 Family-based BT v Patient-based BT 06 Social adjustment: leisure-time activities Comparison: Outcome:

Study	F	amily-based BT	Pa	atient-based BT	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Post-treatment						
Mehta 1990	15	1.90(0.60)	15	2.10(0.60)		-0.32 [-1.05, 0.40]
Subtotal (95% CI)	15		15		•	-0.32 [-1.05, 0.40]
Test for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 0$.	.88 (P = 0.38)					
02 Follow-up at 6 months						
Mehta 1990	15	1.60(0.60)	15	2.00(0.50)		-0.70 [-1.45, 0.04]
Subtotal (95% CI)	15		15		•	-0.70 [-1.45, 0.04]
Fest for heterogeneity: not a	pplicable				-	
Test for overall effect: $Z = 1$.	.86 (P = 0.06)					

Favours family BT Favours patient BT

Favours family BT Favours patient BT

Favours family BT Favours patient BT

Review: OCD: psychological interventions Comparison: 17 Children: Individual CBFT v Group CBFT Outcome: 01 CY-BOCS SMD (fixed) SMD (fixed) Individual CBFT Group CBFT Study or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 22 8.36(6.93) 29 8.28(7.33) 0.01 [-0.54, 0.57] Total (95% CI) 22 0.01 [-0.54, 0.57] Test for heterogeneity: not applicable Test for overall effect: Z = 0.04 (P = 0.97) 10 Favours Ind-CBFT Favours Group-CBFT Review: OCD: psychological interventions Comparison: 17 Children: Individual CBFT v Group CBFT Outcome: 02 NIMH-GOCS Group CBFT SMD (fixed) SMD (fixed) Individual CBFT Study N Ν 95% CI 95% CI or sub-category Mean (SD) Mean (SD) Barrett 2004 3.50(2.30) 29 3.31(2.16) 0.08 [-0.46, 0.63] Total (95% CI) 29 0.08 [-0.46, 0.63] Test for heterogeneity: not applicable Test for overall effect: Z = 0.30 (P = 0.76) -10 10 Favours Ind-CBFT Favours Group-CBFT Review: OCD: psychological interventions Comparison: 17 Children: Individual CBFT v Group CBFT Outcome: 03 Multidimensional Anxiety Scale for Children Individual CBFT Group CBFT SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 50.37(15.31) 23 39.09(18.00) 0.66 [0.03, 1.28] 19 Total (95% CI) 23 0.66 [0.03, 1.28] Test for heterogeneity: not applicable Test for overall effect: Z = 2.06 (P = 0.04)-10 -5 10 Favours Ind-CBFT Favours Group-CBFT OCD: psychological interventions Review: 17 Children: Individual CBFT v Group CBFT Comparison: Outcome: 04 Children's Depression Inventory Individual CBFT Group CBFT SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) Mean (SD) 95% CI 95% CI Barrett 2004 19 6.26(6.59) 23 3.35(4.82) 0.50 [-0.12, 1.12] Total (95% CI) 23 0.50 [-0.12, 1.12] 19 Test for heterogeneity: not applicable Test for overall effect: Z = 1.59 (P = 0.11)-10 10 Favours Ind-CBFT Favours Group-CBFT Review: OCD: psychological interventions 17 Children: Individual CBFT v Group CBFT Comparison: 05 McMaster Family Assessment Device - Mother's rating Outcome: Study Individual CBFT Group CBFT SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CL 95% CL Barrett 2004 18 2.16(0.30) 26 2.16(0.39) 0.00 [-0.60, 0.60] Total (95% CI) 18 26 0.00 [-0.60, 0.60] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) -10 10 Favours Ind-CBFT Favours Group-CBFT Review: OCD: psychological interventions

Barrett 2004 9 2.12(0.37) 13 2.13(0.45) -0.02 [-0.87, 0.83] Total (95% Cl) 9 13 -0.02 [-0.87, 0.83] Test for heterogeneity: not applicable Test for overall effect: Z = 0.05 (P = 0.96)	Study or sub-category	N I	Individual CBFT Mean (SD)	N	Group CBFT Mean (SD)		S	SMD (fixed 95% CI)		SMD (fixed) 95% Cl
Test for heterogeneity: not applicable	Barrett 2004	9	2.12(0.37)	13	2.13(0.45)			+			-0.02 [-0.87, 0.83]
	Test for heterogeneity: not a	• •		13				•			-0.02 [-0.87, 0.83]
						Favo	urs Ind-CE	BFT Fav	ours Gro	up-CBFT	

17 Children: Individual CBFT v Group CBFT

Comparison:

Review: OCD: psychological interventions Comparison: 17 Children: Individual CBFT v Group CBFT Outcome: 07 Depression Anxiety Stress Scale: Mother depression Individual CBFT Group CBFT SMD (fixed) SMD (fixed) Study orsub-category N Ν Mean (SD) 95% CI 95% CI Mean (SD) Barrett 2004 18 27 5.33(7.23) -0.13 [-0.73, 0.47] 4.44(6.12) Total (95% CI) 18 -0.13 [-0.73, 0.47] Test for heterogeneity: not applicable Test for overall effect: Z = 0.42 (P = 0.67)10 Favours Ind-CBFT Favours Group-CBFT Review: OCD: psychological interventions Comparison: 17 Children: Individual CBFT v Group CBFT Outcome: 08 Depression Anxiety Stress Scale: Mother anxiety Individual CBFT Group CBFT SMD (fixed) SMD (fixed) Study Ν 95% CI 95% CI or sub-category Ν Mean (SD) Mean (SD) Barrett 2004 18 2.83(4.20) 27 4.30(7.10) -0.24 [-0.83, 0.36] Total (95% CI) 27 -0.24 [-0.83, 0.36] 18 Test for heterogeneity: not applicable Test for overall effect: Z = 0.77 (P = 0.44) -10 10 Favours Ind-CBFT Favours Group-CBFT OCD: psychological interventions Review Comparison: 17 Children: Individual CBFT v Group CBFT Outcome: 09 Depression Anxiety Stress Scale: Mother stress Individual CBFT Group CBFT SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Barrett 2004 0.14 [-0.46, 0.74] 18 10.06(7.67) 27 8.85(9.00) Total (95% CI) 27 0.14 [-0.46, 0.74] Test for heterogeneity: not applicable Test for overall effect: Z = 0.46 (P = 0.65)-10 -5 10 Favours Ind-CBFT Favours Group-CBFT OCD: psychological interventions Review: 17 Children: Individual CBFT v Group CBFT Comparison: Outcome 10 Depression Anxiety Stress Scale: Father depression Group CBFT SMD (fixed) Study Individual CBFT SMD (fixed) Mean (SD) 95% CI 95% CI or sub-category Mean (SD) Barrett 2004 11 5.55(6.77) 14 3.14(4.94) 0.40 [-0.40, 1.20] Total (95% CI) 0.40 [-0.40, 1.20] 11 14 Test for heterogeneity: not applicable Test for overall effect: Z = 0.98 (P = 0.32) -10 10 Favours Ind-CBFT Favours Group-CBFT Review: OCD: psychological interventions 17 Children: Individual CBFT v Group CBFT Comparison 11 Depression Anxiety Stress Scale: Father anxiety Outcome: Study Individual CBFT Group CBFT SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CL 95% CL Barrett 2004 11 4.82(7.44) 14 3.36(4.36) 0.24 [-0.55, 1.03] Total (95% CI) 14


0.24 [-0.55, 1.03] Test for heterogeneity: not applicable Test for overall effect: Z = 0.59 (P = 0.55) -10

Favours Ind-CBFT Favours Group-CBFT

OCD: psychological interventions Review: Comparison: 17 Children: Individual CBFT v Group CBFT Outcome: 12 Depression Anxiety Stress Scale: Father stress

Individual CBFT Group CBFT SMD (fixed) SMD (fixed) Study or sub-category N N Mean (SD) 95% CI Mean (SD) Barrett 2004 0.49 [-0.31, 1.30] 11 11.64(9.83) 14 7.43(6.77) Total (95% CI) 14 0.49 [-0.31, 1.30] Test for heterogeneity: not applicable Test for overall effect: Z = 1.20 (P = 0.23) Favours Ind-CBFT Favours Group-CBFT

Review: OCD: psychological interventions Comparison: 17 Children: Individual CBFT v Group CBFT Outcome: 13 Children's Depression Inventory: sibling's rating



Review: OCD: psychological interventions


Comparison: 17 Children: Individual CBFT v Group CBFT

Outcome: 14 Multidimensional Anxiety Scale for Children - sibling's ratings

Study or sub-category	N	Individual CBFT Mean (SD)	N	Group CBFT Mean (SD)			D (fixed) 95% CI			SMD (fixed) 95% Cl
Barrett 2004	13	34.08(11.30)	10	30.50(10.16)			+			0.32 [-0.51, 1.15]
Total (95% CI) Test for heterogeneity: not			10				•			0.32 [-0.51, 1.15]
Test for overall effect: Z =	U./5 (P = 0.45)				-10	-5		5	10	


Review: OCD: psychological interventions 17 Children: Individual CBFT v Group CBFT 15 Sibling Accomodation Scale Comparison:

Outcome:




Favours Ind-CBFT Favours Group-CBFT

Psychological vs. Control (BDD)



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 06 Brief Symptom Inventory



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control

Outcome: 07 Y-BOCS (BDD)

Study or sub-category	N	CBT Mean (SD)	N	Control Mean (SD)				O (fixed) 5% Cl		SMD (fixed) 95% Cl
Veale 1996	9	10.75(9.25)	10	24.33(4.55)		_	_			-1.81 [-2.92, -0.70]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			10			-	-			-1.81 [-2.92, -0.70]
					-4	-	2	0	2	4

Favours CBT Favours control

Favours CBT Favours control

Favours CBT Favours control

Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control

Outcome: 08 MADRS

Study or sub-category	N	CBT Mean (SD)	N	Control Mean (SD)			1D (fixed) 95% CI			SMD (fixed) 95% CI
Veale 1996	9	6.87(4.58)	10	18.75(9.25)		-	-			-1.53 [-2.58, -0.47]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 2			10			-	-			-1.53 [-2.58, -0.47]
					-4	-2	Ó	2	4	


Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control

Outcome: 09 Hospital Anxiety

Study or sub-category	N	CBT Mean (SD)	N	Control Mean (SD)		SMD (fi 95%			SMD (fixed) 95% Cl
Veale 1996	9	7.85(4.48)	10	8.45(5.24)		-	_		-0.12 [-1.02, 0.78]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			10			•	-		-0.12 [-1.02, 0.78]
					-4	-2 0		2	4


Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control

Outcome: 10 Hospital Depression




Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control

Outcome: 11 Derriford Scale



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control


Outcome: 12 Social Phobia



Psychological vs. Psychological (BDD)

Review: BDD: psychological interventions Comparison: 02 BT v CT (mid-treatment)

Outcome: 01 Non-responders (Y-BOCS reliable change index)



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 02 Y-BOCS (BDD)

Study or sub-category	B N	ehaviour therapy Mean (SD)	Co N	ognitive therapy Mean (SD)			ID (fixed) 95% Cl		SMD (fixed) 95% CI
Khemlani-Patel 2001	5	22.40(6.39)	5	17.40(2.97)			+-	_	0.91 [-0.43, 2.25]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.3			5				-	-	0.91 [-0.43, 2.25]
					-4	-2	-	2	4

Favours BT Favours CT

Favours BT Favours CT

Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 03 BDD Examination

Study or sub-category	N N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)			MD (fixed) 95% Cl		SMD (fixed) 95% CI
Khemlani-Patel 2001	5	76.60(21.58)	5	49.40(20.31)			-	-	1.17 [-0.23, 2.58]
Total (95% Cl) Test for heterogeneity: not a Test for overall effect: Z = 1			5				-		1.17 [-0.23, 2.58]
					-4	-2	Ó	2	4

Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 04 Defects Related Beliefs Test

Study or sub-category	B N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
Khemlani-Patel 2001	5	35.80(9.91)	5	29.40(6.43)			-	_		0.69 [-0.61, 1.99]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1			5		,		-	_		0.69 [-0.61, 1.99]
					-4	-2	Ó	2	4	
						Favours	BT Favo	ours CT		

Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 05 Beck Anxiety Inventory

Study or sub-category	В N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% CI
Khemlani-Patel 2001	5	17.20(10.55)	5	11.20(5.22)			-			0.65 [-0.64, 1.94]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0.			5				-	-		0.65 [-0.64, 1.94]
					-4	-2	Ó	ż	4	
						Favours B	T Favo	urs CT		

Review: BDD: psychological interventions Comparison: 02 BT v CT (mid-treatment) Outcome: 06 Beck Depression Inventory

Study or sub-category	B N	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)			D (fixed) 5% Cl		SMD (fixed) 95% Cl
Khemlani-Patel 2001	5	18.00(11.45)	5	15.20(10.83)			-		0.23 [-1.02, 1.47]
Total (95% CI) Test for heterogeneity: not app Test for overall effect: Z = 0.3			5				-		0.23 [-1.02, 1.47]
					-4	-2	ó	2	4

Favours BT Favours CT

Favours BT Favours CT

Favours BT Favours CT

Favours BT Favours CT

BDD: psychological interventions 02 BT v CT (mid-treatment) Review: Comparison: Outcome: 07 Body Satisfaction Scale

Study or sub-category	N B	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)			D (fixed) 15% Cl		SMD (fixed) 95% Cl
Khemlani-Patel 2001	5	54.60(19.11)	5	49.20(18.58)		_	-		0.26 [-0.99, 1.51]
Total (95% CI) Test for heterogeneity: not all Test for overall effect: Z = 0.			5			-	-		0.26 [-0.99, 1.51]
					-4	-2	 	2	4

Review: BDD: psychological interventions Comparison: Outcome: 02 BT v CT (mid-treatment)
08 Social Avoidance and Distress Scale

Study or sub-category	N B	ehaviour therapy Mean (SD)	N C	ognitive therapy Mean (SD)			(fixed) % Cl		SMD (fixed) 95% Cl
Khemlani-Patel 2001	5	14.20(5.85)	5	12.80(10.33)		\rightarrow	_		0.15 [-1.09, 1.39]
Total (95% CI) Test for heterogeneity: not ag Test for overall effect: Z = 0.3			5						0.15 [-1.09, 1.39]
					-4	-2 ()	2 .	4

BDD: psychological interventions Review: Comparison: 02 BT v CT (mid-treatment) Outcome: 09 Quality of Life Inventory

Study or sub-category	N E	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)			MD (fixed) 95% CI			SMD (fixed) 95% Cl
Khemlani-Patel 2001	5	-30.31(16.56)	5	-27.81(16.56)		_	+			-0.14 [-1.38, 1.11]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			5			-	•			-0.14 [-1.38, 1.11]
					-4	-2	Ó	2	4	

BDD: psychological interventions Review: Comparison: 03 BT v CBT (post-treatment)

Outcome: 01 Non-responders (Y-BOCS reliable change index)

Study or sub-category	Behavioural therapy n./N	CBT n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Khemlani-Patel 2001	1/5	0/5		3.00 [0.15, 59.89]
Total (95% CI) Total events: 1 (Behavioura Test for heterogeneity: not Test for overall effect: Z = 6	applicable	5		3.00 [0.15, 59.89]
			0.01 0.1 1 10 100 Favours BT Favours CBT	

Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 02 Y-BOCS (BDD)

Behaviour therapy СВТ SMD (fixed) SMD (fixed) Study or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI Khemlani-Patel 2001 5 14.20(6.26) 18.20(8.53) 5 0.48 [-0.79, 1.75] Total (95% CI) 0.48 [-0.79, 1.75] Test for heterogeneity: not applicable Test for overall effect: Z = 0.75 (P = 0.46)

Favours BT Favours CBT

Favours BT Favours CBT

Favours BT Favours CBT

Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 03 BDD Examination

Study or sub-category	B N	ehaviour therapy Mean (SD)	N	CBT Mean (SD)		ID (fixed) 95% CI	SMD (fixed) 95% Cl
Khemlani-Patel 2001	5	63.80(15.01)	5	37.60(22.07)		-	 1.25 [-0.17, 2.68]
Total (95% CI) Test for heterogeneity: not ap			5				1.25 [-0.17, 2.68]
Test for overall effect: Z = 1.7	72 (P = 0.08)				 		-

Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 04 Defects Related Beliefs Test

Study or sub-category	N B	ehaviour therapy Mean (SD)	N	CBT Mean (SD)		5	SMD (fixed) 95% Cl			SMD (fixed) 95% Cl
Khemlani-Patel 2001	5	33.00(7.78)	5	27.00(6.48)			-			0.76 [-0.55, 2.07]
Total (95% CI) Test for heterogeneity: not app Test for overall effect: Z = 1.1			5		,	,	-	- -		0.76 [-0.55, 2.07]
					-4	-2	Ó	2	4	

Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 05 Beck Anxiety Inventory

Study or sub-category	Bi N	ehaviour therapy Mean (SD)	N	CBT Mean (SD)		\$	SMD (fixed 95% CI	d)		SMD (fixed) 95% CI
Khemlani-Patel 2001	5	10.00(9.27)	5	5.80(5.12)			-			0.51 [-0.77, 1.78]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0.			5				-			0.51 [-0.77, 1.78]
					-4	-2	ó	ż	4	
						Favours	BT Fa	vours CBT		


Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 06 Beck Depression Inventory

Study or sub-category	N B	ehaviour therapy Mean (SD)	N	CBT Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% CI
Khemlani-Patel 2001	5	14.40(15.65)	5	12.60(11.26)		_	-	_		0.12 [-1.12, 1.36]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 0.			5				-	-		0.12 [-1.12, 1.36]
					-4	-2	ó	2	4	
						Favours E	T Favo	ours CBT		


Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 07 Body Satisfaction Scale

Study or sub-category	N N	ehaviour therapy Mean (SD)	N	CBT Mean (SD)		,	SMD (fixed 95% CI))		SMD (fixed) 95% Cl
Khemlani-Patel 2001	5	49.80(20.07)	5	46.80(16.60)		-	-	_		0.15 [-1.10, 1.39]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			5				-	-		0.15 [-1.10, 1.39]
					-4	-2	Ó	ż	4	
						Favours	BT Fav	ours CBT		

Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 08 Social Avoidance and Distress Scale



Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 09 Quality of Life Inventory



Treatment Intensity Review

Review: Comparison: Outcome: OCD psychological intensity review 02 Before-after analysis 01 Change from baseline to endpoint

tudy		End of treatment		Before treatment	SMD (fixed)	SMD (fixed)
sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
1 All						
Bouvard 2002	19	16.94(9.22)	19	27.55(7.15)	-	-1.26 [-1.96, -0.56]
Chambless 1999	49	3.42(1.75)	49	6.68(1.04)	-	-2.25 [-2.76, -1.74]
Cordioli 2003	23	15.10(7.80)	23	26.70(4.90)	-	-1.75 [-2.44, -1.06]
De Araujo 1995_Ex	23	7.90(3.90)	23	14.10(2.70)	-	-1.82 [-2.51, -1.12]
De Araujo 1995_Exi	23	7.50(3.20)	23	13.80(2.10)	-	-2.29 [-3.04, -1.53]
Emmelkamp 1983_coupl	6	8.00(3.15)	6	16.20(3.15)	 -	-2.40 [-4.03, -0.77]
Emmelkamp 1983_patie	6	8.00(4.02)	6	16.50(4.02)	 -	-1.95 [-3.43, -0.47]
Emmelkamp 1988_BT	9	12.60(5.40)	9	15.60(4.00)	-= +	-0.60 [-1.55, 0.35]
Emmelkamp 1988_CT	9	11.30(1.70)	9	15.60(2.90)	-	-1.72 [-2.85, -0.60]
Emmelkamp1991_BT	11	11.70(6.10)	11	15.90(4.60)	 -	-0.75 [-1.62, 0.12]
Emmelkamp1991_CT	10	9.60(6.90)	10	15.80(6.70)		-0.87 [-1.80, 0.05]
Enright 1991	24	12.96(6.03)	24	15.46(5.12)		-0.44 [-1.01, 0.13]
Foa 1984 ERP	11	2.55(2.30)	11	6.73(1.21)		-2.19 [-3.29, -1.09]
Foa 1984 Ex	12	4.00(1.99)	12	6.67(1.09)		-1.61 [-2.55, -0.66]
Foa 1984 RP	9	4.33(1.60)	9	6.61(0.78)		-1.73 [-2.85, -0.60]
Foa 1985 Exi	10	5.00(1.27)	10	6.55(0.64)		-1.48 [-2.49, -0.46]
Foa 1985_Exv	9	5.44(1.33)	9	6.44(0.88)		-0.84 [-1.82, 0.13]
Foa 2004	21	11.00(7.90)	29	24.60(4.80)	-	-2.13 [-2.84, -1.42]
Freeston1997	15	12.20(9.60)	15	25.10(5.00)		-1.64 [-2.48, -0.80]
Fritzler 1997	9	17.11(8.91)	9	22.90(7.27)		-0.68 [-1.64, 0.28]
Greist 2002 clinicBT	55	17.60(6.20)	55	25.20(4.60)	-	-1.38 [-1.80, -0.97]
Hiss 1994 associatio	10	9.60(9.60)	10	23.90(7.31)	-	-1.61 [-2.64, -0.57]
Hiss 1994 relapse	8	7.88(2.95)	8	23.13(5.41)		-3.31 [-4.95, -1.66]
Hughes 2004	21	16.50(6.00)	24	22.90(4.40)	-	-1.21 [-1.85, -0.57]
Lindsay 1997	9	11.00(3.81)	9	28.70(4.56)		-4.01 [-5.76, -2.26]
Lovell 1994	6	3.80(2.20)	6	7.20(0.80)		-1.90 [-3.36, -0.43]
McKay 1996	21	15.00(8.29)	21	30.19(3.68)	-	-2.32 [-3.12, -1.52]
McLean 2001 BT	40	16.40(9.28)	40	23.28(5.29)	-	-0.90 [-1.36, -0.44]
McLean 2001 CT	33	16.52(6.93)	33	22.00(5.89)	-	-0.84 [-1.35, -0.34]
Neziroglu 2001	20	10.60(3.60)	20	14.50(3.30)	-	-1.11 [-1.78, -0.44]
O'Connor 1999		13.30(8.60)	6	23.50(4.00)		-1.40 [-2.73, -0.08]
Rosqvist 2001	11	16.91(5.86)	11	22.46(5.20)	-	-0.96 [-1.86, -0.07]
Rothbaum 2000	39	14.61(9.47)	39	24.66(5.59)	-	-1.28 [-1.77, -0.79]
Saxena 2002	170	15.60(5.40)	170	29.00(4.40)	-	-2.71 [-3.01, -2.42]
Taylor 2003 Del	15	6.60(2.90)	15	8.30(3.20)	-	-0.54 [-1.27, 0.19]
Taylor 2003 Imm	11	6.10(3.60)	11	9.70(4.00)	-	-0.91 [-1.80, -0.02]
Van Noppen1997_GBT	17	16.60(7.20)	17	23.90(7.20)	-	-0.99 [-1.71, -0.27]
Van Noppen1997 MFBT	19	15.60(6.50)	19	23.90(5.40)	-	-1.36 [-2.07, -0.65]
Van Oppen 1995_BT	29	17.30(8.30)	29	25.40(7.00)	-	-1.04 [-1.59, -0.49]
Van Oppen 1995 CT	28	13.30(8.50)	28	24.10(5.50)	-	-1.49 [-2.08, -0.89]
VanNoppen 1998	73	16.60(6.10)	73	21.80(5.60)	_	-0.88 [-1.22, -0.54]
Vogel 2004 BT	19	16.10(7.30)	19	23.70(3.20)	-	-1.32 [-2.03, -0.61]
Vogel 2004 CBT	16	16.70(7.20)	16	24.90(2.90)	-	-1.46 [-2.25, -0.67]
Whittal2004_BT	37	13.57(9.27)	37	22.38(5.77)	-	-1.13 [-1.62, -0.64]
Whittal2004_CT	34	11.94(8.21)	34	23.56(4.08)	<u> </u>	-1.77 [-2.34, -1.21]
Subtotal (95% CI)	1055		1066	20.00, 1.00,	•	-1.46 [-1.56, -1.36]
est for heterogeneity: Chi² = 1		44 (P < 0.00001) 2 = 74.8%			[†]	1.10 (1.00, 1.00)
est for neterogeneity. Cril = 1 est for overall effect: Z = 28.9			•			
2 2. 3 roran 0 root. 2 - 20 x						

Review: Comparison: Outcome: OCD psychological intensity review 02 Before-after analysis 02 Change from baseline to endpoint: low intensity

Study	E	End of treatment	E	Before treatment	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
Cordioli 2003	23	15.10(7.80)	23	26.70(4.90)	-	-1.75 [-2.44, -1.06]
Emmelkamp 1983_coupl	6	8.00(3.15)	6	16.20(3.15)	 -	-2.40 [-4.03, -0.77]
Emmelkamp 1983_patie	6	8.00(4.02)	6	16.50(4.02)		-1.95 [-3.43, -0.47]
Enright 1991	24	12.96(6.03)	24	15.46(5.12)	 	-0.44 [-1.01, 0.13]
Fritzler 1997	9	17.11(8.91)	9	22.90(7.27)	-= 	-0.68 [-1.64, 0.28]
Hughes 2004	21	16.50(6.00)	24	22.90(4.40)	-	-1.21 [-1.85, -0.57]
McLean 2001_BT	40	16.40(9.28)	40	23.28(5.29)	-	-0.90 [-1.36, -0.44]
McLean 2001_CT	33	16.52(6.93)	33	22.00(5.89)	-	-0.84 [-1.35, -0.34]
Taylor 2003_Del	15	6.60(2.90)	15	8.30(3.20)	 	-0.54 [-1.27, 0.19]
Taylor 2003_lmm	11	6.10(3.60)	11	9.70(4.00)	-	-0.91 [-1.80, -0.02]
VanNoppen 1998	73	16.60(6.10)	73	21.80(5.60)	-	-0.88 [-1.22, -0.54]
Total (95% CI)	261		264		•	-0.93 [-1.11, -0.75]
Test for heterogeneity: Chi ² = 1	15.51, df = 10	(P = 0.11), I ² = 35.5%			•	
Test for overall effect: Z = 9.9	18 (P < 0.00001)				
					-10 -5 0 5	5 10
					Favours treatment Doesn't fo	avour treat

Favours treatment Doesn't favour treat

Review: OCD psychological intensity review

Comparison: 02 Before-after analysis

Outcome: 03 Change from baseline to endpoint: medium intensity

Study or sub-category	N E	End of treatment Mean (SD)	N E	Before treatment Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
Bouvard 2002				. , ,		1 05 / 1 05 0 551
Chambless 1999	19	16.94(9.22)	19	27.55(7.15)	_+	-1.26 [-1.96, -0.56]
	49	3.42(1.75)	49	6.68(1.04)	<u>-</u>	-2.25 [-2.76, -1.74]
De Araujo 1995_Ex	23	7.90(3.90)	23	14.10(2.70)	<u>.</u>	-1.82 [-2.51, -1.12]
De Araujo 1995_Exi	23	7.50(3.20)	23	13.80(2.10)	- _	-2.29 [-3.04, -1.53]
Emmelkamp 1988_BT	9	12.60(5.40)	9	15.60(4.00)		-0.60 [-1.55, 0.35]
Emmelkamp 1988_CT	9	11.30(1.70)	9	15.60(2.90)		-1.72 [-2.85, -0.60]
Emmelkamp1991_BT	11	11.70(6.10)	11	15.90(4.60)	-• 1	-0.75 [-1.62, 0.12]
Emmelkamp1991_CT	10	9.60(6.90)	10	15.80(6.70)		-0.87 [-1.80, 0.05]
Greist 2002_clinicBT	55	17.60(6.20)	55	25.20(4.60)	-	-1.38 [-1.80, -0.97]
Hiss 1994_associatio	10	9.60(9.60)	10	23.90(7.31)		-1.61 [-2.64, -0.57]
Hiss 1994_relapse	8	7.88(2.95)	8	23.13(5.41)		-3.31 [-4.95, -1.66]
Lindsay 1997	9	11.00(3.81)	9	28.70(4.56)		-4.01 [-5.76, -2.26]
O'Connor 1999	6	13.30(8.60)	6	23.50(4.00)		-1.40 [-2.73, -0.08]
Rothbaum 2000	39	14.61(9.47)	39	24.66(5.59)	-	-1.28 [-1.77, -0.79]
Van Noppen1997_GBT	17	16.60(7.20)	17	23.90(7.20)		-0.99 [-1.71, -0.27]
Van Noppen1997_MFBT	19	15.60(6.50)	19	23.90(5.40)		-1.36 [-2.07, -0.65]
Van Oppen 1995_BT	29	17.30(8.30)	29	25.40(7.00)	-	-1.04 [-1.59, -0.49]
Van Oppen 1995_CT	28	13.30(8.50)	28	24.10(5.50)	-	-1.49 [-2.08, -0.89]
Vogel 2004_BT	19	16.10(7.30)	19	23.70(3.20)	-	-1.32 [-2.03, -0.61]
Vogel 2004_CBT	16	16.70(7.20)	16	24.90(2.90)	-	-1.46 [-2.25, -0.67]
Whittal2004_BT	37	13.57(9.27)	37	22.38(5.77)	-	-1.13 [-1.62, -0.64]
Whittal2004_CT	34	11.94(8.21)	34	23.56(4.08)	-	-1.77 [-2.34, -1.21]
otal (95% CI)	479		479		•	-1.46 [-1.60, -1.31]
est for heterogeneity: Chi² = 4 est for overall effect: Z = 19:						

Review: OCD psychological intensity review

Comparison: 02 Before-after analysis

04 Change from baseline to endpoint: high intensity Outcome:

Study	1	End of treatment	E	Before treatment	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
Foa 1984_ERP	11	2.55(2.30)	11	6.73(1.21)	-	-2.19 [-3.29, -1.09]
Foa 1984_Ex	12	4.00(1.99)	12	6.67(1.09)	-	-1.61 [-2.55, -0.66]
Foa 1984_RP	9	4.33(1.60)	9	6.61(0.78)	-	-1.73 [-2.85, -0.60]
Foa 1985_Exi	10	5.00(1.27)	10	6.55(0.64)	-	-1.48 [-2.49, -0.46]
Foa 1985_Exv	9	5.44(1.33)	9	6.44(0.88)		-0.84 [-1.82, 0.13]
Foa 2004	21	11.00(7.90)	29	24.60(4.80)	-	-2.13 [-2.84, -1.42]
Freeston1997	15	12.20(9.60)	15	25.10(5.00)	-	-1.64 [-2.48, -0.80]
McKay 1996	21	15.00(8.29)	21	30.19(3.68)	-	-2.32 [-3.12, -1.52]
Neziroglu 2001	20	10.60(3.60)	20	14.50(3.30)	-	-1.11 [-1.78, -0.44]
Rosqvist 2001	11	16.91(5.86)	11	22.46(5.20)	-	-0.96 [-1.86, -0.07]
Total (95% CI)	139		147		•	-1.60 [-1.88, -1.33]
Test for heterogeneity: Ch	i ^z = 12.85, df = 9 (P = 0.17), I ² = 30.0%			,	
Test for overall effect: Z =	= 11.41 (P < 0.0000	01)				
					-10 -5 0 5	10
					-10 -5 0 5	10

Favours treatment Doesn't favour treat

Review: Comparison:

OCD psychological intensity review
02 Before-after analysis
05 Change from baseline to endpoint: low intensity (Sensitivity Analysis - excluding Hughes2004) Outcome:

Study	E	End of treatment	E	Before treatment	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
Cordioli 2003	23	15.10(7.80)	23	26.70(4.90)	-	-1.75 [-2.44, -1.06]
Emmelkamp 1983_coupl	6	8.00(3.15)	6	16.20(3.15)		-2.40 [-4.03, -0.77]
Emmelkamp 1983_patie	6	8.00(4.02)	6	16.50(4.02)		-1.95 [-3.43, -0.47]
Enright 1991	24	12.96(6.03)	24	15.46(5.12)		-0.44 [-1.01, 0.13]
Fritzler 1997	9	17.11(8.91)	9	22.90(7.27)	 +	-0.68 [-1.64, 0.28]
McLean 2001_BT	40	16.40(9.28)	40	23.28(5.29)	-	-0.90 [-1.36, -0.44]
McLean 2001_CT	33	16.52(6.93)	33	22.00(5.89)	-	-0.84 [-1.35, -0.34]
Taylor 2003_Del	15	6.60(2.90)	15	8.30(3.20)		-0.54 [-1.27, 0.19]
Taylor 2003_lmm	11	6.10(3.60)	11	9.70(4.00)	-	-0.91 [-1.80, -0.02]
VanNoppen 1998	73	16.60(6.10)	73	21.80(5.60)	-	-0.88 [-1.22, -0.54]
otal (95% CI)	240		240		•	-0.91 [-1.10, -0.72]
est for heterogeneity: Chi² = 1	14.73, $df = 9$ (P = 0.10), I ² = 38.9%			·	
est for overall effect: Z = 9.3	1 (P < 0.00001	1)				

Favours treatment Doesn't favour treat

Review: OCD psychological intensity review

Comparison: 02 Before-after analysis

Outcome: 06 Change from baseline to endpoint: high intensity (Sensitivity Analysis - excluding Foa2004)

or sub-category	N				SMD (fixed)	SMD (fixed)
	.,	Mean (SD)	N	Mean (SD)	95% CI	95% CI
Foa 1984_ERP	11	2.55(2.30)	11	6.73(1.21)	-	-2.19 [-3.29, -1.09]
Foa 1984_Ex	12	4.00(1.99)	12	6.67(1.09)	-	-1.61 [-2.55, -0.66]
Foa 1984_RP	9	4.33(1.60)	9	6.61(0.78)	-	-1.73 [-2.85, -0.60]
Foa 1985_Exi	10	5.00(1.27)	10	6.55(0.64)	-	-1.48 [-2.49, -0.46]
Foa 1985_Exv	9	5.44(1.33)	9	6.44(0.88)		-0.84 [-1.82, 0.13]
Freeston1997	15	12.20(9.60)	15	25.10(5.00)	-	-1.64 [-2.48, -0.80]
McKay 1996	21	15.00(8.29)	21	30.19(3.68)	-	-2.32 [-3.12, -1.52]
Neziroglu 2001	20	10.60(3.60)	20	14.50(3.30)	-	-1.11 [-1.78, -0.44]
Rosqvist 2001	11	16.91(5.86)	11	22.46(5.20)	-	-0.96 [-1.86, -0.07]
Total (95% CI)	118		118		•	-1.51 [-1.81, -1.21]
Test for heterogeneity: Chi ² =	10.34, df = 8 (F	P = 0.24), I ² = 22.6%			,	
Test for overall effect: Z = 9.9	91 (P < 0.00001)				

Review: OCD psychological intensity review

Comparison: 02 Before-after analysis

Outcome: 07 Change from baseline to endpoint: low intensity (Sensitivity Analysis - excluding Hughes2004/Emmelkamp1983

Study	E	End of treatment	E	Before treatment	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
Cordioli 2003	23	15.10(7.80)	23	26.70(4.90)	-	-1.75 [-2.44, -1.06]
Enright 1991	24	12.96(6.03)	24	15.46(5.12)	-	-0.44 [-1.01, 0.13]
Fritzler 1997	9	17.11(8.91)	9	22.90(7.27)		-0.68 [-1.64, 0.28]
McLean 2001_BT	40	16.40(9.28)	40	23.28(5.29)	-	-0.90 [-1.36, -0.44]
McLean 2001_CT	33	16.52(6.93)	33	22.00(5.89)	-	-0.84 [-1.35, -0.34]
Taylor 2003_Del	15	6.60(2.90)	15	8.30(3.20)	-=	-0.54 [-1.27, 0.19]
Taylor 2003_lmm	11	6.10(3.60)	11	9.70(4.00)	-	-0.91 [-1.80, -0.02]
VanNoppen 1998	73	16.60(6.10)	73	21.80(5.60)	-	-0.88 [-1.22, -0.54]
Total (95% CI)	228		228		•	-0.87 [-1.06, -0.67]
Test for heterogeneity: Chi² :	= 9.42, df = 7 (P	= 0.22), I ² = 25.7%			*	,
Test for overall effect: $Z = 8$.	.78 (P < 0.00001)				

Favours treatment Doesn't favour treat

Favours treatment Doesn't favour treat

Review: OCD psychological intensity review

Comparison: 02 Before-after analysis
Outcome: 08 Change from baseline


08 Change from baseline to endpoint: medium intensity (Sensitivity Analysis - excluding Lindsay1997)

tudy	E	End of treatment	E	Before treatment	SMD (fixed)	SMD (fixed)
r sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
Bouvard 2002	19	16.94(9.22)	19	27.55(7.15)	+	-1.26 [-1.96, -0.56]
Chambless 1999	49	3.42(1.75)	49	6.68(1.04)	-	-2.25 [-2.76, -1.74]
De Araujo 1995_Ex	23	7.90(3.90)	23	14.10(2.70)	-	-1.82 [-2.51, -1.12]
De Araujo 1995_Exi	23	7.50(3.20)	23	13.80(2.10)	-	-2.29 [-3.04, -1.53]
Emmelkamp 1988_BT	9	12.60(5.40)	9	15.60(4.00)	 +	-0.60 [-1.55, 0.35]
Emmelkamp 1988_CT	9	11.30(1.70)	9	15.60(2.90)		-1.72 [-2.85, -0.60]
Emmelkamp1991_BT	11	11.70(6.10)	11	15.90(4.60)		-0.75 [-1.62, 0.12]
Emmelkamp1991_CT	10	9.60(6.90)	10	15.80(6.70)		-0.87 [-1.80, 0.05]
Greist 2002_clinicBT	55	17.60(6.20)	55	25.20(4.60)	-	-1.38 [-1.80, -0.97]
O'Connor 1999	6	13.30(8.60)	6	23.50(4.00)	-	-1.40 [-2.73, -0.08]
Rothbaum 2000	39	14.61(9.47)	39	24.66(5.59)	-	-1.28 [-1.77, -0.79]
Van Noppen1997_GBT	17	16.60(7.20)	17	23.90(7.20)	-	-0.99 [-1.71, -0.27]
Van Noppen1997_MFBT	19	15.60(6.50)	19	23.90(5.40)		-1.36 [-2.07, -0.65]
Van Oppen 1995_BT	29	17.30(8.30)	29	25.40(7.00)	-	-1.04 [-1.59, -0.49]
Van Oppen 1995_CT	28	13.30(8.50)	28	24.10(5.50)	-	-1.49 [-2.08, -0.89]
Vogel 2004_BT	19	16.10(7.30)	19	23.70(3.20)	-	-1.32 [-2.03, -0.61]
Vogel 2004_CBT	16	16.70(7.20)	16	24.90(2.90)	-	-1.46 [-2.25, -0.67]
Whittal2004_BT	37	13.57(9.27)	37	22.38(5.77)	-	-1.13 [-1.62, -0.64]
VVhittal2004_CT	34	11.94(8.21)	34	23.56(4.08)	-	-1.77 [-2.34, -1.21]
Total (95% CI)	452		452		•	-1.42 [-1.57, -1.27]
Test for heterogeneity: Chi² = 2 Test for overall effect: Z = 18.7		, ,,			·	

Review: OCD psychological intensity review

Comparison: 02 Before-after analysis

Outcome: 09 Change from baseline to endpoint: high intensity (Sensitivity Analysis - excluding Foa2004/ Hiss1994_relaps



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 10 Change from baseline to endpoint

udy sub-category	N E	End of treatment Mean (SD)	N	Before treatment Mean (SD)	SMD (random) 95% Cl	SMD (random) 95% Cl
					1	
Low intensity					_	
Cordioli 2003	23	15.10(7.80)	23	26.70(4.90)	-	-1.75 [-2.44, -1.06]
Emmelkamp 1983_coupl	6	8.00(3.15)	6	16.20(3.15)	 -	-2.40 [-4.03, -0.77]
Emmelkamp 1983_patie	6	8.00(4.02)	6	16.50(4.02)	 -	-1.95 [-3.43, -0.47]
inright 1991	24	12.96(6.03)	24	15.46(5.12)	<u> </u>	-0.44 [-1.01, 0.13]
ritzler 1997	9	17.11(8.91)	9	22.90(7.27)	_	-0.68 [-1.64, 0.28]
lughes 2004	21	16.50(6.00)	24	22.90(4.40)		-1.21 [-1.85, -0.57]
cLean 2001_BT	40	16.40(9.28)	40	23.28(5.29)	-	-0.90 [-1.36, -0.44]
lcLean 2001_CT	33	16.52(6.93)	33	22.00(5.89)	-	-0.84 [-1.35, -0.34]
aylor 2003_Del	15	6.60(2.90)	15	8.30(3.20)	- 1	-0.54 [-1.27, 0.19]
aylor 2003_lmm	11	6.10(3.60)	11	9.70(4.00)	-	-0.91 [-1.80, -0.02]
/anNoppen 1998	73	16.60(6.10)	73	21.80(5.60)	₹	-0.88 [-1.22, -0.54]
	261		264		*	-0.96 [-1.21, -0.71]
st for heterogeneity: Chi² = 15.51, st for overall effect: Z = 7.60 (P <						
Medium intensity						
Bouvard 2002	19	16.94(9.22)	19	27.55(7.15)	-	-1.26 [-1.96, -0.56]
Chambless 1999	49	3.42(1.75)	49	6.68(1.04)	<u>-</u>	-2.25 [-2.76, -1.74]
De Araujo 1995_Ex	23	7.90(3.90)	23	14.10(2.70)	-	-1.82 [-2.51, -1.12]
De Araujo 1995_Exi	23	7.50(3.50)	23	13.80(2.10)	<u>_</u>	-2.29 [-3.04, -1.53]
Emmelkamp 1988 BT	9	12.60(5.40)	9	15.60(2.10)		-0.60 [-1.55, 0.35]
Emmelkamp 1988 CT	9	11.30(1.70)	9	15.60(4.00)		-1.72 [-2.85, -0.60]
Emmelkamp1991 BT	11	11.70(6.10)	11	15.90(4.60)	1	-0.75 [-1.62, 0.12]
mmelkamp1991_CT	10	9.60(6.90)	10	15.80(6.70)		-0.87 [-1.80, 0.05]
Greist 2002 clinicBT	55	17.60(6.20)	55	25.20(4.60)		-1.38 [-1.80, -0.97]
Hiss 1994_associatio	10	9.60(9.60)	10	23.20(4.80)	<u>. I</u>	-1.61 [-2.64, -0.57]
liss 1994_relapse	8	7.88(2.95)	8	23.13(5.41)		-3.31 [-4.95, -1.66]
iiss 1994_16iapse Lindsay 1997	9	11.00(3.81)	9	28.70(4.56)		-4.01 [-5.76, -2.26]
D'Connor 1999	6	13.30(8.60)	6	23.50(4.00)		-1.40 [-2.73, -0.08]
Rothbaum 2000	39	14.61(9.47)	39	24.66(5.59)		-1.40 [-2.73, -0.08]
√an Noppen1997_GBT	17		17		<u> </u>	-0.99 [-1.71, -0.79]
van Noppen1997_GBT √an Noppen1997_MFBT	19	16.60(7.20) 15.60(6.50)	19	23.90(7.20) 23.90(5.40)	*	-0.99 [-1.71, -0.27] -1.36 [-2.07, -0.65]
van Noppen 1995_BT	29	17.30(8.30)	29	25.40(7.00)	-	
van Oppen 1995_bi Van Oppen 1995_CT	29		29 28		<u>-</u>	-1.04 [-1.59, -0.49]
	28 19	13.30(8.50)	28 19	24.10(5.50)	-	-1.49 [-2.08, -0.89]
Vogel 2004_BT		16.10(7.30)		23.70(3.20)		-1.32 [-2.03, -0.61]
Vogel 2004_CBT	16	16.70(7.20)	16	24.90(2.90)	-	-1.46 [-2.25, -0.67]
Whittal2004_BT	37	13.57(9.27)	37	22.38(5.77)	_*	-1.13 [-1.62, -0.64]
//hittal2004_CT	34	11.94(8.21)	34	23.56(4.08)	-	-1.77 [-2.34, -1.21]
	479		479		+	-1.47 [-1.69, -1.25]
est for heterogeneity: Chi² = 43.32, est for overall effect: Z = 12.99 (P						
B High intensity						
Foa 1984 ERP	11	2.55(2.30)	11	6.73(1.21)		-2.19 [-3.29, -1.09]
Foa 1984 Ex	12	4.00(1.99)	12	6.67(1.09)		-1.61 [-2.55, -0.66]
Foa 1984 RP	9	4.33(1.60)	9	6.61(0.78)		-1.73 [-2.85, -0.60]
Foa 1985_Exi	10	5.00(1.27)	10	6.55(0.64)		-1.48 [-2.49, -0.46]
Foa 1985 Exv	9	5.44(1.33)	9	6.44(0.88)		-0.84 [-1.82, 0.13]
oa 1000_EXT	21	11.00(7.90)	29	24.60(4.80)	<u> </u>	-2.13 [-2.84, -1.42]
Freeston1997	15	12.20(9.60)	15	25.10(5.00)	<u> </u>	-1.64 [-2.48, -0.80]
McKay 1996	21	15.00(8.29)	21	30.19(3.68)		-2.32 [-3.12, -1.52]
Veziroglu 2001	20	10.60(3.60)	20	14.50(3.30)	-	-1.11 [-1.78, -0.44]
Rosqvist 2001	11	16.91(5.86)	11	22.46(5.20)		-0.96 [-1.86, -0.07]
	139	10.51(5.00)	147	22.40(3.20)	•	-1.60 [-1.93, -1.27]
ist for heterogeneity: Chi² = 12.85,		D = 0.17) 2 = 20.0%	147		▼	-1.00 [-1.93, -1.27]
est for neterogeneity. Crif = 12.65, est for overall effect: Z = 9.41 (P <						
otal (95% CI)	879		890		•	-1.37 [-1.54, -1.20]
est for heterogeneity: Chi² = 96.31,	df = 42				'	
est for overall effect: Z = 15.78 (P ·	< U.UUU0	n)				
					-10 -5 0 5	10

Review: Comparison: Outcome:

OCD psychological intensity review 02 Before-after analysis 12 Change from baseline to endpoint (Sensitivity Analysis)

Study		End of treatment	Е	Before treatment	SMD (random)	SMD (random)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Low intensity						
Cordioli 2003	23	15.10(7.80)	23	26.70(4.90)	-	-1.75 [-2.44, -1.06]
Emmelkamp 1983_coupl	6	8.00(3.15)	6	16.20(3.15)		-2.40 [-4.03, -0.77]
Emmelkamp 1983_patie	6	8.00(4.02)	6	16.50(4.02)		-1.95 [-3.43, -0.47]
Enright 1991	24	12.96(6.03)	24	15.46(5.12)		-0.44 [-1.01, 0.13]
Fritzler 1997	9	17.11(8.91)	9	22.90(7.27)		-0.68 [-1.64, 0.28]
Hughes 2004	21	16.50(6.00)	24	22.90(4.40)	_	-1.21 [-1.85, -0.57]
McLean 2001 BT	40	16.40(9.28)	40	23.28(5.29)	I	-0.90 [-1.36, -0.44]
McLean 2001_BT	33	16.52(6.93)	33	22.00(5.89)	-	-0.84 [-1.35, -0.34]
Taylor 2003_Del	15	6.60(2.90)	15	8.30(3.20)		-0.54 [-1.33, -0.34]
Taylor 2003_bei	11	6.10(3.60)	11	9.70(4.00)	<u> </u>	-0.91 [-1.80, -0.02]
VanNoppen 1998	73	16.60(6.10)	73	21.80(5.60)		-0.88 [-1.22, -0.54]
Subtotal (95% CI)	261	16.60(6.10)	264	21.00(5.60)	∡	-0.96 [-1.21, -0.71]
		(D = 0.44), IZ = 35.59	264		▼	-0.96 [-1.21, -0.71]
Test for heterogeneity: $Chi^2 = {}^{\circ}$ Test for overall effect: $Z = 7.6$						
02 Medium intensity (excluding		•				
Bouvard 2002	19	16.94(9.22)	19	27.55(7.15)	-	-1.26 [-1.96, -0.56]
Chambless 1999	49	3.42(1.75)	49	6.68(1.04)	+	-2.25 [-2.76, -1.74]
De Araujo 1995_Ex	23	7.90(3.90)	23	14.10(2.70)	-	-1.82 [-2.51, -1.12]
De Araujo 1995_Exi	23	7.50(3.20)	23	13.80(2.10)	-	-2.29 [-3.04, -1.53]
Emmelkamp 1988_BT	9	12.60(5.40)	9	15.60(4.00)	 	-0.60 [-1.55, 0.35]
Emmelkamp 1988_CT	9	11.30(1.70)	9	15.60(2.90)		-1.72 [-2.85, -0.60]
Emmelkamp1991_BT	11	11.70(6.10)	11	15.90(4.60)	 	-0.75 [-1.62, 0.12]
Emmelkamp1991_CT	10	9.60(6.90)	10	15.80(6.70)		-0.87 [-1.80, 0.05]
Greist 2002_clinicBT	55	17.60(6.20)	55	25.20(4.60)	-	-1.38 [-1.80, -0.97]
O'Connor 1999	6	13.30(8.60)	6	23.50(4.00)		-1.40 [-2.73, -0.08]
Rothbaum 2000	39	14.61(9.47)	39	24.66(5.59)	-	-1.28 [-1.77, -0.79]
Van Noppen1997_GBT	17	16.60(7.20)	17	23.90(7.20)		-0.99 [-1.71, -0.27]
Van Noppen1997_MFBT	19	15.60(6.50)	19	23.90(5.40)	-	-1.36 [-2.07, -0.65]
Van Oppen 1995_BT	29	17.30(8.30)	29	25.40(7.00)	-	-1.04 [-1.59, -0.49]
Van Oppen 1995_CT	28	13.30(8.50)	28	24.10(5.50)	-	-1.49 [-2.08, -0.89]
Vogel 2004_BT	19	16.10(7.30)	19	23.70(3.20)	-	-1.32 [-2.03, -0.61]
Vogel 2004 CBT	16	16.70(7.20)	16	24.90(2.90)		-1.46 [-2.25, -0.67]
Whittal2004 BT	37	13.57(9.27)	37	22.38(5.77)	-	-1.13 [-1.62, -0.64]
Whittal2004 CT	34	11.94(8.21)	34	23.56(4.08)	-	-1.77 [-2.34, -1.21]
Subtotal (95% CI)	452		452		+	-1.41 [-1.61, -1.21]
Test for heterogeneity: Chi² = 1		(P = 0.04), I ² = 39.8%			•	
Test for overall effect: Z = 13.						
03 High intensity					_	
Foa 1984_ERP Foa 1984 Ex	11 12	2.55(2.30) 4.00(1.99)	11 12	6.73(1.21) 6.67(1.09)		-2.19 [-3.29, -1.09]
_					-	-1.61 [-2.55, -0.66]
Foa 1984_RP	9	4.33(1.60)	9 10	6.61(0.78)	- <u>-</u>	-1.73 [-2.85, -0.60]
Foa 1985_Exi	10	5.00(1.27)		6.55(0.64)		-1.48 [-2.49, -0.46]
Foa 1985_Exv	9	5.44(1.33)	9	6.44(0.88)		-0.84 [-1.82, 0.13]
Foa 2004	21	11.00(7.90)	29	24.60(4.80)	-	-2.13 [-2.84, -1.42]
Freeston1997	15	12.20(9.60)	15	25.10(5.00)		-1.64 [-2.48, -0.80]
Hiss 1994_associatio	10	9.60(9.60)	10	23.90(7.31)		-1.61 [-2.64, -0.57]
Hiss 1994_relapse	8	7.88(2.95)	8	23.13(5.41)		-3.31 [-4.95, -1.66]
McKay 1996	21	15.00(8.29)	21	30.19(3.68)	-	-2.32 [-3.12, -1.52]
Neziroglu 2001	20	10.60(3.60)	20	14.50(3.30)	-	-1.11 [-1.78, -0.44]
Rosqvist 2001	11	16.91(5.86)	11	22.46(5.20)	,- 1	-0.96 [-1.86, -0.07]
Subtotal (95% CI)	157		165		♦	-1.66 [-1.99, -1.33]
Test for heterogeneity: $Chi^2 = 1$ Test for overall effect: $Z = 9.75$						
Total (95% CI)	870		881		<u>.</u>	_1 24 (_1 51 _1 101
		(D = 0.0004) 12 = 50.00(991		•	-1.34 [-1.51, -1.18]
Test for heterogeneity: Chi ² = 8						
Test for overall effect: Z = 16.	13 (P < 0.000l	יוי)				
					-10 -5 0 5	10

Appendix 17b: Forest plots for clinical evidence reviews on pharmacological interventions

SSRIs (OCD, adults)

Clomipramine (OCD, adults)

TCAs (OCD)

SNRIs (OCD)

MAOIs (OCD)

Anxiolytics (OCD)

Other Pharmacological (OCD)

Augmentation (OCD)

SSRIs (OCD, children)

Clomipramine (OCD, children)


Pharmacological (BDD)

SSRIs (OCD, adults)

Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 01 Adverse events



Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase)


Outcome: 02 Serious adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI	
01 Paroxetine					
Kamijima 2004	3/95	3/94		0.99 [0.20, 4.78]	
Subtotal (95% CI) Total events: 3 (SSRI), 3 (Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.01 (P =		94		0.99 [0.20, 4.78]	
Total (95% CI) Total events: 3 (SSRI), 3 (Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.01 (P =		94		0.99 [0.20, 4.78]	
		0.:	1 0.2 0.5 1 2 5 10		
			Favours SSRI Favours Placebo		

Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 03 Suicide attempts



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 04 Leaving study early

1 Citalopram Montgomery 2001 ubtotal (95% CI) otal events: 46 (SSRI), 17 (Placebo)	46/300 300	17/101		
fontgomery 2001 ubtotal (95% CI)	•	17 (101		
	300	1//101		0.91 [0.55, 1.51]
otal events: 46 (SSRI), 17 (Placebo)		101		0.91 [0.55, 1.51]
			T	
est for heterogeneity; not applicable				
est for overall effect: $Z = 0.36$ (P = 0	.72)			
2 Fluoxetine				
enike 1997	4/23	3/21		1.22 [0.31, 4.82]
Montgomery 1993	41/160	15/57		0.97 [0.59, 1.62]
ubtotal (95% CI)	183	78		1.00 [0.62, 1.62]
otal events: 45 (SSRI), 18 (Placebo)			T	
est for heterogeneity: Chi² = 0.09, df	$= 1 (P = 0.76), I^2 = 09$	6		
est for overall effect: $Z = 0.02$ (P = 0	.99)			
3 Fluvoxamine				
∂oodman 1989	2/23	6/23 ◀		0.33 [0.07, 1.48]
∂oodman 1996	23/80	17/80	+-	1.35 [0.78, 2.33]
follander 2003b	43/127	31/126	 	1.38 [0.93, 2.03]
enike 1990a	0/18	0/20		Not estimable
fallya 1992	5/19	6/20		0.88 [0.32, 2.40]
erse 1987	1/10	1/10		→ 1.00 [0.07, 13.87]
ubtotal (95% CI)	277	279	◆	1.21 [0.91, 1.62]
otal events: 74 (SSRI), 61 (Placebo)				
est for heterogeneity: Chi² = 3.85, df	= 4 (P = 0.43), I ² = 09	6		
est for overall effect: Z = 1.30 (P = 0	.19)			
4 Paroxetine				
Burnham 1993	28/82	20/77	+-	1.31 [0.81, 2.13]
follander 2003d	53/259	15/89	 	1.21 [0.72, 2.04]
Iohar 1996a	49/201	39/99	 -j	0.62 [0.44, 0.87]
ubtotal (95% CI)	542	265	•	0.91 [0.71, 1.16]
otal events: 130 (SSRI), 74 (Placebo)				
est for heterogeneity: Chi² = 8.21 , df est for overall effect: Z = 0.76 (P = 0	, ,,	.6%		
•	•			
5 Sertraline Chouinard 1990	3/43	7/44		0.44 [0.12, 1.59]
Freist 1995a	65/241	24/84		0.94 [0.63, 1.40]
enike 1990b	0/10	0/9	T	Not estimable
(ronig 1999	25/86	25/81		0.94 [0.59, 1.50]
ubtotal (95% CI)	380	218		0.89 [0.67, 1.20]
otal events: 93 (SSRI), 56 (Placebo)	300	210	T	0.05 (0.07, 1.20)
est for heterogeneity: Chi² = 1.30, df	= 2 (P = 0.52) P = 09	6		
est for overall effect: Z = 0.76 (P = 0	, ,,	-		
otal (95% CI)	1682	941	•	0.98 [0.85, 1.13]
otal events: 388 (SSRI), 226 (Placebo			Ţ	
est for heterogeneity: Chi² = 16.94, d	,	23.3%		
est for overall effect: Z = 0.26 (P = 0				
		0.1	0.2 0.5 1 2 5	10
			Favours SSRI Favours placeb	

Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 05 Leaving study early due to adverse events

01 Citalopram			95% CI	95% CI
Montgomery 2001	14/300	2/101		2.36 [0.54, 10.19]
Subtotal (95% CI)	300	101		2.36 [0.54, 10.19]
otal events: 14 (SSRI), 2 (Plac		101		2:00 (0:04, 10:15)
Test for heterogeneity: not appl	-			
Test for overall effect: Z = 1.15				
02 Fluoxetine				
Beasley 1992	59/266	2/89		9.87 [2.46, 39.57]
Montgomery 1993	7/160	2/57		1.25 [0.27, 5.83]
Subtotal (95% CI)	426	146		5.59 [2.06, 15.16]
otal events: 66 (SSRI), 4 (Plac		140		3.35 (2.00, 13.10)
est for heterogeneity: Chi² = 4	,	60/		
est for neterogeneity. Cris = 4 est for overall effect: Z = 3.38		076		
03 Fluvoxamine				
Goodman 1989	2/23	0/23		
Goodman 1996	•	0/23 6/80		— 5.00 [0.25, 98.75]
	15/80	·		2.50 [1.02, 6.12]
Hollander 2003b	23/127	8/126		2.85 [1.33, 6.13]
Subtotal (95% CI)	230	229	-	2.78 [1.57, 4.92]
otal events: 40 (SSRI), 14 (Pla	,			
「est for heterogeneity: Chi² = 0 「est for overall effect: Z = 3.51				
04 Paroxetine				
Burnham 1993	15/82	8/77	 -	1.76 [0.79, 3.92]
Hollander 2003d	29/259	7/89	- 	1.42 [0.65, 3.14]
Kamijima 2004	9/95	9/96		1.01 [0.42, 2.43]
Zohar 1996a	18/201	6/99		1.48 [0.61, 3.61]
Subtotal (95% CI)	637	361	•	1.41 [0.93, 2.14]
otal events: 71 (SSRI), 30 (Pla				
est for heterogeneity: Chi² = 0		,		
est for overall effect: Z = 1.62				
05 Sertraline				
Chouinard 1990	1/43	0/44		— 3.07 [0.13, 73.30]
Greist 1995a	23/241	5/84		1.60 [0.63, 4.08]
Kronig 1999	9/86	4/81		2.12 [0.68, 6.61]
Subtotal (95% CI)	370	209		1.84 [0.91, 3.71]
otal events: 33 (SSRI), 9 (Placi		200		2.01 (0.51, 0.71)
est for heterogeneity: Chi² = 0				
est for overall effect: Z = 1.70				
otal (95% CI)	1963	1046	•	2.15 [1.62, 2.86]
otal events: 224 (SSRI), 59 (Pl			•	2122 (2112)
fest for heterogeneity: Chi² = 1 fest for overall effect: Z = 5.30	1.30, df = 12 (P = 0.50), l² = 0	9%		
23. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3	. (0.01	0.1 1 10	100
		0.01	Favours SSRI Favours placeb	


Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 06 Non-responders (OCD) (CGI or Y-BOCS)

Study SSRI

or sub-cetegory pM



0.90 [0.69, 1.18]

0.90 [0.69, 1.18]

10

18/23

23

20/23

23

0.1 0.2

0.5

Favours SSRI Favours placebo


Goodman 1989

Subtotal (95% CI)

Total events: 18 (SSRI), 20 (Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.77 (P = 0.44) Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 08 Non-remitters



Favours SSRI Favours placebo

Review: Comparison: Outcome: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) 09 Y-BOCS

Study or sub-category I	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Citalopram						
2 /	102	-8.40(7.30)	101	-5.60(6.90)		-0.39 [-0.67, -0.11]
	102		101		•	-0.39 [-0.67, -0.11]
Test for heterogeneity: not applicable						
Fest for overall effect: Z = 2.77 (P = 1	0.006)					
02 Fluoxetine						
Beasley 1992	75	18.90(8.30)	76	23.60(7.50)		-0.59 [-0.92, -0.27]
Jenike 1997	19	16.20(6.30)	18	18.70(6.10)	 +	-0.39 [-1.05, 0.26]
Montgomery 1993	52	-5.13(6.41)	56	-3.70(5.98)		-0.23 [-0.61, 0.15]
	146		150		◆	-0.43 [-0.66, -0.20]
[est for heterogeneity: Chi² = 2.03, d [est for overall effect: Z = 3.66 (P = □		= 0.36), I² = 1.5%				
•	,					
03 Fluvoxamine						
Goodman 1989	21	19.40(7.00)	21	28.00(7.00)		-1.21 [-1.87, -0.54]
Goodman 1996	78	-3.95(6.28)	78	-1.71(4.88)		-0.40 [-0.71, -0.08]
	117	-8.50(7.57)	120	-5.60(7.67)	-	-0.38 [-0.64, -0.12]
Jenike 1990a	18	18.80(4.00)	20	21.80(7.60)		-0.48 [-1.12, 0.17]
	234		239		◆	-0.46 [-0.64, -0.27]
Γest for heterogeneity: Chi² = 5.39, d Γest for overall effect: Z = 4.88 (P < ι						
04 Paroxetine						
Burnham 1993	79	-5.61(7.47)	75	-4.60(7.53)	-	-0.13 [-0.45, 0.18]
Kamijima 2004	94	-8.11(8.00)	94	-3.46(6.10)	-	-0.65 [-0.94, -0.36]
Zohar 1996a	198	-8.00(8.00)	99	-5.00(7.90)	-	-0.38 [-0.62, -0.13]
Subtotal (95% CI)	371		268		•	-0.40 [-0.56, -0.23]
「est for heterogeneity: Chi² = 5.56, d 「est for overall effect: Z = 4.82 (P < I						
05 Sertraline						
Jenike 1990b	10	20.60(9.20)	8	22.30(7.80)		-0.19 [-1.12, 0.74]
Subtotal (95% CI)	10		8		-	-0.19 [-1.12, 0.74]
lest for heterogeneity: not applicable	9				7	
est for overall effect: Z = 0.40 (P =	0.69)					
Total (95% CI)	863		766		•	-0.42 [-0.52, -0.32]
Test for heterogeneity: Chi ² = 13.50,	df = 11	(P = 0.26), I ² = 18.5%			•	
「est for overall effect: Z = 8.23 (P < I	0.00001)				
· · ·				-4	-2 0 2	4
				-4	Favours SSRI Favours place	•

Outcome: 10 NIMH-OC SMD (fixed) SMD (fixed) Study Placebo or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Citalopram Montgomery 2001 102 -2.80(2.50) 101 -1.80(2.30) -0.41 [-0.69, -0.14] Subtotal (95% CI) 102 101 -0.41 [-0.69, -0.14] Test for heterogeneity: not applicable Test for overall effect: Z = 2.92 (P = 0.003) Jenike 1997 19 7.00(1.10) 18 7.20(1.30) -0.16 [-0.81, 0.48] Subtotal (95% CI) 19 18 -0.16 [-0.81, 0.48] Test for heterogeneity: not applicable Test for overall effect: Z = 0.49 (P = 0.62) 03 Fluvoxamine Goodman 1996 78 -1.32(2.25) 78 -0.40(1.78) -0.45 [-0.77, -0.13] Jenike 1990a 20 -0.65 [-1.31, 0.00] 18 8.00(2.20) Subtotal (95% CI) 96 98 -0.49 [-0.78, -0.20] Test for heterogeneity: Chi² = 0.30, df = 1 (P = 0.59), l² = 0% Test for overall effect: Z = 3.36 (P = 0.0008) 04 Paroxetine -0.18 [-0.50, 0.13] 75 Burnham 1993 79 -1.42(2.04)-1.04(2.08)-0.38 [-0.62, -0.14] -0.31 [-0.50, -0.11] Zohar 1996a 198 -2.50(2.90) 99 -1.40(2.90) Subtotal (95% CI) Test for heterogeneity: $Chi^2 = 0.91$, df = 1 (P = 0.34), $I^2 = 0\%$ Test for overall effect: Z = 3.11 (P = 0.002)05 Sertraline Jenike 1990b 8.20(2.00) 9 9.30(2.50) -0.47 [-1.38, 0.45] Subtotal (95% CI) 10 -0.47 [-1.38, 0.45] Test for heterogeneity: not applicable Test for overall effect: Z = 1.00 (P = 0.32)Total (95% CI) 400 -0.37 [-0.50, -0.23] Test for heterogeneity: Chi² = 2.84, df = 6 (P = 0.83), l² = 0% Test for overall effect: Z = 5.39 (P < 0.00001)Favours SSRI Favours placebo OCD adults: SSRIs Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 11 General Rating Scale: compulsions SSRI SMD (fixed) SMD (fixed) Study Placebo or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Fluvoxamine -0.74 [-1.76, 0.29] Perse 1987 3.56(2.00) 5.12(2.00) Subtotal (95% CI) -0.74 [-1.76, 0.29] Test for heterogeneity: not applicable Test for overall effect: Z = 1.41 (P = 0.16) 10 Favours SSRI Favours placebo Review: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) Comparison: Outcome: 12 General Rating Scale: obsessions Study SSRI Placebo SMD (fixed) SMD (fixed) Mean (SD) Ν or sub-category Ν Mean (SD) 95% CI 95% CI 01 Fluvoxamine Perse 1987 3.07(1.98) 8 4.31(2.67) -0.50 [-1.50, 0.50] Subtotal (95% CD) -0.50 [-1.50, 0.50] Test for heterogeneity: not applicable Test for overall effect: Z = 0.98 (P = 0.33) -10 -5 10 Favours SSRI Favours placebo Review: OCD adults: SSRIs Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 13 Maudsley Obsessive Compulsive Inventory SMD (fixed) Study Placebo SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Fluvoxamine Perse 1987 8 13.87(5.32) 8 16.12(4.59) -0.43 [-1.42, 0.57] Subtotal (95% CI) -0.43 [-1.42, 0.57] Test for heterogeneity: not applicable Test for overall effect: Z = 0.84 (P = 0.40)

Favours SSRI Favours placebo

Review:

Comparison:

OCD adults: SSRIs

01 SSRIs vs placebo (acute phase)

Review: OCD adults: SSRIs Comparison: 01 SSRIs vs placebo (acute phase) 14 Obsessive-Compulsive Checklist Outcome: Study or sub-category Ν 01 Fluvoxamine Perse 1987 Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.85 (P = 0.39) Review: OCD adults: SSRIs

Placebo SMD (fixed) SMD (fixed) Mean (SD) Ν Mean (SD) 95% CI 95% CI -0.43 [-1.43, 0.56] -0.43 [-1.43, 0.56] 20.06(12.92) 26.19(13.88) -10 10

Favours SSRI Favours placebo

Favours SSRI Favours placebo

Favours SSRI Favours placebo

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 15 OCD Scale (CPRS)

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Fluoxetine										
Jenike 1997	19	6.70(2.60)	18	5.80(3.30)			=			0.30 [-0.35, 0.95]
Subtotal (95% CI)	19		18				₩.			0.30 [-0.35, 0.95]
Test for heterogeneity: not	: applicable						ľ			
Test for overall effect: Z =	0.90 (P = 0.37)									
					-10	-5	 	5	10	

Review: OCD adults: SSRIs

Comparison: 01 SSRIs vs placebo (acute phase) 16 Beck Depression Inventory Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		5	SMD (fixed) 95% CI			SMD (fixed) 95% Cl
01 Fluvoxamine										
Perse 1987	8	9.73(7.51)	8	12.37(7.56)			-			-0.33 [-1.32, 0.66]
Subtotal (95% CI)	8		8				•			-0.33 [-1.32, 0.66]
Test for heterogeneity: not	t applicable						7			
Test for overall effect: Z =	0.66 (P = 0.51)									
					-10	-5	-	5	10	

OCD adults: SSRIs Review:

Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 17 Hamilton Rating Scale for Depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Fluoxetine						
Montgomery 1993	52	-1.85(6.04)	56	-1.34(6.92)	<u> </u>	-0.08 [-0.46, 0.30]
Subtotal (95% CI)	52		56		•	-0.08 [-0.46, 0.30]
Test for heterogeneity: not	applicable				Ţ	,
Test for overall effect: Z =	0.40 (P = 0.69)					
02 Fluvoxamine						
Perse 1987	8	9.47(5.55)	8	12.93(5.02)		-0.62 [-1.63, 0.39]
Subtotal (95% CI)	8		8			-0.62 [-1.63, 0.39]
Test for heterogeneity: not	applicable				_	
Test for overall effect: Z =	1.20 (P = 0.23)					
Total (95% CI)	60		64		•	-0.14 [-0.50, 0.21]
Test for heterogeneity: Chi	2 = 0.96, df = 1 (P	= 0.33), I ² = 0%			٦	
Test for overall effect: Z =		**				
					-4 -2 0 2	4
					Favours SSRI Favours pl	acebo

Review: OCD adults: SSRIs Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 18 Montgomery-Asberg Depression Rating Scale SMD (fixed) SMD (fixed) Study Placebo or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Citalopram -0.32 [-0.60, -0.04] Montgomery 2001 102 -3.40(6.30) 101 -1.30(6.70) Subtotal (95% CI) 102 101 -0.32 [-0.60, -0.04] Test for heterogeneity: not applicable Test for overall effect: Z = 2.28 (P = 0.02) 02 Fluoxetine Montgomery 1993 52 -2.96(8.09) 56 -2.88(9.27) -0.01 [-0.39, 0.37] Subtotal (95% CI) 52 56 -0.01 [-0.39, 0.37] Test for heterogeneity: not applicable Test for overall effect: Z = 0.05 (P = 0.96) 03 Paroxetine Zohar 1996a 198 -3.40(7.90) 99 -0.60(7.90) -0.35 [-0.60, -0.11] -0.35 [-0.60, -0.11] Subtotal (95% CI) 198 Test for heterogeneity: not applicable Test for overall effect: Z = 2.85 (P = 0.004) Total (95% CI) 256 -0.28 [-0.44, -0.11] 352 Test for heterogeneity: $Chi^2 = 2.42$, df = 2 (P = 0.30), $I^2 = 17.2\%$ Test for overall effect: Z = 3.30 (P = 0.0010) 0.5 -0.5 Favours SSRI Favours placebo Review: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) Comparison: Outcome: 19 Hamilton Anxiety Scale Study SSRI Placebo SMD (fixed) SMD (fixed) Mean (SD) N or sub-category Ν Mean (SD) 95% CI 95% CI 01 Fluvoxamine Perse 1987 7.69(3.60) 12.37(7.56) -0.75 [-1.77, 0.28] Subtotal (95% CI) -0.75 [-1.77, 0.28] Test for heterogeneity; not applicable Test for overall effect: Z = 1.43 (P = 0.15) -10 10 Favours SSRI Favours placebo OCD adults: SSRIs Review: Comparison: 01 SSRIs vs placebo (acute phase) Outcome: 20 Clinical Global Impression SSRI SMD (fixed) SMD (fixed) Study Placebo or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 01 Fluoxetine Jenike 1997 19 3.10(1.00) 18 3.20(1.00) -0.10 [-0.74, 0.55] -0.10 [-0.74, 0.55] Subtotal (95% CI) 19 Test for heterogeneity: not applicable Test for overall effect: Z = 0.30 (P = 0.77) -10 10 -5 Favours SSRI Favours placebo Review: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) Comparison: 21 Clinical Global Impressions: severity Outcome: Study SSRI Placebo SMD (fixed) SMD (fixed) Mean (SD) Ν Mean (SD) 95% CI or sub-category 95% CI 01 Paroxetine Zohar 1996a 194 -1.20(1.40) 99 -0.70(1.30) -0.36 [-0.61, -0.12] Subtotal (95% CI) 194 99 -0.36 [-0.61, -0.12] Test for heterogeneity: not applicable Test for overall effect: Z = 2.93 (P = 0.003) -10 -5 0 5 10 Favours SSRI Favours placebo OCD adults: SSRIs Review: Comparison 01 SSRIs vs placebo (acute phase) Outcome: 22 Sheehan Disability Scale: family Study SSRI Placebo SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI

> -0.33 [-0.61, -0.06] -0.33 [-0.61, -0.06]

102

-1.80(2.40)

101

-1.00(2.40)

Favours SSRI Favours placebo

01 Citalopram Montgomery 2001

Test for heterogeneity: not applicable Test for overall effect: Z = 2.35 (P = 0.02)

01 SSRIs vs placebo (acute phase) 23 Sheehan Disability Scale: social Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			SMD (fixe 95% CI			SMD (fixed) 95% Cl
O1 Citalopram Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		-2.00(2.20)	101 101	-1.30(2.00)			•			-0.33 [-0.61, -0.05] -0.33 [-0.61, -0.05]
					-10	-5	ó	5	10	
						Favours	SSRI Fa	vours plac	ebo	

Review: Comparison: OCD adults: SSRIs 01 SSRIs vs placebo (acute phase) Outcome: 24 Sheehan Disability Scale: work

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	S	MD (fixed) 95% CI		SMD (fixed) 95% Cl
01 Citalopram								
Montgomery 2001	102	-1.90(2.40)	101	-1.10(2.10)				-0.35 [-0.63, -0.08]
Subtotal (95% CI)	102		101			•		-0.35 [-0.63, -0.08]
Test for heterogeneity: not a	pplicable					Ì		
Test for overall effect: $Z = 2$.50 (P = 0.01)							

Review: OCD adults: SSRIs

01 SSRIs vs placebo (acute phase) Comparison: Outcome: 25 Symptom Checklist-90

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			D (fixed) 5% Cl			SMD (fixed) 95% Cl
01 Paroxetine										
Zohar 1996a	169	-29.00(47.10)	77	-19.50(37.30)						-0.21 [-0.48, 0.06]
Subtotal (95% CI)	169		77				₹			-0.21 [-0.48, 0.06]
Test for heterogeneity: not	t applicable						1			
Test for overall effect: Z =	1.55 (P = 0.12)									
-					-10	-5	 	5	10	

Favours SSRI Favours placebo

Favours SSRI Favours placebo

OCD adults: SSRIs Review:

Comparison: 01 SSRIs vs placebo (acute phase)

Outcome: 26 Subanalysis: Y-BOCS in patients with comorbid depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
02 Fluoxetine						
Beasley 1992	75	18.90(8.30)	76	23.60(7.50)	-	-0.59 [-0.92, -0.27]
Montgomery 1993	52	-5.13(6.41)	56	-3.70(5.98)	- 	-0.23 [-0.61, 0.15]
Subtotal (95% CI)	127		132		•	-0.44 [-0.68, -0.19]
Test for heterogeneity: Chi² =	= 2.02, df = 1 (P	= 0.16), I ² = 50.4%			*	•
Test for overall effect: $Z = 3$.	47 (P = 0.0005)					
03 Fluvoxamine						
Goodman 1989	21	19.40(7.00)	21	28.00(7.00)		-1.21 [-1.87, -0.54]
Subtotal (95% CI)	21		21		•	-1.21 [-1.87, -0.54]
Test for heterogeneity: not ap	pplicable				-	
Test for overall effect: $Z = 3$.	56 (P = 0.0004)	l				
04 Paroxetine						
Kamijima 2004	94	-8.11(8.00)	94	-3.46(6.10)	-	-0.65 [-0.94, -0.36]
Subtotal (95% CI)	94		94		•	-0.65 [-0.94, -0.36]
Test for heterogeneity: not ap	pplicable				•	
Test for overall effect: $Z = 4$.	35 (P < 0.0001)	l				
Total (95% CI)	242		247		•	-0.58 [-0.76, -0.40]
Test for heterogeneity: Chi ² =	6.94, df = 3 (P	= 0.07), I ² = 56.8%			•	
Test for overall effect: $Z = 6$.	22 (P < 0.00001)				

Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 27 Subanalysis: Non-responders (OCD) (CGI or Y-BOCS) in patients with comorbid depression

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
02 Fluoxetine				
Beasley 1992	190/266	82/89	-	0.78 [0.70, 0.85]
Montgomery 1993	92/160	46/57		0.71 [0.59, 0.86]
Subtotal (95% CI)	426	146	•	0.75 [0.69, 0.82]
Total events: 282 (SSRI), 128	3 (Placebo)		-	
Test for heterogeneity: Chi2 :	$= 0.69$, df $= 1 (P = 0.41)$, $I^2 = 0$?	6		
Test for overall effect: $Z = 6$.18 (P < 0.00001)			
04 Paroxetine				
Kamijima 2004	48/95	74/96		0.66 [0.52, 0.82]
Subtotal (95% CI)	95	96		0.66 [0.52, 0.82]
Total events: 48 (SSRI), 74 (I	Placebo)		_	
Test for heterogeneity: not a	pplicable			
Test for overall effect: $Z = 3$.65 (P = 0.0003)			
Total (95% CI)	521	242	•	0.73 [0.66, 0.79]
Total events: 330 (SSRI), 202			•	,
	= 2.58, df = 2 (P = 0.28), l² = 22	2.4%		
Test for overall effect: Z = 7				
		0.5	0.7 1 1.5	2
			Favours SSRI Favours placel	00

Review: OCD adults: SSRIs

Comparison: OCD adults: SSRIs
Outcome: O1 Adverse events
OCD adults: SSRIs
OUtcome: O1 Adverse events

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
	ram 20mg			
Montgomery 2001	67/98	74/102		0.94 [0.79, 1.13]
Subtotal (95% CI)	98	102	-	0.94 [0.79, 1.13]
Total events: 67 (Dose 1), 74 ((Dose 2)		-	
Test for heterogeneity: not app	olicable			
Test for overall effect: $Z = 0.6$	5 (P = 0.52)			
02 Citalopram 60mg vs Citalopi	ram 20mg			
Montgomery 2001	72/100	74/102		0.99 [0.84, 1.18]
Subtotal (95% CI)	100	102	•	0.99 [0.84, 1.18]
Total events: 72 (Dose 1), 74 ((Dose 2)		Ī	
Test for heterogeneity: not app	olicable			
Test for overall effect: $Z = 0.0$	9 (P = 0.93)			
03 Citalopram 60mg vs Citalopi	ram 40mg			
Montgomery 2001	72/100	67/98		1.05 [0.88, 1.26]
Subtotal (95% Cl)	100	98		1.05 [0.88, 1.26]
Total events: 72 (Dose 1), 67 ((Dose 2)			
Test for heterogeneity: not app	olicable			
Test for overall effect: $Z = 0.5$	6 (P = 0.58)			
04 Sertraline rapid titration vs :	slow titration			
Bogetto 2002	13/17	11/15		1.04 [0.70, 1.56]
Subtotal (95% CI)	17	15		1.04 [0.70, 1.56]
Total events: 13 (Dose 1), 11 ((Dose 2)			
Test for heterogeneity: not app				
Test for overall effect: $Z = 0.2$				


Favours Dose 1 Favours Dose 2

Review: Comparison: Outcome:

OCD adults: SSRIs 02 SSRIs at different doses (acute phase) 02 Leaving study early


Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
D1 Citalopram 40mg vs Citalopr Montgomery 2001 Subtotal (95% CI) fotal events: 15 (Dose 1), 16 (i fest for heterogeneity: not app fest for overall effect: Z = 0.07	15/98 98 Dose 2) Jlicable	16/102 102	+	0.98 [0.51, 1.86] 0.98 [0.51, 1.86]
2 Citalopram 60mg vs Citalopr Montgomery 2001 Subtotal (95% CI) otal events: 15 (Dose 1), 16 (I est for heterogeneity: not app est for overall effect: Z = 0.14	15/100 100 Dose 2) Jlicable	16/102 102	+	0.96 [0.50, 1.83] 0.96 [0.50, 1.83]
3 Citalopram 60mg vs Citalopr Montgomery 2001 Subtotal (95% CI) otal events: 15 (Dose 1), 15 (i est for heterogeneity not app est for overall effect: Z = 0.06	ram 40mg 15/100 100 Dose 2) Jlicable	15/98 98	+	0.98 [0.51, 1.89] 0.98 [0.51, 1.89]
14 Fluoxetine 40mg vs Fluoxeti Montgomery 1993 Subtotal (95% CI) Total events: 13 (Dose 1), 14 (Test for heterogeneity, not app Test for overall effect: Z = 0.17	ine 20mg 13/52 52 Dose 2) Jlicable	14/53 53	+	0.95 [0.49, 1.81] 0.95 [0.49, 1.81]
IS Fluoxetine 60mg vs Fluoxeti Montgomery 1993 Subtotal (95% CI) Total events: 14 (Dose 1), 14 (Test for heterogeneity: not app Test for overall effect: Z = 0.11	ine 20mg 14/55 55 Dose 2) Jlicable	14/53 53	+	0.96 [0.51, 1.82] 0.96 [0.51, 1.82]
06 Fluoxetine 60mg vs Fluoxeti Montgomery 1993 Subtotal (95% CI) fotal events: 14 (Dose 1), 13 (I fest for heterogeneity: not app fest for overall effect: Z = 0.05	ine 40mg 14/55 55 Dose 2) Jiicable	13/52 52	+	1.02 [0.53, 1.96] 1.02 [0.53, 1.96]
17 Paroxetine 40mg vs Paroxel Hollander 2003d Subtotal (95% CI) Sotal events: 20 (Dose 1), 14 (I Sest for heterogeneity: not app Sest for overall effect: Z = 1.21	tine 20mg 20/86 86 Dose 2) Jlicable	14/88 88	-	1.46 [0.79, 2.70] 1.46 [0.79, 2.70]
i8 Paroxetine 60mg vs Paroxet Hollander 2003d Subtotal (95% CI) otal events: 19 (Dose 1), 14 (I est for heterogeneity: not app	tine 20mg 19/85 85 Dose 2) Jicable	14/88 88	-	1.41 [0.75, 2.62] 1.41 [0.75, 2.62]
est for overall effect: Z = 1.07 9 Paroxetine 60mg vs Paroxet Hollander 2003d Hubtotal (95% CI) Otal events: 19 (Dose 1), 20 (I) est for heterogeneity: not app	tine 40mg 19/85 85 Dose 2) Jicable	20/86 86	+	0.96 [0.55, 1.67] 0.96 [0.55, 1.67]
est for overall effect: Z = 0.14 0 Sertraline 100mg vs Sertrali Greist 1995a Subtotal (95% CI) otal events: 27 (Dose 1), 17 (i est for heterogeneity: not app est for overall effect: Z = 1.88	ine 50mg 27/81 81 Dose 2) Jicable	17/80 80	-	1.57 [0.93, 2.64] 1.57 [0.93, 2.64]
est for overall effect. Z = 1, as 1 Sertraline 200mg vs Sertrali 3 September 1995a Subtotal (95% CI) 5 CI) 5 CI) 6 Set for heterogeneity: not app 6 est for overall effect: Z = 0,74	ine 50mg 21/80 80 Dose 2) Jicable	17/80 80	-	1.24 [0.71, 2.16] 1.24 [0.71, 2.16]
est for overall effect: Z = 0.74 2 Sertraline 200mg vs Sertrali Greist 1995a ubtotal (95% Cl) otal events: 21 (Dose 1), 27 (l est for heterogeneity: not app est for overall effect: Z = 0.95	ine 100mg 21/80 80 Dose 2) Jicable	27/81 81	-	0.79 [0.49, 1.27] 0.79 [0.49, 1.27]
3 Sertraline rapid titration vs s Bogetto 2002 Subtotal (95% CI) Total events: 3 (Dose 1), 2 (Do Test for heterogeneity: not app	slow titration 3/17 17 ise 2)	2/15 15		- 1.32 [0.25, 6.88] - 1.32 [0.25, 6.88]

Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 03 Leaving study early due to adverse events



Comparison: 02 SSRIs at different doses (acute phase)

Outcome: 04 Non-responders



02 SSRIs at different doses (acute phase) 05 Y-BOCS Comparison:

Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
01 Citalopram 40mg vs Citaloprar Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 0.49 (98 98 able	-8.90(7.00)	102 102	-8.40(7.30)	=	-0.07 [-0.35, 0.21] -0.07 [-0.35, 0.21]
02 Citalopram 60mg vs Citaloprar Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 1.98 (100 100 able	-10.40(6.90)	102 102	-8.40(7.30)	₹	-0.28 [-0.56, 0.00] -0.28 [-0.56, 0.00]
03 Citalopram 60mg vs Citaloprar Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 1.51 (100 100 able	-10.40(6.90)	98 98	-8.90(7.00)	₹	-0.22 [-0.49, 0.06] -0.22 [-0.49, 0.06]
04 Fluoxetine 40mg vs Fluoxetine Beasley 1992 Montgomery 1993 Subtotal (95% Cl) Test for heterogeneity: Chi² = 0.3 Test for overall effect: Z = 0.26 (67 52 119 85, df = 1 (F	18.10(7.90) -4.76(6.89) P = 0.55), P = 0%	75 52 127	18.90(8.30) -5.13(6.41)	-	-0.10 [-0.43, 0.23] 0.06 [-0.33, 0.44] -0.03 [-0.28, 0.22]
05 Fluoxetine 60mg vs Fluoxetine Beasley 1992 Montgomery 1993 Subtotal (95% Ct) Test for heterogeneity: Chi² = 0.2 Test for overall effect: Z = 1.63 (68 54 122 21, df = 1 (F	16.80(7.80) -6.07(6.92) P=0.64), P=0%	75 52 127	18.90(8.30) -5.13(6.41)	-	-0.26 [-0.59, 0.07] -0.14 [-0.52, 0.24] -0.21 [-0.46, 0.04]
06 Fluoxetine 60mg vs Fluoxetine Beasley 1992 Montgomery 1993 Subtotal (95% Cl) Test for heterogeneity: Chi ² = 0.0 Test for overall effect; Z = 1.36 (68 54 122)1, df = 1 (F	16.80(7.80) -6.07(6.92) P=0.93), P=0%	67 52 119	18.10(7.90) -4.76(6.89)	-	-0.16 [-0.50, 0.17] -0.19 [-0.57, 0.19] -0.18 [-0.43, 0.08]
07 Sertraline rapid titration vs slo Bogetto 2002 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 0.71 (w titration 14 14 able	12.43(3.78)	13 13	13.54(4.03)	-	-0.28 [-1.03, 0.48] -0.28 [-1.03, 0.48]
Review: OCD adults: SS Comparison: 02 SSRIs at diff Outcome: 06 NIMH-OC		es (acute phase)			-4 -2 0 2 4 Favours Dose 1 Favours Dose 2	
Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Citalopram 40mg vs Citalopram Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 0.27 (98 98 able	-2.90(2.80)	102 102	-2.80(2.50)	+	-0.04 [-0.31, 0.24] -0.04 [-0.31, 0.24]
02 Citalopram 60mg vs Citaloprar Montgomery 2001 Subtotal (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 0.83 (100 100 able	-3.10(2.60)	102 102	-2.80(2.50)	-	-0.12 [-0.39, 0.16] -0.12 [-0.39, 0.16]

98 98

-2.90(2.80)

-3.10(2.60)

-0.07 [-0.35, 0.20] -0.07 [-0.35, 0.20]

0.5

-0.5

Favours Dose 1 Favours Dose 2

03 Citalopram 60mg vs Citalopram 40mg Montgomery 2001 100 Subtotal (95% CI) 100

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)

02 SSRIs at different doses (acute phase) 07 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine 40mg vs Fluox	etine 20mg					
Montgomery 1993	52	-2.55(6.77)	52	-1.85(6.04)		-0.11 [-0.49, 0.28]
Subtotal (95% CI)	52		52			-0.11 [-0.49, 0.28]
Test for heterogeneity: not a	pplicable					•
Test for overall effect: Z = 0						
02 Fluoxetine 60mg vs Fluox	etine 20mg					
Montgomery 1993	54	-3.41(6.23)	52	-1.85(6.04)		-0.25 [-0.63, 0.13]
Subtotal (95% CI)	54		52			-0.25 [-0.63, 0.13]
Test for heterogeneity: not a	pplicable					
Test for overall effect: Z = 1	.29 (P = 0.20)					
03 Fluoxetine 60mg vs Fluox	etine 40mg					
Montgomery 1993	54	-3.41(6.23)	52	-2.55(6.77)		-0.13 [-0.51, 0.25]
Subtotal (95% CI)	54		52			-0.13 [-0.51, 0.25]
Test for heterogeneity: not a	pplicable					•
Test for overall effect: $Z = 0$.	.68 (P = 0.50)					
					1 -0.5 0 0.5	1

Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 08 Montgomery-Asberg Depression Rating Scale

Study		Dose 1		Dose 2	SMD (fixed)	SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI
01 Citalopram 40mg vs Citalopram 2	20mg					
Montgomery 2001	98	-3.90(5.20)	102	-3.40(6.30)		-0.09 [-0.36, 0.19]
Subtotal (95% CI)	98		102			-0.09 [-0.36, 0.19]
Test for heterogeneity: not applicab	ole				-	
Fest for overall effect: Z = 0.61 (P =	= 0.54)					
02 Citalopram 60mg vs Citalopram 2	20ma					
Montgomery 2001	100	-4.00(6.50)	102	-3.40(6.30)	 _	-0.09 [-0.37, 0.18]
Subtotal (95% CI)	100		102			-0.09 [-0.37, 0.18]
Test for heterogeneity: not applicab	ole					
Test for overall effect: Z = 0.66 (P =						
03 Citalopram 60mg vs Citalopram 4	10ma					
Montgomery 2001	100	-4.00(6.50)	98	-3.90(5.20)		-0.02 [-0.30, 0.26]
Subtotal (95% CI)	100	,,	98		_	-0.02 [-0.30, 0.26]
Test for heterogeneity: not applicab	ole					
Test for overall effect: Z = 0.12 (P =						
04 Fluoxetine 40mg vs Fluoxetine 2	!Omq					
Montgomery 1993	52	-5.20(8.19)	52	-2.96(8.09)		-0.27 [-0.66, 0.11]
Subtotal (95% CI)	52		52			-0.27 [-0.66, 0.11]
Test for heterogeneity: not applicab	ole					
est for overall effect: Z = 1.39 (P =						
05 Fluoxetine 60mg vs Fluoxetine 2	!Oma					
Montgomery 1993	54	-5.20(8.73)	52	-2.96(8.09)		-0.26 [-0.65, 0.12]
Subtotal (95% CI)	54		52			-0.26 [-0.65, 0.12]
Test for heterogeneity: not applicab	ole					
Test for overall effect: Z = 1.35 (P =						
06 Fluoxetine 60mg vs Fluoxetine 4	Omg					
Montgomery 1993	54	-5.20(8.73)	52	-5.20(8.19)		0.00 [-0.38, 0.38]
Subtotal (95% CI)	54		52		-	0.00 [-0.38, 0.38]
Test for heterogeneity: not applicab						
Test for overall effect: Z = 0.00 (P =						
				-1	-0.5 0 0.5	1

Favours Dose 1 Favours Dose 2

02 SSRIs at different doses (acute phase) 09 Sheehan Disability Score: family Comparison: Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
	oram 20mg					
Montgomery 2001	98	-2.10(2.30)	102	-1.80(2.40)	 _	-0.13 [-0.40, 0.15]
Subtotal (95% CI)	98		102			-0.13 [-0.40, 0.15]
est for heterogeneity: not ap	plicable				-	
Fest for overall effect: $Z = 0$.	90 (P = 0.37)					
02 Citalopram 60mg vs Citalop	oram 20mg					
Montgomery 2001	100	-2.30(2.40)	102	-1.80(2.40)		-0.21 [-0.48, 0.07]
Subtotal (95% CI)	100		102			-0.21 [-0.48, 0.07]
est for heterogeneity: not ap	plicable				-	
est for overall effect: $Z = 1$.	47 (P = 0.14)					
3 Citalopram 60mg vs Citalo	oram 40mg					
Montgomery 2001	100	-2.30(2.40)	98	-2.10(2.30)		-0.08 [-0.36, 0.19]
Subtotal (95% CI)	100		98			-0.08 [-0.36, 0.19]
est for heterogeneity: not ap	plicable				7	•
Test for overall effect: $Z = 0$.	60 (P = 0.55)					

Favours Dose 1 Favours Dose 2

Favours Dose 1 Favours Dose 2

Favours Dose 1 Favours Dose 2

Review:

OCD adults: SSRIs 02 SSRIs at different doses (acute phase) 10 Sheehan Disability Score: social Comparison: Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Citalopram 40mg vs Citalo	pram 20mg					
Montgomery 2001	98	-1.90(2.30)	102	-2.00(2.20)		0.04 [-0.23, 0.32]
Subtotal (95% CI)	98		102			0.04 [-0.23, 0.32]
est for heterogeneity: not a	pplicable				Γ	
est for overall effect: Z = 0	.31 (P = 0.75)					
) 2 Citalopram 60mg vs Citalo	pram 20mg					
Montgomery 2001	100	-2.40(2.50)	102	-2.00(2.20)		-0.17 [-0.45, 0.11]
Subtotal (95% CI)	100		102			-0.17 [-0.45, 0.11]
est for heterogeneity; not a	pplicable				-	
est for overall effect: Z = 1	.20 (P = 0.23)					
03 Citalopram 60mg vs Citalo	pram 40mg					
Montgomery 2001	100	-2.40(2.50)	98	-1.90(2.30)		-0.21 [-0.49, 0.07]
Subtotal (95% CI)	100		98		-	-0.21 [-0.49, 0.07]
est for heterogeneity; not a	pplicable					
est for overall effect: Z = 1						

Review: OCD adults: SSRIs

02 SSRIs at different doses (acute phase) 11 Sheehan Disability Score: work Comparison: Outcome:

Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
	ram 20mg					
Montgomery 2001	98	-2.10(2.30)	102	-1.90(2.40)		-0.08 [-0.36, 0.19]
Subtotal (95% CI)	98		102			-0.08 [-0.36, 0.19]
Test for heterogeneity: not ap	plicable				-	
Test for overall effect: $Z = 0.6$	60 (P = 0.55)					
02 Citalopram 60mg vs Citalop	ram 20mg					
Montgomery 2001	100	-2.00(2.50)	102	-1.90(2.40)	 _	-0.04 [-0.32, 0.24]
Subtotal (95% CI)	100		102			-0.04 [-0.32, 0.24]
Test for heterogeneity: not ap	plicable				7	
Test for overall effect: $Z = 0.3$						
03 Citalopram 60mg vs Citalop	oram 40mg					
Montgomery 2001	100	-2.00(2.50)	98	-2.10(2.30)		0.04 [-0.24, 0.32]
Subtotal (95% CI)	100		98			0.04 [-0.24, 0.32]
Test for heterogeneity: not ap	plicable				T-	•
Test for overall effect: Z = 0.3						
	` ′					

Comparison: 03 SSRIs vs other SSRIs (acute phase)

Outcome: 01 Leaving study early

Study or sub-category	SSRI1 n/N	SSRI 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Citalopram vs Fluvoxamine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/11 0	0/10 0		Not estimable Not estimable
02 Citalopram vs Paroxetine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/11 0	0/9 0		Not estimable Not estimable
03 Fluoxetine vs Sertraline Bergeron 2002 Subtotal (95% CI) Total events: 22 (SSRI 1), 22 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: Z = 0.21 (P = 0.8	22/73 73 33)	22/77 77		1.05 [0.64, 1.73] 1.05 [0.64, 1.73]
04 Fluvoxamine vs Paroxetine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/10 0	0/9 0		Not estimable Not estimable
		0	5 0.7 1 1.5 Favours SSRI 1 Favours SSRI 2	2

Review: OCD adults: SSRIs

Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 02 Leaving study early due to adverse events

Study or sub-category	SSRI1 n/N	SSRI 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Citalopram vs Fluvoxamine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/11 0	0/10 0		Not estimable Not estimable
02 Citalopram vs Paroxetine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/11 0	0/9		Not estimable Not estimable
03 Fluoxetine vs Sertraline Bergeron 2002 Subtotal (95% CI) Total events: 10 (SSRI 1), 15 (SSRI 2) Test for heterogeneity: not applicable Test for overall effect: Z = 0.94 (P = 0.)	10/73 73 35)	15/77 77		0.70 [0.34, 1.46] 0.70 [0.34, 1.46]
04 Fluvoxamine vs Paroxetine Mundo 1997a Subtotal (95% CI) Total events: 0 (SSRI 1), 0 (SSRI 2) Test for heterogenety: not applicable Test for overall effect: not applicable	0/10 0	0/9 0		Not estimable Not estimable
		0	.1 0.2 0.5 1 2 5 Favours SSRI1 Favours SSRI	10 2

Comparison: 03 SSRIs vs other SSRIs (acute phase)

Outcome: 03 Non-responders

Study or sub-category	SSRI1 n/N	SSRI 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Citalopram vs Paroxetine				
Mundo 1997a	7/11	5/9		1.15 [0.55, 2.39]
Subtotal (95% CI) Total events: 7 (SSRI 1), 5 (SSRI Test for heterogeneity: not applic		9		1.15 [0.55, 2.39]
Test for overall effect: $Z = 0.36$ (I	P = 0.72)			
03 Fluvoxamine vs Citalopram				
Mundo 1997a	4/10	7/11		0.63 [0.26, 1.52]
Subtotal (95% CI)	10	11		0.63 [0.26, 1.52]
Total events: 4 (SSRI 1), 7 (SSRI	2)			
Test for heterogeneity: not applic				
Test for overall effect: Z = 1.03 (I				
04 Fluvoxamine vs Paroxetine				
Mundo 1997a	4/10	5/9		0.72 [0.28, 1.88]
Subtotal (95% CI)	10	9		0.72 [0.28, 1.88]
Total events: 4 (SSRI 1), 5 (SSRI	2)		_	·
Test for heterogeneity: not applic	able			
Test for overall effect: Z = 0.67 (I				
		0	.1 0.2 0.5 1 2 5	10
			Favours SSRI1 Favours SSRI2	1

Review: OCD adults: SSRIs Comparison: 03 SSRIs vs other SSRIs (acute phase)

Outcome: 04 Non-remitters

Study or sub-category	SSRI 1 n/N	SSRI 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine vs Sertraline Bergeron 2002 Subtotal (95% Cl) Total events: 57 (SSRI 1), 50 (Test for heterogeneity: not ap Test for overall effect: Z = 1.7	pplicable	50/77 77	+	1.20 [0.98, 1.47] 1.20 [0.98, 1.47]
		0.5	0.7 1 1.5	2

Favours SSRI1 Favours SSRI2

Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 05 Y-BOCS

Study or sub-category	N	SSRI 1 Mean (SD)	N	SSRI 2 Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
02 Fluoxetine vs Sertraline at	12 weeks						
Bergeron 2002	72	-6.10(5.40)	76	-8.40(6.20)		<u> </u>	0.39 [0.07, 0.72]
Subtotal (95% CI)	72		76			<u>♦</u>	0.39 [0.07, 0.72]
Test for heterogeneity: not ap	plicable						
Test for overall effect: $Z = 2.3$	37 (P = 0.02)						
03 Fluvoxamine vs Citalopram	1						
Mundo 1997a	10	16.20(8.90)	11	19.80(10.10)			-0.36 [-1.23, 0.50]
Subtotal (95% CI)	10		11			₩	-0.36 [-1.23, 0.50]
Test for heterogeneity: not ap	plicable						
Test for overall effect: $Z = 0.8$	32 (P = 0.41)						
04 Fluvoxamine vs Paroxetine	•						
Mundo 1997a	10	16.20(8.90)	9	21.60(7.60)			-0.62 [-1.55, 0.31]
Subtotal (95% CI)	10		9			•	-0.62 [-1.55, 0.31]
Test for heterogeneity: not ap	plicable						
Test for overall effect: $Z = 1.3$	31 (P = 0.19)						
05 Paroxetine vs Citalopram							
Mundo 1997a	9	21.60(7.60)	11	19.80(10.10)		-	0.19 [-0.69, 1.07]
Subtotal (95% CI)	9		11			•	0.19 [-0.69, 1.07]
Test for heterogeneity: not ap	plicable						
Test for overall effect: $Z = 0.4$	42 (P = 0.67)						
					-10	-5 0	5 10
					Favo	ırs SSRI1 Favours	SSRI 2

03 SSRIs vs other SSRIs (acute phase) 06 NIMH-OC Comparison:

Outcome:

Study or sub-category 1	N	SSRI 1 Mean (SD)	N	SSRI 2 Mean (SD)		SMD (fixe 95% Cl	d)	SMD (fixed) 95% Cl
01 Fluoxetine vs Sertraline								
Bergeron 2002	72	5.70(2.60)	76	5.50(2.80)		-		0.07 [-0.25, 0.40]
Subtotal (95% CI)	72		76			•		0.07 [-0.25, 0.40]
Test for heterogeneity: not applicable	Э					ſ		
Test for overall effect: $Z = 0.45$ (P = 0	0.65)							
02 Fluvoxamine vs Citalopram								
Mundo 1997a	10	6.23(1.81)	11	8.58(1.88)				-1.22 [-2.17, -0.27]
Subtotal (95% CI)	10		11					-1.22 [-2.17, -0.27]
Fest for heterogeneity: not applicable	Э					-		
Test for overall effect: $Z = 2.52$ (P = 1	0.01)							
03 Fluvoxamine vs Paroxetine								
Mundo 1997a	10	6.23(1.81)	9	7.77(2.02)		_		-0.77 [-1.71, 0.17]
Subtotal (95% CI)	10		9					-0.77 [-1.71, 0.17]
est for heterogeneity; not applicable	9					-		
est for overall effect: Z = 1.60 (P = 0	0.11)							
04 Paroxetine vs Citalopram								
Mundo 1997a	9	7.77(2.02)	11	8.58(1.88)				-0.40 [-1.29, 0.49]
Subtotal (95% CI)	9		11			-		-0.40 [-1.29, 0.49]
Fest for heterogeneity: not applicable	Э					-		
Test for overall effect: $Z = 0.88$ (P = 0.00)	0.38)							
					-4	-2 0	2	4
					Fo	vours SSRI1 Fa	avours SSRI :	2
					га	YOURS SSINE FR	avours sorti.	4

Review:

OCD adults: SSRIs 03 SSRIs vs other SSRIs (acute phase) 07 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	SSRI 1 Mean (SD)	N	SSRI 2 Mean (SD)		S	SMD (fixed) 95% CI		SMD (fixed) 95% CI	
01 Fluoxetine vs Sertraline Bergeron 2002 Subtotal (95% CI) Test for heterogeneity: not app	72 72	7.10(5.40)	76 76	6.20(4.60)			-	 	0.18 [-0.14, 0.50 0.18 [-0.14, 0.50	
Test for overall effect: Z = 1.0					- ;	-0.5		0.5	-:	

Favours SSRI1 Favours SSRI2

OCD adults: SSRIs Review:


Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 01 Adverse events

tudy r sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
1 Fluvoxamine vs Clomipramine	e			
reeman 1994	30/34	24/30		1.10 [0.89, 1.37]
(oran 1996a	35/37	39/41	-	0.99 [0.90, 1.10]
/Jundo 2001	81/115	84/112		0.94 [0.80, 1.10]
ubtotal (95% CI)	186	183	•	0.98 [0.89, 1.09]
otal events: 146 (SSRI), 147 (0 est for heterogeneity: Chi² = 1. est for overall effect: Z = 0.36	.47, df = $2 (P = 0.48)$, $I^2 = 0$	%		
2 Paroxetine vs Clomipramine				
Burnham 1993	77/82	80/82	-	0.96 [0.90, 1.03]
Zohar 1996a	163/201	85/99		0.94 [0.85, 1.05]
ubtotal (95% CI)	283	181	•	0.95 [0.89, 1.02]
otal events: 240 (SSRI), 165 (0	Clomipramine)		·	
est for heterogeneity: Chi² = 0.	.13, df = 1 (P = 0.72), $I^2 = 0$	%		
est for overall effect: Z = 1.45	(P = 0.15)			
3 Sertraline vs Clomipramine				
Askin 1999	7/18	13/18		0.54 [0.28, 1.03]
Bisserbe 1997	56/86	57/82		0.94 [0.76, 1.16]
ubtotal (95% Cl)	104	100	-	0.86 [0.71, 1.06]
otal events: 63 (SSRI), 70 (Cloi	mipramine)			
est for heterogeneity: Chi² = 2.	.62, $df = 1 (P = 0.11), I^2 = 6$	1.8%		
est for overall effect: Z = 1.41	(P = 0.16)			
otal (95% CI)	573	464	•	0.95 [0.89, 1.00]
otal events: 449 (SSRI), 382 (0	Clomipramine)		•	
est for heterogeneity: Chi² = 5. est for overall effect: Z = 1.80		%		

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 02 Attempted suicide



Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 03 Leaving study early

Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine vs Clomipramine				
Lopez-Ibor 1996	5/30	4/25		1 04 (0 0) 0 471
Subtotal (95% CI)	5/30	4/25 4/25		1.04 [0.31, 3.47] 1.04 [0.31, 3.47]
Test for heterogeneity: not app	•	4/25		1.04 [0.31, 3.47]
Test for overall effect: Z = 0.07				
02 Fluvoxamine vs Clomipramir	ne			
Freeman 1994	6/34	11/32		0.51 [0.22, 1.23]
Koran 1996a	8/37	15/42		0.61 [0.29, 1.26]
Milanfranchi 1997	0/13	1/13	_	- 0.33 [0.01, 7.50]
Mundo 2001	19/115	26/112		0.71 [0.42, 1.21]
Smeraldi 1992	1/6	1/6 ←	_	1.00 [0.08, 12.56]
Subtotal (95% CI)	34/205	54/205	-	0.64 [0.44, 0.93]
Test for heterogeneity: Chi ² = 0		-	—	0.01 (0.11, 0.50,
Test for overall effect: Z = 2.3				
03 Paroxetine vs Clomipramine	•			
Burnham 1993	28/82	28/82		1.00 [0.65, 1.53]
Zohar 1996a	49/201	34/99		0.71 [0.49, 1.02]
Subtotal (95% CI)	77/283	62/181		0.82 [0.62, 1.08]
Test for heterogeneity: Chi ² = 1	1.44 , df = 1 (P = 0.23), $I^2 = 3$	0.4%	T	
Test for overall effect: Z = 1.4				
04 Sertraline vs Clomipramine				
Askin 1999	2/20	4/22 —	<u> </u>	0.55 [0.11, 2.69]
Bisserbe 1997	23/86	35/82		0.63 [0.41, 0.96]
Subtotal (95% CI)	25/106	39/104	-	0.62 [0.41, 0.94]
Test for heterogeneity: Chi ² = 0	0.02, df = 1 (P = 0.88), l ² = 0	%	-	•
Test for overall effect: Z = 2.29	5 (P = 0.02)			
Total (95% CI)	141/624	159/515	•	0.72 [0.59, 0.88]
Test for heterogeneity: $Chi^2 = 4$ Test for overall effect: $Z = 3.25$		%	-	•
rest for overall effect. Z = 3.23	9 (F = 0.001)	0.1	0.2 0.5 1 2 5	10

Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 04 Leaving study early due to adverse events



Comparison: 04 SSRIs vs Clomipramine (acute phase)

05 Non-responders Outcome:

Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine vs Clomipramine	00.400	11.405	_	1 68 (1 00 0 80)
Lopez-Ibor 1996 Subtotal (95% CI)	22/30 30	11/25 25		1.67 [1.02, 2.73]
otal events: 22 (SSRI), 11 (Clomi)		25		1.67 [1.02, 2.73]
est for heterogeneity; not applica				
est for neterogeneity, not applica est for overall effect: Z = 2.03 (P				
02 Fluvoxamine vs Clomipramine				
Koran 1996a	18/37	21/42		0.97 [0.62, 1.52]
Milanfranchi 1997	2/13	3/13 -		0.67 [0.13, 3.35]
Mundo 2001	46/115	44/112	-	1.02 [0.74, 1.40]
Subtotal (95% CI)	165	167	•	0.99 [0.76, 1.28]
otal events: 66 (SSRI), 68 (Clomi;	oramine)		Ī	•
est for heterogeneity: Chi² = 0.27	$I_1 df = 2 (P = 0.88), I^2 = 0$	%		
est for overall effect: Z = 0.08 (P	= 0.93)			
3 Paroxetine vs Clomipramine				
Burnham 1993	47/82	42/82	 - 	1.12 [0.84, 1.48]
Zohar 1996a	92/201	47/99	- •	0.96 [0.75, 1.25]
Subtotal (95% CI)	283	181	•	1.03 [0.85, 1.24]
Fotal events: 139 (SSRI), 89 (Clorn Fest for heterogeneity: Chi² = 0.59 Fest for overall effect: Z = 0.27 (P	P_{i} , df = 1 ($P = 0.44$), $P_{i} = 0$	%		
04 Sertraline vs Clomipramine				
Bisserbe 1997	24/86	29/82		0.79 [0.50, 1.24]
Subtotal (95% CI) fotal events: 24 (SSRI), 29 (Clomi; fest for heterogenetty: not applics fest for overall effect: Z = 1.04 (P	able	82		0.79 [0.50, 1.24]
Fotal (95% CI) Fotal events: 251 (SSRI), 197 (Clo Fest for heterogeneity: Chi ² = 6.01 Fest for overall effect: Z = 0.24 (P	, $df = 6 (P = 0.42), I^2 = 0$	455	•	1.02 [0.89, 1.17]
		0.1	0.2 0.5 1 2 5	10
OOD anti-they CODIn			Favours SSRI Favours Clomip	ramine

Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 06 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipramine						
Lopez-lbor 1996	30	-7.50(9.29)	24	-8.90(7.13)		0.16 [-0.37, 0.70]
Subtotal (95% CI)	30		24			0.16 [-0.37, 0.70]
Test for heterogeneity: not appli	cable				- -	
Test for overall effect: $Z = 0.60$	(P = 0.55)					
02 Fluvoxamine vs Clomipramine	е					
Koran 1996a	34	17.80(7.70)	39	17.00(8.55)	- •	0.10 [-0.36, 0.56]
Milanfranchi 1997	13	18.40(9.20)	12	16.50(11.00)		- 0.18 [-0.60, 0.97]
Mundo 2001	67	14.70(10.10)	61	12.50(8.00)		0.24 [-0.11, 0.59]
Smeraldi 1992	5	18.20(2.50)	5	15.20(12.40)		→ 0.30 [-0.95, 1.55]
Subtotal (95% CI)	119		117			0.19 [-0.06, 0.45]
Test for heterogeneity: $Chi^2 = 0$.	26, df = 3 (P	= 0.97), I ² = 0%			_	
Test for overall effect: $Z = 1.46$	(P = 0.14)					
03 Paroxetine vs Clomipramine						
Burnham 1993	79	-5.61(7.47)	78	-7.73(7.42)		0.28 [-0.03, 0.60]
Zohar 1996a	198	-8.00(8.00)	94	-8.00(8.20)	- + -	0.00 [-0.25, 0.25]
Subtotal (95% CI)	277		172		-	0.11 [-0.09, 0.30]
Test for heterogeneity: Chi² = 1.		= 0.16), I ² = 48.4%				
Test for overall effect: Z = 1.09	(P = 0.28)					
Total (95% CI)	426		313		•	0.14 [-0.01, 0.29]
Test for heterogeneity: Chi² = 2.		= 0.87), I ² = 0%				
Test for overall effect: $Z = 1.85$	(P = 0.06)					
				-1	-0.5 0 0.5	1

04 SSRIs vs Clomipramine (acute phase) 07 NIMH-OC Comparison:

Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluvoxamine vs Clomiprami	ine					
Mundo 2001	112	5.90(3.10)	105	5.90(2.80)		0.00 [-0.27, 0.27]
Subtotal (95% CI)	112		105			0.00 [-0.27, 0.27]
est for heterogeneity: not ap	plicable				T	
est for overall effect: $Z = 0.0$	00 (P = 1.00)					
2 Paroxetine vs Clomipramine	•					
Burnham 1993	79	-1.42(2.04)	78	-2.06(2.03)		0.31 [0.00, 0.63]
Zohar 1996a	198	-2.50(2.90)	94	-2.50(2.60)		0.00 [-0.25, 0.25]
ubtotal (95% CI)	277		172		-	0.12 [-0.08, 0.31]
est for heterogeneity: Chi² =	2.36, df = 1 (P	= 0.12), I ² = 57.6%			-	
est for overall effect: $Z = 1.2$	0 (P = 0.23)					
otal (95% CI)	389		277		•	0.08 [-0.08, 0.23]
est for heterogeneity: Chi ² =	2.86, df = 2 (P	= 0.24), I ² = 30.0%				
est for overall effect: Z = 0.9	7 (P = 0.33)					

Favours SSRI Favours Clomipramine

Review: Comparison:

OCD adults: SSRIs 04 SSRIs vs Clomipramine (acute phase) 08 Comprehensive Psychopathological Rating Scale: obsessive-compulsive Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipran	nine					
Lopez-lbor 1996	30	-8.10(7.64)	24	-10.90(7.33)		— 0.37 [-0.17, 0.91]
Subtotal (95% CI)	30		24			0.37 [-0.17, 0.91]
Test for heterogeneity: not	: applicable				 -	
Test for overall effect: Z =	1.33 (P = 0.18)					
					1 .05 0 05	

Favours SSRI Favours Clomipramine OCD adults: SSRIs

04 SSRIs vs Clomipramine (acute phase) 09 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipran	nine					
Lopez-lbor 1996	30	-7.50(5.93)	24	-9.40(7.71)		0.28 [-0.26, 0.82]
Subtotal (95% CI)	30		24			0.28 [-0.26, 0.82]
Test for heterogeneity: not	: applicable					
Test for overall effect: Z =	1.00 (P = 0.32)					
02 Fluvoxamine vs Clomipr	amine					
Koran 1996a	34	6.10(3.30)	39	5.80(4.70)		0.07 [-0.39, 0.53]
Mundo 2001	112	7.70(6.00)	105	7.00(4.50)	- 	0.13 [-0.14, 0.40]
Subtotal (95% CI)	146		144		-	0.12 [-0.11, 0.35]
Test for heterogeneity: Chi	$i^2 = 0.05$, $df = 1$ (P	= 0.83), I ² = 0%			-	
Test for overall effect: Z =	0.99 (P = 0.32)					
Total (95% CI)	176		168			0.14 [-0.07, 0.35]
Test for heterogeneity: Chi	P = 0.33, df = 2 (P	= 0.85), I ² = 0%				
Test for overall effect: $Z =$	1.30 (P = 0.19)					
				-1	-0.5 0 0.5	1

Favours SSRI Favours Clomipramine

Comparison: 04 SSRIs vs Clomipramine (acute phase) 10 Montgomery-Asberg Depression Rating Scale Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
D1 Fluoxetine vs Clomiprami	ine					
Lopez-lbor 1996	30	-10.10(8.20)	24	-13.80(9.09)	+-	0.42 [-0.12, 0.97]
Subtotal (95% CI)	30		24		•	0.42 [-0.12, 0.97]
Fest for heterogeneity: not a	applicable				-	
Test for overall effect: Z = 1	1.53 (P = 0.13)					
02 Fluvoxamine vs Clomipra	amine					
Smeraldi 1992	5	11.80(6.80)	5	9.60(10.30)		0.23 [-1.02, 1.47]
Subtotal (95% CI)	5		5			0.23 [-1.02, 1.47]
est for heterogeneity: not a	applicable				_	
Test for overall effect: $Z = 0$	0.36 (P = 0.72)					
03 Paroxetine vs Clomipram	nine					
Zohar 1996a	198	-3.40(7.90)	94	-2.40(7.30)	=	-0.13 [-0.38, 0.12]
Subtotal (95% CI)	198		94		₩	-0.13 [-0.38, 0.12]
est for heterogeneity; not a	applicable				1	
est for overall effect: Z = 1	1.03 (P = 0.30)					
Total (95% CI)	233		123		•	-0.03 [-0.25, 0.19]
est for heterogeneity: Chi²	$^{2} = 3.47$, df = 2 (P	' = 0.18), I ² = 42.4%			Ī	
「est for overall effect: Z = 0	0.24 (P = 0.81)	••				
				-4	-2 0 2	4

Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

OCD adults: SSRIs Review:

Comparison: 04 SSRIs vs Clomipramine (acute phase) Outcome: 11 Depression (HRSD; MADRS)

Study		SSRI	Clomipramine		SMD (fixed)	SMD (fixed)	
or sub-category	N	Mean (SD)	N	Mean (SD)	95% CI	95% CI	
01 Fluvoxamine vs Clomipr	amine						
Koran 1996a	34	6.10(3.30)	39	5.80(4.70)		0.07 [-0.39, 0.53]	
Mundo 2001	112	7.70(6.00)	105	7.00(4.50)	 -	0.13 [-0.14, 0.40]	
Smeraldi 1992	5	11.80(6.80)	5	9.60(10.30)	 	0.23 [-1.02, 1.47]	
Subtotal (95% CI)	151		149		*	0.12 [-0.11, 0.35]	
Test for heterogeneity: Chi Test for overall effect: Z =	1.04 (P = 0.30)	= 0.96), I ² = 0%					
02 Paroxetine vs Clomiprar					_		
Zohar 1996a	198	-3.40(7.90)	94	-2.40(7.30)	7	-0.13 [-0.38, 0.12]	
Subtotal (95% CI)	198		94		•	-0.13 [-0.38, 0.12]	
Test for heterogeneity: not Test for overall effect: Z =	• •						
Total (95% CI) Test for heterogeneity: Chi Test for overall effect: Z =		= 0.53), l² = 0%	243		•	0.01 [-0.16, 0.17]	

Review: OCD adults: SSRIs

04 SSRIs vs Clomipramine (acute phase) 12 Clinical Anxiety Scale Comparison:

Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)		\$	SMD (fixed 95% CI)		SMD (fixed) 95% CI	
01 Fluvoxamine vs Clomipr	amine										
Mundo 2001	112	7.00(4.60)	105	6.70(4.30)			_	_		0.07 [-0.20, 0.33]	
Subtotal (95% CI)	112		105				-	- -		0.07 [-0.20, 0.33]	
Test for heterogeneity: not	: applicable									•	
Test for overall effect: Z =	0.49 (P = 0.62)										
-								0.5			—
					-1	-0.5	U	0.5	1		

Review: Comparison: OCD adults: SSRIs 04 SSRIs vs Clomipramine (acute phase) 13 Covi Anxiety Scale

Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)		SMD (fi: 95%			SMD (fixed) 95% CI
01 Fluoxetine vs Clomipram	nine								
Lopez-lbor 1996	30	-2.40(3.10)	24	-2.40(3.09)					0.00 [-0.54, 0.54]
Subtotal (95% CI)	30		24						0.00 [-0.54, 0.54]
est for heterogeneity: not	applicable					T			
Test for overall effect: Z = I	0.00 (P = 1.00)								
					-1	-0.5 0	0.5	1	
						Favours SSRI	Favours Clor	ipramine	

Comparison:

04 SSRIs vs Clomipramine (acute phase) 14 Anxiety (Clinical Anxiety Scale; Covi Anxiety Scale) Outcome:

	y ıb-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
pramine	uoxetine vs Clomipra	nine					
	ez-lbor 1996	30	-2.40(3.10)	24	-2.40(3.09)		0.00 [-0.54, 0.54]
	otal (95% CI)	30		24			0.00 [-0.54, 0.54]
not applic	for heterogeneity: n	t applicable				T	
Z = 0.00 (for overall effect: Z	0.00 (P = 1.00)					
mipramine	uvoxamine vs Clomij	ramine					
	ndo 2001	112	7.00(4.60)	105	6.70(4.30)		0.07 [-0.20, 0.33]
	otal (95% CI)	112		105			0.07 [-0.20, 0.33]
not applic	for heterogeneity: n	t applicable					
Z = 0.49 (for overall effect: Z	0.49 (P = 0.62)					
	(95% CI)	142		129			0.05 [-0.18, 0.29]
$Chi^2 = 0.0$	for heterogeneity: C	i ² = 0.05, df = 1 (P =	= 0.83), I ² = 0%				
Z = 0.44 (for overall effect: Z	0.44 (P = 0.66)					
	for heterogeneity: C	i² = 0.05, df = 1 (P =	= 0.83), ² = 0%			-0.5	n's

Review: OCD adults: SSRIs

04 SSRIs vs Clomipramine (acute phase) 15 Clinical Global Impressions: global improvement Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipramin	ne					
Lopez-Ibor 1996	30	-2.60(1.13)	24	-2.60(1.19)		0.00 [-0.54, 0.54]
Subtotal (95% CI)	30		24			0.00 [-0.54, 0.54]
Test for heterogeneity: not a	pplicable				T	
Test for overall effect: $Z = 0$.00 (P = 1.00)					
02 Fluvoxamine vs Clomipran	mine					
Mundo 2001	112	2.30(1.00)	105	2.30(1.00)		0.00 [-0.27, 0.27]
Subtotal (95% CI)	112		105			0.00 [-0.27, 0.27]
Test for heterogeneity: not a	pplicable				Ī	
Test for overall effect: $Z = 0$.	.00 (P = 1.00)					
Total (95% CI)	142		129		•	0.00 [-0.24, 0.24]
Test for heterogeneity: Chi ² :	= 0.00, df = 1 (P	= 1.00), I ² = 0%				
Test for overall effect: $Z = 0$.00 (P = 1.00)					
					.1 -0.5 0 0.5	1

Favours SSRI Favours Clomipramine


Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs Comparison: Outcome: 04 SSRIs vs Clomipramine (acute phase) 16 Clinical Global Impressions: severity of illness

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)) (fixed) 5% Cl			SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipramine										
Lopez-lbor 1996	30	-0.90(1.23)	24	-1.90(1.14)			-	-		0.83 [0.27, 1.39]
Subtotal (95% CI)	30		24				•	•		0.83 [0.27, 1.39]
Test for heterogeneity: not appli	cable						-			
Test for overall effect: $Z = 2.89$	(P = 0.004)									
02 Fluvoxamine vs Clomipramine	е									
Mundo 2001	112	3.40(1.30)	105	3.20(1.20)			 			0.16 [-0.11, 0.43]
Subtotal (95% CI)	112		105				•			0.16 [-0.11, 0.43]
Test for heterogeneity: not appli	cable						1			
Test for overall effect: $Z = 1.17$	(P = 0.24)									
03 Paroxetine vs Clomipramine										
Zohar 1996a	194	-1.20(1.40)	94	-1.10(1.20)			-			-0.07 [-0.32, 0.17]
Subtotal (95% CI)	194		94				•			-0.07 [-0.32, 0.17]
Test for heterogeneity: not appli	cable						1			
Test for overall effect: $Z = 0.59$	(P = 0.55)									
Total (95% CI)	336		223				•			0.11 [-0.06, 0.28]
Test for heterogeneity: Chi² = 8.		= 0.01), I ² = 76.7%					ľ			
Test for overall effect: Z = 1.23	(P = 0.22)									
					-4	-2	Ó	2	4	
					Fa	vours SSR	l Favo	urs Clomij	oramine	

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 17 Symptom Checklist-90



Review: OCD adults: SSRIs

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 18 Subanalysis: Non-responders in patients with comorbid depression

Study or sub-category	SSRI Clomipramine n/N n/N		RR (fixed) 95% Cl	RR (fixed) 95% Cl			
01 Fluoxetine vs Clomipramine							
Lopez-lbor 1996	22/30	11/25		1.67 [1.02, 2.73]			
Subtotal (95% CI)	30	25	-	1.67 [1.02, 2.73]			
Total events: 22 (SSRI), 11 (Clomipra	mine)		-				
Test for heterogeneity; not applicable							
Test for overall effect: Z = 2.03 (P =	0.04)						
02 Fluvoxamine vs Clomipramine							
Mundo 2001	46/115	44/112	_ 	1.02 [0.74, 1.40]			
Subtotal (95% CI)	115	112	•	1.02 [0.74, 1.40]			
Total events: 46 (SSRI), 44 (Clomipra	mine)		Ī				
Test for heterogeneity: not applicable	•						
Test for overall effect: Z = 0.11 (P =	0.91)						
Total (95% CI)	145	137		1.16 [0.88, 1.51]			
Total events: 68 (SSRI), 55 (Clomipra	mine)		-	,			
Test for heterogeneity: Chi ² = 2.72, d	$f = 1 (P = 0.10), I^2 = 6$	3.3%					
Test for overall effect: Z = 1.06 (P =	0.29)						
		0.1	0.2 0.5 1 2 5	10			

Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 04 SSRIs vs Clomipramine (acute phase)

Outcome: 19 Subanalysis: Y-BOCS in patients with comorbid depression

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine vs Clomipramin	ie					
Lopez-lbor 1996	30	-7.50(9.29)	24	-8.90(7.13)		0.16 [-0.37, 0.70]
Subtotal (95% CI)	30		24			0.16 [-0.37, 0.70]
Test for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 0$.	.60 (P = 0.55)					
02 Fluvoxamine vs Clomipran	nine					
Mundo 2001	67	14.70(10.10)	61	12.50(8.00)		0.24 [-0.11, 0.59]
Smeraldi 1992	5	18.20(2.50)	5	15.20(12.40)		0.30 [-0.95, 1.55]
Subtotal (95% CI)	72		66			0.24 [-0.09, 0.58]
「est for heterogeneity: Chi² =	= 0.01, df = 1 (P	= 0.92), I ² = 0%			-	
Test for overall effect: $Z = 1$.	.42 (P = 0.16)					
Total (95% CI)	102		90		-	0.22 [-0.06, 0.51]
Test for heterogeneity: Chi² =	= 0.07, df = 2 (P	= 0.97), I ² = 0%			-	
Test for overall effect: $Z = 1$.	52 (P = 0.13)					
					-1 -0.5 0	0.5 1

Comparison:

04 SSRts vs Clomigramine (acute phase)
20 Subanalysis: Hamilton Rating Scale for Depression in patients with comorbid depression Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl	
01 Fluoxetine vs Clomipran	nine						
Lopez-lbor 1996	30	-7.50(5.93)	24	-9.40(7.71)		0.28 [-0.26, 0.82]	
Subtotal (95% CI)	30		24			0.28 [-0.26, 0.82]	
Test for heterogeneity: not	t applicable						
Test for overall effect: Z =	1.00 (P = 0.32)						
02 Fluvoxamine vs Clomipr	ramine						
Mundo 2001	112	7.70(6.00)	105	7.00(4.50)	- 	0.13 [-0.14, 0.40]	
Subtotal (95% CI)	112		105			0.13 [-0.14, 0.40]	
est for heterogeneity; not	t applicable						
Test for overall effect: Z =	0.96 (P = 0.34)						
Fotal (95% CI)	142		129			0.16 [-0.08, 0.40]	
Fest for heterogeneity: Chi	i ² = 0.22, df = 1 (P	= 0.64), I ² = 0%			-		
Test for overall effect: Z =	1.31 (P = 0.19)	• •					
				-1	-0.5 0 0.5	1	

Favours SSRI Favours Clomipramine

Favours SSRI Favours other drug

OCD adults: SSRIs

Comparison: Outcome: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase) 01 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
01 Fluoxetine vs Phenelzine							
Jenike 1997	19	16.20(6.30)	17	16.30(7.00)	-+ -	-0.01 [-0.67, 0.64]	
Subtotal (95% CI)	19		17		•	-0.01 [-0.67, 0.64]	
[est for heterogeneity: not app [est for overall effect: Z = 0.04							
02 Fluvoxamine vs Desipramine	•						
Goodman 1990a	21	19.50(9.00)	19	25.80(6.00)		-0.80 [-1.45, -0.15]	
Subtotal (95% CI)	21		19		-	-0.80 [-1.45, -0.15]	
est for heterogeneity: not appl	licable				-		
est for overall effect: Z = 2.42	(P = 0.02)						
3 Clomipramine vs Buspirone							
Pato 1991	9	17.67(4.97)	9	16.78(6.46)		0.15 [-0.78, 1.07]	
ubtotal (95% CI)	9		9			0.15 [-0.78, 1.07]	
est for heterogeneity: not appl est for overall effect: Z = 0.31							
4 Sertraline vs Desipramine							
Hoehn-Saric 2000	79	-8.40(8.00)	85	-6.00(8.30)	_	-0.29 [-0.60, 0.02]	
Subtotal (95% CI)	79	,,	85	,,	<u> </u>	-0.29 [-0.60, 0.02]	
est for heterogeneity; not app					7		
est for overall effect: Z = 1.86							
Total (95% CI)	128		130		•	-0.30 [-0.54, -0.05]	
est for heterogeneity: Chi² = 3		= 0.27), I ² = 23.3%					
est for overall effect: Z = 2.35	(P = 0.02)						


Review:

OCD adults: SSRIs 05 SSRIs/Clomipramine vs Non-SRIs (acute phase) 02 NIMH-OC Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
01 Fluoxetine vs Phenelzina	e						
Jenike 1997	19	7.00(1.10)	17	6.80(1.40)		— 0.16 [-0.50, 0.81]	
Subtotal (95% CI)	19		17			- 0.16 [-0.50, 0.81]	
Test for heterogeneity: not	applicable				-		
Test for overall effect: Z =	0.47 (P = 0.64)						
02 Sertraline vs Desipramin	ne						
Hoehn-Saric 2000	79	-2.70(2.67)	85	-1.70(2.77)		-0.37 [-0.67, -0.06]	
Subtotal (95% CI)	79		85			-0.37 [-0.67, -0.06]	
Test for heterogeneity: not	applicable				_		
Test for overall effect: Z =	2.32 (P = 0.02)						
03 Clomipramine vs Buspiro	one						
Pato 1991	9	21.22(5.49)	9	19.22(5.97)		0.33 [-0.60, 1.26]	
Subtotal (95% CI)	9		9			0.33 [-0.60, 1.26]	
Test for heterogeneity: not	applicable				— _		
Test for overall effect: Z =	0.70 (P = 0.48)						
Total (95% CI)	107		111			-0.22 [-0.49, 0.05]	
Test for heterogeneity: Chi ²	2 = 3.47, df = 2 (P	= 0.18), I ² = 42.3%			- - -	·	
Test for overall effect: Z =		• •					
				-	1 -0.5 0 0.5	1	

Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)

Outcome: 03 Adverse events



Review: OCD adults: SSRIs

Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 04 Leaving study early due to adverse events

ly SSRI ub-category n/N		Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 Sertraline vs Desipramine						
Hoehn-Saric 2000	8/80	22/86	-	0.39 [0.18, 0.83]		
Subtotal (95% CI)	80	86	◆	0.39 [0.18, 0.83]		
otal events: 8 (SSRI), 22 (Other drug)						
Fest for heterogeneity: not applicable Fest for overall effect: Z = 2.46 (P = 0.01)					
)2 Clomipramine vs Imipramine						
oz Cionipranii le vs inipranii le Volavka 1985	2/11	2/12		1.09 [0.18, 6.48]		
Subtotal (95% CI)	11	12		1.09 [0.18, 6.48]		
otal events: 2 (SSRI), 2 (Other drug)		12		1:05 (0:10, 0:40)		
est for heterogeneity: not applicable						
est for overall effect: Z = 0.10 (P = 0.92)					
3 Fluvoxamine vs Desipramine						
Goodman 1990a	0/21	2/19		0.18 [0.01, 3.56]		
Subtotal (95% CI)	21	19		0.18 [0.01, 3.56]		
otal events: 0 (SSRI), 2 (Other drug)						
est for heterogeneity: not applicable						
est for overall effect: Z = 1.12 (P = 0.26	0)					
04 Clomipramine vs Buspirone						
Pato 1991	1/10	0/10		3.00 [0.14, 65.90]		
Subtotal (95% CI)	10	10	-	3.00 [0.14, 65.90]		
otal events: 1 (SSRI), 0 (Other drug) est for heterogeneity: not applicable						
est for overall effect: Z = 0.70 (P = 0.49)					
05 Clomipramine vs Phenelzine						
Vallejo 1992	1/16	0/14		2.65 [0.12, 60.21]		
Subtotal (95% CI)	16	14		2.65 [0.12, 60.21]		
otal events: 1 (SSRI), 0 (Other drug)						
est for heterogeneity: not applicable						
est for overall effect: Z = 0.61 (P = 0.54)					
otal (95% CI)	138	141	•	0.51 [0.28, 0.95]		
otal events: 12 (SSRI), 26 (Other drug)						
est for heterogeneity: Chi² = 3.98, df = 4 est for overall effect: Z = 2.14 (P = 0.03						
	*	0.001	0.01 0.1 1 10 100	1000		
		5.55	Favours SSRI Favours other d			

05 SSRIs/Clomipramine vs Non-SRIs (acute phase) 05 Non-responders (OCD) Comparison:

Outcome:

Study or sub-category	SSRI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
02 Sertraline vs Desipramine				
Hoehn-Saric 2000	42/80	40/86		1.13 [0.83, 1.54]
Subtotal (95% CI)	80	86		1.13 [0.83, 1.54]
Total events: 42 (SSRI), 40 (Other drug)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.77 (P = 0.4	4)			
Total (95% CI)	80	86		1.13 [0.83, 1.54]
Total events: 42 (SSRI), 40 (Other drug)				•
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.77$ (P = 0.4)	4)			
		0.5	0.7 1 1.5	2

Favours SSRI Favours other drug

Favours SSRI Favours placebo

Review: OCD adults: SSRIs

06 SSRIs vs placebo (continuation phase) Comparison:

Outcome: 01 Leaving study early

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine				
Beasley 1992	3/23	2/6		0.39 [0.08, 1.84]
Montgomery 1993	16/61	2/12		1.57 [0.41, 5.97]
Romano 2001	16/36	23/35		0.68 [0.44, 1.05]
Subtotal (95% CI)	120	53		0.75 [0.50, 1.12]
Total events: 35 (SSRI), 27 (Pla			7	,,
Test for heterogeneity: Chi² = 2	•	3%		
Test for overall effect: Z = 1.40				
02 Paroxetine				
Hollander 2003d	19/53	37/52	-	0.50 [0.34, 0.75]
Subtotal (95% CI)	53	52	•	0.50 [0.34, 0.75]
Total events: 19 (SSRI), 37 (Pla	cebo)			
Test for heterogeneity: not appl	licable			
Test for overall effect: $Z = 3.36$	(P = 0.0008)			
T. I. I. (050) OD			•	
Total (95% CI)	173	105	◆	0.61 [0.46, 0.81]
Total events: 54 (SSRI), 64 (Pla	•			
Test for heterogeneity: Chi ² = 3		.1%		
Test for overall effect: $Z = 3.39$	((P = 0.0007)			
		0.01	0.1 1 10	100

Review: OCD adults: SSRIs


06 SSRIs vs placebo (continuation phase) Comparison: Outcome: 02 Leaving study early due to adverse events

Study or sub-category	SSRI Placebo RR (fixed) pry n/N n/N 95% Cl			RR (fixed) 95% Cl
O1 Fluoxetine				
Montgomery 1993	2/61	0/12		1.05 [0.05, 20.58]
Romano 2001	2/36	1/35		1.94 [0.18, 20.49]
Subtotal (95% CI)	97	47		1.54 [0.25, 9.58]
Total events: 4 (SSRI), 1 (Placebo)			-	
Test for heterogeneity: Chi² = 0.10, df =	= 1 (P = 0.75), I ² = 0%	•		
Test for overall effect: $Z = 0.46$ (P = 0.1	34)			
02 Paroxetine				
Hollander 2003d	3/53	20/52		0.15 [0.05, 0.47]
Subtotal (95% CI)	53	52	•	0.15 [0.05, 0.47]
Fotal events: 3 (SSRI), 20 (Placebo)			_	
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 3.26$ (P = 0.1	001)			
Total (95% CI)	150	99	•	0.26 [0.11, 0.63]
Total events: 7 (SSRI), 21 (Placebo)			-	•
Fest for heterogeneity: Chi² = 4.58, df =	$= 2 (P = 0.10), I^2 = 56.$.3%		
Test for overall effect: $Z = 3.00 (P = 0.0)$	003)			
		0	.01 0.1 1 10	100
			Favours SSRI Favours placeb	0

OCD adults: SSRIs Review:

06 SSRIs vs placebo (continuation phase) Comparison:

03 Non-responders Outcome:



Favours SSRI Favours placebo

Favours SSRI Favours placebo

Favours SSRI Favours placebo

Review:

OCD adults: SSRIs 06 SSRIs vs placebo (continuation phase) Comparison: Outcome:

04 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% Cl	
01 Fluoxetine										
Beasley 1992	23	9.80(7.30)	6	8.50(6.70)			-			0.18 [-0.72, 1.08]
Romano 2001	35	1.46(7.08)	34	2.50(6.16)			-			-0.15 [-0.63, 0.32]
Subtotal (95% CI)	58		40				•			-0.08 [-0.50, 0.34]
Test for heterogeneity: Ch	$i^2 = 0.41$, $df = 1$ (P :	= 0.52), I ² = 0%					1			
Test for overall effect: Z =	0.39 (P = 0.70)									
					-4	-2	-	2	4	_

Review: OCD adults: SSRIs

06 SSRIs vs placebo (continuation phase) 05 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl		SMD (fixed) 95% Cl	
01 Fluoxetine									
Romano 2001	35	1.20(5.37)	34	1.79(5.06)			 	-0.11 [-0.58, 0.36]	
Subtotal (95% CI)	35		34					-0.11 [-0.58, 0.36]	
Test for heterogeneity: not	t applicable					_			
Test for overall effect: Z =	0.46 (P = 0.64)								
					-1	-0.5	0 05	1	

OCD adults: SSRIs Review:

Comparison: 06 SSRIs vs placebo (continuation phase)

Outcome: 06 SF-36; social functioning

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (95%	fixed) 6 Cl		SMD (fixed) 95% Cl
01 Fluoxetine									
Romano 2001	34	9.56(19.23)	34	5.88(27.22)			_		0.15 [-0.32, 0.63]
Subtotal (95% CI)	34		34						0.15 [-0.32, 0.63]
Test for heterogeneity: not	applicable						_		
Test for overall effect: Z =	0.64 (P = 0.53)								
					-1	-0.5 (0.5	1	
					F	avours SSRI	Favours placel	00	

Review: OCD adults: SSRIs


Comparison: 07 SSRIs vs placebo (discontinuation phase)

01 Death Outcome:

Study or sub-category	SSRI n/N	Placebo n/N	RR (fi) 95%	,	RR (fixed) 95% Cl
01 Sertraline					
Koran 2002	0/109	1/114			0.35 [0.01, 8.46]
Subtotal (95% CI)	109	114			0.35 [0.01, 8.46]
Total events: 0 (SSRI), 1 (Plac	ebo)				•
Test for heterogeneity: not ap	plicable				
Test for overall effect: $Z = 0.6$	5 (P = 0.52)				
			0.01 0.1 1	10	100
			Favours SSRI	Favours placeb	00

Comparison: 07 SSRIs vs placebo (discontinuation phase)

Outcome: 02 Leaving study early



Review: OCD adults: SSRIs

Comparison: 07 SSRIs vs placebo (discontinuation phase) Outcome: 03 Leaving study early due to adverse effects

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Sertraline Koran 2002 Subtotal (95% CI)	5/109 109	12/114 114		0.44 [0.16, 1.20] 0.44 [0.16, 1.20]
Total events: 5 (SSRI), 12 (Placeb Test for heterogeneity: not applica Test for overall effect: Z = 1.61 (F	able			
		0.	.1 0.2 0.5 1 2 5	10

Review: OCD adults: SSRIs

Comparison: 07 SSRIs vs placebo (discontinuation phase)

Outcome: 04 Relapse

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Sertraline				
Koran 2002	4/109	6/114 -		0.70 [0.20, 2.40]
Subtotal (95% CI)	109	114		0.70 [0.20, 2.40]
Total events: 4 (SSRI), 6 (Plac	ebo)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: Z = 0.5	7 (P = 0.57)			
			3 05 1 3	

Favours SSRI Favours placebo

Favours SSRI Favours placebo

OCD adults: SSRIs Review:

Comparison: 07 SSRIs vs placebo (discontinuation phase)


05 Y-BOCS Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixe 95% Cl	•	SMD (fixed) 95% Cl
01 Sertraline Koran 2002 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		11.40(7.50)	113 113	14.20(7.70)	+		-0.37 [-0.63, -0.10] -0.37 [-0.63, -0.10]
					-1 -0.5 0	0.5 1	
					Favours SSRI Fa	vours placebo	

Review: OCD adults: SSRIs

07 SSRIs vs placebo (discontinuation phase) Comparison:

06 NIMH-OC Outcome:



Favours SSRI Favours placebo

07 SSRIs vs placebo (discontinuation phase) 07 QoL Enjoyment and Satisfaction Comparison:

Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			(fixed) i% Cl	SMD (fixed) 95% CI
O1 Sertraline Koran 2002 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		-77.30(16.10)	109 109	-67.50(20.30)	-	.		-0.53 [-0.80, -0.26] -0.53 [-0.80, -0.26]
					-1	-0.5	0 0.5	1

Favours SSRI Favours placebo

Favours Dose 1 Favours Dose 2

Review: OCD adults: SSRIs

08 SSRIs at different doses (continuation phase) Comparison:

Outcome: 01 Leaving study early

n/N 6/21	n/N	95% CI	95% CI
6/21			
6/21			
	3/23		2.19 [0.63, 7.67]
6/20	5/18		1.08 [0.40, 2.94]
41	41		1.47 [0.68, 3.19]
		-	
= 1 (P = 0.39), I ² = 0%			
33)			
3/26	3/23		0.88 [0.20, 3.96]
5/23	5/18		0.78 [0.27, 2.29]
49	41		0.82 [0.34, 1.97]
		-	
= 1 (P = 0.90), I ² = 0%			
66)			
3/26	6/21		0.40 [0.11, 1.43]
5/23	6/20		0.72 [0.26, 2.02]
49	41		0.56 [0.26, 1.24]
1 (P = 0.48), I ² = 0%			
15)			
			10
3	3/26 5/23 49 =1 (P = 0.90), ² = 0% 56) 3/26 5/23 49	33) 3/26	33) 3/26

Review: OCD adults: SSRIs

Comparison: 08 SSRIs at different doses (continuation phase) Outcome: 02 Leaving study early due to adverse events

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 40mg Fluoxetine v 20mg Fluoxetine				
Montgomery 1993	1/20	0/18		— 2.71 [0.12, 62.70]
Subtotal (95% CI)	20	18		- 2.71 [0.12, 62.70]
Total events: 1 (Dose 1), 0 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.62$ (P = 0.9)	53)			
02 60mg Fluoxetine v 20mg Fluoxetine				
Montgomery 1993	1/23	0/18		— 2.38 [0.10, 55.06]
Subtotal (95% CI)	23	18		- 2.38 [0.10, 55.06]
Total events: 1 (Dose 1), 0 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.54$ (P = 0.5	59)			
03 60mg Fluoxetine v 40mg Fluoxetine				
Montgomery 1993	1/23	1/20		0.87 [0.06, 13.02]
Subtotal (95% CI)	23	20		0.87 [0.06, 13.02]
Total events: 1 (Dose 1), 1 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.10$ (P = 0.9)	92)			
			0.01 0.1 1 10	100
			Favours Dose 1 Favours Dose	2

OCD adults: SSRIs Review:

08 SSRIs at different doses (continuation phase) Comparison:

03 Non-responders Outcome:

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine 40mg v Fluoxetine 20mg				
Beasley 1992	12/21	14/23		0.94 [0.57, 1.54]
Subtotal (95% CI)	21	23		0.94 [0.57, 1.54]
Total events: 12 (Dose 1), 14 (Dose 2))			
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.25$ (P = 0	.80)			
02 Fluoxetine 60mg v Fluoxetine 20mg				
Beasley 1992	11/26	14/23		0.70 [0.40, 1.21]
Subtotal (95% CI)	26	23		0.70 [0.40, 1.21]
Total events: 11 (Dose 1), 14 (Dose 2))		_	
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 1.28$ (P = 0	.20)			
03 Fluoxetine 60mg v Fluoxetine 40mg				
Beasley 1992	11/26	12/21		0.74 [0.41, 1.32]
Subtotal (95% CI)	26	21		0.74 [0.41, 1.32]
Total events: 11 (Dose 1), 12 (Dose 2))			
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 1.01$ (P = 0	.31)			
			0.2 0.5 1 2	5
			Favours Dose 1 Favours Dose 2	2

OCD adults: SSRIs

08 SSRIs at different doses (continuation phase) 04 Y-BOCS Comparison:

Outcome:


Study or sub-category	N	Dose 1 Mean (SD)	N	Dose 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Fluoxetine 40mg v Fluoxe	etine 20mg					
Beasley 1992	21	9.40(6.00)	23	9.80(7.30)	_ _	-0.06 [-0.65, 0.53]
Subtotal (95% CI)	21		23		•	-0.06 [-0.65, 0.53]
est for heterogeneity; not a	applicable				Ī	
est for overall effect: Z = 0	0.19 (P = 0.85)					
)2 Fluoxetine 60mg v Fluox	etine 20mg					
Beasley 1992	26	7.00(5.40)	23	9.80(7.30)		-0.43 [-1.00, 0.13]
ubtotal (95% CI)	26		23		•	-0.43 [-1.00, 0.13]
est for heterogeneity: not a	applicable				-	
est for overall effect: Z = 1	1.49 (P = 0.14)					
3 Fluoxetine 60mg v Fluox	etine 40mg					
Beasley 1992	26	7.00(5.40)	21	9.40(6.00)		-0.42 [-1.00, 0.17]
Subtotal (95% CI)	26	•	21		→	-0.42 [-1.00, 0.17]
est for heterogeneity: not a	applicable				-	•
est for overall effect: Z = 1						

Favours Dose 1 Favours Dose 2

OCD adults: SSRIs Review:

Comparison: 09 SSRIs v Clomipramine (continuation phase)

Outcome: 01 Leaving study early



Comparison: 09 SSRIs vs Clomipramine (continuation phase) Outcome: 02 Leaving study early due to adverse events

Study	SSRI	Clomipramine	RR (fixed)	RR (fixed)
or sub-category	n/N	n/N	95% CI	95% CI
01 Fluoxetine 60mg vs Clomipi	ramine 200mg (non-respond	ders)		
Lopez-lbor 1996	2/14	0/8		3.00 [0.16, 55.72]
Subtotal (95% CI)	14	8		3.00 [0.16, 55.72]
Total events: 2 (SSRI), 0 (Clori	nipramine)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 0.7$	4 (P = 0.46)			
02 Fluoxetine 20mg vs Clomipi	ramine 100mg (responders)	1		
Lopez-lbor 1996	1/11	1/13		1.18 [0.08, 16.78]
Subtotal (95% CI)	11	13		1.18 [0.08, 16.78]
Total events: 1 (SSRI), 1 (Clori	nipramine)		T	
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 0.1$	2 (P = 0.90)			
		0.0	1 0.1 1 10	100
			Favours SSRI Favours Clo	mipramine

Review: OCD adults: SSRIs

Comparison: Outcome: 09 SSRIs vs Clomipramine (continuation phase) 03 Y-BOCS


Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine 60mg vs Clor	mipramine 200mg ((non-responders)				
Lopez-lbor 1996	11	8.80(5.79)	13	13.70(11.79)		-0.50 [-1.31, 0.32]
Subtotal (95% CI)	11		13			-0.50 [-1.31, 0.32]
Test for heterogeneity: not	applicable				-	
Test for overall effect: Z =	1.19 (P = 0.23)					
02 Fluoxetine 20mg vs Clor	mipramine 100mg ((responders)				
Lopez-Ibor 1996	14	24.00(7.54)	8	15.00(9.32)		1.05 [0.12, 1.99]
Subtotal (95% CI)	14		8		-	1.05 [0.12, 1.99]
Test for heterogeneity: not	applicable				-	
Test for overall effect: Z =	2.21 (P = 0.03)					
Total (95% CI)	25		21		•	0.18 [-0.44, 0.79]
Test for heterogeneity: Chi-	² = 5.99, df = 1 (P	= 0.01), I ² = 83.3%			ľ	
Test for overall effect: Z =	0.56 (P = 0.57)	••				
				-4	-2 0 2	4

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 10 Sertraline standard dose vs high dose (non-responders)


Outcome: 01 Leaving study early



Review: OCD adults: SSRIs


Comparison: 10 Sertraline standard dose vs high dose (non-responders)

Outcome: 02 Leaving study early due to adverse events



Comparison: 10 Sertraline standard dose vs high dose (non-responders)

Outcome: 03 Non-responders



Review: OCD adults: SSRIs

Comparison: 11 SSRI vs Placebo (maintenance)

Outcome: 01 Leaving the study early

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl				RR (fixed) 95% Cl
01 Paroxetine							
Ansseau 1995	19/51	7/12		_			0.64 [0.35, 1.16]
Subtotal (95% CI)	51	12			-		0.64 [0.35, 1.16]
Total events: 19 (SSRI), 7 (PI	lacebo)			-			
Test for heterogeneity: not a	pplicable						
Test for overall effect: Z = 1	.47 (P = 0.14)						
		0.	1 0.2	0.5 1	2	5 10	

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Review: OCD adults: SSRIs

Comparison: 11 SSRI vs Placebo (maintenance)

Outcome: 02 Leaving the study early due to adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl					RR (fixed) 95% Cl
01 Paroxetine								
Ansseau 1995	8/51	2/12	_					0.94 [0.23, 3.88]
Subtotal (95% CI)	51	12	-			_		0.94 [0.23, 3.88]
Total events: 8 (SSRI), 2 (Place	ebo)				T			
Test for heterogeneity: not app	olicable							
Test for overall effect: Z = 0.00	8 (P = 0.93)							
		0	.1 0.2	0.5	1 2	5	10	

Review: OCD adults: SSRIs

Comparison: 11 SSRI vs Placebo (maintenance)

Outcome: 03 Adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine	40 (51	0.410	_	1.24 (2.21 1.22)
Ansseau 1995 Subtotal (95% Cl)	42/51 51	8/12 12	-	1.24 [0.81, 1.88] 1.24 [0.81, 1.88]
Total events: 42 (SSRI), 8 (Plants for heterogeneity: not ap				
Test for overall effect: Z = 0.	99 (P = 0.32)			
		0.1	0.2 0.5 1 2	5 10

Review: OCD adults: SSRIs

Comparison: 11 SSRI vs Placebo (maintenance)


Outcome: 04 Severe adverse events

Study or sub-category	SSRI n/N	Placebo n/N		•	fixed) % Cl		RR (fixed) 95% Cl		
01 Paroxetine									
Ansseau 1995	18/51	3/12				_		1.41 [0.49, 4.03]	
Subtotal (95% CI)	51	12				_		1.41 [0.49, 4.03]	
Total events: 18 (SSRI), 3 (Pl	acebo)				- -				
Test for heterogeneity: not ap	oplicable								
Test for overall effect: $Z = 0$.	64 (P = 0.52)								
			0.1 0.2	0.5	1 2	5	10		
			Favo	urs SSRI	Favours	Placebo)		

OCD adults: SSRIs Review:

11 SSRI vs Placebo (maintenance) Comparison:

05 Non-responders (Y-BOCS 25% reduction) Outcome:



Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Review:

OCD adults: SSRIs 11 SSRI vs Placebo (maintenance) Comparison: Outcome:

06 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	SMD (fixed) 95% CI	ı		SMD (fixed) 95% Cl
01 Paroxetine										
Ansseau 1995	51	-14.70(7.20)	12	-11.00(6.90)						-0.51 [-1.15, 0.12]
Subtotal (95% CI)	51		12				•			-0.51 [-1.15, 0.12]
Test for heterogeneity: not	applicable						Ĭ			
Test for overall effect: Z =	1.58 (P = 0.11)									
					-10	-5	-	5	10	

OCD adults: SSRIs Review:

Comparison: 11 SSRI vs Placebo (maintenance)

Outcome: 07 NIMH-OCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		5	SMD (fixed 95% CI)		SMD (fixed) 95% Cl
01 Paroxetine Ansseau 1995		5 0040 601	1.0	0.6040.604						0.61.7.1.05.0001
Subtotal (95% CI)	51 51	-5.20(2.60)	12 12	-3.60(2.60)			<u>-</u>			-0.61 [-1.25, 0.03] -0.61 [-1.25, 0.03]
Test for heterogeneity: not Test for overall effect: Z =	applicable		12							-0.61 (-1.25, 0.03)
					-10	-5	ó	5	10	

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 01 Leaving the study early

Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
O1 Paroxetine Ansseau 1995 Subtotal (95% CI) Total events: 19 (SSRI), 8 (C Test for heterogeneity: not a Test for overall effect: Z = 0	pplicable	8/20 20	+	0.93 [0.49, 1.77] 0.93 [0.49, 1.77]
		0.1	0.2 0.5 1 2 5	10

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)


Outcome: 02 Leaving the study early due to adverse events

Study or sub-category	SSRI n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine				
Ansseau 1995	8/51	6/20		0.52 [0.21, 1.32]
Subtotal (95% CI)	51	20		0.52 [0.21, 1.32]
Total events: 8 (SSRI), 6 (Clomipran	nine)			
Test for heterogeneity; not applicab	ole .			
Test for overall effect: Z = 1.38 (P :	= 0.17)			
				5 10
			0.2 0.0 1 2	

Favours SSRI Favours Clomipramine

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 03 Adverse events



Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 04 Severe adverse events

Study or sub-category	SSRI n/N	Clomipramine n <i>i</i> N	RR (fixed) 95% Cl		RR (fixed) 95% Cl
01 Paroxetine					
Ansseau 1995	18/51	2/20		 ;	3.53 [0.90, 13.84]
Subtotal (95% CI)	51	20	-	-	3.53 [0.90, 13.84]
Total events: 18 (SSRI), 2 (C	lomipramine)		-		
Test for heterogeneity: not a	pplicable				
Test for overall effect: $Z = 1$.81 (P = 0.07)				
		0.01	0.1 1	10 100	_

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 05 Responders (Y-BOCS 25% reduction)

Study or sub-category	SSRI n/N	Clomipramine n/N		RR (fi 95%			RR (fixed) 95% Cl
01 Paroxetine							
Ansseau 1995	8/51	3/20				-	1.05 [0.31, 3.55]
Subtotal (95% CI)	51	20				-	1.05 [0.31, 3.55]
Total events: 8 (SSRI), 3 (Clorn	ipramine)			I			
Test for heterogeneity: not app	olicable						
Test for overall effect: Z = 0.07	7 (P = 0.94)						
		0.1	0.2	0.5 1	2	5	10

Favours SSRI Favours Clomipramine

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)


Outcome: 06 Y-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Clomipramine Mean (SD)		\$	SMD (fixed) 95% CI	ı		(fixed) % Cl
01 Paroxetine										·
Ansseau 1995	51	-14.70(7.20)	20	-14.60(7.10)					-0.01 [-0.5	3, 0.50]
Subtotal (95% CI)	51		20				•		-0.01 [-0.5	3, 0.50]
Test for heterogeneity: not	applicable						I			
Test for overall effect: Z =	0.05 (P = 0.96)									
					40			<u> </u>	40	
					-10	-5	U	5	10	

Review: OCD adults: SSRIs

Comparison: 12 SSRI vs Clomipramine (maintenance)

Outcome: 07 NIMH-OCS



Favours SSRI Favours Clomipramine

Favours SSRI Favours Clomipramine

Comparison: 13 SSRI vs Placebo (relapse prevention)

Outcome: 01 Leaving the study early

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 2 months				
Ansseau 1995	0/14	3/18 -		0.18 [0.01, 3.24]
Subtotal (95% CI)	14	18		0.18 [0.01, 3.24]
Total events: 0 (Paroxetine), 3 (P	Placebo)		_	
Test for heterogeneity: not applic	cable			
Test for overall effect: $Z = 1.16$ ((P = 0.25)			
02 Paroxetine at 6 months				
Bailer 1995	9/20	16/24	-	0.68 [0.39, 1.18]
Subtotal (95% CI)	20	24	•	0.68 [0.39, 1.18]
Total events: 9 (Paroxetine), 16 ((Placebo)			
Test for heterogeneity: not applic	cable			
Test for overall effect: Z = 1.37 ((P = 0.17)			
Total (95% CI)	34	42	•	0.59 [0.33, 1.04]
Total events: 9 (Paroxetine), 19 ((Placebo)			
Test for heterogeneity: Chi² = 0.8	37, df = 1 (P = 0.35), l² = 0%	6		
Test for overall effect: Z = 1.83 ((P = 0.07)			
		0.0	01 0.1 1 10	100
		F	Favours Paroxetine Favours Placet	00

Review: OCD adults: SSRIs

Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 02 Leaving the study early due to adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 6 months				
Bailer 1995	0/20	9/24		0.06 [0.00, 1.01]
Subtotal (95% CI)	20	24		0.06 [0.00, 1.01]
Total events: 0 (Paroxetine),	9 (Placebo)			
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 1	.95 (P = 0.05)			
			0.001 0.01 0.1 1 10 100	1000

Favours Paroxetine Favours Placebo

Review: OCD adults: SSRIs

Comparison: 13 SSRI vs Placebo (relapse prevention)

Outcome: 03 Full relapse (Y-BOCS and CGI Severity increase)

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 6 months				
Bailer 1995	1/20	6/24		0.20 [0.03, 1.53]
Subtotal (95% CI)	20	24		0.20 [0.03, 1.53]
Total events: 1 (Paroxetine),	6 (Placebo)			
Test for heterogeneity; not a	pplicable			
Test for overall effect: $Z = 1$.	55 (P = 0.12)			
			0.01 0.1 1 10	100
			Favours Paroxetine Favours Pla	acebo

Comparison: 13 SSRI vs Placebo (relapse prevention)

Outcome: 04 Partial relapse (Y-BOCS or CGI Severity increase)

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 2 months				
Ansseau 1995	2/14	7/18		0.37 [0.09, 1.50]
Subtotal (95% CI)	14	18		0.37 [0.09, 1.50]
Total events: 2 (Paroxetine), Test for heterogeneity: not a Test for overall effect: Z = 1	pplicable			
02 Paroxetine at 6 months				
Bailer 1995	9/20	16/24	-	0.68 [0.39, 1.18]
Subtotal (95% CI)	20	24	-	0.68 [0.39, 1.18]
Total events: 9 (Paroxetine),	16 (Placebo)		-	
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 1	.37 (P = 0.17)			
		0	.01 0.1 1 10	100
			Favours Paroxetine Favours Placeb	о

Review: OCD adults: SSRIs

Comparison: 13 SSRI vs Placebo (relapse prevention)

Outcome: 05 Adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 2 months				
Ansseau 1995	8/14	9/18		1.14 [0.60, 2.18]
Subtotal (95% CI)	14	18		1.14 [0.60, 2.18]
Total events: 8 (Paroxetine)	, 9 (Placebo)		_	,
Test for heterogeneity: not a	applicable			
Test for overall effect: Z = 0	0.40 (P = 0.69)			
		0.1	0.2 0.5 1 2	5 10

Favours Paroxetine Favours Placebo

Review: OCD adults: SSRIs

Comparison: 13 SSRI vs Placebo (relapse prevention)

Outcome: 06 Severe adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine at 2 months				
Ansseau 1995	1/14	4/18		0.32 [0.04, 2.57]
Subtotal (95% CI)	14	18	-	0.32 [0.04, 2.57]
Total events: 1 (Paroxetine),	4 (Placebo)			·
Test for heterogeneity; not a				
Test for overall effect: Z = 1	• •			
			0.01 0.1 1 10	100
			Favours Paroxetine Favours F	Placebo

Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 07 Y-BOCS

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Paroxetine at 2 months						
Ansseau 1995	12	0.80(1.60)	12	0.90(3.20)	+	-0.04 [-0.84, 0.76]
Subtotal (95% CI)	12		12		•	-0.04 [-0.84, 0.76]
Test for heterogeneity: not app	licable					
Test for overall effect: $Z = 0.09$	9 (P = 0.93)					
02 Paroxetine at 6 months						
Bailer 1995	12	-3.50(3.60)	8	0.88(3.59)	-	-1.17 [-2.15, -0.19]
Subtotal (95% CI)	12		8		•	-1.17 [-2.15, -0.19]
Test for heterogeneity: not app	licable				-	
Test for overall effect: $Z = 2.33$	3 (P = 0.02)					
Total (95% CI)	24		20		•	-0.49 [-1.11, 0.13]
Test for heterogeneity: Chi² = 3	3.05, df = 1 (P	= 0.08), l ² = 67.2%			1	
Test for overall effect: Z = 1.54						
					-10 -5 0	5 10
					Favours Paroxetine Favours	s Placebo

OCD adults: SSRIs 13 SSRI vs Placebo (relapse prevention) 08 NIMH-OC Review: Comparison: Outcome:


Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Paroxetine at 2 months							
Ansseau 1995	11	0.20(0.90)	9	1.30(2.30)		-	-0.63 [-1.54, 0.28]
Subtotal (95% CI)	11		9			•	-0.63 [-1.54, 0.28]
Test for heterogeneity: not a	applicable						
Test for overall effect: $Z = 1$.36 (P = 0.17)						
02 Paroxetine at 6 months							
Bailer 1995	12	-0.67(1.66)	8	0.38(1.67)		-	-0.60 [-1.52, 0.31]
Subtotal (95% CI)	12		8			•	-0.60 [-1.52, 0.31]
Test for heterogeneity: not a	applicable]	
Test for overall effect: $Z = 1$.29 (P = 0.20)						
Total (95% CI)	23		17			•	-0.62 [-1.26, 0.03]
Test for heterogeneity: Chi ² :	= 0.00, df = 1 (P	= 0.97), I ² = 0%					
Test for overall effect: $Z = 1$.87 (P = 0.06)						
				-	10 -5	0 5	10
					Favours Pare	oxetine Favours Place	ebo

Clomipramine (OCD, adults)

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase

Outcome: 01 Adverse events



Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase

Outcome: 02 Leaving study early

Study or sub-category	Clomipramine n/N	Placebo n <i>i</i> N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
Burnham 1993	28/82	20/77		1.31 [0.81, 2.13]		
CCSG 1991(1)	17/118	13/121		1.34 [0.68, 2.64]		
CCSG 1991(2)	14/142	12/139		1.14 [0.55, 2.38]		
Stein 1992	7/21	2/23	-	→ 3.83 [0.89, 16.44]		
Zohar 1996a	34/99	39/99	-	0.87 [0.60, 1.26]		
Total (95% CI)	462	459	•	1.15 [0.90, 1.47]		
Total events: 100 (Clomipra	mine), 86 (Placebo)		T	•		
Test for heterogeneity: Chi ²	= 5.32, df = 4 (P = 0.26), l ² = 24.	9%				
Test for overall effect: Z = 1	1.11 (P = 0.27)					
		0.1	0.2 0.5 1 2 5	10		

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 03 Leaving study early due to adverse events

Study or sub-category	Clomipramine n/N	Placebo n/N				(fixed) 5% Cl			RR (fixed) 95% Cl
Burnham 1993	17/82	8/77							2.00 [0.91, 4.36]
Zohar 1996a	17/99	6/99					<u> </u>		2.83 [1.17, 6.89]
Total (95% CI)	181	176				-	-		2.35 [1.31, 4.22]
Total events: 34 (Clomipram	nine), 14 (Placebo)								
Test for heterogeneity: Chi ²	² = 0.34, df = 1 (P = 0.56), l ² = 0%								
Test for overall effect: Z = :	2.86 (P = 0.004)								
			0.1	0.2	0.5	1 2	5	10	_

Favours Clomipramine Favours Placebo

Favours Clomipramine Favours Placebo

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase


Outcome: 04 Non-responders (Y-BOCS)

Study or sub-category	Clomipramine n/N	Placebo n/N	RR (fixed) RR (fixed) 95% Cl 95% Cl
Burnham 1993	42/82	45/77	0.88 [0.66, 1.16]
Zohar 1996a	47/99	64/99	0.73 [0.57, 0.95]
Total (95% CI)	181	176	0.79 [0.66, 0.96]
Total events: 89 (Clomipran			
Test for heterogeneity: Chi ²	² = 0.83, df = 1 (P = 0.36), l ² = 0%		
Test for overall effect: Z =	2.40 (P = 0.02)		
-			0.1 0.2 0.5 1 2 5 10
			Favours Clomipramine Favours Placebo

OCD adults: Clomipramine Review:

01 Clomipramine vs placebo: acute phase Comparison:

05 Non-responders (CGI) Outcome:



Favours Clomipramine

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase

Outcome: 06 Non-responders (all)

Study or sub-category	Clomipramine n/N	Placebo n/N			RR (f 95%				RR (fixed) 95% Cl
Burnham 1993	42/82	45/77			_	_			0.88 [0.66, 1.16]
Stein 1992	14/21	17/23				_			0.90 [0.61, 1.33]
Zohar 1996a	47/99	64/99			-				0.73 [0.57, 0.95]
Total (95% CI)	202	199			•				0.81 [0.68, 0.96]
Total events: 103 (Clomipra	mine), 126 (Placebo)				*				
	$= 1.17$, df $= 2$ (P = 0.56), $I^2 = 0\%$								
Test for overall effect: Z = :	2.44 (P = 0.01)								
-			0.1	0.2	0.5 1	2	5	10	

Favours Clomipramine Favours placebo

Review: OCD adults: Clomipramine

Comparison: 01 Clomipramine vs placebo: acute phase

Outcome: 07 Non-remitters

Study or sub-category	Clomipramine n <i>i</i> N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
CCSG 1991 (pooled)	136/260	252/260	=	0.54 [0.48, 0.61]
Total (95% CI) Total events: 136 (Clomipramir Test for heterogeneity: not app Test for overall effect: Z = 10.	plicable	260	•	0.54 [0.48, 0.61]
-			1	5 10

Favours Clomipramine Favours placebo

OCD adults: Clomipramine Review:

01 Clomipramine vs placebo: acute phase 08 Y-BOCS Comparison:

Outcome:


Study or sub-category	N	Clomipramine Mean (SD)	N	Placebo Mean (SD)) (fixed) 5% Cl			SMD (fixed) 95% Cl
Burnham 1993	78	-7.73(7.42)	75	-4.60(7.53)		-	-			-0.42 [-0.74, -0.10]
CCSG 1991(1)	118	16.23(7.93)	120	25.11(6.68)		-				-1.21 [-1.48, -0.93]
CCSG 1991(2)	134	14.70(7.87)	129	25.59(6.01)		-				-1.55 [-1.82, -1.27]
Zohar 1996a	94	-8.00(8.20)	99	-5.00(7.90)		-	•			-0.37 [-0.66, -0.09]
Total (95% CI)	424		423			•				-0.93 [-1.07, -0.78]
Test for heterogeneity: Ch	$hi^2 = 47.71$, $df = 3$ ($(P < 0.00001), I^2 = 93.7\%$				•				·
Test for overall effect: Z	= 12.62 (P < 0.000)	01)								
					-4	-2	0	<u>;</u>	4	
					Favours	: Clomipramine	Favo	urs Place	bo	

Review: OCD adults: Clomipramine Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 09 OCD Scale (CPRS) SMD (fixed) SMD (fixed) Study Clomipramine Placebo orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Thoren 1980a 8 6.38(2.75) 8 8.75(3.18) -0.75 [-1.78, 0.27] Total (95% CI) -0.75 [-1.78, 0.27] Test for heterogeneity: not applicable Test for overall effect: Z = 1.44 (P = 0.15)Favours Clomipramine Favours Placebo Review: OCD adults: Clomipramine 01 Clomipramine vs placebo; acute phase Comparison: 10 6-item OCD Scale - amelioration Outcome: Study Clomipramine Placebo SMD (fixed) SMD (fixed) Ν Mean (SD) or sub-category Ν Mean (SD) 95% CI 95% CI Montgomery 1990 -10.00(5.11) 7 -0.71(5.11) -1.70 [-2.99, -0.42] Total (95% CI) 7 -1.70 [-2.99, -0.42] Test for heterogeneity: not applicable Test for overall effect: Z = 2.60 (P = 0.009)Favours Clomipramine Favours placebo OCD adults: Clomipramine Review: Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 11 OCD (OCD-CPRS; 6-item OCD Scale-amelioration) SMD (fixed) Study Clomipramine Placebo SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Montgomery 1990 -0.71(5.11) -10.00(5.11) -1.70 [-2.99, -0.42] Thoren 1980a 8 -0.75 [-1.78, 0.27] 6.38(2.75) 8.75(3.18) Total (95% CI) 15 -1.12 [-1.92, -0.32] Test for heterogeneity: Chi² = 1.28, df = 1 (P = 0.26), l² = 21.8% Test for overall effect: Z = 2.75 (P = 0.006) -10 10 Favours Clomipramine Favours placebo Review: OCD adults: Clomipramine Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 12 Y-BOCS/CPRS Clomipramine Placebo SMD (fixed) SMD (fixed) Study or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Y-BOCS Burnham 1993 78 -7.73(7.42) 75 -4.60(7.53) -0.42 [-0.74, -0.10] CCSG 1991(1) 118 16.23(7.93) 120 -1.21 [-1.48, -0.93] 25.11(6.68) CCSG 1991(2) 134 14.70(7.87) 129 25.59(6.01) -1.55 [-1.82, -1.27] -0.37 [-0.66, -0.09] -0.93 [-1.07, -0.78] Zohar 1996a 94 -8.00(8.20) 99 -5.00(7.90) Subtotal (95% CI) 423 424 Test for heterogeneity: Chi² = 47.71, df = 3 (P < 0.00001), l² = 93.7% Test for overall effect: Z = 12.62 (P < 0.00001)

02 OCD-CPRS Thoren 1980a 6.38(2.75) 8.75(3.18) -0.75 [-1.78, 0.27] Subtotal (95% CI) -0.75 [-1.78, 0.27] Test for heterogeneity: not applicable Test for overall effect: Z = 1.44 (P = 0.15) 03 6-item OCD Scale - amelioration -1.70 [-2.99, -0.42] -1.70 [-2.99, -0.42] Montgomery 1990 -10.00(5.11) -0.71(5.11)Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.60 (P = 0.009)Total (95% CI) -0.93 [-1.07, -0.79] 438 Test for heterogeneity: Chi² = 49.22, df = 5 (P < 0.00001), l² = 89.8% Test for overall effect: Z = 12.91 (P < 0.00001)

Favours Clomipramine Favours Placebo

Removing heterogeneity from Clomipramine v Placebo (Y-BOCS/CPRS): Burnham1993 and Zohar1996a removed because they reported change scores



Favours Clomipramine

Favours placebo

Test for overall effect: Z = 0.97 (P = 0.33)

Review: OCD adults: Clomipramine Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 16 Leyton Obsessional Inventory: resistance SMD (fixed) SMD (fixed) Study Clomipramine Placebo orsub-category N Ν Mean (SD) 95% CI 95% CI Thoren 1980a 8 -13.00(19.60) 8 -4.30(18.60) -0.43 [-1.43, 0.56] Total (95% CI) -0.43 [-1.43, 0.56] Test for heterogeneity: not applicable Test for overall effect: Z = 0.85 (P = 0.40) -10 10 Favours Clomipramine Favours placebo Review: OCD adults: Clomipramine Comparison 01 Clomipramine vs placebo: acute phase Outcome: 17 Leyton Obsessional Inventory: interference Study Clomipramine Placebo SMD (fixed) SMD (fixed) Ν Ν Mean (SD) 95% CI 95% CI or sub-category Mean (SD) Thoren 1980a -12.30(24.00) -8.40(15.90) -0.18 [-1.16, 0.80] Total (95% CI) -0.18 [-1.16, 0.80] Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72) Favours Clomipramine Favours placebo Review: OCD adults: Clomipramine Comparison: 01 Clomipramine vs placebo: acute phase Outcome: 18 Self-Rating Obsessive-Compulsive Personality Inventory Study Clomipramine Placebo SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Stein 1992 21 45.17(7.36) 23 49.31(7.36) -0.55 [-1.16, 0.05] Total (95% CI) 23 -0.55 [-1.16, 0.05] Test for heterogeneity: not applicable Test for overall effect: Z = 1.79 (P = 0.07)-10 10 Favours Clomipramine Favours Placebo OCD adults: Clomipramine Review: 01 Clomipramine vs placebo: acute phase Comparison: Outcome: 19 Montgomery-Asberg Depression Rating Scale Study Clomipramine Placebo SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Mean (SD) 95% CI 95% CI Zohar 1996a -2.40(7.30) 99 -0.60(7.90) -0.24 [-0.52, 0.05] Total (95% CI) 99 -0.24 [-0.52, 0.05] Test for heterogeneity: not applicable Test for overall effect: Z = 1.63 (P = 0.10) -10 -5 0 10 Favours Placebo Favours Clomipramine Review: OCD adults: Clomipramine Comparison 01 Clomipramine vs placebo: acute phase Outcome: 20 Clinical Global Impressions: severity of illness SMD (fixed) Study Placebo SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Zohar 1996a 94 -1.10(1.20) 99 -0.70(1.30) -0.32 [-0.60, -0.03] Total (95% CI) 99 -0.32 [-0.60, -0.03] Test for heterogeneity: not applicable Test for overall effect: Z = 2.20 (P = 0.03)-10 -5 10 Favours Clomipramine Favours Placebo Review: OCD adults: Clomipramine 01 Clomipramine vs placebo: acute phase Comparison: Outcome 21 Symptom Checklist-90 SMD (fixed) SMD (fixed) Study Clomipramine Placebo or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI Zohar 1996a 74 -31.90(39.90) 77 -19.50(37.30) -0.32 [-0.64, 0.00] Total (95% CI) 77 -0.32 [-0.64, 0.00] Test for heterogeneity: not applicable Test for overall effect: Z = 1.95 (P = 0.05) -5 5 10

Favours Placebo


Favours Clomipramine

Review: OCD adults: Clomipramine

Test for overall effect: Z = 1.00 (P = 0.32)

Comparison: 02 Clomipramine vs SSRIs: acute phase

Outcome: 01 Adverse events



0.01

0.1

Favours Clomipramine Favours SSRI

10

100

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 03 Leaving study early

Study	Clomipramine	SSRI	RR (fixed)	RR (fixed)
or sub-category	n/N	n/N	95% CI	95% CI
01 Clomipramine vs Fluoxetine				
Lopez-lbor 1996	4/25	5/30		0.96 [0.29, 3.20]
Subtotal (95% CI)	25	30		0.96 [0.29, 3.20]
otal events: 4 (Clomipramine),	5 (SSRI)		Т	
est for heterogeneity: not appl	licable			
est for overall effect: Z = 0.07	' (P = 0.95)			
02 Clomipramine vs Fluvoxamin	ie			
Freeman 1994	11/32	6/34	 •	1.95 [0.82, 4.65]
Koran 1996a	15/42	8/37	+-	1.65 [0.79, 3.45]
Milanfranchi 1997	1/13	0/13		— 3.00 [0.13, 67.51]
Mundo 2001	26/112	19/115	+	1.41 [0.83, 2.39]
Smeraldi 1992	1/6	1/6	+	1.00 [0.08, 12.56]
Subtotal (95% CI)	205	205	•	1.57 [1.07, 2.29]
Fotal events: 54 (Clomipramine)), 34 (SSRI)		'	
Test for heterogeneity: Chi² = 0	i.71, df = 4 (P = 0.95), i ² = 0%			
Fest for overall effect: Z = 2.34	(P = 0.02)			
03 Clomipramine vs Paroxetine				
Burnham 1993	28/82	28/82	+	1.00 [0.65, 1.53]
Zohar 1996a	34/99	49/201	 •	1.41 [0.98, 2.03]
Subtotal (95% CI)	181	283	♦	1.22 [0.92, 1.61]
'otal events: 62 (Clomipramine)				
est for heterogeneity: Chi² = 1		4%		
est for overall effect: Z = 1.41	(P = 0.16)			
04 Clomipramine vs Sertraline				
Askin 1999	4/22	2/20	- •	1.82 [0.37, 8.88]
Bisserbe 1997	35/82	23/86	 • -	1.60 [1.04, 2.45]
Subtotal (95% CI)	104	106	•	1.61 [1.06, 2.45]
otal events: 39 (Clomipramine)), 25 (SSRI)			
est for heterogeneity: Chi² = 0				
est for overall effect: Z = 2.25	5 (P = 0.02)			
otal (95% CI)	515	624	*	1.39 [1.14, 1.68]
otal events: 159 (Clomipramine				
est for heterogeneity: Chi² = 4				
Test for overall effect: $Z = 3.29$	9 (P = 0.001)			
		0.01	0.1 1 10	100
		Favo	urs Clomipramine Favours SSRI	

Outcome: 04 Leaving study early due to adverse events SSRI RR (fixed) RR (fixed) Study Clomipramine or sub-category nΝ n/N 95% CI 95% CI 01 Clomipramine vs Fluoxetine Lopez-Ibor 1996 1/25 1/30 1.20 [0.08, 18.23] Subtotal (95% CI) 25 30 1.20 [0.08, 18.23] Total events: 1 (Clomipramine), 1 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.13 (P = 0.90) 02 Clomipramine vs Fluvoxamine Freeman 1994 4/30 5/34 0.91 [0.27, 3.07] Koran 1996a 7/42 5/37 1.23 [0.43, 3.56] Milanfranchi 1997 0/13 0/13 Not estimable 2.05 [0.96, 4.38] 0.33 [0.02, 6.86] Mundo 2001 9/115 18/112 Smeraldi 1992 0/6 1/6 Subtotal (95% CI) 203 205 1.45 [0.85, 2.46] Total events: 29 (Clomipramine), 20 (SSRI) Test for heterogeneity: Chi² = 2.38, df = 3 (P = 0.50), l² = 0% Test for overall effect: Z = 1.38 (P = 0.17)03 Clomipramine vs Paroxetine 1.13 [0.61, 2.11] Burnham 1993 17/82 15/82 Zohar 1996a 17/99 18/201 1.92 [1.03, 3.56] Subtotal (95% CI) 181 283 1.48 [0.96, 2.29] Total events: 34 (Clomipramine), 33 (SSRI) Test for heterogeneity: $Chi^2 = 1.38$, df = 1 (P = 0.24), $I^2 = 27.5\%$ Test for overall effect: Z = 1.77 (P = 0.08) 04 Clomipramine vs Sertraline Bisserbe 1997 21/82 9/86 2.45 [1.19, 5.03] Subtotal (95% CI) 2.45 [1.19, 5.03] Total events: 21 (Clomipramine), 9 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.44 (P = 0.01) Total (95% CI) 491 604 1.61 [1.19, 2.18] Total events: 85 (Clomipramine), 63 (SSRI) Test for heterogeneity: $Chi^2 = 5.41$, df = 7 (P = 0.61), $I^2 = 0\%$ Test for overall effect: Z = 3.11 (P = 0.002) 0.01 0.1 10 100 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine 02 Clomipramine vs SSRIs; acute phase Comparison: Outcome: 05 Non-responders (25% Y-BOCS) SSRI RR (fixed) RR (fixed) Study Clomipramine or sub-category n/N nΝ 95% CI 95% CI 01 Clomipramine vs Fluvoxamine Koran 1996a 21/42 18/37 1.03 [0.66, 1.61] Subtotal (95% CI) 1.03 [0.66, 1.61] 42 37 Total events: 21 (Clomipramine), 18 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.12 (P = 0.90) 02 Clomipramine vs Paroxetine Zohar 1996a 47/99 92/201 1.04 [0.80, 1.34] Subtotal (95% CI) 99 201 1.04 [0.80, 1.34] Total events: 47 (Clomipramine), 92 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) Total (95% Ch. 238 1.03 [0.83, 1.29] Total events: 68 (Clomipramine), 110 (SSRI) Test for heterogeneity: $Chi^2 = 0.00$, df = 1 (P = 0.97), $I^2 = 0\%$ Test for overall effect: Z = 0.30 (P = 0.76)0.2 0.5 10 5

Favours Clomipramine Favours SSRI

Review:

Comparison:

OCD adults: Clomipramine

02 Clomipramine vs SSRIst acute phase

Review: OCD adults: Clomipramine 02 Clomipramine vs SSRIs; acute phase Comparison: Outcome: 06 Non-responders (35% Y-BOCS) SSRI RR (fixed) RR (fixed) Study Clomipramine or sub-category n/Ν n/Ν 95% CI 95% CI 01 Clomipramine vs Fluvoxamine Mundo 2001 44/112 46/115 0.98 [0.71, 1.35] Subtotal (95% CI) 112 115 0.98 [0.71, 1.35] Total events: 44 (Clomipramine), 46 (SSRI) Test for heterogeneity; not applicable Test for overall effect: Z = 0.11 (P = 0.91) 0.1 0.2 0.5 5 10 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine Comparison: 02 Clomipramine vs SSRIs: acute phase 07 Non-responders (CGI; 25% Y-BOCS) Outcome: SSRL RR (fixed) Study Clomipramine RR (fixed) or sub-category nΝ n/N 95% CI 95% CI 01 Clomipramine vs Fluoxetine 0.60 [0.37, 0.98] Lopez-lbor 1996 11/25 22/30 Subtotal (95% CI) 25 30 0.60 [0.37, 0.98] Total events: 11 (Clomipramine), 22 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.03 (P = 0.04) 02 Clomipramine vs Paroxetine Burnham 1993 42/82 47/82 0.89 [0.67, 1.18] Subtotal (95% CI) 82 0.89 [0.67, 1.18] Total events: 42 (Clomipramine), 47 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.78 (P = 0.43) Total (95% Ch. 0.81 [0.63, 1.03] 107 112 Total events: 53 (Clomipramine), 69 (SSRI) Test for heterogeneity: Chi² = 1.90, df = 1 (P = 0.17), l² = 47.3% Test for overall effect: Z = 1.73 (P = 0.08) 0.2 0.5 10 Favours SSRI Favours Clomipramine Review: OCD adults: Clomipramine Comparison: 02 Clomipramine vs SSRIs; acute phase Outcome: 09 Non-responders (CGI-I) Study SSRI RR (fixed) RR (fixed) Clomipramine or sub-category 95% CL 95% CL n/N n/Ν 01 Clomipramine vs Fluvoxamine Milanfranchi 1997 3/13 2/13 1.50 [0.30, 7.55] Subtotal (95% CI) 1.50 [0.30, 7.55] 13 13 Total events: 3 (Clomipramine), 2 (SSRI) Test for heterogeneity; not applicable Test for overall effect: Z = 0.49 (P = 0.62) 02 Clomipramine vs Sertraline 1.27 [0.81, 1.98] 1.27 [0.81, 1.98] Bisserbe 1997 29/82 24/86

82

86

99

0.2

Favours Clomipramine

0.5

5 10

Favours SSRI

1.29 [0.83, 1.98]

Subtotal (95% CI)

Total (95% CI)

Total events: 29 (Clomipramine), 24 (SSRI) Test for heterogeneity: not applicable Test for overall effect: Z = 1.04 (P = 0.30)

Total events: 32 (Clomipramine), 26 (SSRI)

Test for overall effect: Z = 1.14 (P = 0.25)

Test for heterogeneity: $Chi^2 = 0.04$, df = 1 (P = 0.84), $I^2 = 0\%$

Review: OCD adults: Clomipramine

Comparison: 02 Clomipramine vs SSRIs: acute phase

10 Non-responders (all) Outcome:

Study	Clomipramine	SSRI	RR (fixed)	RR (fixed)
or sub-category	n/N	n/N	95% CI	95% CI
1 Clomipramine vs Fluoxetine				
Lopez-Ibor 1996	11/25	22/30		0.60 [0.37, 0.98]
ubtotal (95% CI)	25	30		0.60 [0.37, 0.98]
otal events: 11 (Clomipramine), 22 (SSRI)		-	·
est for heterogeneity: not app	olicable			
est for overall effect: Z = 2.03	3 (P = 0.04)			
2 Clomipramine vs Fluvoxamir	ne			
(oran 1996a	21/42	18/37		1.03 [0.66, 1.61]
Milanfranchi 1997	3/13	2/13		- 1.50 [0.30, 7.55]
Mundo 2001	44/112	46/115		0.98 [0.71, 1.35]
ubtotal (95% CI)	167	165	•	1.01 [0.78, 1.31]
otal events: 68 (Clomipramine), 66 (SSRI)		T	,
est for heterogeneity: Chi² = 0	0.27 , df = 2 (P = 0.88), I^2 = 0%			
est for overall effect: Z = 0.08	8 (P = 0.93)			
3 Clomipramine vs Paroxetine				
Burnham 1993	42/82	47/82		0.89 [0.67, 1.18]
ohar 1996a	47/99	92/201	-	1.04 [0.80, 1.34]
ubtotal (95% CI)	181	283	•	0.97 [0.81, 1.18]
otal events: 89 (Clomipramine), 139 (SSRI)			
est for heterogeneity: Chi² = 0 est for overall effect: Z = 0.27	0.59, df = 1 (P = 0.44), l² = 0% 7 (P = 0.79)			
4 Clomipramine vs Sertraline				
Bisserbe 1997	29/82	24/86	+-	1.27 [0.81, 1.98]
ubtotal (95% Cl)	82	86	-	1.27 [0.81, 1.98]
otal events: 29 (Clomipramine), 24 (SSRI)		-	
est for heterogeneity: not app				
est for overall effect: Z = 1.04	4 (P = 0.30)			
otal (95% CI)	455	564	\	0.98 [0.85, 1.13]
otal events: 197 (Clomipramin				
	6.01 , $df = 6$ (P = 0.42), $I^2 = 0.1$	%		
est for overall effect: Z = 0.24	4 (P = 0.81)			
			0.1 0.2 0.5 1 2 5	10
		1	Favours Clomipramine Favours SSRI	
outown OCD adulta: Clamb	promino			

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 11 Y-BOCS

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Clomipramine vs Fluoxeti	ne					
Lopez-lbor 1996	24	-8.90(7.13)	30	-7.50(9.29)		-0.16 [-0.70, 0.37]
Subtotal (95% CI)	24		30			-0.16 [-0.70, 0.37]
Test for heterogeneity: not a	applicable					
Test for overall effect: $Z = 0$).60 (P = 0.55)					
02 Clomipramine vs Fluvoxa	mine					
Koran 1996a	39	17.00(8.55)	34	17.80(7.70)		-0.10 [-0.56, 0.36]
Milanfranchi 1997	12	16.50(11.00)	13	18.40(9.20)		-0.18 [-0.97, 0.60]
Mundo 2001	61	12.50(8.00)	67	14.70(10.10)		-0.24 [-0.59, 0.11]
Smeraldi 1992	5	15.20(12.40)	5	18.20(2.50)	+ ·	-0.30 [-1.55, 0.95]
Subtotal (95% CI)	117		119			-0.19 [-0.45, 0.06]
Test for heterogeneity: Chi ²	= 0.26, df $= 3$ (P	= 0.97), I ² = 0%				
Test for overall effect: $Z = 1$.46 (P = 0.14)					
03 Clomipramine vs Paroxeti	ine					
Burnham 1993	78	-7.73(7.42)	79	-5.61(7.47)		-0.28 [-0.60, 0.03]
Zohar 1996a	94	-8.00(8.20)	198	-8.00(8.00)	- + -	0.00 [-0.25, 0.25]
Subtotal (95% CI)	172		277		-	-0.11 [-0.30, 0.09]
Test for heterogeneity: Chi ²		= 0.16), I ² = 48.4%				
Test for overall effect: $Z = 1$.09 (P = 0.28)					
Total (95% CI)	313		426		•	-0.14 [-0.29, 0.01]
Test for heterogeneity: Chi ²		= 0.87), I ² = 0%				
Test for overall effect: $Z = 1$.85 (P = 0.06)					
					-1 -0.5 0 0.5	1
					Favours Clomipramine Favours SS	RI

Review: OCD adults: Clomipramine

02 Clomipramine vs SSRIs: acute phase 12 NIMH-OC Comparison:

Outcome:

N	Mean (SD)	N	Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
105	5.90(2.80)	112	5.90(3.10)		0.00 [-0.27, 0.27]
105		112		-	0.00 [-0.27, 0.27]
able				T	
P = 1.00)					
78	-2.06(2.03)	79	-1.42(2.04)		-0.31 [-0.63, 0.00]
94	-2.50(2.60)	198	-2.50(2.90)		0.00 [-0.25, 0.25]
172		277		-	-0.12 [-0.31, 0.08]
6, df = 1 (P)	P = 0.12), I ² = 57.6%			-	
P = 0.23)					
277		389		•	-0.08 [-0.23, 0.08]
6, df = 2 (P	P = 0.24), I ² = 30.0%				
P = 0.33)					
3 (1)	105 105 cable (P = 1.00) 78 94 172 36, df = 1 (F P = 0.23)	105 5.90(2.80) 105 table (P = 1.00) 78 -2.06(2.03) 94 -2.50(2.60) 172 36, df = 1 (P = 0.12), P = 57.6% (P = 0.23) 277 36, df = 2 (P = 0.24), P = 30.0%	105 5.90(2.80) 112 105 112 table (P = 1.00) 78 -2.06(2.03) 79 94 -2.50(2.60) 198 172 277 36, df = 1 (P = 0.12), P = 57.6% (P = 0.23) 277 389	105 5.90(2.80) 112 5.90(3.10) 105 112 cable (P = 1.00) 78 -2.06(2.03) 79 -1.42(2.04) 94 -2.50(2.60) 198 -2.50(2.90) 172 277 36, df = 1 (P = 0.12), F = 57.6% (P = 0.23) 277 389	105 5.90(2.80) 112 5.90(3.10) 105 112 cable P = 1.00) 78 -2.06(2.03) 79 -1.42(2.04) 94 -2.50(2.60) 198 -2.50(2.90) 172 277 36, df = 1 (P = 0.12), P = 57.6% P = 0.23) 277 389

Review:

Comparison:

OCD adults: Clomipramine
02 Clomipramine vs SSRIs: acute phase
13 Comprehensive Psychopathological Rating Scale: obsessive-compulsive Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)		S	SMD (fixed 95% CI)	;	SMD (fixed) 95% Cl
01 Clomipramine vs Fluoxe Lopez-lbor 1996 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =	24 24 applicable	-10.90(7.33)	30 30	-8.10(7.64)	_	-				-0.91, 0.17] -0.91, 0.17]
					-1	-0.5	0	0.5	1	

Review: OCD adults: Clomipramine

02 Clomipramine vs SSRIs: acute phase 14 Hamilton Rating Scale for Depression Comparison: Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Clomipramine vs Fluoxetin	ne					
Lopez-Ibor 1996	24	-9.40(7.71)	30	-7.50(5.93)		-0.28 [-0.82, 0.26]
Subtotal (95% Cl)	24		30			-0.28 [-0.82, 0.26]
Test for heterogeneity: not a	pplicable					
Test for overall effect: Z = 1	.00 (P = 0.32)					
02 Clomipramine vs Fluvoxar	nine					
Koran 1996a	39	5.80(4.70)	34	6.10(3.30)		-0.07 [-0.53, 0.39]
Mundo 2001	105	7.00(4.50)	112	7.70(6.00)		-0.13 [-0.40, 0.14]
Subtotal (95% CI)	144		146			-0.12 [-0.35, 0.11]
Test for heterogeneity: Chi ² :	= 0.05, df = 1 (F	² = 0.83), I ² = 0%			-	
Test for overall effect: Z = 0	.99 (P = 0.32)					
Total (95% CI)	168		176			-0.14 [-0.35, 0.07]
Test for heterogeneity: Chi ² :	= 0.33, df $= 2$ (F	² = 0.85), I ² = 0%				
Test for overall effect: Z = 1	.30 (P = 0.19)	**				

Favours Clomipramine Favours SSRI

Favours Clomipramine Favours SSRI

Comparison: 02 Clomipramine vs SSRIs: acute phase Outcome: 15 Montgomery-Asberg Depression Rating Scale SMD (fixed) SMD (fixed) Study SSRI Clomipramine or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Fluoxetine Lopez-lbor 1996 24 -13.80(9.09) 30 -10.10(8.20) -0.42 [-0.97, 0.12] Subtotal (95% CI) 24 30 -0.42 [-0.97, 0.12] Test for heterogeneity: not applicable Test for overall effect: Z = 1.53 (P = 0.13) Smeraldi 1992 5 9.60(10.30) 5 11.80(6.80) -0.23 [-1.47, 1.02] Subtotal (95% CI) 5 -0.23 [-1.47, 1.02] Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72) 03 Clomipramine vs Paroxetine Zohar 1996a 94 -2.40(7.30) 198 -3.40(7.90)0.13 [-0.12, 0.38] Subtotal (95% CI) 198 0.13 [-0.12, 0.38] Test for heterogeneity: not applicable Test for overall effect: Z = 1.03 (P = 0.30) Total (95% CI) 233 0.03 [-0.19, 0.25] Test for heterogeneity: $Chi^2 = 3.47$, df = 2 (P = 0.18), $I^2 = 42.4\%$ Test for overall effect: Z = 0.24 (P = 0.81) Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine 02 Clomipramine vs SSRIs; acute phase Comparison: 16 Depression (HRSD; MADRS) Outcome: Study Clomipramine SSRI SMD (fixed) SMD (fixed) Ν Mean (SD) or sub-category Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Fluvoxamine Koran 1996a 39 5.80(4.70) 34 6.10(3.30) -0.07 [-0.53, 0.39] Mundo 2001 105 7.00(4.50) 112 7,70(6,00) -0.13 [-0.40, 0.14] Smeraldi 1992 -0.23 [-1.47, 1.02] 5 11.80(6.80) 9.60(10.30) 5 Subtotal (95% CI) -0.12 [-0.35, 0.11] Test for heterogeneity: Chi² = 0.08, df = 2 (P = 0.96), l² = 0% Test for overall effect: Z = 1.04 (P = 0.30) 02 Clomipramine vs Paroxetine Zohar 1996a -2.40(7.30) 198 -3.40(7.90) 0.13 [-0.12, 0.38] Subtotal (95% CI) 94 198 0.13 [-0.12, 0.38] Test for heterogeneity: not applicable Test for overall effect: Z = 1.03 (P = 0.30) Total (95% CI) 349 -0.01 [-0.17, 0.16] Test for heterogeneity: Chi² = 2.21, df = 3 (P = 0.53), l² = 0% Test for overall effect: Z = 0.06 (P = 0.95) -2 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine Comparison: 02 Clomipramine vs SSRIs; acute phase Outcome: 17 Clinical Anxiety Scale SSRI SMD (fixed) SMD (fixed) Study Clomipramine N Mean (SD) 95% CI or sub-category Mean (SD) 01 Clomipramine vs Fluvoxamine Mundo 2001 6.70(4.30) 7.00(4.60) -0.07 [-0.33, 0.20] 105 112 Subtotal (95% CI) 105 112 -0.07 [-0.33, 0.20] Test for heterogeneity: not applicable Test for overall effect: Z = 0.49 (P = 0.62) -0.5 0.5 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine 02 Clomipramine vs SSRIs; acute phase Comparison: 18 Covi Anxiety Scale Outcome: Study Clomipramine SSRI SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Fluoxetine Lopez-lbor 1996 -2.40(3.09) 30 -2.40(3.10) 0.00 [-0.54, 0.54] Subtotal (95% CI) 24 30 0.00 [-0.54, 0.54]

-5

Favours Clomipramine Favours SSRI

10

Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)

Review:

OCD adults: Clomipramine

Review: OCD adults: Clomipramine

Comparison: 02 Clomipramine vs SSRIs; acute phase

19 Anxiety (Clinical Anxiety Scale; Covi Anxiety Scale) Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Clomipramine vs Fluvox	amine					
Mundo 2001	105	6.70(4.30)	112	7.00(4.60)		-0.07 [-0.33, 0.20]
Subtotal (95% CI)	105		112			-0.07 [-0.33, 0.20]
Test for heterogeneity: not	applicable				٦	·
Test for overall effect: Z =	0.49 (P = 0.62)					
02 Clomipramine vs Fluoxet	tine					
Lopez-lbor 1996	24	-2.40(3.09)	30	-2.40(3.10)		0.00 [-0.54, 0.54]
Subtotal (95% CI)	24		30			0.00 [-0.54, 0.54]
Test for heterogeneity: not	applicable				_T_	·
Test for overall effect: Z =	0.00 (P = 1.00)					
Total (95% CI)	129		142			-0.05 [-0.29, 0.18]
Test for heterogeneity: Chi-	$^{2} = 0.05$, df = 1 (F	P = 0.83), I ² = 0%			٦	
Test for overall effect: Z =	0.44 (P = 0.66)	••				
					-1 -0.5 0 0.5	1

Review: OCD adults: Clomipramine

Comparison: 02 Clomipramine vs SSRIs; acute phase 20 Clinical Global Impressions: global improvement Outcome:

Study SSRI SMD (fixed) SMD (fixed) Clomipramine or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Fluoxetine Lopez-lbor 1996 -2.60(1.19) 30 -2.60(1.13) 0.00 [-0.54, 0.54] 24 Subtotal (95% CI) 30 0.00 [-0.54, 0.54] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) 02 Clomipramine vs Fluvoxamine Mundo 2001 Subtotal (95% CI) 0.00 [-0.27, 0.27] 0.00 [-0.27, 0.27] 105 2.30(1.00) 112 2.30(1.00) 105 112 Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) Total (95% CI) 0.00 [-0.24, 0.24] Total (95% CI) 129 Test for heterogeneity: $Chi^2 = 0.00$, df = 1 (P = 1.00), $I^2 = 0\%$ 142 Test for overall effect: Z = 0.00 (P = 1.00)

> -0.5 Favours Clomipramine Favours SSRI

0.5

Favours Clomipramine Favours SSRI

Review: OCD adults: Clomipramine

02 Clomipramine vs SSRIs; acute phase 21 Clinical Global Impressions; severity of illness Comparison: Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	SSRI Mean (SD)			(fixed) 5% Cl		SMD (fixed) 95% CI
01 Clomipramine vs Fluoxetine									
Lopez-lbor 1996	24	-1.90(1.14)	30	-0.90(1.23)		-			-0.83 [-1.39, -0.27]
Subtotal (95% CI)	24		30			•			-0.83 [-1.39, -0.27]
Test for heterogeneity: not app	licable								
Test for overall effect: Z = 2.89	9 (P = 0.004)								
02 Clomipramine vs Fluvoxamin	ne								
Mundo 2001	105	3.20(1.20)	112	3.40(1.30)			=		-0.16 [-0.43, 0.11]
Subtotal (95% CI)	105		112				•		-0.16 [-0.43, 0.11]
Test for heterogeneity: not app	licable								
Test for overall effect: $Z = 1.17$	7 (P = 0.24)								
03 Clomipramine vs Paroxetine									
Zohar 1996a	94	-1.10(1.20)	194	-1.20(1.40)			-		0.07 [-0.17, 0.32]
Subtotal (95% CI)	94		194				*		0.07 [-0.17, 0.32]
Test for heterogeneity: not app	licable								
Test for overall effect: $Z = 0.59$	9 (P = 0.55)								
Total (95% CI)	223		336				•		-0.11 [-0.28, 0.06]
Test for heterogeneity: Chi² = 8	3.57, $df = 2$ (F	P = 0.01), I ² = 76.7%					1		·
Test for overall effect: Z = 1.23	3 (P = 0.22)	• •							
					-4	-2	0 2	4	
					Favours Cl	lominramine	Favours SS	21	

Outcome: 22 Symptom Checklist-90 SMD (fixed) SMD (fixed) Study SSRI Clomipramine orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Paroxetine Zohar 1996a -31.90(39.90) 169 -29.00(47.10) -0.06 [-0.34, 0.21] Subtotal (95% CI) 169 -0.06 [-0.34, 0.21] Test for heterogeneity: not applicable Test for overall effect: Z = 0.46 (P = 0.65)0.5 Favours Clomipramine Favours SSRI Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs 01 Leaving study early Outcome: Clomipramine TCA RR (fixed) RR (fixed) Study 95% CI 95% CI or sub-category n/N nΝ 01 Clomipramine vs Imipramine 0.82 [0.23, 2.87] Volavka 1985 3/11 4/12 Subtotal (95% CI) 12 0.82 [0.23, 2.87] 11 Total events: 3 (Clomipramine), 4 (TCA) Test for heterogeneity: not applicable Test for overall effect: Z = 0.31 (P = 0.75) 02 Clomipramine vs Amitriptyline Ananth 1981 1/10 2/10 0.50 [0.05, 4.67] 0.50 [0.05, 4.67] Subtotal (95% CI) 10 10 Total events: 1 (Clomipramine), 2 (TCA) Test for heterogeneity: not applicable Test for overall effect: Z = 0.61 (P = 0.54) Total (95% CI) 22 0.71 [0.24, 2.12] 21 Total events: 4 (Clomipramine), 6 (TCA) Test for heterogeneity: $Chi^2 = 0.14$, df = 1 (P = 0.70), $I^2 = 0\%$ Test for overall effect: Z = 0.62 (P = 0.54) 0.01 0.1 10 100 Favours Clomipramine Favours TCA Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 02 Leaving study early due to adverse effects Clomipramine TCA RR (fixed) RR (fixed) Study or sub-category nΝ n/Ν 95% CI 95% CI 01 Clomipramine vs Imipramine Volavka 1985 2/11 2/12 1.09 [0.18, 6.48] Subtotal (95% CI) 12 1.09 [0.18, 6.48] 11 Total events: 2 (Clomipramine), 2 (TCA) Test for heterogeneity: not applicable Test for overall effect: Z = 0.10 (P = 0.92) 0.2 0.1 0.5 5 10 Favours Clomipramine Favours TCA Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 03 Levton Obsessional Inventory: symptom Study TCA SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Nortriptyline -3.00(3.10) -4.40(9.60) -0.19 [-1.17, 0.80]

-0.19 [-1.17, 0.80]

Favours Clomipramine Favours TCA

Subtotal (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.37 (P = 0.71)

OCD adults: Clomipramine

02 Clomipramine vs SSRIs; acute phase

Review: Comparison:

Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 04 Leyton Obsessional Inventory: trait TCA SMD (fixed) SMD (fixed) Study Clomipramine or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Nortriptyline Thoren 1980a -1.90(2.30) -1.50(1.10) -0.21 [-1.19, 0.77] Subtotal (95% CI) -0.21 [-1.19, 0.77] Test for heterogeneity: not applicable Test for overall effect: Z = 0.42 (P = 0.68) Favours Clomipramine Favours TCA Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 05 Leyton Obsessional Inventory: resistance Study Clomipramine TCA SMD (fixed) SMD (fixed) Ν Ν Mean (SD) 95% CI 95% CI or sub-category Mean (SD) 01 Clomipramine vs Nortriptyline Thoren 1980a -13.00(19.60) 8 -4.60(15.90) -0.45 [-1.44, 0.55] Subtotal (95% CI) -0.45 [-1.44, 0.55] Test for heterogeneity: not applicable Test for overall effect: Z = 0.88 (P = 0.38) Favours TCA Favours Clomipramine Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 06 Leyton Obsessional Inventory: interference Study Clomipramine SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Nortriptyline Thoren 1980a 8 -12.30(24.00) 8 -19.00(15.90) 0.31 [-0.68, 1.30] Subtotal (95% CI) 0.31 [-0.68, 1.30] Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) Favours Clomipramine Favours TCA OCD adults: Clomipramine Review: Comparison: 03 Clomipramine vs TCAs Outcome Study Clomipramine TCA SMD (fixed) SMD (fixed) Mean (SD) or sub-category N Mean (SD) 95% CI 95% CI 01 Clomipramine vs Nortriptyline Thoren 1980a 6.38(2.75) 8 7.31(2.89) -0.31 [-1.30, 0.68] Subtotal (95% CI) -0.31 [-1.30, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) Favours Clomipramine Favours TCA OCD adults: Clomipramine Review: Comparison 03 Clomipramine vs TCAs Outcome: 08 Self-Rating Obsessive Compulsive Personality Inventory SMD (fixed) Study TCA SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Imipramine Volavka 1985 47.90(14.40) 68.70(12.90) -1.44 [-2.57, -0.30] Subtotal (95% CI) -1.44 [-2.57, -0.30] Test for heterogeneity: not applicable Test for overall effect: Z = 2.48 (P = 0.01)Favours Clomipramine Favours TCA Review: OCD adults: Clomipramine 03 Clomipramine vs TCAs Comparison: 09 Self-Rating Obsessional Neurotic Scale SMD (fixed) SMD (fixed) Study Clomipramine TCA or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI 01 Clomipramine vs Imipramine -1.17 [-2.26, -0.09] -1.17 [-2.26, -0.09] Volavka 1985 8 41.90(13.90) 8 63.60(20.50) Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.11 (P = 0.03) 0

Favours Clomipramine Favours TCA

Review: OCD adults: Clomipramine Comparison: 03 Clomipramine vs TCAs Outcome: 10 Hamilton Rating Scale for Depression Study or sub-category N 01 Clomipramine vs Imipramine Volavka 1985 Subtotal (95% CI)

TCA SMD (fixed) SMD (fixed) Clomipramine Mean (SD) N Mean (SD) 95% CI 95% CI 2.01(2.20) 6.20(4.90) -1.04 [-2.11, 0.02] 8 -1.04 [-2.11, 0.02] Test for heterogeneity: not applicable Test for overall effect: Z = 1.92 (P = 0.05)

Favours Clomipramine Favours TCA

Favours Clomipramine Favours TCA

OCD adults: Clomipramine Review: Comparison: 03 Clomipramine vs TCAs Outcome: 11 Global Evaluation of Efficacy

Study or sub-category	N	Clomipramine Mean (SD)	N	TCA Mean (SD)			MD (fixed) 95% Cl)		SMD (fixed) 95% Cl
01 Clomipramine vs Imiprar Volavka 1985 Subtotal (95% Cl) Test for heterogeneity: not Test for overall effect: Z =	8 8 t applicable	1.75(0.89)	8 8	2.88(1.13)		4				-1.05 [-2.12, 0.02] -1.05 [-2.12, 0.02]
					-4	-2	Ó	2	4	

OCD adults: Clomipramine Review: Comparison: 04 Clomipramine vs other drugs 01 Adverse effects Outcome:

Study Clomipramine Other drug RR (fixed) RR (fixed) or sub-category n/Ν nN95% CI 95% CI 01 Clomipramine vs Venlafaxine Albert 2002 43/47 16/26 1.49 [1.08, 2.04] Subtotal (95% CI) 47 26 1.49 [1.08, 2.04] Total events: 43 (Clomipramine), 16 (Other drug) Test for heterogeneity: not applicable Test for overall effect: Z = 2.46 (P = 0.01) 0.2 0.5 5

Favours Clomipramine Favours other drug

Favours Clomipramine Favours other drug

ż

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs Outcome: 02 Leaving study early

Study or sub-category	Clomipramine n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clomipramine vs Buspirone				
Pato 1991	1/10	1/10	<u>-</u>	1.00 [0.07, 13.87]
Subtotal (95% CI)	10	10		1.00 [0.07, 13.87]
Total events: 1 (Clomipramine), 1 (Other drug)		T	
Test for heterogeneity: not applica	ble			
Test for overall effect: Z = 0.00 (P	= 1.00)			
02 Clomipramine vs Phenelzine				
Vallejo 1992	2/16	2/14		0.88 [0.14, 5.42]
Subtotal (95% CI)	16	14		0.88 [0.14, 5.42]
Total events: 2 (Clomipramine), 2 (Other drug)		T	
Test for heterogeneity: not applica	ble			
Test for overall effect: Z = 0.14 (P	= 0.89)			
03 Clomipramine vs Venlafaxine				
Albert 2002	7/47	1/26		3.87 [0.50, 29.77]
Subtotal (95% CI)	47	26		3.87 [0.50, 29.77]
fotal events: 7 (Clomipramine), 1 (Other drug)			·
est for heterogeneity: not applica				
Test for overall effect: Z = 1.30 (P				
		0.01	0.1 1 10	100

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs

Outcome: 03 Leaving study early due to adverse effects

RR (fixed) 95% Cl
[0.14, 65.90]
[0.14, 65.90]
[0.12, 60.21]
[0.12, 60.21]
•
[0.36, 107.66]
[0.36, 107.66]
_

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs

Outcome: 04 Non-responders

Study or sub-category	Clomipramine n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clomipramine vs Venlafa	xine			
Albert 2002	27/47	17/26		0.88 [0.61, 1.28]
Subtotal (95% CI)	47	26		0.88 [0.61, 1.28]
Total events: 27 (Clomipram	ine), 17 (Other drug)		_	
Test for heterogeneity: not a	applicable			
Test for overall effect: Z = 0	0.68 (P = 0.50)			
			0.5 0.7 1 1.5	2

Favours Clomipramine Favours other drug

Favours Clomipramine Favours other drug

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs

Outcome: 05 Y-BOCS

Study or sub-category	N	Clomipramine Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Clomipramine vs Buspiron	ie					
Pato 1991	9	17.67(4.97)	9	16.78(6.46)		0.15 [-0.78, 1.07]
Subtotal (95% CI)	9		9		-	0.15 [-0.78, 1.07]
est for heterogeneity; not a	pplicable				T-	
est for overall effect: $Z = 0$.	31 (P = 0.76)					
02 Clomipramine vs Venlafax	tine					
Albert 2002	47	17.30(6.15)	26	18.36(7.11)	-	-0.16 [-0.64, 0.32]
Subtotal (95% CI)	47		26		•	-0.16 [-0.64, 0.32]
est for heterogeneity; not a	pplicable				7	•
Test for overall effect: $Z = 0$.	.66 (P = 0.51)					

Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs

Outcome: 06 NIMH-OC

SMD (fixed) 95% Cl SMD (fixed) 95% CI Other drug Study Clomipramine Mean (SD) or sub-category Ν Mean (SD) N 01 Clomipramine vs Buspirone 0.08 [-0.84, 1.01] 0.08 [-0.84, 1.01] 9 9 5.11(1.27) Pato 1991 5.22(1.20) Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.18 (P = 0.86) -2 Favours Clomipramine Favours other drug


Review: OCD adults: Clomipramine Comparison: 04 Clomipramine vs other drugs Outcome: 07 Maudsley Obsessive-Compulsive Inventory SMD (fixed) SMD (fixed) Study Clomipramine Other drug orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Clomipramine vs Phenelzine Vallejo 1992 12.10(4.70) 10.10(6.90) 0.33 [-0.44, 1.11] 12 14 Subtotal (95% CI) 14 12 0.33 [-0.44, 1.11] Test for heterogeneity: not applicable Test for overall effect: Z = 0.84 (P = 0.40) Favours Clomipramine Favours other drug OCD adults: Clomipramine Review: Comparison 04 Clomipramine vs other drugs 08 Hamilton Rating Scale for Depression Outcome SMD (fixed) SMD (fixed) Study Clomipramine Other drug Ν or sub-category Ν Mean (SD) Mean (SD) 95% CI 95% CI 01 Clomipramine vs Buspirone Pato 1991 9 9.33(4.58) 9 9.89(6.75) -0.09 [-1.02, 0.83] Subtotal (95% CI) -0.09 [-1.02. 0.83] Test for heterogeneity: not applicable Test for overall effect: Z = 0.20 (P = 0.84) 02 Clomipramine vs Phenelzine Vallejo 1992 11.50(6.90) 12 7.00(5.70) 0.68 [-0.11, 1.48] Subtotal (95% CI) 0.68 [-0.11, 1.48] Test for heterogeneity: not applicable Test for overall effect: Z = 1.68 (P = 0.09)Favours Clomipramine Favours other drug OCD adults: Clomipramine Review: Comparison: 04 Clomipramine vs other drugs 09 Hamilton Rating Scale for Anxiety SMD (fixed) SMD (fixed) Study Clomipramine Other drug N Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category 01 Clomipramine vs Phenelzine 0.88 [0.07, 1.69] 0.88 [0.07, 1.69] Vallein 1992 14 14.10(8.70) 12 7.00(6.60) Subtotal (95% CI) 12 14 Test for heterogeneity: not applicable Test for overall effect: Z = 2.12 (P = 0.03) -2 Favours Clomipramine Favours other drug Review: OCD adults: Clomipramine 05 Intravenous Clomipramine vs IV placebo Comparison: 01 Leaving study early Outcome: Study IV Clomipramine IV Placebo RR (fixed) RR (fixed) or sub-category nΝ n/Ν 95% CI 95% CI Fallon 1998 2/25 0.43 [0.04, 4.48] 1/29 Total (95% CI) 29 25 0.43 [0.04, 4.48] Total events: 1 (IV Clomipramine), 2 (IV Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.70 (P = 0.48) 0.01 100 0.1 10 Favours Clomipramine Favours Placebo Review: OCD adults: Clomipramine Comparison: 05 Intravenous Clomipramine vs IV placebo Outcome: 02 Non-responders

IV Placebo RR (fixed) RR (fixed) Study IV Clomipramine or sub-category nΝ n/N 95% CI 95% CI Fallon 1998 23/29 25/25 0.79 [0.66, 0.96] Total (95% CI) 29 0.79 [0.66, 0.96] 25 Total events: 23 (IV Clomipramine), 25 (IV Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 2.44 (P = 0.01) 0.5 1.5 ż Favours Placebo Favours Clomipramine

Review: OCD adults: Clomipramine

Comparison: 05 Intravenous Clomipramine vs IV placebo

Outcome: 03 Y-BOCS



Review: OCD adults: Clomipramine

Comparison: 05 Intravenous Clomipramine vs IV placebo

Outcome: 04 NIMH-OC

Study or sub-category	Ν '	IV Clomipramine Mean (SD)	N	IV Placebo Mean (SD)	D (fixed) 95% Cl	SMD (fixed) 95% Cl
Fallon 1998	28	10.40(2.00)	23	10.80(1.00)		-0.24 [-0.80, 0.31]
Total (95% Cl) Test for heterogeneity: not app Test for overall effect: Z = 0.8			23			-0.24 [-0.80, 0.31]

Favours Clomipramine Favours Placebo

Favours Clomipramine Favours Placebo

Favours Clomipramine Favours Placebo

Review: OCD adults: Clomipramine

Comparison: 05 Intravenous Clomipramine vs IV placebo Outcome: 05 Clinical Global Impressions: severity

Study or sub-category	N I	V Clomipramine Mean (SD)	N	IV Placebo Mean (SD)			(fixed) % Cl	SMD (fixed) 95% Cl
Fallon 1998	28	5.30(1.00)	23	5.70(5.00)		-		-0.11 [-0.67, 0.44]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			23					-0.11 [-0.67, 0.44]
					-1	-0.5	0 0.5	1

Review: OCD adults: Clomipramine


Comparison: 05 Intravenous Clomipramine vs IV placebo Outcome: 06 Hamilton Rating Scale for Depression

Study or sub-category	N	IV Clomipramine Mean (SD)	N	IV Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
Fallon 1998	28	12.00(6.00)	23	12.70(7.00)	-	-0.11 [-0.66, 0.45]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			23			-0.11 [-0.66, 0.45]
					-1 -0.5 0 0.5	1

Review: OCD adults: Clomipramine

Comparison: 06 Intravenous Clomipramine vs oral Clomipramine


Outcome: 01 Adverse effects



Review: OCD adults: Clomipramine

Comparison: 06 Intravenous Clomipramine vs oral Clomipramine

Outcome: 02 Leaving study early



Review: OCD adults: Clomipramine

Comparison: 06 Intravenous Clomipramine vs oral Clomipramine

Outcome: 03 Non-responders

Study or sub-category	IV Clomipramine n/N	Oral Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Koran 1997	1/7	7/8		0.16 [0.03, 1.02]
Total (95% CI) Total events: 1 (IV Clomipra Test for heterogeneity: not Test for overall effect: Z =	• •	8		0.16 [0.03, 1.02]
		C	.01 0.1 1 10	100

Favours IV Favours Oral

Favours IV Favours Oral

Favours Placebo

Review: OCD adults: Clomipramine

Comparison: 06 Intravenous Clomipramine vs oral Clomipramine

Outcome: 04 Y-BOCS

Study or sub-category	N I	V Clomipramine Mean (SD)	Or N	al Clomipramine Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl
Koran 1997	7	16.71(3.30)	8	25.00(7.86)		-	_			-1.26 [-2.40, -0.12]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 2			8			-	-			-1.26 [-2.40, -0.12]
					-4	-2	ò	2	4	

Review: OCD adults: Clomipramine

Comparison: 07 Clomipramine vs placebo: continuation phase

Outcome: 01 Adverse effects

Study or sub-category	Clomipramine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
Katz 1990	108/110	9/14	_	1.53 [1.03, 2.26]
Total (95% CI) Total events: 108 (Clomipra Test for heterogeneity: not Test for overall effect: Z =	applicable	14		1.53 [1.03, 2.26]
		0.2	0.5 1 2	5

Favours Clomipramine

Review: OCD adults: Clomipramine


Comparison: 07 Clomipramine vs placebo: continuation phase Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Clomipramine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Katz 1990	17/110	0/14	-	4.73 [0.30, 74.65]
Total (95% CI) Total events: 17 (Clomipran Test for heterogeneity: not Test for overall effect: Z =	applicable	14	-	4.73 [0.30, 74.65]
		0.01	0.1 1 10	100
		Favo	ours Clomipramine Favours Placebo	

Review: OCD adults: Clomipramine

Comparison: 07 Clomipramine vs placebo: continuation phase

03 NIMH-OC Outcome:



Review: Comparison: OCD adults: Clomipramine 07 Clomipramine vs placebo: continuation phase

Outcome: 04 Physician's Global Evaluation

Study or sub-category	N	Clomipramine Mean (SD)	N	Placebo Mean (SD)			(fixed) % Cl		SMD (fixed) 95% Cl
Katz 1990	101	1.89(0.94)	12	3.33(0.89)		-			-1.53 [-2.16, -0.90]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =)	12			•			-1.53 [-2.16, -0.90]
					-4	-2	0 2	4	

Favours Clomipramine Favours Placebo

Favours SSRI

OCD adults: Clomipramine Review:

08 Clomipramine vs SSRIs: continuation phase Comparison:

Outcome: 01 Leaving study early

Study or sub-category	Clomipramine n/N	SSRI n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl	
01 Clomipramine 200mg vs F	luoxetine 60mg (non-responders)			
Lopez-Ibor 1996	3/8	6/14		0.88 [0.30, 2.58]	
Subtotal (95% CI)	8	14		0.88 [0.30, 2.58]	
Total events: 3 (Clomipramin	e), 6 (SSRI)			,	
Test for heterogeneity: not a					
Test for overall effect: Z = 0	.24 (P = 0.81)				
02 Clomipramine 100mg vs F	luoxetine 20mg (responders)				
Lopez-lbor 1996	6/13	3/11		1.69 [0.55, 5.24]	
Subtotal (95% CI)	13	11		1.69 [0.55, 5.24]	
Total events: 6 (Ćlomipramin	e), 3 (SSRI)			,	
Test for heterogeneity: not a					
Test for overall effect: Z = 0	• •				
		0.1	0.2 0.5 1 2 5	10	

Favours Clomipramine

Review: OCD adults: Clomipramine

Comparison: 08 Clomipramine vs SSRIs; continuation phase Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Clomipramine n <i>i</i> N	SSRI n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clomipramine 200mg vs F	luoxetine 60mg (non-responders)		
Lopez-lbor 1996	0/8	2/14		0.33 [0.02, 6.19]
Subtotal (95% CI)	8	14		0.33 [0.02, 6.19]
Total events: 0 (Clomipramine	e), 2 (SSRI)			,
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 0	.74 (P = 0.46)			
02 Clomipramine 100mg vs F	luoxetine 20mg (responders)			
Lopez-Ibor 1996	1/13	1/11		- 0.85 [0.06, 12.01]
Subtotal (95% CI)	13	11		- 0.85 [0.06, 12.01]
Total events: 1 (Clomipramine	e), 1 (SSRI)			•
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 0	.12 (P = 0.90)			
			0.01 0.1 1 1	0 100
			Favours Clomipramine Favours	SSRI

Review: OCD adults: Clomipramine

Comparison: 09 Clomipramine same dose vs half dose vs none: continuation/discontinuation

Outcome: 01 Leaving study early

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Same dose (150mg) vs half dose (7	'5mg)			
Ravizza 1996a	2/14	0/15	- - - - - - - - - - 	5.33 [0.28, 102.26]
Subtotal (95% CI)	14	15		5.33 [0.28, 102.26]
Total events: 2 (Dose 1), 0 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 1.11 (P = 0.)	27)			
02 Same dose (150mg) vs none				
Ravizza 1996a	2/14	1/14	- - 	2.00 [0.20, 19.62]
Subtotal (95% CI)	14	14	-	2.00 [0.20, 19.62]
Total events: 2 (Dose 1), 1 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 0.59 (P = 0.	55)			
03 Half dose (75mg) vs none				
Ravizza 1996a	0/15	1/14		0.31 [0.01, 7.09]
Subtotal (95% CI)	15	14		0.31 [0.01, 7.09]
Total events: 0 (Dose 1), 1 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.73$ (P = 0.	47)			
		0.0	01 0.01 0.1 1 10 100 1	000

Favours Dose 1 Favours Dose 2

Favours Dose 1 Favours Dose 2


Review: OCD adults: Clomipramine

Comparison: 09 Clomipramine same dose vs half dose vs none: continuation/discontinuation

Outcome: 02 Relapse (CGI; 25% Y-BOCS)

Study or sub-category	Dose 1 n/N	Dose 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Same dose (150mg) vs half dose (75ma)			
Ravizza 1996a	5/14	4/15		1.34 [0.45, 4.00]
Subtotal (95% CI)	14	15		1.34 [0.45, 4.00]
Total events: 5 (Dose 1), 4 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 0.52$ (P = 0	1.60)			
02 Same dose (150mg) vs none				
Ravizza 1996a	5/14	11/14		0.45 [0.21, 0.97]
Subtotal (95% CI)	14	14		0.45 [0.21, 0.97]
Total events: 5 (Dose 1), 11 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 2.05 (P = 0	1.04)			
03 Half dose (75mg) vs none				
Ravizza 1996a	4/15	11/14		0.34 [0.14, 0.82]
Subtotal (95% CI)	15	14		0.34 [0.14, 0.82]
Total events: 4 (Dose 1), 11 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 2.40 (P = 0	1.02)			
04 Continuation v discontinuation				
Ravizza 1996a	9/29	11/14		0.39 [0.22, 0.73]
Subtotal (95% CI)	29	14		0.39 [0.22, 0.73]
Total events: 9 (Dose 1), 11 (Dose 2)				
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 3.00$ (P = 0	1.003)			
		0.1	0.2 0.5 1 2 5	10


TCAs (OCD)



Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)

Outcome: 01 Adverse effects



Favours TCA Favours other drug

Favours TCA Favours other drug

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)

Outcome: 02 Leaving study early

study TCA r sub-category n/N		Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 Amitriptyline vs Clomipramine			_			
Ananth 1981	2/10	1/10		2.00 [0.21, 18.69]		
Subtotal (95% CI)	10	10		2.00 [0.21, 18.69]		
Total events: 2 (TCA), 1 (Other drug) Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.61 (P = 0.5	54)					
02 Desipramine vs Fluvoxamine						
Goodman 1990a	6/19	2/21	+	3.32 [0.76, 14.49]		
Subtotal (95% CI)	19	21	-	3.32 [0.76, 14.49]		
Total events: 6 (TCA), 2 (Other drug)						
Test for heterogeneity: not applicable	445					
Test for overall effect: Z = 1.59 (P = 0.1	11)					
03 Desipramine vs Sertraline						
Hoehn-Saric 2000	33/86	14/80		2.19 [1.27, 3.79]		
Subtotal (95% CI)	86	80	◆	2.19 [1.27, 3.79]		
Total events: 33 (TCA), 14 (Other drug))					
Test for heterogeneity: not applicable	005)					
Test for overall effect: $Z = 2.82$ (P = 0.0	005)					
04 Imipramine vs Clomipramine						
Volavka 1985	4/12	3/11		1.22 [0.35, 4.28]		
Subtotal (95% CI)	12	11		1.22 [0.35, 4.28]		
Total events: 4 (TCA), 3 (Other drug)						
Test for heterogeneity: not applicable						
Test for overall effect: $Z = 0.31$ (P = 0.3)	75)					
		0.01	0.1 1 10	100		

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)

Outcome: 03 Leaving study early due to adverse effects

2/19 19	0/21 21		5.50 [0.28, 107.78]
			E EO (O 20 107 701
19	21		3.30 [0.20, 107.78]
	Z.1		5.50 [0.28, 107.78]
		- -	
3/86	9/80		2.38 [1.17, 4.83]
86	80	-	2.38 [1.17, 4.83]
		-	·
2/12	2/11		0.92 [0.15, 5.44]
12	11		0.92 [0.15, 5.44]
		T	
	0.001	0.01 0.1 1 10 100	1000
		Favours TCA Favours other dr	210
	86	86 80 2/12 2/11 12 11	2/12 2/11 12 11 0.001 0.01 0.1 1 10 100

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)
Outcome: 04 Non-responders (OCD)

Study or sub-category	TCA n/N	Other drug n/N	` ,			RR (fixed) 95% Cl
01 Desipramine vs Sertraline Hoehn-Saric 2000 Subtotal (95% CI) Total events: 40 (TCA), 42 (Ot Test for heterogeneity: not ap Test for overall effect: Z = 0.7	plicable	42/80 80		-		89 [0.65, 1.21] 89 [0.65, 1.21]
		0.	5 0.7	1 1.5	2	

Favours TCA Favours other drug

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)
Outcome: 05 Non-responders (MDD)

Study or sub-category	TCA n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
01 Desipramine vs Sertraline						
Hoehn-Saric 2000	43/86	29/80		- 1.38 [0.96, 1.98]		
Subtotal (95% CI)	86	80		- 1.38 [0.96, 1.98]		
Total events: 43 (TCA), 29 (Othe	r drug)			, ,		
Test for heterogeneity: not applic						
Test for overall effect: Z = 1.75 ((P = 0.08)					
		0.5	0.7 1 1.5	2		
			Favours TCA Favours other dro	ug		

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)
Outcome: 06 Non-remitters (HRSD>17)

Study or sub-category	TCA n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl	
01 Desipramine vs Sertraline					
Hoehn-Saric 2000	56/86	41/80		1.27 [0.98, 1.65]	
Subtotal (95% CI)	86	80	-	1.27 [0.98, 1.65]	
Total events: 56 (TCA), 41 (C	ther drug)			·	
Test for heterogeneity: not ap	oplicable				
Test for overall effect: $Z = 1$.	78 (P = 0.08)				
		0.5	0.7 1 1.5 2	!	
			Favours TCA Favours other drug		

Comparison: 02 TCAs vs other drugs (adults) Outcome: 07 Y-BOCS SMD (fixed) SMD (fixed) Study TCA Other drug or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Designamine vs Fluvoxamine Goodman 1990a 19 25.80(6.00) 21 19.50(9.00) 0.80 [0.15, 1.45] Subtotal (95% CI) 19 21 0.80 [0.15, 1.45] Test for heterogeneity: not applicable Test for overall effect: Z = 2.42 (P = 0.02) 02 Desipramine vs Sertraline Hoehn-Saric 2000 85 -6.00(8.30) 79 -8.40(8.00) 0.29 [-0.02, 0.60] Subtotal (95% CI) 85 79 0.29 [-0.02, 0.60] Test for heterogeneity: not applicable Test for overall effect: Z = 1.86 (P = 0.06) Total (95% CI) 0.39 [0.11, 0.66] 100 Test for heterogeneity: $Chi^2 = 1.92$, df = 1 (P = 0.17), $I^2 = 47.8\%$ Test for overall effect: Z = 2.72 (P = 0.006) Favours TCA Favours other drug Review: OCD: TCAs Comparison: 02 TCAs vs other drugs (adults) Outcome: 08 NIMH-OC SMD (fixed) Study TCA Other drug SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Desipramine vs Sertraline Hoehn-Saric 2000 85 -1.70(2.77) 79 -2.70(2.67) 0.37 [0.06, 0.67] Subtotal (95% CI) 0.37 [0.06, 0.67] Test for heterogeneity: not applicable Test for overall effect: Z = 2.32 (P = 0.02)-0.5 0.5 Favours TCA Favours other drug OCD: TCAs Review: 02 TCAs vs other drugs (adults) Comparison: 09 Leyton Obsessional Inventory: symptom Outcome: Study TCA Other drug SMD (fixed) SMD (fixed) Mean (SD) N Mean (SD) or sub-category Ν 95% CI 95% CI 01 Nortriptyline vs Clomipramine Thoren 1980a -3.00(3.10) -4.40(9.60) 0.19 [-0.80, 1.17] Subtotal (95% CI) 8 0.19 [-0.80, 1.17] Test for heterogeneity: not applicable Test for overall effect: Z = 0.37 (P = 0.71) Favours TCA Favours other drug OCD: TCAs Review: Comparison: 02 TCAs vs other drugs (adults) Outcome: 10 Leyton Obsessional Inventory: trait SMD (fixed) SMD (fixed) Study Other drug or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Nortriptyline vs Clomipramine Thoren 1980a -1.50(1.10) -1.90(2.30) 0.21 [-0.77, 1.19] Subtotal (95% CI) 0.21 [-0.77, 1.19] Test for heterogeneity: not applicable Test for overall effect: Z = 0.42 (P = 0.68) ż Favours TCA Favours other drug OCD: TCAs Review: Comparison: 02 TCAs vs other drugs (adults) 11 Leyton Obsessional Inventory: resistance Outcome: Study TCA Other drug SMD (fixed) SMD (fixed) Mean (SD) or sub-category Ν Ν Mean (SD) 95% CI 95% CI 01 Nortriptyline vs Clomipramine

-4.60(15.90)

8

-13.00(19.60)

Favours TCA

Favours other drug

0.45 [-0.55, 1.44]

0.45 [-0.55, 1.44]

Thoren 1980a

Subtotal (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.88 (P = 0.38)

OCD: TCAs

Review:

OCD: TCAs Review: Comparison: 02 TCAs vs other drugs (adults) Outcome: 12 Leyton Obsessional Inventory: interference TCA Other drug SMD (fixed) SMD (fixed) Study orsub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Nortriptyline vs Clomipramine Thoren 1980a -19.00(15.90) -12.30(24.00) -0.31 [-1.30, 0.68] Subtotal (95% CI) -0.31 [-1.30, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) Favours TCA Favours other drug OCD: TCAs Review: 02 TCAs vs other drugs (adults) Comparison: 13 CPRS: obsessive-compulsive Outcome: Study TCA Other drug SMD (fixed) SMD (fixed) Mean (SD) or sub-category Ν Ν Mean (SD) 95% CI 95% CI 01 Nortriptyline vs Clomipramine Thoren 1980a 8 7.31(2.89) 8 6.38(2.75) 0.31 [-0.68, 1.30] Subtotal (95% CI) 8 0.31 [-0.68, 1.30] Test for heterogeneity: not applicable Test for overall effect: Z = 0.62 (P = 0.54) Favours TCA Favours other drug Review: OCD: TCAs Comparison: 02 TCAs vs other drugs (adults) Outcome: 14 Self-Rating Obsessive Compulsive Personality Inventory SMD (fixed) Study Other drug SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Imipramine vs Clomipramine Volavka 1985 8 68.70(12.90) 8 47.90(14.40) 1.44 [0.30, 2.57] Subtotal (95% CI) 1.44 [0.30, 2.57] Test for heterogeneity: not applicable Test for overall effect: Z = 2.48 (P = 0.01)Favours TCA Favours other drug Review: OCD: TCAs 02 TCAs vs other drugs (adults) Comparison: 15 Self-Rating Obsessional Neurotic Scale Outcome SMD (fixed) Study TCA Other drug SMD (fixed) Mean (SD) N Mean (SD) or sub-category 95% CI 95% CI 01 Imipramine vs Clomipramine Volavka 1985 63.60(20.50) 8 41.90(13.90) 1.17 [0.09, 2.26] Subtotal (95% CI) 1.17 [0.09, 2.26] Test for heterogeneity: not applicable Test for overall effect: Z = 2.11 (P = 0.03) Favours TCA Favours other drug Review: OCD: TCAs Comparison: 02 TCAs vs other drugs (adults) 16 Hamilton Rating Scale for Depression Outcome: Study Other drug SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Desipramine vs Fluvoxamine Goodman 1990a 17.70(15.00) 0.32 [-0.30, 0.94] 22.30(13.00) Subtotal (95% CI) 19 21 0.32 [-0.30, 0.94] Test for heterogeneity: not applicable Test for overall effect: Z = 1.00 (P = 0.32) 02 Desipramine vs Sertraline Hoehn-Saric 2000 85 -11.50(10.14) 79 -14.80(9.78) 0.33 [0.02, 0.64] Subtotal (95% CI) 85 0.33 [0.02, 0.64] Test for heterogeneity: not applicable

2.01(2.20)

-2

Favours TCA Favours other drug

1.04 [-0.02, 2.11]

1.04 [-0.02, 2.11]

6.20(4.90)

Test for overall effect: Z = 2.09 (P = 0.04)


Test for heterogeneity: not applicable Test for overall effect: Z = 1.92 (P = 0.05)

03 Imipramine vs Clomipramine Volavka 1985

Subtotal (95% CI)

Review: OCD: TCAs

Comparison: 02 TCAs vs other drugs (adults)
Outcome: 17 Global Evaluation of Efficacy



Review: OCD: TCAs

Comparison: 03 Designamine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 01 Leaving the study early (only during the 2-month substitution period)

Study or sub-category	Desipramine n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Leonard 1991a	1/10	0/11		3.27 [0.15, 72.23]
Total (95% CI) Total events: 1 (Desipramin Test for heterogeneity: not Test for overall effect: Z = I	applicable	11		3.27 [0.15, 72.23]
		0.01	0.1 1 10	100

Favours Desipramine Favours Clomipramine

Review: OCD: TCAs

Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)

Outcome: 02 Relapse (Physician's Relapse Scale)

Study or sub-category	Desipramine n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Leonard 1991a	8/9	2/11	-	4.89 [1.37, 17.49]
Total (95% CI) Total events: 8 (Desipramin Test for heterogeneity: not a Test for overall effect: Z = 2	applicable	11		4.89 [1.37, 17.49]
		0.01	0.1 1 10	100

Favours Desipramine

Review: OCD: TCAs

Comparison: 03 Designamine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 03 Comprehensive Psychopathological Rating Scale: obsessive-compulsive

Study or sub-category	N	Desipramine Mean (SD)	N	Clomipramine Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
Leonard 1991a	9	6.30(3.30)	11	5.20(4.00)			-		0.	28 [-0.60, 1.17]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			11				+		0.	28 [-0.60, 1.17]
Test for overall effect. 2 =	0.03 (F = 0.33)				-4	-2	0	2	4	


Favours Desipramine Favours Clomipramine

Favours Clomipramine

Review: OCD: TCAs

Comparison: 03 Designamine substitution vs Clomipramine continuation (child/adolescent)

Outcome: 04 NIMH-OC



SNRIs (OCD)

Review: OCD: SNRIs

Comparison: 01 SNRIs vs other drugs Outcome: 01 Adverse effects

Study or sub-category	SNRI n/N	Other drug n/N		RR (fixed 95% CI	•		RR (fixed) 95% Cl
01 Venlafaxine vs Clomipram	nine						
Albert 2002	16/26	43/47	_	_			0.67 [0.49, 0.92]
Subtotal (95% CI)	26	47	-	-			0.67 [0.49, 0.92]
Total events: 16 (SNRI), 43 (Other drug)			-			
Test for heterogeneity: not a	pplicable						
Test for overall effect: $Z = 2$.	46 (P = 0.01)						
		0.2	0.5	1	- <u>;</u>	5	

Favours SNRI Favours other drug

Review: OCD: SNRIs

Comparison: 01 SNRIs vs other drugs Outcome: 02 Leaving study early

Study or sub-category	SNRI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Venlafaxine vs Clomiprami	ne			
Albert 2002	1/26	7/47		0.26 [0.03, 1.99]
Subtotal (95% CI)	26	47		0.26 [0.03, 1.99]
Total events: 1 (SNRI), 7 (Oth	er drug)			,
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 1.3$	30 (P = 0.19)			
		0.01	0.1 1 10	100

Favours SNRI Favours other drug

Review: OCD: SNRIs


Comparison: 01 SNRIs vs other drugs

Outcome: 03 Leaving study early due to adverse effects

Study or sub-category	SNRI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Venlafaxine vs Paroxetine				
Denys 2003a	2/75	6/75		0.33 [0.07, 1.60]
Subtotal (95% CI)	75	75		0.33 [0.07, 1.60]
Total events: 2 (SNRI), 6 (Other	er drug)		-	
Test for heterogeneity: not ap				
Test for overall effect: Z = 1.3	37 (P = 0.17)			
02 Venlafaxine vs Clomiprami	ne			
Albert 2002	0/26	5/47		0.16 [0.01, 2.81]
Subtotal (95% CI)	26	47		0.16 [0.01, 2.81]
Total events: 0 (SNRI), 5 (Other	er drug)			,
Test for heterogeneity; not ap	plicable			
Test for overall effect: Z = 1.2	25 (P = 0.21)			
		0.001	0.01 0.1 1 10 100	1000

OCD: SNRIs Review:

Comparison: 01 SNRIs vs other drugs 04 Non-responders Outcome:



Review: OCD: SNRIs

Comparison: Outcome: 01 SNRIs vs other drugs 05 Y-BOCS

Study or sub-category	N	SNRI Mean (SD)	N	Other drug Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
11 Venlafaxine vs Paroxetine	•					
Denys 2003a	73	-7.20(7.50)	72	-7.80(5.40)		0.09 [-0.23, 0.42]
Subtotal (95% CI)	73		72			0.09 [-0.23, 0.42]
est for heterogeneity: not ap	oplicable				_	
est for overall effect: $Z = 0$.	55 (P = 0.58)					
2 Venlafaxine vs Clomipram	ine					
Albert 2002	26	18.36(7.11)	47	17.30(6.15)		0.16 [-0.32, 0.64]
ubtotal (95% CI)	26		47			0.16 [-0.32, 0.64]
est for heterogeneity: not a	oplicable				-	
est for overall effect: $Z = 0$.	66 (P = 0.51)					

Favours SNRI Favours other drug

OCD: SNRIs Review:

Comparison:

01 SNRIs vs other drugs 06 Hamilton Rating Scale for Depression Outcome:

Study or sub-category	N	SNRI Mean (SD)	N	Other drug Mean (SD)		S	SMD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Venlafaxine vs Paroxeti	ine									
Denys 2003a	73	-2.80(5.60)	72	-3.50(4.60)		_		_		0.14 [-0.19, 0.46]
Subtotal (95% CI)	73		72						_	0.14 [-0.19, 0.46]
Test for heterogeneity: not	applicable							_		·
Test for overall effect: Z =	0.82 (P = 0.41)									
					-0.5	-0.25	-	0.25	0.5	

Favours SNRI Favours other drug


Favours SNRI Favours other drug

Review:

Comparison: 01 SNRIs vs other drugs 07 Hamilton Anxiety Scale Outcome:

Study or sub-category	N	SNRI Mean (SD)	N	Other drug Mean (SD)		s	MD (fixed 95% CI	1)		SMD (fixed) 95% Cl
01 Venlafaxine vs Paroxet	ine									
Denys 2003a	73	-4.90(5.00)	72	-4.70(7.00)						-0.03 [-0.36, 0.29]
Subtotal (95% CI)	73		72				حيق			-0.03 [-0.36, 0.29]
Test for heterogeneity: not	: applicable									
Test for overall effect: Z =	0.20 (P = 0.84)									
					-0.5	-0.25	0	0.25	0.5	

MAOIs (OCD)



Favours MAOI Favours placebo

Review: OCD: MAOIs

02 MAOIs vs other drugs Comparison: Outcome: 01 Leaving study early

Study or sub-category	MAOI n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Phenelzine vs Clomipramin	e			
Vallejo 1992	2/14	2/16		1.14 [0.18, 7.08]
Subtotal (95% CI)	14	16		1.14 [0.18, 7.08]
Total events: 2 (MAOI), 2 (Oth	er drug)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 0.1$	4 (P = 0.89)			
02 Phenelzine vs Fluoxetine				
Jenike 1997	3/20	4/23		0.86 [0.22, 3.40]
Subtotal (95% CI)	20	23		0.86 [0.22, 3.40]
Total events: 3 (MAOI), 4 (Oth	er drug)			•
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 0.2$	21 (P = 0.83)			
				10
		0.1	0.2 0.5 1 2 5	10

Favours MAOI Favours other drug

-0.5

0.5

Review: OCD: MAOIs

02 MAOIs vs other drugs Comparison:

02 Leaving study early due to adverse effects Outcome:

Study or sub-category	MAOI n/N	Other drug n/N		(fixed) % Cl	RR (fixed) 95% Cl
01 Phenelzine vs Clomipramine					
Vallejo 1992	0/14	1/16		 	0.38 [0.02, 8.59]
Subtotal (95% CI)	14	16			0.38 [0.02, 8.59]
Total events: 0 (MAOI), 1 (Other	drug)				
Test for heterogeneity: not applic	cable				
Test for overall effect: Z = 0.61 ((P = 0.54)				
			0.01 0.1	1 10	100

Favours MAOI Favours other drug OCD: MAOIs Review:

02 MAOIs vs other drugs Comparison:

Outcome: 03 Y-BOCS

SMD (fixed) 95% Cl SMD (fixed) 95% Cl MAOI Mean (SD) Study Other drug N N Mean (SD) or sub-category 01 Phenelzine vs Fluoxetine 0.01 [-0.64, 0.67] 0.01 [-0.64, 0.67] Jenike 1997 17 16.30(7.00) 19 19 16.20(6.30) Subtotal (95% CI) 17 Test for heterogeneity: not applicable Test for overall effect: Z = 0.04 (P = 0.96)

Favours MAOI Favours other drug

OCD: MAOIs

02 MAOIs vs other drugs 04 NIMH-OC Comparison:

Outcome:

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)		5	SMD (fixed 95% CI	d)		SMD (fixed) 95% Cl
01 Phenelzine vs Fluoxetin	e									
Jenike 1997	17	6.80(1.40)	19	7.00(1.10)	-		-		-0	.16 [-0.81, 0.50]
Subtotal (95% CI)	17		19		-			_	-0	.16 [-0.81, 0.50]
Test for heterogeneity: not	applicable						_			
Test for overall effect: Z =	0.47 (P = 0.64)									
					-1	-0.5		0.5	1	

Favours MAOI Favours other drug OCD: MAOIs Review:

Comparison: 02 MAOIs vs other drugs

Outcome: 05 Maudsley Obsessive-Compulsive Inventory

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)			O (fixed) 5% Cl			SMD (fixed) 95% Cl
01 Phenelzine vs Clomiprar	mine									
Vallejo 1992	12	10.10(6.90)	14	12.10(4.70)		_	_			-0.33 [-1.11, 0.44]
Subtotal (95% CI)	12		14				-			-0.33 [-1.11, 0.44]
Test for heterogeneity: not	applicable						-			
Test for overall effect: Z =	0.84 (P = 0.40)									
					-4	-2	0	2	4	
					F	avours MAO	l Favo	urs other	drug	

Review: OCD: MAOIs

Comparison: 02 MAOIs vs other drugs Outcome: 06 OCD Scale (CPRS)

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)		S	MD (fixed 95% Cl)		SMD (fixed) 95% CI
01 Phenelzine vs Fluoxetin	e									
Jenike 1997	17	6.50(3.80)	19	6.70(2.60)					-0.06 [-0.72, 0.59]
Subtotal (95% CI)	17		19				حوقه		-0.06 [-0.72, 0.59]
Test for heterogeneity: not	applicable						7			
Test for overall effect: Z =	0.18 (P = 0.86)									
						-0.5	_	0.5	-	
					-1	-0.5	U	0.5	1	

Review: OCD: MAOIs

Comparison: 02 MAOIs vs other drugs

Outcome: 07 Hamilton Rating Scale for Depression

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)	SMD (fi:		SMD (fixed) 95% Cl
01 Phenelzine vs Clomipramir Vallejo 1992 Subtotal (95% Cl) Test for heterogeneity: not ap Test for overall effect: Z = 1.1	12 12 oplicable	7.00(5.70)	14 14	11.50(6.90)	+		-0.68 [-1.48, 0.11] -0.68 [-1.48, 0.11]

Review: OCD: MAOIs


Comparison: 02 MAOIs vs other drugs

Outcome: 08 Hamilton Rating Scale for Anxiety

Study or sub-category	N	MAOI Mean (SD)	N	Other drug Mean (SD)		SMD (fixed) 95% CI			SMD (fixed) 95% CI
01 Phenelzine vs Clomipra Vallejo 1992 Subtotal (95% Cl) Test for heterogeneity: not Test for overall effect: Z =	12 12 t applicable	7.00(6.60)	14 14	14.10(8.70)		‡	•		-0.88 [-1.69, -0.07] -0.88 [-1.69, -0.07]
-					-4	-2	,	2	4

Review: OCD: MAOIs

Comparison: 02 MAOIs vs other drugs Outcome: 09 Clinical Global Impression



Favours MAOI Favours other drug

Favours MAOI Favours other drug

Favours MAOI Favours other drug

Anxiolytics (OCD)

Review: OCD: anxiolytics Comparison: 01 Anxiolytics vs placebo Outcome: 01 Leaving study early

Study or sub-category	Anxiolytic n/N	Placebo n/N		RR (fixed) 95% Cl				RR (fixed) 95% Cl
01 Clonazepam								
Hollander 2003c	5/17	4/10	_		\vdash			0.74 [0.26, 2.12]
Subtotal (95% CI)	17	10				_		0.74 [0.26, 2.12]
Total events: 5 (Anxiolytic),	4 (Placebo)							
Test for heterogeneity: not a	pplicable							
Test for overall effect: Z = 0	.57 (P = 0.57)							
			0.2	0.5	1	2	5	

Favours anxiolytic Favours placebo

OCD: anxiolytics Review: Comparison: 01 Anxiolytics vs placebo

Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Anxiolytic n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Clonazepam				
Hollander 2003c	3/17	2/10		0.88 [0.18, 4.41]
Subtotal (95% CI)	17	10		0.88 [0.18, 4.41]
Total events: 3 (Anxiolytic),	2 (Placebo)			·
Test for heterogeneity: not a	applicable			
Test for overall effect: $Z = 0$	0.15 (P = 0.88)			
			0.1 0.2 0.5 1 2 5	<u>, </u>

Favours anxiolytic Favours placebo

OCD: anxiolytics Review: 01 Anxiolytics vs placebo Comparison: 03 Non-responders Outcome:

Study or sub-category	Anxiolytic n/N	Placebo n/N		RR (fixed) 95% Cl		RR (fixed) 95% Cl
01 Clonazepam						
Hollander 2003c	16/17	8/10			-	1.18 [0.84, 1.64]
Subtotal (95% CI)	17	10			-	1.18 [0.84, 1.64]
Total events: 16 (Anxiolytic)	, 8 (Placebo)					
Test for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 0$.96 (P = 0.34)					
		0.5	0.7	1 1.5	2	

Favours anxiolytic Favours placebo

Review: OCD: anxiolytics 01 Anxiolytics vs placebo 04 Y-BOCS Comparison:

Outcome:

Study or sub-category	N	Anxiolytic Mean (SD)	N	Placebo Mean (SD)		SMD (1 95%		SMD (fixed) 95% CI
01 Clonazepam Hollander 2003c	16	-1.70(4.30)	9	-0.67(5.10)		-		-0.22 [-1.04, 0.60]
Subtotal (95% CI)	16		9			•	•	-0.22 [-1.04, 0.60]
Test for heterogeneity: not	t applicable]		
Test for overall effect: Z =	0.52 (P = 0.60)							
					-10	-5 0	5	10

Favours anxiolytic Favours placebo

OCD: anxiolytics Comparison: 01 Anxiolytics vs placebo


05 NIMH-ÓC

Review:

Study or sub-category	N	Anxiolytic Mean (SD)	N	Placebo Mean (SD)		:	SMD (fixed 95% Cl)		SMD (fixed) 95% Cl
01 Clonazepam										
Hollander 2003c	16	0.13(2.40)	9	0.00(2.50)			_			0.05 [-0.77, 0.87]
Subtotal (95% CI)	16		9				•			0.05 [-0.77, 0.87]
Test for heterogeneity: not	: applicable						Γ			
Test for overall effect: Z =	0.12 (P = 0.90)									
					-4	-2	-	- <u> </u>	4	
					Fav	ours anxio	lvtic Fav	ours placeb	00	

Review: OCD: anxiolytics Comparison: 01 Anxiolytics vs placebo

Outcome: 06 Hamilton Rating Scale for Depression



Review: OCD: anxiolytics
Comparison: 01 Anxiolytics vs placebo
Outcome: 07 Hamilton Anxiety Scale

Study or sub-category	N	Anxiolytic Mean (SD)	N	Placebo Mean (SD)		S	MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Clonazepam										
Hollander 2003c	16	-1.10(7.70)	9	0.33(9.80)			-			-0.16 [-0.98, 0.66]
Subtotal (95% CI)	16		9				•			-0.16 [-0.98, 0.66]
Test for heterogeneity: no	t applicable						1			
Test for overall effect: Z =	0.39 (P = 0.70)									
					-10	-5	-	5	10	

Review: OCD: anxiolytics Comparison: 02 Anxiolytics vs other drugs

Outcome: 01 Leaving study early

Study or sub-category	Anxiolytic n/N	Other drug n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Buspirone vs Clomipramir	ne			
Pato 1991	1/10	1/10		1.00 [0.07, 13.87]
Subtotal (95% CI)	10	10		1.00 [0.07, 13.87]
Total events: 1 (Anxiolytic),	1 (Other drug)		T	
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 0	.00 (P = 1.00)			
		0.0	1 01 1 10	100

Favours anxiolytic Favours other drug

Favours anxiolytic Favours placebo

Review: OCD: anxiolytics

Comparison: 02 Anxiolytics vs other drugs


Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Anxiolytic n/N	Other drug n/N		RR (fix) 95% (,		RR (fixed) 95% Cl
01 Buspirone vs Clomipramine	•						
Pato 1991	0/10	1/10					0.33 [0.02, 7.32]
Subtotal (95% CI)	10	10			_		0.33 [0.02, 7.32]
Total events: 0 (Anxiolytic), 1	(Other drug)						
Test for heterogeneity: not ap							
Test for overall effect: $Z = 0.7$	'0 (P = 0.49)						
			0.01 0	0.1 1	10	100	
					avours other		

Review: OCD: anxiolytics

Comparison: 02 Anxiolytics vs other drugs


Outcome: 03 Y-BOCS



Review: OCD: anxiolytics


02 Anxiolytics vs other drugs 04 NIMH-OC Comparison:

Outcome:




OCD: anxiolytics Review:

02 Anxiolytics vs other drugs 05 Hamilton Rating Scale for Depression Comparison: Outcome:



Other Pharmacological (OCD)

Review: OCD: other pharmacological Comparison: 01 Inositol vs placebo Outcome: 01 Y-BOCS



Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 01 Adverse effects

Study or sub-category	Oxytocin n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Den Boer 1992	6/6	1/6	-	6.00 [1.00, 35.91]
Total (95% CI) Total events: 6 (Oxytocin), 1 Test for heterogeneity: not ay Test for overall effect: Z = 1.	pplicable	6		6.00 [1.00, 35.91]
		0.01	0.1 1 10	100

Favours Oxytocin Favours Placebo

Favours Oxytocin Favours Placebo

Favours Oxytocin Favours Placebo

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 02 Leaving study early

Study or sub-category	Oxytocin n/N	Placebo n/N	,	iixed) 6 Cl	RR (fixed) 95% Cl
Den Boer 1992	0/6	0/6			Not estimable
Total (95% CI) Total events: 0 (Oxytocin), 0 (Placebo Test for heterogeneity: not applicable Test for overall effect: not applicable	0	0			Not estimable
		0.1	1 0.2 0.5 1	1 2 5	10

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 03 Hamilton Depression Scale

Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)		5	SMD (fixed) 95% Cl			SMD (fixed) 95% Cl
Den Boer 1992	6	8.20(3.10)	6	7.00(2.80)			-	_		0.38 [-0.77, 1.52]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0.			6				-	-		0.38 [-0.77, 1.52]
•					-4	-2	Ó	2	4	

Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 04 Self Rating Depression Scale

Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl				SMD (fixed) 95% Cl
Den Boer 1992	6	50.80(6.90)	6	50.80(6.00)		_	+	-		0.00 [-1.13, 1.13]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6			-	+	•		0.00 [-1.13, 1.13]
					-4	-2	Ó	2	4	
					Favours Oxytocin Favours Placebo					

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 05 Hamilton Anxiety Scale

Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
Den Boer 1992	6	12.20(5.10)	6	11.20(3.10)		_	-	-		0.22 [-0.92, 1.36]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6			-	+	•		0.22 [-0.92, 1.36]
					-4	-2	0	2	4	

Favours Oxytocin Favours Placebo

Favours Oxytocin Favours Placebo

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 06 State Anxiety Inventory


Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)			D (fixed) 15% Cl			SMD (fixed) 95% Cl
Den Boer 1992	6	48.70(13.40)	6	61.20(7.90)		-	_			-1.05 [-2.29, 0.19]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6			-				-1.05 [-2.29, 0.19]
					-4	-2	6	2	4	

Review: OCD: other pharmacological Comparison: 02 Oxytocin vs placebo Outcome: 07 General Symptom Index

Study or sub-category	N	Oxytocin Mean (SD)	N	Placebo Mean (SD)			MD (fixed 95% CI)		SMD (fixed) 95% Cl
Den Boer 1992	6	1.50(0.70)	6	1.50(0.40)		_	•	-		0.00 [-1.13, 1.13]
Fotal (95% CI) Fest for heterogeneity: not ag Fest for overall effect: Z = 0.0			6				+			0.00 [-1.13, 1.13]
					-4	-2	Ó	2	4	
					Favo	ours Oxytoo	cin Fav	ours Place	ebo	

Augmentation (OCD)

Review: OCD: augmentation strategies Comparison: 01 Buspirone vs placebo Outcome: 01 Non-responders



Review: OCD: augmentation strategies Comparison: 01 Buspirone vs placebo

Outcome: 02 Y-BOCS

Study or sub-category	N	FLV+Buspirone Mean (SD)	N	FLV+Placebo Mean (SD)		S	MD (fixed) 95% CI		SMD (fixed) 95% Cl
01 FLV+Buspirone v FLV+	-Placebo								
McDougle 1993a	19	24.90(6.60)	14	21.00(9.10)			+		0.49 [-0.21, 1.19]
Subtotal (95% CI)	19		14				-		0.49 [-0.21, 1.19]
Test for heterogeneity: not	t applicable						-		
Test for overall effect: Z =	1.37 (P = 0.17)								
					4			-	4

Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

Review: OCD: augmentation strategies
Comparison: 01 Buspirone vs placebo
Outcome: 03 Hamilton Depression Rating Scale

Study FLV+Buspirone FLV+Placebo SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 FLV+Buspirone v FLV+Placebo McDougle 1993a 17.90(10.70) 11.70(7.40) 0.64 [-0.07, 1.35] 14 Subtotal (95% CI) 0.64 [-0.07, 1.35] Test for heterogeneity: not applicable Test for overall effect: Z = 1.77 (P = 0.08)

Review: OCD: augmentation strategies Comparison: 01 Buspirone vs placebo Outcome: 04 Hamilton Anxiety Scale

Study or sub-category	N	FLV+Buspirone Mean (SD)	N	FLV+Placebo Mean (SD)		S	MD (fixed) 95% CI			SMD (fixed) 95% Cl
01 FLV+Buspirone v FLV+F		11 5045 001	1.4	0.6044.001						0.40.7.0.00.1.101
McDougle 1993a Subtotal (95% CI)	19 19	11.60(6.80)	14 14	8.60(4.90)			-			0.48 [-0.22, 1.18] 0.48 [-0.22, 1.18]
Test for heterogeneity: not	applicable									
Test for overall effect: $Z = 1$	1.35 (P = 0.18)									
					-4	-2	- 6	2	4	
					Favours	augmentat	tion Favo	ours non-a	aug	

Review: OCD: augmentation strategies
Comparison: 02 Citalopram+Clomipramine vs Citalopram
Outcome: 01 Non-responders (Y-BOCS 35%)

Study or sub-category	Citalopram+CMI n/N	Citalopram n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl		
Pallanti 1999	0/9	6/7		0.06 [0.00, 0.94]		
Total (95% CI) Total events: 0 (Citalopram+ Test for heterogeneity: not a Test for overall effect: Z = 2	applicable	7		0.06 [0.00, 0.94]		
			0.001 0.01 0.1 1 10 100 100 Favours augmentation Favours non-aug	00		

Review: OCD: augmentation strategies Comparison: 02 Citalopram+Clomipramine vs Citalopram Outcome: 02 Y-BOCS SMD (fixed) SMD (fixed) Study Citalopram+CMI Citalopram or sub-category N . Mean (SD) Ν Mean (SD) 95% CI 95% CI Pallanti 1999 9 15.90(3.80) 7 25.60(4.80) -2.15 [-3.46, -0.84] Total (95% CI) -2.15 [-3.46, -0.84] Test for heterogeneity: not applicable Test for overall effect: Z = 3.22 (P = 0.001) Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison 02 Citalopram+Clomipramine vs Citalopram 03 Hamilton Depression Rating Scale Outcome: Study Citalopram+CMI Citalopram SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Pallanti 1999 9 5.60(2.60) 6.40(1.80) -0.33 [-1.33, 0.67] Total (95% CI) 7 -0.33 [-1.33, 0.67] Test for heterogeneity: not applicable Test for overall effect: Z = 0.65 (P = 0.52) Favours augmentation Favours non-aug OCD: augmentation strategies Review: Comparison: 03 Desipramine vs placebo Outcome: 01 Y-BOCS at 6 weeks Study SSRI+Placebo SMD (fixed) SSRI+Desipramine SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 SSRI+Desipramine v SSRI+Placebo -1.97 [-3.00, -0.93] -1.97 [-3.00, -0.93] Barr 1997 24.52(2.94) 18.52(2.94) 13 10 Subtotal (95% CI) 10 Test for heterogeneity: not applicable Test for overall effect: Z = 3.73 (P = 0.0002) Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 03 Desipramine vs placebo 02 Y-BOCS at 10 weeks Outcome: SMD (fixed) Study SSRI+Desipramine SSRI+Placebo SMD (fixed) N 95% CI or sub-category N Mean (SD) Mean (SD) 95% CI 01 SSRI+Desipramine v SSRI+Placebo Barr 1997 10 19.30(3.78) 13 22.43(3.78) -0.80 [-1.66, 0.06] Subtotal (95% CI) 10 13 -0.80 [-1.66, 0.06] Test for heterogeneity: not applicable Test for overall effect: Z = 1.81 (P = 0.07) Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 04 Haloperidol vs placebo Outcome: 01 Non-responders Study FLV+Haloperidol FLV+Placebo RR (fixed) RR (fixed) n/N n/Ν 95% CI 95% CI or sub-category 01 FLV+Haloperidol v FLV+Placebo 0.59 [0.40, 0.88] McDougle 1994a 10/17 17/17 Subtotal (95% CI) 17 0.59 [0.40, 0.88] Total events: 10 (FLV+Haloperidol), 17 (FLV+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 2.61 (P = 0.009) 0.2 0.5 5


Favours augmentation

Favours non-aug

Review: OCD: augmentation strategies 04 Haloperidol vs placebo 02 Y-BOCS Comparison: Outcome: Study FLV+Haloperidol or sub-category Ν 01 FLV+Haloperidol v FLV+Placebo McDougle 1994a Subtotal (95% CI) 17 Test for heterogeneity: not applicable Test for overall effect: Z = 4.94 (P < 0.00001)

Mean (SD)

18.53(2.71)



Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

Review: Comparison: OCD: augmentation strategies 05 Inositol vs placebo Outcome: 01 Y-BOCS

Of SRI+Inositol v SRI+Placebo Fux 1999 6 16.33 (9.46) 4 18.75 (8.85) -0.24 [-1.51, 1.04] Subtotal (95% Cl) 6 4 -0.24 [-1.51, 1.04] Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72)	Study or sub-category	N	SRI+Inositol Mean (SD)	N	SRI+Placebo Mean (SD)		MD (fixed) 95% Cl		SMD (fixed) 95% CI
Subtotal (95% CI) 6 4 -0.24 [-1.51, 1.04] Test for heterogeneity: not applicable	01 SRI+Inositol v SRI+Placebo								
Test for heterogeneity: not applicable	Fux 1999	6	16.33(9.46)	4	18.75(8.85)		_		-0.24 [-1.51, 1.04]
	Subtotal (95% CI)	6		4					-0.24 [-1.51, 1.04]
Test for overall effect: Z = 0.36 (P = 0.72)	Test for heterogeneity: not app	plicable					7		
	Test for overall effect: $Z = 0.3$	6 (P = 0.72)							

OCD: augmentation strategies Review: 06 Lithium vs placebo Comparison: Outcome: 01 Non-responders

Study or sub-category	FLV+Lithium n/N	FLV+Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 FLV+Lithium v FLV+Placel	bo at 2 weeks			
McDougle 1991 (1)	9/11	9/9		0.82 [0.62, 1.08]
Subtotal (95% CI)	11	9		0.82 [0.62, 1.08]
Total events: 9 (FLV+Lithium)), 9 (FLV+Placebo)			
Test for heterogeneity: not ap	oplicable			
Test for overall effect: Z = 1.	41 (P = 0.16)			
02 FLV+Lithium v FLV+Placel	bo at 4 weeks			
McDougle 1991 (2)	5/5	5/5		Not estimable
Subtotal (95% CI)	0	0		Not estimable
Total events: 0 (FLV+Lithium)), 0 (FLV+Placebo)			
Test for heterogeneity: not as	oplicable			
Test for overall effect; not ap	plicable			
Total (95% CI)	16	14		0.82 [0.62, 1.08]
Total events: 14 (FLV+Lithium	n), 14 (FLV+Placebo)			
Test for heterogeneity: not as				
Test for overall effect: Z = 1.	•			
		0.5	0.7 1 1.5	2


OCD: augmentation strategies 06 Lithium vs placebo Review: Comparison: Outcome: 02 Y-BOCS change score

Study or sub-category	N	FLV+Lithium Mean (SD)	N	FLV+Placebo Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 FLV+Lithium v FLV+Place	ebo at 2 weeks						
McDougle 1991 (1)	11	-4.00(5.23)	9	1.22(5.24)	_		-0.96 [-1.90, -0.01]
Subtotal (95% CI)	11		9		-		-0.96 [-1.90, -0.01]
Test for heterogeneity; not a	applicable					_	
Test for overall effect: Z = 1							
02 FLV+Lithium v FLV+Place	ebo at 4 weeks						
McDougle 1991 (2)	5	2.60(3.58)	5	-1.40(2.07)			1.24 [-0.19, 2.66]
Subtotal (95% CI)	5		5				1.24 [-0.19, 2.66]
Test for heterogeneity: not a	applicable						
Test for overall effect: Z = 1	.70 (P = 0.09)						
Total (95% CI)	16		14				-0.29 [-1.07, 0.50]
Test for heterogeneity: Chi ²	= 6.34, df = 1 (P	= 0.01), I ² = 84.2%				7	·
Test for overall effect: Z = 0	.72 (P = 0.47)	• •					
					-4 -2	0 2	4
					Favours augme	ntation Favours non-aug	1

Review: OCD: augmentation strategies

Comparison: 06 Lithium vs placebo

03 Hamilton Depression Scale change score Outcome:



Review: OCD: augmentation strategies

Comparison: 06 Lithium vs placebo Outcome:

04 Hamilton Anxiety Scale change score

Study or sub-category	N	FLV+Lithium Mean (SD)	N	FLV+Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 FLV+Lithium v FLV+Placel	oo at 2 weeks					
McDougle 1991 (1)	11	-0.73(4.67)	9	-1.11(3.26)	 _	0.09 [-0.79, 0.97]
Subtotal (95% CI)	11		9			0.09 [-0.79, 0.97]
Fest for heterogeneity: not ap	oplicable				T	
est for overall effect: $Z = 0$.	20 (P = 0.84)					
02 FLV+Lithium v FLV+Placel	oo at 4 weeks					
McDougle 1991 (2)	5	1.40(3.51)	5	-3.20(3.27)	 	1.22 [-0.19, 2.64]
ubtotal (95% CI)	5		5			1.22 [-0.19, 2.64]
est for heterogeneity: not ap	oplicable				-	
est for overall effect: $Z = 1$.	69 (P = 0.09)					
Total (95% CI)	16		14		•	0.41 [-0.34, 1.15]
est for heterogeneity: Chi² =	1.78, df = 1 (P	= 0.18), I ² = 43.8%				
Test for overall effect: $Z = 1$.	06 (P = 0.29)					

Review: OCD: augmentation strategies Comparison:

07 Nortriptyline vs placebo 01 Y-BOCS

Outcome:

Study or sub-category	C N	MI+Nortriptyline Mean (SD)	N	CMI+Placebo Mean (SD)		S	MD (fixed 95% Cl)		SMD (fixed) 95% Cl
01 CMI+Nortriptyline v CMI+ Noorbala 1998 Subtotal (95% CI) Test for heterogeneity: not	15 15	8.33(5.56)	15 15	19.17(5.56)		<u></u>				-1.90 [-2.78, -1.02] -1.90 [-2.78, -1.02]
Test for overall effect: Z =					-			<u>.</u>	- :	
					-4 Favours	-2 augmentat	0 ion Fav	2 /ours non-	4 aug	

Favours augmentation Favours non-aug

OCD: augmentation strategies Review: Comparison: 08 Olanzapine vs placebo Outcome: 01 Leaving the study early

Study or sub-category	FLX+Olanzapine n/N	FLX+Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 FLX+Olanzapine v FLX+	-Placebo			
Shapira 2004	5/22	2/22		2.50 [0.54, 11.54]
Subtotal (95% CI)	22	22		2.50 [0.54, 11.54]
Total events: 5 (FLX+Olanz	rapine), 2 (FLX+Placebo)			
Test for heterogeneity; not	applicable			
Test for overall effect: Z =	1.17 (P = 0.24)			
		(0.01 0.1 1 10	100
		F	avours augmentation Favours non-aug	I


Review: OCD: augmentation strategies Comparison: 08 Olanzapine vs placebo Outcome: 02 Leaving the study early due to adverse effects FLX+Olanzapine FLX+Placebo RR (fixed) RR (fixed) Study or sub-category n/Ν nΝ 95% CI 95% CI 01 FLX+Olanzapine v FLX+Placebo Shapira 2004 2/22 2/22 1.00 [0.15, 6.48] Subtotal (95% CI) 22 1.00 [0.15, 6.48] Total events: 2 (FLX+Olanzapine), 2 (FLX+Placebo) Test for heterogeneity; not applicable Test for overall effect: Z = 0.00 (P = 1.00) 0.5 0.2 Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 08 Olanzapine vs placebo 03 Non-responders (Y-BOCS 25%) Outcome: Study FLX+Olanzapine FLX+Placebo RR (fixed) RR (fixed) or sub-category nNn/Ν 95% CI 95% CI 01 FLX+Olanzapine v FLX+Placebo 1.00 [0.61, 1.64] Shapira 2004 13/22 13/22 Subtotal (95% CI) 22 22 1.00 [0.61, 1.64] Total events: 13 (FLX+Olanzapine), 13 (FLX+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)0.5 0.7 1.5 Favours augmentation Favours non-aug OCD: augmentation strategies Review: Comparison: 08 Olanzapine vs placebo 04 Y-BOCS change score Outcome: SMD (fixed) FLX+Placebo Study FLX+Olanzapine SMD (fixed) N or sub-category N 95% CI 95% CI Mean (SD) Mean (SD) 01 FLX+Olanzapine v FLX+Placebo Shapira 2004 22 -5.10(4.90) 22 -3.80(3.80) -0.29 [-0.89, 0.30] Subtotal (95% CI) 22 22 -0.29 [-0.89, 0.30] Test for heterogeneity: not applicable Test for overall effect: Z = 0.96 (P = 0.34) -0.5 0.5 0 Favours augmentation Favours non-aug Review: OCD: augmentation strategies 09 Pindolol vs placebo Comparison: 01 Leaving the study early Outcome: Study Paroxetine+Pindolol Paroxetine+Placebo RR (fixed) RR (fixed) or sub-category 95% CI 95% CI nNnΝ 01 PAR+Pindolol v PAR+Placebo Dannon 2000 0/8 2/8 0.20 [0.01, 3.61] Subtotal (95% CI) 8 8 0.20 [0.01, 3.61] Total events: 0 (Paroxetine+Pindolol), 2 (Paroxetine+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 1.09 (P = 0.28)0.01 100 0.1 10 Favours augmentation Favours non-aug Review: OCD: augmentation strategies 09 Pindolol vs placebo Comparison: Outcome: 02 Leaving the study early due to adverse effects Paroxetine+Placebo Study Paroxetine+Pindolol RR (fixed) RR (fixed)

or sub-category n/N nΝ 95% CI 95% CI 01 PAR+Pindolol v PAR+Placebo 0.20 [0.01, 3.61] Dannon 2000 0/8 2/8 Subtotal (95% CI) 0.20 [0.01, 3.61] 8 Total events: 0 (Paroxetine+Pindolol), 2 (Paroxetine+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 1.09 (P = 0.28) 0.01 100 Favours augmentation Favours non-aug

Review: OCD: augmentation strategies 09 Pindolol vs placebo 03 Y-BOCS Comparison: Outcome: Paroxetine+Pindolol Study or sub-category N 01 PAR+Pindolol v PAR+Placebo Dannon 2000 Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.98 (P = 0.003)

Mean (SD)

21.40(3.70)



Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

Favours augmentation Favours non-aug

OCD: augmentation strategies 09 Pindolol vs placebo Review: Comparison:

Outcome: 04 MADRS

Study or sub-category	P: N	aroxetine+Pindolol Mean (SD)	Pa N	roxetine+Placebo Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 PAR+Pindolol v PAR+Pl	acebo									
Dannon 2000	8	11.80(7.60)	6	11.50(4.90)		_	_			0.04 [-1.02, 1.10]
Subtotal (95% CI)	8		6			-	-			0.04 [-1.02, 1.10]
Test for heterogeneity: not	t applicable						T			
Test for overall effect: Z =	0.08 (P = 0.94)									
					-4	-2	-	2	4	

Review: OCD: augmentation strategies Comparison: 09 Pindolol vs placebo 05 Hamilton Anxiety Scale Outcome:

Study or sub-category	P N	aroxetine+Pindolol Mean (SD)	Par N	oxetine+Placebo Mean (SD)			(fixed) % Cl		SMD (fixed) 95% CI
01 PAR+Pindolol v PAR	8 8 t applicable	10.25(3.80)	6 6	11.70(5.20)		4	-		-0.31 [-1.37, 0.76] -0.31 [-1.37, 0.76]
					-4	-2	ò	2	4

OCD: augmentation strategies Review: Comparison: 10 Quetiapine vs placebo Outcome: 01 Adverse effects

Study or sub-category	SRI+Quetiapine n/N	SRI+placebo n/N			(fixed) 15% Cl)			RR (f 95%	,
01 SRI+Quetiapine v SRI+PI	acebo									
Atmaca 2002	9/14	4/13			+		_		2.09 [0.85	, 5.16]
Subtotal (95% CI)	14	13			-	<u> </u>	-		2.09 [0.85	, 5.16]
Total events: 9 (SRI+Quetia	pine), 4 (SRI+placebo)					_				
Test for heterogeneity: not	applicable									
Test for overall effect: Z =	1.60 (P = 0.11)									
		0.1	0.2	0.5	1	2	5	10		

Favours augmentation Favours non-aug OCD: augmentation strategies

Review: Comparison: 10 Quetiapine vs placebo Outcome: 02 Leaving the study early

Not estimable
Not estimable

Favours augmentation Favours non-aug

Review: OCD: augmentation strategies Comparison: 10 Quetiapine vs placebo 03 Non-responders (Y-BOCS 30%) Outcome: SRI+Quetiapine SRI+placebo RR (fixed) RR (fixed) Study or sub-category n/Ν n/Ν 95% CI 95% CI 01 SRI+Quetiapine v SRI+Placebo Atmaca 2002 4/14 13/13 0.29 [0.12, 0.65] Subtotal (95% CI) 13 0.29 [0.12, 0.65] Total events: 4 (SRI+Quetiapine), 13 (SRI+placebo) Test for heterogeneity; not applicable Test for overall effect: Z = 2.96 (P = 0.003) 0.2 0.5 Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 10 Quetiapine vs placebo Outcome: 04 Y-BOCS Study SRI+Quetiapine SRI+Placebo SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 SRI+Quetiapine v SRI+Placebo Atmaca 2002 13.40(3.20) 13 21.40(4.30) -2.06 [-3.02, -1.10] Subtotal (95% CI) 13 -2.06 [-3.02, -1.10] 14 Test for heterogeneity; not applicable Test for overall effect: Z = 4.20 (P < 0.0001) Favours augmentation Favours non-aug OCD: augmentation strategies Review: 10 Quetiapine vs placebo Comparison: Outcome: 05 CGI: severity of illness SRI+Placebo SMD (fixed) SMD (fixed) Study SRI+Quetiapine or sub-category Mean (SD) Mean (SD) 95% CI 01 SRI+Quetiapine v SRI+Placebo 3.76(1.40) -1.15 [-1.98, -0.33] -1.15 [-1.98, -0.33] Atmaca 2002 2.42(0.80) 13 Subtotal (95% CI) 13 14 Test for heterogeneity: not applicable Test for overall effect: Z = 2.74 (P = 0.006) Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 11 Risperidone vs placebo Outcome: 01 Adverse effects SRI+Risperidone SRI+Placebo RR (fixed) RR (fixed) Study or sub-category nΝ n/N 95% CI 95% CI 01 SRI+Risperidone v SRI+Placebo 1.20 [0.31, 4.69] 0.96 [0.79, 1.16] Hollander 2003e 2/6 4/10 McDougle 2000a 18/20 15/16 Subtotal (95% CI) 30 22 0.99 [0.77, 1.28] Total events: 22 (SRI+Risperidone), 17 (SRI+Placebo) Test for heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67), I2 = 0% Test for overall effect: Z = 0.07 (P = 0.95) 0.5 Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 11 Risperidone vs placebo Outcome: 02 Leaving the study early Study SRI+Risperidone SRI+Placebo RR (fixed) RR (fixed) or sub-category n/N 95% CI n/N 95% CI 01 SRI+Risperidone v SRI+Placebo Hollander 2003e 1/10 2/6 0.30 [0.03, 2.65] McDougle 2000a 2/20 1/16 1.60 [0.16, 16.10] Subtotal (95% CI) 22 0.70 [0.16, 3.01] 30 Total events: 3 (SRI+Risperidone), 3 (SRI+Placebo) Test for heterogeneity: $Chi^2 = 1.07$, df = 1 (P = 0.30), $I^2 = 6.9\%$ Test for overall effect: Z = 0.48 (P = 0.63)

0.01

0.1

Favours augmentation Favours non-aug

10

100

Comparison: 11 Risperidone vs placebo Outcome: 03 Leaving the study early due to adverse effects SRI+Risperidone SRI+Placebo RR (fixed) RR (fixed) Study or sub-category n/Ν nΝ 95% CI 95% CI 01 SRI+Risperidone v SRI+Placebo McDougle 2000a 1/20 0/16 2.43 [0.11, 55.89] Subtotal (95% CI) 20 16 2.43 [0.11, 55.89] Total events: 1 (SRI+Risperidone), 0 (SRI+Placebo) Test for heterogeneity; not applicable Test for overall effect: Z = 0.55 (P = 0.58) 0.01 100 0.110 Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 11 Risperidone vs placebo Outcome: 04 Non-responders SRI+Risperidone SRI+Placebo RR (fixed) Study RR (fixed) or sub-category nΝ n/N 95% CI 95% CI 01 SRI+Risperidone v SRI+Placebo: CGI much or very much improved, Y-BOCS>=35% reduction McDougle 2000a 16/16 0.80 [0.64, 1.00] 16/20 Subtotal (95% CI) 20 16 0.80 [0.64, 1.00] Total events: 16 (SRI+Risperidone), 16 (SRI+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 2.00 (P = 0.05) 02 SRI+Risperidone v SRI+Placebo: CGI much or very much improved, Y-BOCS>=25% reduction Hollander 2003e 0.60 [0.36, 1.00] 6/10 6/6 Subtotal (95% CI) 10 6 0.60 [0.36, 1.00] Total events: 6 (SRI+Risperidone), 6 (SRI+Placebo) Test for heterogeneity: not applicable Test for overall effect: Z = 1.98 (P = 0.05) Total (95% Ch. 0.74 [0.60, 0.91] 30 22 Total events: 22 (SRI+Risperidone), 22 (SRI+Placebo) Test for heterogeneity: Chi² = 1.14, df = 1 (P = 0.29), l² = 12.3% Test for overall effect: Z = 2.81 (P = 0.005) 0.5Favours augmentation Favours non-aug Review: OCD: augmentation strategies Comparison: 11 Risperidone vs placebo 05 Y-BOCS change score Study SRI+Risperidone SRI+Placebo SMD (fixed) SMD (fixed) Ν Mean (SD) 95% CI or sub-category Mean (SD) 01 SRI+Risperidone v SRI+Placebo Hollander 2003e 10 -6.10(8.18) 6 -1.33(3.14)-0.66 [-1.71, 0.38] McDougle 2000a 20 -8.00(7.32) 16 -0.25 [-0.91, 0.41] -6.60(0.97)30 -0.37 [-0.92, 0.19] Test for heterogeneity: $Chi^2 = 0.43$, df = 1 (P = 0.51), $I^2 = 0\%$ Test for overall effect: Z = 1.28 (P = 0.20) Favours augmentation Favours non-aug OCD: augmentation strategies Review: Comparison: 11 Risperidone vs placebo 06 Hamilton Depression Scale SRI+Placeho SMD (fixed) SMD (fixed) Study SRI+Risperidone N Ν Mean (SD) or sub-category Mean (SD) 95% CI 95% CI 01 SRI+Risperidone v SRI+Placebo

18

18

7.60(4.90)

15

15

15.20(8.70)

-4 -2 0 2
Favours augmentation Favours non-aug

-1.08 [-1.82, -0.34]

-1.08 [-1.82, -0.34]

McDougle 2000a


Test for heterogeneity: not applicable Test for overall effect: Z = 2.86 (P = 0.004)

Subtotal (95% CI)

Review:

OCD: augmentation strategies

Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 07 Hamilton Anxiety Scale



Review: OCD: augmentation strategies Comparison: 12 All antipsychotics v placebo

Outcome: 01 Adverse effects

Study or sub-category	Augmentation n/N	non-augmentation n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 SRI+Quetiapine v SRI+Pla	acebo			
Atmaca 2002	9/14	4/13	+	2.09 [0.85, 5.16]
Subtotal (95% CI)	14	13		2.09 [0.85, 5.16]
Total events: 9 (Augmentation	on), 4 (non-augmentation)		-	
Test for heterogeneity: not a	applicable			
Test for overall effect: $Z = 1$	I.60 (P = 0.11)			
02 SRI+Risperidone v SRI+P	lacebo			
Hollander 2003e	4/10	2/6		1.20 [0.31, 4.69]
McDougle 2000a	18/20	15/16	<u> </u>	0.96 [0.79, 1.16]
Subtotal (95% CI)	30	22	•	0.99 [0.77, 1.28]
Total events: 22 (Augmental	tion), 17 (non-augmentation)			
Test for heterogeneity: Chi²	$= 0.18$, df $= 1 (P = 0.67)$, $I^2 = 09$	6		
Test for overall effect: Z = 0	0.07 (P = 0.95)			
Total (95% CI)	44	35	•	1.19 [0.89, 1.58]
Total events: 31 (Augmental	tion), 21 (non-augmentation)			,
, -	$= 6.13$, df = 2 (P = 0.05), $l^2 = 67$	7.3%		
Test for overall effect: Z = 1				
		0.1	0.2 0.5 1 2 5	10
		Favou	ırs augmentation Favours non-a	ug

Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 02 Leaving the study early

Study or sub-category	Augmentation n/N	non-augmentation n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 FLX+Olanzapine v FLX+Pla	acebo			
Shapira 2004	5/22	2/22		2.50 [0.54, 11.54]
Subtotal (95% CI)	22	22		2.50 [0.54, 11.54]
Total events: 5 (Augmentation	i), 2 (non-augmentation)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: $Z = 1.1$	17 (P = 0.24)			
02 SRI+Quetiapine v SRI+Plac	ebo			
Atmaca 2002	0/14	0/13		Not estimable
Subtotal (95% CI)	0	0		Not estimable
Total events: 0 (Augmentation	i), 0 (non-augmentation)			
Test for heterogeneity: not ap	plicable			
Test for overall effect: not ap	plicable			
03 SRI+Risperidone v SRI+Pla	cebo			
Hollander 2003e	1/10	2/6		0.30 [0.03, 2.65]
McDougle 2000a	2/20	1/16		1.60 [0.16, 16.10]
Subtotal (95% CI)	30	22		0.70 [0.16, 3.01]
Total events: 3 (Augmentation	n), 3 (non-augmentation)		-	
Test for heterogeneity: Chi ² =	1.07 , $df = 1$ ($P = 0.30$), $I^2 = 6.9$	%		
Test for overall effect: Z = 0.4	48 (P = 0.63)			
Total (95% CI)	66	57	—	1.34 [0.49, 3.67]
Total events: 8 (Augmentation	n), 5 (non-augmentation)			·
Test for heterogeneity: Chi² =	2.48, df = 2 (P = 0.29), l2 = 19.	3%		
Test for overall effect: $Z = 0.5$	57 (P = 0.57)			
		0	.01 0.1 1 10	100
		F8	vours augmentation Favours non-aug	g

Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 03 Leaving the study early due to adverse effects

Study or sub-category	Augmentation n/N	non-augmentation n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
	ebo			
Shapira 2004	2/22	2/22		1.00 [0.15, 6.48]
Subtotal (95% CI)	22	22		1.00 [0.15, 6.48]
Total events: 2 (Augmentation), Test for heterogeneity: not appl Test for overall effect: Z = 0.00	licable			
02 SRI+Risperidone v SRI+Place	ebo			
McDougle 2000a	1/20	0/16		- 2.43 [0.11, 55.89]
Subtotal (95% CI)	20	16		
Fotal events: 1 (Augmentation), Fest for heterogeneity: not appl Fest for overall effect: Z = 0.55	licable			
Total (95% CI) Total events: 3 (Augmentation), Test for heterogeneity: Chi² = 0 Test for overall effect: Z = 0.33	.23, df = 1 (P = 0.63), $I^2 = 0$	38		1.31 [0.27, 6.35]
		0.01	0.1 1 10	100
		Favo	ours augmentation Favours non-au	ug


Review: OCD: augmentation strategies Comparison: 12 All antipsychotics v placebo

Outcome: 04 Non-responders

Study or sub-category	Augmentation n/N	non-augmentation n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 FLV+Haloperidol v FLV+Place	bo			
McDougle 1994a	10/17	17/17		0.59 [0.40, 0.88]
Subtotal (95% CI)	17	17	•	0.59 [0.40, 0.88]
Total events: 10 (Augmentation),				
Test for heterogeneity: not applic				
Test for overall effect: Z = 2.61 (P = 0.009)			
02 FLX+Olanzapine v FLX+Placel	bo			
Shapira 2004	13/22	13/22	-	1.00 [0.61, 1.64]
Subtotal (95% CI)	22	22	-	1.00 [0.61, 1.64]
Total events: 13 (Augmentation),	13 (non-augmentation)			
Test for heterogeneity: not applic				
Test for overall effect: Z = 0.00 (P = 1.00)			
03 SRI+Quetiapine v SRI+Placebo)			
Atmaca 2002	4/14	13/13		0.29 [0.12, 0.65]
Subtotal (95% CI)	14	13		0.29 [0.12, 0.65]
Total events: 4 (Augmentation), 1	, -			
Test for heterogeneity: not applic				
Test for overall effect: Z = 2.96 (P = 0.003)			
04 SRI+Risperidone v SRI+Placeb	00			
Hollander 2003e	6/10	6/6		0.60 [0.36, 1.00]
McDougle 2000a	16/20	16/16	-	0.80 [0.64, 1.00]
Subtotal (95% CI)	30	22	•	0.74 [0.60, 0.91]
Total events: 22 (Augmentation),	22 (non-augmentation)		`	
Test for heterogeneity: Chi² = 1.1		6		
Test for overall effect: Z = 2.81 (P = 0.005)			
Total (95% CI)	83	74	•	0.66 [0.54, 0.81]
Total events: 49 (Augmentation),	65 (non-augmentation)		*	• •
Test for heterogeneity: Chi² = 9.9	8, df = 4 (P = 0.04), l ² = 59.9%	5		
Test for overall effect: $Z = 4.05$ (P < 0.0001)			
			0.1 0.2 0.5 1 2 5 10	0
			Favours augmentation Favours non-aug	

Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo

Outcome: 05 Y-BOCS



Favours augmentation Favours non-aug

SSRIs (OCD, children)

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 01 Adverse events


Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine				
Geller 2001	53/71	27/32		0 00 10 72 1 001
Liebowitz 2002	21/21	19/22	 _	0.88 [0.72, 1.08]
	92	·		1.16 [0.98, 1.37]
Subtotal (95% CI)		54		0.98 [0.85, 1.12]
Total events: 74 (SSRI), 46 (0.000		
Test for neterogeneity: Cni ² Test for overall effect: Z = 0	= 4.99, df = 1 (P = 0.03), l² = 80 1 34 (P = 0.73)	1.0%		
1031 101 0401 all 011001. 2 = 0	3.04 (1 = 0.10)			
02 Fluvoxamine				
Riddle 2001	48/57	48/63	 •	1.11 [0.93, 1.32]
Subtotal (95% CI)	57	63		1.11 [0.93, 1.32]
Total events: 48 (SSRI), 48 ((Placebo)		-	
Test for heterogeneity: not a	applicable			
Test for overall effect: $Z = 1$	I.10 (P = 0.27)			
03 Paroxetine				
Geller 2004	83/98	77/105		1.15 [1.00, 1.33]
Subtotal (95% CI)	98	105		1.15 [1.00, 1.33]
Total events: 83 (SSRI), 77 (200		1110 (1110), 1110),
Test for heterogeneity: not a				
Test for overall effect: Z = 1				
1000 101 01010111011000. 2 = 1	1.55 (1 = 5.55)			
Total (95% CI)	247	222	•	1.09 [0.99, 1.19]
Total events: 205 (SSRI), 17	1 (Placebo)		-	•
Test for heterogeneity: Chi²	$= 5.30$, df $= 3$ (P = 0.15), $I^2 = 43$	3.4%		
Test for overall effect: $Z = 1$	I.80 (P = 0.07)			
		0.5	0.7 1 1.5	2
		0.0	Favours SSRI Favours Placeb	_
			Tayouts sort Tayouts Flaces	· · · · · · · · · · · · · · · · · · ·

Review: OCD children: SSRIs Comparison: 01 SSRI vs placebo (acute phase) Outcome: 02 Serious adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
01 Paroxetine				
Geller 2004	3/98	1/105	- 	3.21 [0.34, 30.39]
Subtotal (95% CI)	98	105		3.21 [0.34, 30.39]
Total events: 3 (SSRI), 1 (Placebo)			-	
Test for heterogeneity: not applicable				
Test for overall effect: $Z = 1.02$ (P = 0.31))			
Total (95% CI)	98	105	-	3.21 [0.34, 30.39]
Total events: 3 (SSRI), 1 (Placebo) Test for heterogeneity: not applicable				
= ,				
Test for overall effect: $Z = 1.02$ (P = 0.31)	J			
		0.0	1 0.1 1 10 10	0
			Favours SSRI Favours Placebo	

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 03 Leaving the study early



Comparison:

01 SSRI vs placebo (acute phase)
04 Leaving the study early due to adverse events Outcome:


34]
Le
.64]
10]
.98]
.98]
.16]
.64]
.48]
. 60]
.60]
•
001

OCD children: SSRIs Review:

Comparison: 01 SSRI vs placebo (acute phase) Outcome: 05 Non-responders (25% CY-BOCS)

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Riddle 2001	33/57	46/63		0.79 [0.61, 1.04]
Subtotal (95% CI)	57	63	•	0.79 [0.61, 1.04]
fotal events: 33 (SSRI), 46 (Place	bo)		-	
Test for heterogeneity: not applica	able			
Test for overall effect: $Z = 1.70$ (F	P = 0.09)			
02 Paroxetine				
Geller 2004	39/100	65/107		0.64 [0.48, 0.86]
Subtotal (95% CI)	100	107	◆	0.64 [0.48, 0.86]
Total events: 39 (SSRI), 65 (Place	:bo)		-	
Test for heterogeneity: not applica	able			
Test for overall effect: Z = 3.01 (F	P = 0.003)			
Total (95% CI)	157	170	•	0.70 [0.58, 0.86]
Total events: 72 (SSRI), 111 (Plac	ebo)		-	
Test for heterogeneity: Chi² = 1.15	5, df = 1 (P = 0.28), l ² = 13	3.2%		
Test for overall effect: Z = 3.44 (F	P = 0.0006)			
		0.1	0.2 0.5 1 2 5	10
			Favours SSRI Favours Placel	bo

Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 06 Non-responders (40% CY-BOCS)



Favours SSRI Favours Placebo

Review: OCD children: SSRIs

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 07 Non-responders (all)

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
O1 Fluoxetine				
Geller 2001	36/71	24/32	-	0.68 [0.50, 0.92]
Subtotal (95% CI)	71	32	-	0.68 [0.50, 0.92]
otal events: 36 (SSRI), 24 (Placebo))		•	,,
est for heterogeneity: not applicable				
est for overall effect: Z = 2.52 (P = 0				
02 Fluvoxamine				
Riddle 2001	33/57	46/63		0.79 [0.61, 1.04]
Subtotal (95% CI)	57	63	◆	0.79 [0.61, 1.04]
Total events: 33 (SSRI), 46 (Placebo)				
Test for heterogeneity: not applicable				
Test for overall effect: Z = 1.70 (P = 0	0.09)			
03 Paroxetine				
Geller 2004	39/100	65/107	-	0.64 [0.48, 0.86]
Subtotal (95% CI)	100	107	◆	0.64 [0.48, 0.86]
Total events: 39 (SSRI), 65 (Placebo)				
Fest for heterogeneity: not applicable				
Fest for overall effect: Z = 3.01 (P = 0	0.003)			
Fotal (95% CI)	228	202	◆	0.70 [0.59, 0.83]
fotal events: 108 (SSRI), 135 (Placek	00)			
Fest for heterogeneity: Chi² = 1.24, d	, ,,			
「est for overall effect: Z = 4.18 (P < 0	0.0001)			
		0.	1 0.2 0.5 1 2 5	10
OOD stillers COD			Favours SSRI Favours placet	00

Review: OCD children: SSRIs

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 08 Non-responders (CGI Global Improvement)

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Paroxetine				
Geller 2004	55/100	72/107	-	0.82 [0.66, 1.02]
Subtotal (95% CI)	100	107	•	0.82 [0.66, 1.02]
Total events: 55 (SSRI), 72 (I	Placebo)		-	
Test for heterogeneity: not a	pplicable			
Test for overall effect: Z = 1	.79 (P = 0.07)			
			0.1 0.2 0.5 1 2 5	10
			Favours SSRI Favours Placebo	

01 SSRI vs placebo (acute phase) 09 Remission (CY-BOCS < 11) Comparison: Outcome:

Study or sub-category	Sertraline n <i>I</i> N	Placebo n/N				(fixed % Cl)			RR (fixed) 95% Cl
01 Sertraline										
POTS 2004	22/28	27/28			-	H				0.81 [0.66, 1.00]
Subtotal (95% CI)	28	28								0.81 [0.66, 1.00]
Total events: 22 (Sertraline),	27 (Placebo)				,					•
Test for heterogeneity: not a	pplicable									
Test for overall effect: Z = 1	.95 (P = 0.05)									
			0.1	0.2	0.5	1	2	5	10	

Favours Sertraline Favours Placebo

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 10 CY-BOCS

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
D1 Fluoxetine						
Geller 2001	71	-9.50(9.20)	32	-5.20(7.40)		-0.49 [-0.91, -0.07]
Liebowitz 2002	21	14.71(8.73)	22	18.55(11.44)	-	-0.37 [-0.97, 0.23]
Riddle 1992	7	13.60(5.70)	6	14.80(7.00)	•	-0.18 [-1.27, 0.92]
Subtotal (95% CI)	99		60			-0.43 [-0.76, -0.10]
rest for heterogeneity: Chi² =	0.33, df = 2 (P	= 0.85), I ² = 0%				
Test for overall effect: $Z = 2.5$	53 (P = 0.01)					
02 Fluvoxamine						
Riddle 2001	57	18.20(8.60)	63	20.90(8.50)		-0.31 [-0.67, 0.05]
Subtotal (95% CI)	57		63			-0.31 [-0.67, 0.05]
Test for heterogeneity: not ap	oplicable					
Test for overall effect: $Z = 1.7$	71 (P = 0.09)					
03 Sertraline						
March 1998	92	-6.80(8.35)	95	-3.40(8.00)		-0.41 [-0.70, -0.12]
POTS 2004	28	16.50(9.10)	28	21.50(5.40)	-	-0.66 [-1.20, -0.12]
Subtotal (95% CI)	120		123		-	-0.47 [-0.72, -0.21]
Test for heterogeneity: Chi² =	0.61, df = 1 (P	= 0.43), I ² = 0%			_	
Test for overall effect: $Z = 3.6$	60 (P = 0.0003)					
04 Paroxetine						
Geller 2004	94	-8.78(7.65)	102	-5.34(7.78)		-0.44 [-0.73, -0.16]
Subtotal (95% CI)	94		102		-	-0.44 [-0.73, -0.16]
Test for heterogeneity: not ap						
Test for overall effect: Z = 3.0	07 (P = 0.002)					
Total (95% CI)	370		348		•	-0.43 [-0.58, -0.28]
Test for heterogeneity: Chi² =						
Test for overall effect: $Z = 5.5$	59 (P < 0.00001)				
					-1 -0.5 0 0.5	1
					Favours SSRI Favours Plac	eho

Review: OCD children: SSRIs

01 SSRI vs placebo (acute phase) 11 NIMH-OC Comparison:


Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine						
Geller 2001	71	-3.10(3.00)	32	-1.30(2.20)	←	-0.64 [-1.07, -0.22]
Liebowitz 2002	21	6.24(2.45)	22	7.18(2.75)	-	-0.35 [-0.96, 0.25]
Subtotal (95% CI)	92		54			-0.55 [-0.89, -0.20]
Test for heterogeneity: Chi ²	² = 0.59, df = 1 (P	$= 0.44$), $I^2 = 0\%$				•
Test for overall effect: Z =	3.07 (P = 0.002)					
02 Fluvoxamine						
Riddle 2001	57	7.50(3.20)	63	8.30(2.60)		-0.27 [-0.63, 0.09]
Subtotal (95% CI)	57		63			-0.27 [-0.63, 0.09]
Test for heterogeneity: not	applicable					
Test for overall effect: Z =	1.49 (P = 0.14)					
03 Sertraline						
March 1998	92	-2.20(2.78)	95	-1.30(2.63)		-0.33 [-0.62, -0.04]
Subtotal (95% CI)	92		95			-0.33 [-0.62, -0.04]
Test for heterogeneity: not	applicable				_	
Test for overall effect: Z = :	2.25 (P = 0.02)					
Total (95% CI)	241		212		•	-0.38 [-0.57, -0.19]
Test for heterogeneity: Chi ² Test for overall effect: Z = 3					-	
					-1 -0.5 0 0.5	1

Favours SSRI Favours Placebo

Comparison: 01 SSRI vs placebo (acute phase)

12 Child Obsessive Compulsive Impact Scale (Parent Version) Outcome:



OCD children: SSRIs Review:

01 SSRI vs placebo (acute phase) Comparison:

Outcome: 13 Leyton Obsessional Inventory (Child Version): interference

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			O (fixed) 5% Cl		SMD (fixed) 95% Cl	
01 Fluoxetine										
Riddle 1992	7	20.60(19.40)	6	21.00(19.30)			•		-0.02 [-1.11, 1.07]	
Subtotal (95% CI)	7		6						-0.02 [-1.11, 1.07]	
Test for heterogeneity: not	applicable						T			
Test for overall effect: Z =	0.03 (P = 0.97)									
					-4	-2	<u> </u>	2	4	

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Review: OCD children: SSRIs

Comparison: 01 SSRI vs placebo (acute phase)

14 Leyton Obsessional Inventory (Child Version): resistance Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	MD (fixed) 95% CI			SMD (fixed) 95% CI
01 Fluoxetine										
Riddle 1992	7	19.60(14.40)	6	22.00(23.10)		_	_			-0.12 [-1.21, 0.97]
Subtotal (95% CI)	7		6			-	-			-0.12 [-1.21, 0.97]
Test for heterogeneity: not	applicable						7			
Test for overall effect: Z =	0.21 (P = 0.83)									
					-4	-2	-	<u>;</u>	4	

OCD children: SSRIs Review:

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 15 Leyton Obsessional Inventory (Child Version): symptoms

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	SMD (fixed) 95% CI			SMD (fixed) 95% Cl
01 Fluoxetine Riddle 1992 Subtotal (95% CI)	7 7	16.30(8.40)	6 6	13.80(12.10)			-			0.23 [-0.87, 1.32] 0.23 [-0.87, 1.32]
Test for heterogeneity: not Test for overall effect: Z =										
					-4	-2	0	2	4	

Review: OCD children: SSRIs

Comparison:

01 SSRI vs placebo (acute phase) 16 Children's Depression Rating Scale (Revised Version) Outcome:

01 Fluvoxamine Riddle 2001 57 27.40(8.00) 63 27.10(8.00 Subtotal (95% CI) 57 63	0.04 [-0.32, 0.40]
	0.04 [-0.32 0.40]
Subtotal (95% CI) 57 63	
	0.04 [-0.32, 0.40]
Test for heterogeneity: not applicable	
Test for overall effect: Z = 0.20 (P = 0.84)	

OCD children: SSRIs Review:

Comparison: 01 SSRI vs placebo (acute phase) Outcome: 17 Hamilton Rating Scale for Depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		(fixed) % Cl	SMD (fixed) 95% CI
O1 Fluoxetine Liebowitz 2002 Subtotal (95% CI) Test for heterogeneity: not Test for overall effect: Z =		9.14(6.56)	22 22	7.09(7.39)		-	0.29 [-0.31, 0.89] 0.29 [-0.31, 0.89]
					-1 -0.5 Favours SSRI	0 0.5 1 Favours Placebo	

Comparison: 01 SSRI vs placebo (acute phase) Outcome: 18 Depression (CDRS; HRSD)

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (fixe 95% CI	d)	SMD (fixed) 95% Cl
01 Fluoxetine								
Liebowitz 2002	21	9.14(6.56)	22	7.09(7.39)				0.29 [-0.31, 0.89]
Subtotal (95% CI)	21		22					0.29 [-0.31, 0.89]
Test for heterogeneity: not	t applicable					-		
Test for overall effect: Z =	0.94 (P = 0.35)							
02 Fluvoxamine								
Riddle 2001	57	27.40(8.00)	63	27.10(8.00)				0.04 [-0.32, 0.40]
Subtotal (95% CI)	57		63			-		0.04 [-0.32, 0.40]
Test for heterogeneity: not	t applicable					T		
Test for overall effect: Z =	0.20 (P = 0.84)							
Total (95% CI)	78		85					0.10 [-0.20, 0.41]
Test for heterogeneity: Ch	i ² = 0.49, df = 1 (P	= 0.48), I ² = 0%					_	
Test for overall effect: Z =								
					-1 -0		0.5	
					-1 -0	i.5 U	0.5	1
					Favo	urs SSRI Fa	vours placebo	

Review: OCD children: SSRIs

Comparison:

01 SSRI vs placebo (acute phase) 19 Multidimensional Anxiety Scale for Children Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine Geller 2001 Subtotal (95% CI)	71 71	-9.00(18.60)	32 32	-4.50(16.50)	-	-0.25 [-0.67, 0.17] -0.25 [-0.67, 0.17]
Test for heterogeneity: not a Test for overall effect: Z = 1					1 -05 0 05	

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

Favours SSRI Favours placebo

OCD children: SSRIs 01 SSRI vs placebo (acute phase) Review: Comparison:

Outcome: 20 Revised Children's Manifest Anxiety Scale

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Fluoxetine							
Riddle 1992	6	45.70(13.30)	5	40.20(16.90)			0.34 [-0.86, 1.53]
Subtotal (95% CI)	6		5			-	0.34 [-0.86, 1.53]
Test for heterogeneity: not	: applicable					_	
Test for overall effect: Z =	0.55 (P = 0.58)						
					4	5 1	4

Review: OCD children: SSRIs

01 SSRI vs placebo (acute phase) 21 Anxiety (MASC; RCMAS) Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Fluoxetine										
Geller 2001	71	-9.00(18.60)	32	-4.50(16.50)			-			-0.25 [-0.67, 0.17]
Riddle 1992	6	45.70(13.30)	5	40.20(16.90)		-	\lnot•			0.34 [-0.86, 1.53]
Subtotal (95% CI)	77		37				•			-0.19 [-0.58, 0.21]
Test for heterogeneity: Chi	i ² = 0.81, df = 1 (P	$= 0.37$), $I^2 = 0\%$					1			·
Test for overall effect: Z =	0.92 (P = 0.36)									
					-4	-2		-	4	

OCD children: SSRIs

01 SSRI vs placebo (acute phase) 22 Children's Global Assessment Scale Comparison: Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	SMD (fixed 95% CI)		SMD (fixed) 95% CI
O1 Fluoxetine Riddle 1992 Sulototal (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.		70.40(13.20)	6 6	62.00(8.40)			-	-		0.69 [-0.44, 1.83] 0.69 [-0.44, 1.83]
					-4	-2	ö	2	4	
						Favours S	SRI Fav	ours Place	ebo	

01 SSRI vs placebo (acute phase) 23 Systolic blood pressure - supine Comparison: Outcome:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Sertraline v Placebo (at 1 v	week)					
March 1998	92	108.50(12.50)	95	107.60(10.60)	<u>=</u>	0.08 [-0.21, 0.36]
Subtotal (95% CI)	92		95		∓	0.08 [-0.21, 0.36]
Test for heterogeneity: not ap	plicable					
Test for overall effect: $Z = 0.5$	3 (P = 0.60)					
02 Sertraline v Placebo (at 4 v	weeks)					
March 1998	92	108.10(12.10)	95	107.00(11.00)	<u> </u>	0.09 [-0.19, 0.38]
Subtotal (95% CI)	92		95			0.09 [-0.19, 0.38]
Test for heterogeneity: not ap	plicable				ſ	
Test for overall effect: $Z = 0.6$	65 (P = 0.52)					
03 Sertraline v Placebo (at 12	weeks)					
March 1998	92	107.00(11.00)	95	107.40(10.60)	<u> </u>	-0.04 [-0.32, 0.25]
Subtotal (95% CI)	92		95			-0.04 [-0.32, 0.25]
Test for heterogeneity: not ap	plicable					
Test for overall effect: $Z = 0.3$	25 (P = 0.80)					

Favours sertraline Favours placebo

Favours sertraline Favours placebo

Review:

OCD children: SSRIs 01 SSRI vs placebo (acute phase) 24 Systolic blood pressure - standing Comparison: Outcome:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Sertraline v Placebo (at 1	week)					
March 1998	92	108.40(11.00)	95	107.40(10.90)	<u>=</u>	0.09 [-0.20, 0.38]
Subtotal (95% CI)	92		95		T	0.09 [-0.20, 0.38]
Test for heterogeneity: not a	pplicable				ĺ	
Test for overall effect: $Z = 0$.62 (P = 0.53)					
02 Sertraline v Placebo (at 4	weeks)					
March 1998	92	106.20(11.40)	95	107.20(11.70)	<u> </u>	-0.09 [-0.37, 0.20]
Subtotal (95% CI)	92		95		▼	-0.09 [-0.37, 0.20]
Test for heterogeneity: not a	pplicable					
Test for overall effect: $Z = 0$.59 (P = 0.56)					
03 Sertraline v Placebo (at 1	2 weeks)					
March 1998	92	105.80(10.80)	95	107.10(10.90)	<u>=</u>	-0.12 [-0.41, 0.17]
Subtotal (95% CI)	92		95		₹	-0.12 [-0.41, 0.17]
Test for heterogeneity: not a	pplicable				1	•
Test for overall effect: $Z = 0$.81 (P = 0.42)					

Review: OCD children: SSRIs

Comparison: 01 SSRI vs placebo (acute phase) Outcome: 25 Diastolic blood pressure - supine

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)		:	SMD (fixed) 95% Cl	ı		SMD (fixed) 95% Cl
	k)									
March 1998	92	64.80(8.50)	95	64.40(10.20)						0.04 [-0.24, 0.33]
Subtotal (95% CI)	92		95				•			0.04 [-0.24, 0.33]
Test for heterogeneity: not applicate	able									
Test for overall effect: $Z = 0.29$ (F	P = 0.77)									
02 Sertraline v Placebo (at 4 wee	ks)									
March 1998	92	63.00(8.70)	95	63.80(9.40)						-0.09 [-0.37, 0.20]
Subtotal (95% CI)	92		95				- ▼			-0.09 [-0.37, 0.20]
Test for heterogeneity: not applica	able									
Test for overall effect: $Z = 0.60$ (F	P = 0.55)									
03 Sertraline v Placebo (at 12 we	eks)									
March 1998	92	63.70(10.90)	95	64.50(8.80)						-0.08 [-0.37, 0.21]
Subtotal (95% CI)	92		95				- ₹			-0.08 [-0.37, 0.21]
Test for heterogeneity: not applicate	able]			
Test for overall effect: $Z = 0.55$ (F	P = 0.58)									
					-10	-5	- 6	5	10	
					Favo	urs sertra	aline Fav	ours place	ebo	

01 SSRI vs placebo (acute phase) 26 Diastolic blood pressure - standing Comparison: Outcome:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Sertraline v Placebo (at 1	week)					
March 1998	92	67.60(9.40)	95	67.70(10.60)	<u> </u>	-0.01 [-0.30, 0.28]
Subtotal (95% CI)	92		95			-0.01 [-0.30, 0.28]
Test for heterogeneity: not a	applicable]	
Test for overall effect: $Z = 0$	0.07 (P = 0.95)					
02 Sertraline v Placebo (at 4	weeks)					
March 1998	92	67.20(10.60)	95	67.40(9.80)	<u> </u>	-0.02 [-0.31, 0.27]
Subtotal (95% CI)	92		95		▼	-0.02 [-0.31, 0.27]
Test for heterogeneity: not a	applicable					
Test for overall effect: $Z = 0$).13 (P = 0.89)					
03 Sertraline v Placebo (at 1	2 weeks)					
March 1998	92	67.10(9.20)	95	67.80(8.90)	<u> </u>	-0.08 [-0.36, 0.21]
Subtotal (95% CI)	92		95			-0.08 [-0.36, 0.21]
Test for heterogeneity: not a	applicable				Ī	•
Test for overall effect: $Z = 0$).53 (P = 0.60)					

Favours sertraline Favours placebo

Favours sertraline Favours placebo

Review:

OCD children: SSRIs 01 SSRI vs placebo (acute phase) 27 Heart rate - supine Comparison:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1	I week)					
March 1998	92	75.40(12.70)	95	77.80(13.00)	<u>=</u>	-0.19 [-0.47, 0.10]
Subtotal (95% CI)	92		95		∓	-0.19 [-0.47, 0.10]
Test for heterogeneity: not a	applicable					
Test for overall effect: $Z = 1$	1.27 (P = 0.20)					
02 Sertraline v Placebo (at 4	4 weeks)					
March 1998	92	76.90(11.50)	95	78.10(11.80)	<u>=</u>	-0.10 [-0.39, 0.18]
Subtotal (95% CI)	92		95			-0.10 [-0.39, 0.18]
Fest for heterogeneity: not a	applicable					
Test for overall effect: $Z = 0$	0.70 (P = 0.48)					
D3 Sertraline v Placebo (at 1	12 weeks)					
March 1998	92	77.30(9.80)	95	78.40(13.00)	<u>=</u>	-0.09 [-0.38, 0.19]
Subtotal (95% CI)	92		95			-0.09 [-0.38, 0.19]
Fest for heterogeneity: not a	applicable					,
Test for overall effect: Z = 0						

Review: OCD children: SSRIs 01 SSRI vs placebo (acute phase) 28 Heart rate - standing Comparison:

Outcome:

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)		\$	SMD (fixed) 95% CI)		SMD (fixed) 95% Cl
01 Sertraline v Placebo (at 1	week)									
March 1998	92	81.40(13.90)	95	86.10(13.30)						-0.34 [-0.63, -0.06]
Subtotal (95% CI)	92		95				•			-0.34 [-0.63, -0.06]
Test for heterogeneity: not ap	pplicable						Ì			
Test for overall effect: $Z = 2$.	34 (P = 0.02)									
02 Sertraline v Placebo (at 4	weeks)									
March 1998	92	83.90(13.80)	95	84.50(12.00)						-0.05 [-0.33, 0.24]
Subtotal (95% Cl)	92		95				₩			-0.05 [-0.33, 0.24]
Test for heterogeneity: not ap	pplicable						1			
Test for overall effect: $Z = 0$.	32 (P = 0.75)									
03 Sertraline v Placebo (at 12	2 weeks)									
March 1998	92	85.10(12.10)	95	86.20(15.30)						-0.08 [-0.37, 0.21]
Subtotal (95% CI)	92		95				•			-0.08 [-0.37, 0.21]
Test for heterogeneity: not ap	pplicable						Ī			•
Test for overall effect: Z = 0.										
					-10	-5	-	5	10	
					Favour	s sertra	iline Fav	ours place	ebo	

Comparison: 01 SSRI vs placebo (acute phase)

Outcome: 29 Suicidality (Columbia reclassification - "Outcome 3: definitive suicidal behaviour/ ideation")

tudy r sub-category	Treatment n/N	Control n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
1 Fluoxetine				
Seller 2001	1/71	0/32		1.38 [0.06, 32.87]
ubtotal (95% CI)	71	32		1.38 [0.06, 32.87]
otal events: 1 (Treatment), 0 (Con				
est for heterogeneity: not applicat est for overall effect: Z = 0.20 (P :				
sst for overall effect. Z = 0.20 (F	- 0.04)			
2 Fluvoxamine				
Riddle 2001	2/57	0/63	-	→ 5.52 [0.27, 112.55]
ubtotal (95% CI)	57	63		- 5.52 [0.27, 112.55]
otal events: 2 (Treatment), 0 (Con				
est for heterogeneity: not applicat				
est for overall effect: Z = 1.11 (P	= 0.27)			
3 Paroxetine				
9eller 2004	1/99	0/107		- 3.24 [0.13, 78.62]
ubtotal (95% CI)	99	107		→ 3.24 [0.13, 78.62]
otal events: 1 (Treatment), 0 (Con				
est for heterogeneity: not applicat				
est for overall effect: Z = 0.72 (P	= 0.47)			
4 Sertraline				
March 1998	0/92	1/95		0.34 [0.01, 8.34]
ubtotal (95% CI)	92	95		0.34 [0.01, 8.34]
otal events: 0 (Treatment), 1 (Con				
est for heterogeneity: not applicat				
est for overall effect: Z = 0.66 (P	= 0.51)			
otal (95% CI)	319	297		1.81 [0.46, 7.13]
otal events: 4 (Treatment), 1 (Con				
est for heterogeneity: Chi² = 1.72,	, df = 3 (P = 0.63), l ² = 0%			
est for overall effect: Z = 0.84 (P	= 0.40)			
		0.	01 0.1 1 10	100
			Favours treatment Favours control	

Review: OCD children: SSRIs

Comparison: 02 SSRI vs placebo (continuation phase)

Outcome: 01 Adverse events

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Fluoxetine				
Liebowitz 2002	3/11	0/7		4.67 [0.28, 78.68]
Subtotal (95% CI)	11	7		4.67 [0.28, 78.68]
Total events: 3 (SSRI), 0 (Place	cebo)		- -	
Test for heterogeneity; not as	pplicable			
Test for overall effect: $Z = 1$.	07 (P = 0.29)			
			0.01 0.1 1 10 100	
			Favours SSRI Favours Placebo	

Review: OCD children: SSRIs


Comparison: 02 SSRI vs placebo (continuation phase)

Outcome: 02 Leaving study early

Study or sub-category	SSRI n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixe 95% (•
01 Fluoxetine Liebowitz 2002 Subtotal (95% CI)	1/12 1/12	0/7 0/7		1.85 [0.09, 1.85 [0.09,	
Test for heterogeneity: not ap Test for overall effect: Z = 0.3					
			0.01 0.1 1	10 100	
			Favours SSRI Favo	ours Placebo	

02 SSRI vs placebo (continuation phase) 03 CY-BOCS Comparison:

Outcome:



OCD children: SSRIs Review:

Comparison: 02 SSRI vs placebo (continuation phase)

Outcome: 04 NIMH-OC

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		S	MD (fixed) 95% Cl			SMD (fixed) 95% Cl
01 Fluoxetine										
Liebowitz 2002	11	3.73(1.74)	7	5.43(3.10)			-			-0.69 [-1.67, 0.29]
Subtotal (95% CI)	11		7				•			-0.69 [-1.67, 0.29]
Test for heterogeneity: not	t applicable						1			
Test for overall effect: Z =	1.38 (P = 0.17)									
					-10	-5	-	5	10	

Review: OCD children: SSRIs

Comparison: 02 SSRI vs placebo (continuation phase)

05 Child Obsessive Compulsive Impact Scale (Parent version) Outcome:

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% Cl	
01 Fluoxetine										
Liebowitz 2002	11	23.00(20.57)	7	49.29(32.70)						-0.97 [-1.98, 0.04]
Subtotal (95% CI)	11		7				∓			-0.97 [-1.98, 0.04]
Test for heterogeneity: not	t applicable									
Test for overall effect: Z =	: 1.88 (P = 0.06)									
					-100	-50	-	50	100	

Favours SSRI Favours Placebo

Favours SSRI Favours Placebo

OCD children: SSRIs Review:

Comparison: 02 SSRI vs placebo (continuation phase) Outcome: 06 Hamilton Rating Scale for Depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% Cl					SMD (fixed) 95% CI
01 Fluoxetine										
Liebowitz 2002	11	4.64(6.14)	7	7.14(5.24)			-			-0.41 [-1.37, 0.55]
Subtotal (95% CI)	11		7				•			-0.41 [-1.37, 0.55]
Test for heterogeneity: not	applicable						1			
Test for overall effect: Z =	0.84 (P = 0.40)									
					-10	-5	-	5	10	
						Favours S	SRI Fav	ours Plac	ebo	

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)

Outcome: 01 Adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Carpenter 1999	73/95	80/98	-	0.94 [0.81, 1.09]
Total (95% CI) Total events: 73 (Paroxetine Test for heterogeneity: not a Test for overall effect: Z = 0	applicable	98		0.94 [0.81, 1.09]
		0	.5 0.7 1 1.5	2
		1	Favours Paroxetine Favours Placel	bo

Comparison: 03 SSRIs vs placebo (discontinuation)

Outcome: 02 Serious adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% CI	RR (fixed) 95% Cl
Carpenter 1999	2/95	2/98		1.03 [0.15, 7.18]
Total (95% CI) Total events: 2 (Paroxetine), Test for heterogeneity: not a Test for overall effect: Z = 0	pplicable	98		1.03 [0.15, 7.18]
			0.1 0.2 0.5 1 2 5 10)
			Favours Paroxetine Favours Placebo	

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)

Outcome: 03 Leaving the study early

Study or sub-category	Paroxetine n/N	Placebo n/N		t (fixed) 5% Cl		RR (fixed) 95% Cl
Carpenter 1999	54/96	65/98	-	+		0.85 [0.68, 1.06]
Total (95% CI) Total events: 54 (Paroxetine Test for heterogeneity: not a Test for overall effect: Z = 1	applicable	98				0.85 [0.68, 1.06]
		C	0.5 0.7	1 1.5	5 2	

Favours Paroxetine Favours Placebo

Favours Paroxetine Favours Placebo

Favours Paroxetine Favours Placebo

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)

Outcome: 04 Leaving the study early due to adverse events

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
Carpenter 1999	8/95	11/98		0.75 [0.32, 1.78]
Total (95% CI) Total events: 8 (Paroxetine), Test for heterogeneity: not a Test for overall effect: Z = 0	pplicable	98		0.75 [0.32, 1.78]
		0.	1 0.2 0.5 1 2 5	10

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 05 Non-responders (25% CY-BOCS)

Study or sub-category	Paroxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Carpenter 1999	72/96	85/98	-	0.86 [0.75, 0.99]
Total (95% CI) Total events: 72 (Paroxetine Test for heterogeneity: not a Test for overall effect: Z = 2	applicable	98	-	0.86 [0.75, 0.99]
		0	.5 0.7 1	1.5 2

Review: OCD children: SSRIs

Comparison: 03 SSRIs vs placebo (discontinuation)


Outcome: 06 Non-responders (CGI Global Improvement < "much improved")

Study or sub-category	Paroxetine Placebo RR (fixed) itegory n/N n/N 95% CI				RR (fixed) 95% Cl
Carpenter 1999	42/96	55/98			0.78 [0.59, 1.04]
Total (95% Cl) Total events: 42 (Paroxetine) Test for heterogeneity: not a Test for overall effect: Z = 1	pplicable	98			0.78 [0.59, 1.04]
			0.5 0.7 1	1.5 2	

OCD children: SSRIs Review:

03 SSRIs vs placebo (discontinuation) Comparison:

07 Relapse (CGI Global Improvement score increase) Outcome:



Favours Paroxetine Favours Placebo

Review:

OCD children: SSRIs 03 SSRIs vs placebo (discontinuation) 08 CY-BOCS Comparison: Outcome:

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)			(fixed) % Cl		SMD (fixed) 95% Cl
Carpenter 1999	92	3.60(8.82)	98	6.90(8.51)			•		-0.38 [-0.67, -0.09]
Total (95% CI) Test for heterogeneity: not			98				•		-0.38 [-0.67, -0.09]
Test for overall effect: Z =	2.59 (P = 0.010)				-10	- - 5	0	5	10

Favours treatment Favours control OCD children: SSRIs

Review:

Comparison: 03 SSRIs vs placebo (discontinuation) Outcome: 09 Hamilton Rating Scale for Depression

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl
Carpenter 1999	92	1.90(4.80)	98	3.10(5.64)			•			-0.23 [-0.51, 0.06]
Total (95% CI) Test for heterogeneity: not	92 applicable		98				+			-0.23 [-0.51, 0.06]
Test for overall effect: Z =	1.56 (P = 0.12)									
					-10	-5	Ó	5	10	

Favours treatment Favours control

Review:

OCD children: SSRIs 03 SSRIs vs placebo (discontinuation) Comparison: Outcome: 10 Hamilton Rating Scale for Anxiety

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)		SMD (fixed) 95% Cl			SMD (fixed) 95% CI	
Carpenter 1999	92	1.80(5.08)	98	3.10(5.74)						-0.24 [-0.52, 0.05]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.6			98				•			-0.24 [-0.52, 0.05]
					-10	-5	Ó	5	10	

Favours treatment Favours control


OCD children: SSRIs Review:

Comparison: 03 SSRIs vs placebo (discontinuation) Outcome: 11 Global Assessment of Functioning

Study or sub-category	N	Paroxetine Mean (SD)	N	Placebo Mean (SD)		:	SMD (fixed 95% CI	1)		SMD (fixed) 95% CI
Carpenter 1999	93	-5.80(11.77)	98	-8.10(12.47)			-			0.19 [-0.10, 0.47]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			98				•			0.19 [-0.10, 0.47]
					-10	-5	0	5	10	

Clomipramine (OCD, children)

Review: OCD children: Clomipramine Comparison: 01 Clomipramine vs placebo 01 Leaving study early Outcome:



Review: OCD children: Clomipramine Comparison: 01 Clomipramine vs placebo

Outcome: 02 Leaving study early due to adverse effects

Study or sub-category	Clomipramine n/N	Placebo n/N		R (fixed) 95% Cl	RR (fixed) 95% Cl
DeVeaugh-Geiss 1992	2/31	0/29	_		— 4.69 [0.23, 93.70]
March 1990	1/8	0/8		-	3.00 [0.14, 64.26]
Total (95% CI)	39	37			3.86 [0.45, 32.80]
Total events: 3 (Clomipramine),	0 (Placebo)			- - -	
Test for heterogeneity: Chi ² = 0	.04, df = 1 (P = 0.84), I ² = 0%				
Test for overall effect: Z = 1.24	(P = 0.22)				
		0.0	1 0.1	1 10	100

Favours Clomipramine

Favours Placebo

Favours Clomipramine Favours Placebo

OCD children: Clomipramine Review: Comparison: 01 Clomipramine vs placebo

Outcome: 03 Y-BOCS

Study or sub-category	N	Clomipramine Mean (SD)	N	Placebo Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
March 1990	8	19.30(8.60)	8	25.60(2.40)		-	\vdash			-0.94 [-1.99, 0.11]
Total (95% Cl) Test for heterogeneity: not Test for overall effect: Z =			8			<				-0.94 [-1.99, 0.11]
					-4	-2	ö	2	4	

Review: OCD children: Clomipramine Comparison: Outcome: 01 Clomipramine vs placebo 04 NIMH-OC

Study or sub-category	N	Clomipramine Mean (SD)	N	Placebo Mean (SD)			(fixed) % Cl			SMD (fixed) 95% Cl
March 1990	8	7.20(2.70)	8	9.50(1.90)		-	-			-0.93 [-1.98, 0.12]
Total (95% Cl) Test for heterogeneity: not ap Test for overall effect: Z = 1.7			8			-	-			-0.93 [-1.98, 0.12]
					-4	-2	Ó	2	4	
					Favours	Clomipramine	Favou	urs Placel	00	

OCD children: Clomipramine Review:

02 Clomipramine continuation vs Desipramine substitution Comparison:


Outcome: 01 Leaving study early

Study or sub-category	Clomipramine n/N	Desipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Leonard 1991a	0/11	1/10		0.31 [0.01, 6.74]
Total (95% CI) Total events: 0 (Clomipramir Test for heterogeneity: not a Test for overall effect: Z = 0	applicable	10		0.31 [0.01, 6.74]
		(0.01 0.1 1 10	100
		F	avours Clomipramine Favours Desipra	mine

OCD children: Clomipramine Review:

Comparison: 02 Clomipramine continuation vs Desipramine substitution

02 Relapse (Physician's Relapse Scale) Outcome:



Favours Clomipramine Favours Desipramine

OCD children: Clomipramine Review:

Comparison: Outcome: 02 Clomipramine continuation vs Desipramine substitution

03 Comprehensive Psychopathological Rating Scale: obsessive-compulsive

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)		SMD (fixed 95% CI)	SMD (fixed) 95% CI
Leonard 1991a	11	5.20(4.00)	9	6.30(3.30)		-		-0.28 [-1.17, 0.60]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			9					-0.28 [-1.17, 0.60]
					_	'	$\overline{}$	4

Favours Clomipramine Favours Desipramine

Review: OCD children: Clomipramine

Comparison: 02 Clomipramine continuation vs Desipramine substitution

Outcome: 04 NIMH-OC

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)			D (fixed) 15% CI			SMD (fixed) 95% Cl
Leonard 1991a	11	5.00(2.30)	9	5.80(0.40)		-	-		-0.4	4 [-1.34, 0.45]
Total (95% Cl) Test for heterogeneity: not Test for overall effect: Z =			9			-			-0.4	4 [-1.34, 0.45]
					-4	-2	Ö	2	4	

Favours Clomipramine Favours Desipramine

Pharmacological (BDD)

Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo Outcome: 01 Adverse effects

Study or sub-category	Fluoxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Phillips 2002b	28/34	21/33	-	1.29 [0.96, 1.75]
Total (95% CI) Test for heterogeneity: not applic Test for overall effect: Z = 1.68 (21/33		1.29 [0.96, 1.75]
		0.5	0.7 1 1.5	2

Favours Fluoxetine Favours Placebo

Favours Placebo

Favours Placebo

Favours Placebo

Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo Outcome: 02 Leaving study early

Study or sub-category	Fluoxetine n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Phillips 2002b	3/34	5/33		0.58 [0.15, 2.24]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0		5/33		0.58 [0.15, 2.24]
			0.1 0.2 0.5 1 2 5	10

Favours Fluoxetine

Favours Fluoxetine

Favours Fluoxetine

Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo

Outcome: 03 Leaving study early due to adverse effects

Study or sub-category	Fluoxetine n/N	Placebo n/N	RR (fi 95%	,	RR (fixed) 95% Cl
Phillips 2002b	0/34	0/33			Not estimable
Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: not applicable	0/0	0/0			Not estimable
		0.1	0.2 0.5 1	2 5 10	


Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo Outcome: 04 Non-responders

Study or sub-category	Fluoxetine n/N	Placebo n/N	,	fixed) % Cl	RR (fixed) 95% CI
Phillips 2002b	16/34	27/33	-		0.58 [0.39, 0.85]
Total (95% CI) Test for heterogeneity: not appl Test for overall effect: Z = 2.77		27/33	-		0.58 [0.39, 0.85]
		0	2 0.5	1 2	5

Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo

Outcome: 05 BDD-YBOCS



Review: BDD: pharmacological interventions 01 Fluoxetine vs placebo 06 BDD-NIMH Comparison:

Outcome:

Study or sub-category	N	Fluoxetine Mean (SD)	N	Placebo Mean (SD)		(fixed) % Cl	SMD (fixed) 95% CI
Phillips 2002b	34	6.60(3.00)	33	7.90(2.20)			-0.49 [-0.97, 0.00]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			33		-	-	-0.49 [-0.97, 0.00]
					-1 -0.5	0 0.5	i
					Favours Fluoxetine	Favours Placebo	

BDD: pharmacological interventions 01 Fluoxetine vs placebo 07 Hamilton Rating Scale for Depression Review:

Comparison:

Outcome:

tudy r sub-category	N	Fluoxetine Mean (SD)	N	Placebo Mean (SD)			(fixed) % Cl			SMD (fixed) 95% Cl	
Phillips 2002b	34	12.50(10.10)	33	19.50(10.50)		-				-0.67 [-1.16, -0.18]	
otal (95% Cl) est for heterogeneity: not a est for overall effect: Z = 2			33			•				-0.67 [-1.16, -0.18]	
et for overall effect: Z = Z	2.67 (P = 0.008)				-4	-2	<u> </u>	2	4		

Review: BDD: pharmacological interventions

Comparison: 01 Fluoxetine vs placebo

08 Global Assessment of Functioning Scale Outcome:

Study or sub-category	N	Fluoxetine Mean (SD)	N	Placebo Mean (SD)		SMD (fi 95%		SMD (fixed) 95% Cl
Phillips 2002b	34	-68.90(15.70)	33	-57.00(12.30)		-		-0.83 [-1.33, -0.33]
Total (95% Cl) Test for heterogeneity: not Test for overall effect: Z =			33			•		-0.83 [-1.33, -0.33]
					-4	-2 0	2	1

Favours Fluoxetine Favours Placebo

Favours Fluoxetine Favours Placebo

BDD: pharmacological interventions Review:

Comparison: 01 Fluoxetine vs placebo

09 Social & Occupational Functioning Scale Outcome:

Study or sub-category	N	Fluoxetine Mean (SD)	N	Placebo Mean (SD)			MD (fixed 95% CI	1)		SMD (fixed) 95% CI
Phillips 2002b	34	-71.10(17.80)	33	-59.90(14.60)		+	-			-0.68 [-1.17, -0.19]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 2			33				•			-0.68 [-1.17, -0.19]
					-4	-2	Ó	ż	4	
					Favo	urs Fluoxeti	ine Fav	vours Place	ebo	

Review: BDD: pharmacological interventions 02 Clomipramine v Desipramine 01 BDD-YBOCS at 8 weeks Comparison: Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)			(fixed) 5% Cl			SMD (fixed) 95% CI
Hollander 1999	12	17.41(6.85)	11	23.14(7.86)		-	+			-0.75 [-1.60, 0.10]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 1.			11			-	•			-0.75 [-1.60, 0.10]
					-4	-2	ò	2	4	
						Favours CMI	Favo	ours DMI		

BDD: pharmacological interventions Review: Comparison: 02 Clomipramine v Desipramine Outcome: 02 NIMH-BDD at 8 weeks

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)			(fixed) % Cl		SMD (fixed) 95% Cl
Hollander 1999	12	5.92(1.83)	11	9.09(2.35)		-			-1.46 [-2.40, -0.52]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 3			11			•			-1.46 [-2.40, -0.52]
					-4	-2 Favours CMI	5 2 Favours DMI	4	

Review: BDD: pharmacological interventions 02 Clomipramine v Desipramine 03 HAM-D at 8 weeks Comparison:

Outcome:

Study or sub-category	N	Clomipramine Mean (SD)	N	Desipramine Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl
Hollander 1999	12	9.42(7.89)	11	14.64(5.61)		-	\vdash			-0.73 [-1.58, 0.12]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1			11							-0.73 [-1.58, 0.12]
					-4	-2	ó	2	4	

Favours CMI Favours DMI

Favours Pimozide Favours Placebo

Favours Pimozide Favours Placebo

Review: BDD: pharmacological interventions

Comparison: 03 Pimozide v Placebo

01 Non-responders (Y-BOCS 30%) Outcome:

Study or sub-category	Pimozide n/N	Placebo n/N	RR (fi: 95%			RR (fixed) 95% Cl
Phillips_in press	9/11	14/17	-	H		0.99 [0.70, 1.42]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 0.0	•	14/17	•	-		0.99 [0.70, 1.42]
		0.2	0.5 1	2	5	

Review: BDD: pharmacological interventions

03 Pimozide v Placebo Comparison:

Outcome: 02 Leaving the study early

Study or sub-category	Pimozide n/N	Placebo n/N	RR (fixed) 95% Cl	RR (fixed) 95% CI
Phillips_in press	6/11	13/17		0.71 [0.39, 1.30]
Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 1,10 (P = 0.3)	6/11 27)	13/17		0.71 [0.39, 1.30]
		n	.2 0.5 1 2	5

BDD: pharmacological interventions Review:

Comparison: 03 Pimozide v Placebo

Outcome: 03 Y-BOCS

Study or sub-category	N	Pimozide Mean (SD)	N	Placebo Mean (SD)		D (random) 95% Cl
Phillips_in press	11	23.90(6.60)	17	28.00(7.80)	-4.10 [-9	9.48, 1.28]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1.			17		-4.10 [-9	9.48, 1.28]
					-10 -5 0 5 10	
					Favours Pimozide Favours Placebo	

Review:

BDD: pharmacological interventions 03 Pimozide v Placebo 04 Brown Assessment of Beliefs Scale Comparison: Outcome:

Study or sub-category	N	Pimozide Mean (SD)	N	Placebo Mean (SD)		VVI	MD (rando 95% Cl	m)		WMD (random) 95% Cl
Phillips_in press	11	13.50(7.30)	17	17.20(6.00)	_	-	+			-3.70 [-8.87, 1.47]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z = 1			17							-3.70 [-8.87, 1.47]
					-10	-5	Ó	5	10	
					Fau	oure Dimoz	ida Fas	oure Place	aho	

Review: BDD: pharmacological interventions Comparison: 03 Pimozide v Placebo


Outcome: 05 Hamilton Depression Rating Scale

Study or sub-category	N	Pimozide Mean (SD)	N	Placebo Mean (SD)			ID (randor 95% CI	n)		VVMD (random) 95% Cl
Phillips_in press	11	17.90(5.60)	17	16.90(7.70)		_	-			1.00 [-3.93, 5.93]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			17			-	+	- -	ı	1.00 [-3.93, 5.93]
					-10	-5	ó	5	10	

Favours Pimozide Favours Placebo

Review: Comparison: BDD: pharmacological interventions 03 Pimozide v Placebo 06 Brief Psychiatric Rating Scale

Outcome:




Appendix 17c: Forest plots for clinical evidence reviews on psychological vs. pharmacological interventions, combination therapy and other medical interventions

Psychological vs. Pharmacological (OCD) Combination therapy (OCD) Other medical interventions

Psychological vs. Pharmacological (OCD)

Review: OCD: psychological v pharmacological Comparison: 01 ERP vs Clomipramine

Outcome: 01 Y-BOCS or Compulsion checklist




Review: OCD: psychological v pharmacological

Comparison: 01 ERP vs Clomipramine
Outcome: 02 Leaving the study early

Study or sub-category	ERP n/N	Clomipramine n/N	RR (fixed) 95% CI	RR (fixed) 95% Cl
Foa 2005	16/37	20/47	-	1.02 [0.62, 1.67]
Total (95% CI) Total events: 16 (ERP), 20 (Clon Test for heterogeneity: not appl Test for overall effect: Z = 0.06	applicable	47	+	1.02 [0.62, 1.67]
		0.1	0.2 0.5 1 2 5	10
			Favours ERP Favours Clomi	pramine

Review: OCD: psychological v pharmacological

Comparison: 01 ERP vs Clomipramine Outcome: 03 Non-responders (CGI)



OCD: psychological v pharmacological Review: 02 Children: CBT v Clomipramine Comparison: Outcome: 01 Leaving the study early

Study or sub-category	CBT n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
de Haan 1998	1/13	0/10		2.36 [0.11, 52.41]
Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.54 (P = 0.5	1/13 59)	0/10		2.36 [0.11, 52.41]
		0.01	0.1 1 10	100

Favours CBT Favours Clomipramine

Favours CBT Favours Clomipramine

Favours CBT Favours Clomipramine

Review: OCD: psychological v pharmacological 02 Children: CBT v Clomipramine Comparison:

02 Non-responders (CY-BOCS 30%) Outcome:

Study or sub-category	CBT n/N	Clomipramine n/N	RR (fix 95%	•	RR (fixed) 95% Cl
de Haan 1998	5/13	5/10	-		0.77 [0.30, 1.94]
Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.56 (P = 0.5	5/13 8)	5/10		- -	0.77 [0.30, 1.94]
			0.1 0.2 0.5 1	2 5 10	
			Favours CBT	Favours Clomipramine	

OCD: psychological v pharmacological 02 Children: CBT v Clomipramine 03 CY-BOCS Review: Comparison:

Outcome:

Study or sub-category	N	CBT Mean (SD)	N	Clomipramine Mean (SD)		SMD (fix 95% (SMD (fixed) 95% Cl
de Haan 1998	12	9.10(9.10)	10	17.60(11.80)		-		-0.79 [-1.66, 0.09]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			10			-		-0.79 [-1.66, 0.09]
Test for overall effect. Z =	- 1.76 (P = 0.06)				-4	-2 0	 	<u> </u>

OCD: psychological v pharmacological 02 Children: CBT v Clomipramine Review: Comparison: Outcome: 04 Leyton Inventory - child version

Study or sub-category	N	CBT Mean (SD)	N	Clomipramine Mean (SD)		SMD (* 95%			SMD (fixed) 95% CI
de Haan 1998	12	12.70(9.30)	10	17.50(10.50)		-	_		-0.47 [-1.32, 0.38]
Total (95% CI)	12		10			-	-		-0.47 [-1.32, 0.38]
Test for heterogeneity: not									
Test for overall effect: Z =	: 1.08 (P = 0.28)								
					-4	-2 0	1 2	2	4

OCD: psychological v pharmacological 02 Children: CBT v Clomipramine 05 Child Behaviour Checklist Review: Comparison:

Study or sub-category	N	CBT Mean (SD)	N	Clomipramine Mean (SD)			ID (fixed) 95% CI)		SMD (fixed) 95% Cl
de Haan 1998	11	57.60(12.60)	8	60.50(9.30)		_				-0.24 [-1.16, 0.67]
Total (95% CI) Test for heterogeneity: not a	11 applicable		8			-	-			-0.24 [-1.16, 0.67]
Test for overall effect: Z = 0	0.52 (P = 0.60)									
					-4	-2	Ó	2	4	
						Favours CB	T Fav	ours Clomiș	oramine	

OCD: psychological v pharmacological 02 Children: CBT v Clomipramine Review: Comparison: 06 Children's Depression Inventory Outcome:

Study or sub-category	N	CBT Mean (SD)	N	Clomipramine Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% CI	
de Haan 1998	11	129.20(50.80)	9	143.20(37.90)					-0.	29 [-1.18, 0.59]	
Total (95% CI) Test for heterogeneity: not ag Test for overall effect: Z = 0.0			9			-			-0.	29 [-1.18, 0.59]	
					-4	-2	ó	2	4		

Favours CBT Favours Clomipramine

Favours CBT Favours Sertraline

Review: OCD: psychological v pharmacological

03 Children: CBT v Sertraline Comparison: Outcome: 01 Leaving the study early

RR (fixed) 95% Cl Sertraline CBT RR (fixed) Study n/N n/N 95% CI or sub-category POTS 2004 1.50 [0.27, 8.30] 3/28 2/28 Total (95% CI) 3/28 2/28 1.50 [0.27, 8.30] Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64) 0.1 0.2 0.5 10


Review: OCD: psychological v pharmacological

Comparison: Outcome: 03 Children: CBT v Sertraline 02 CY-BOCS

Study or sub-category	N	CBT Mean (SD)	N	Sertraline Mean (SD)			D (fixed 95% CI	t)		SMD (fixed) 95% CI
POTS 2004	28	14.00(9.50)	28	16.50(9.10)	_	-		-		-0.27 [-0.79, 0.26]
Total (95% CI) 28 Test for heterogeneity: not applicable Test for overall effect: Z = 0.99 (P = 0.32)		28		- -			-		-0.27 [-0.79, 0.26]	
					-1	-0.5	Ó	0.5	1	
						Favours CB	T Fav	vours Sertra	aline	

Combination therapy (OCD)

Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: Outcome: 01 Leaving the study early



Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome:


02 Leaving the study early due to adverse effects

Study or sub-category	ERP+ SRI n/N	ERP n/N	,	fixed) % Cl	RR (fixed) 95% Cl	
01 ERP + Fluvoxamine v ERP + p	lacebo					
Cottraux 1990	2/20	1/20			2.00 [0.20, 20.33]	l
Subtotal (95% CI)	2/20	1/20			2.00 [0.20, 20.33]	ı
Test for heterogeneity; not applie	cable					
Test for overall effect: Z = 0.59	(P = 0.56)					
			0.01 0.1	1 10	100	
			Favours ERP+SRI	Favours ERP		


OCD: combination therapy Review:

Comparison: 01 ERP+ SRI v ERP

03 Non-responders (Y-BOCS 35%) Outcome:



OCD: combination therapy Review: 01 ERP+ SRI v ERP Comparison: 04 Non-responders (CGI) Outcome:



Favours ERP+SRI Favours ERP

Favours ERP+SRI Favours ERP

Favours ERP+SRI Favours ERP

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome: 06 Global criterion of non-improvement (duration of rituals)

Study	ERP + SRI	ERP	RR (fixed)	RR (fixed)
or sub-category	n/N	n/N	95% CI	95% CI
01 ERP + Fluvoxamine v ERP +	placebo: post-treatment			
Cottraux 1990	9/20	14/20		0.64 [0.37, 1.13]
Subtotal (95% CI)	9/20	14/20		0.64 [0.37, 1.13]
Test for heterogeneity: not app	olicable		-	
Test for overall effect: Z = 1.5	4 (P = 0.12)			
02 ERP + Fluvoxamine v ERP +	placebo: 6 months follow-up)		
Cottraux 1990	11/20	14/20		0.79 [0.48, 1.28]
Subtotal (95% CI)	11/20	14/20	-	0.79 [0.48, 1.28]
Test for heterogeneity; not app	olicable		-	•
Test for overall effect: Z = 0.9	7 (P = 0.33)			
03 ERP + Fluvoxamine v ERP +	placebo: 1 year follow-up			
Cottraux 1990	11/20	12/20		0.92 [0.54, 1.56]
Subtotal (95% CI)	11/20	12/20		0.92 [0.54, 1.56]
Test for heterogeneity: not app	licable		- T	•
Test for overall effect: $Z = 0.3$				

OCD: combination therapy 01 ERP+ SRI v ERP Review: Comparison: Outcome: 07 Y-BOCS

itudy r sub-category	N	ERP + SRI Mean (SD)	N	ERP Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
11 ERP + Fluvoxamine v ERP						
van Balkom 1998	18	12.60(6.60)	19	17.10(8.40)		-0.58 [-1.24, 0.08]
Subtotal (95% CI)	18		19		-	-0.58 [-1.24, 0.08]
Fest for heterogeneity: not a	oplicable					
Test for overall effect: Z = 1.	73 (P = 0.08)					
02 MBT + Fluvoxamine v MB1	+ placebo					
Hohagen 1998	24	12.40(6.80)	25	15.90(7.90)		-0.47 [-1.03, 0.10]
Subtotal (95% CI)	24		25		◆	-0.47 [-1.03, 0.10]
Test for heterogeneity: not ap	oplicable				-	
Test for overall effect: $Z = 1$.	61 (P = 0.11)					
03 ERP + Clomipramine v ERF	ı					
Foa 2005	19	10.50(8.20)	21	11.00(7.90)	-	-0.06 [-0.68, 0.56]
Subtotal (95% CI)	19		21		•	-0.06 [-0.68, 0.56]
Test for heterogeneity: not a	oplicable				Ī	
Test for overall effect: Z = 0.	19 (P = 0.85)					
Total (95% CI)	61		65		•	-0.37 [-0.72, -0.01]
Test for heterogeneity: Chi² =	: 1.46, df = 2 (F	⁰ = 0.48), I ² = 0%			-	
Test for overall effect: $Z = 2$.	04 (P = 0.04)					


Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome: 08 Padua Inventory ERP + SRI **ERP** SMD (fixed) SMD (fixed) Study orsub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 43.20(23.50) 57.20(20.60) -0.62 [-1.28, 0.04] 19 18 Subtotal (95% CI) 18 19 -0.62 [-1.28, 0.04] Test for heterogeneity: not applicable Test for overall effect: Z = 1.84 (P = 0.07) Favours ERP+SRI Favours ERP OCD: combination therapy Review: 01 ERP+ SRI v ERP Comparison: 09 Depression scales (post treatment) Outcome: SMD (fixed) SMD (fixed) Study BT+ SRI BT Ν Mean (SD) or sub-category Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP -1.19 [-1.89, -0.48] -1.19 [-1.89, -0.48] van Balkom 1998 18 10.10(7.20) 19 19.90(8.80) Subtotal (95% CI) 18 19 Test for heterogeneity: not applicable Test for overall effect: Z = 3.30 (P = 0.0010) 02 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 11.50(9.20) 25 14.00(10.20) -0.25 [-0.82, 0.31] Subtotal (95% CI) -0.25 [-0.82, 0.31] Test for heterogeneity: not applicable Test for overall effect: Z = 0.88 (P = 0.38) 03 ERP + Fluvoxamine v ERP + placebo Cottraux 1990 16 9.12(6.03) 15 15.13(5.74) -0.99 [-1.75, -0.24] Subtotal (95% CI) 16 15 -0.99 [-1.75, -0.24] Test for heterogeneity: not applicable Test for overall effect: Z = 2.59 (P = 0.010) 04 Exposure + Clomipramine v Exposure + placebo (at 7 weeks) Marks 1980 8.10(8.30) 10 16.50(11.10) -0.82 [-1.74, 0.10] 10 Subtotal (95% CI) -0.82 [-1.74, 0.10] Test for heterogeneity: not applicable Test for overall effect: Z = 1.75 (P = 0.08) 69 -0.73 [-1.08, -0.38] Test for heterogeneity: Chi² = 4.90, df = 3 (P = 0.18), l² = 38.8% Test for overall effect: Z = 4.07 (P < 0.0001)Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome 10 Hamilton Depression Rating scale (follow-up) **ERP** SMD (fixed) Study ERP+ SRI SMD (fixed) N or sub-category Mean (SD) Mean (SD) 01 ERP + Fluvoxamine v ERP + placebo (6 months follow-up) Cottraux 1990 12.17(10.38) -0.17 [-0.94, 0.60] 14 10.71(6.27) 12 Subtotal (95% CI) -0.17 [-0.94, 0.60] Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67) 02 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 0.28 [-0.54, 1.10] 11.80(7.90) 11 9.50(7.90) Subtotal (95% CI) 11 0.28 [-0.54, 1.10] Test for heterogeneity; not applicable Test for overall effect: Z = 0.67 (P = 0.50) Favours ERP+SRI Favours ERP Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: Outcome: 11 Symptom Checklist-90 SMD (fixed) BT + SRI ΒТ SMD (fixed) Study or sub-category Mean (SD) Mean (SD) 01 ERP + Fluvoxamine v ERP van Balkom 1998 184.30(55.50) -0.54 [-1.20, 0.11] 18 154.50(51.40) 19 Subtotal (95% CI) -0.54 [-1.20, 0.11] 18 19 Test for heterogeneity: not applicable Test for overall effect: Z = 1.62 (P = 0.10)

Favours BT+SRI Favours BT

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome: 12 Anxiety Discomfort Scale: patient's ratings ВΤ SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 13.00(4.90) 17.80(7.60) -0.73 [-1.40, -0.06] 18 19 Subtotal (95% CI) 18 19 -0.73 [-1.40, -0.06] Test for heterogeneity: not applicable Test for overall effect: Z = 2.14 (P = 0.03) Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome: 13 Anxiety Discomfort Scale: therapist's ratings BT + SRI ВΤ SMD (fixed) SMD (fixed) Study Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category Ν 01 ERP + Fluvoxamine v ERP van Balkom 1998 18 14.20(10.30) 19 20.60(10.50) -0.60 [-1.26, 0.06] Subtotal (95% CI) -0.60 [-1.26, 0.06] 18 19 Test for heterogeneity: not applicable Test for overall effect: Z = 1.79 (P = 0.07) Favours BT+SRI Favours BT Review: OCD: combination therapy Comparison: 01 ERP+ SRLv ERP 14 Anxiety Discomfort Scale: assessor's ratings Outcome: BT + SRI SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 18 14.20(8.70) 19 19.40(8.70) -0.58 [-1.24, 0.08] Subtotal (95% CI) 19 -0.58 [-1.24, 0.08] Test for heterogeneity: not applicable Test for overall effect: Z = 1.74 (P = 0.08)Favours BT+SRI Favours BT Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: Outcome: 15 Clinical Anxiety Scale ВΤ SMD (fixed) SMD (fixed) Study BT+ SRI or sub-category Mean (SD) Mean (SD) 95% CI 95% CI 01 MBT + Fluvoxamine v MBT + placebo -0.21 [-0.78, 0.35] Hohagen 1998 24 5.40(3.90) 25 6.40(5.20) Subtotal (95% CI) -0.21 [-0.78, 0.35] 24 25 Test for heterogeneity: not applicable Test for overall effect: Z = 0.74 (P = 0.46) Favours BT+SRI Favours BT Review: OCD: combination therapy 01 ERP+ SRLv ERP Comparison: 16 Global Assessment Scale Outcome: Study BT+ SRI ΒT SMD (fixed) SMD (fixed) or sub-category Mean (SD) Ν Mean (SD) 95% CL 95% CI 01 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 -63.10(14.40) 25 -59.80(16.60) -0.21 [-0.77, 0.35] Subtotal (95% CI) 25 -0.21 [-0.77, 0.35] Test for heterogeneity: not applicable Test for overall effect: Z = 0.73 (P = 0.47) Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome: 17 CGI - therapist rating BT+ SRI SMD (fixed) SMD (fixed) Study orsub-category N Mean (SD) Ν Mean (SD) 95% CI 01 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 -7.90(1.40) -0.27 [-0.84. 0.29] 25 -7.40(2.10)24 -0.27 [-0.84, 0.29] Test for heterogeneity: not applicable Test for overall effect: Z = 0.96 (P = 0.34)

Favours BT+SRI Favours BT

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP 18 CGI - patient rating Outcome:



OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP

Outcome: 19 Compulsive activity checklist (post treatment)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
01 ERP + Fluvoxamine v ER	P + placebo (pos	t treatment)						
Cottraux 1990	16	14.56(17.38)	15	24.33(18.36)			-0.53 [-1.25, 0.	19]
Subtotal (95% CI)	16		15				-0.53 [-1.25, 0.	19]
Test for heterogeneity: not	applicable					-		
Test for overall effect: Z = 1	1.45 (P = 0.15)							
02 Exposure + Clomipramino	e v Exposure + p	lacebo: assessor-rated (at	7 weeks)					
Marks 1980	10	20.10(15.60)	10	31.30(20.50)			-0.59 [-1.49, 0.	31]
Subtotal (95% CI)	10		10			-	-0.59 [-1.49, 0.	31]
Test for heterogeneity: not:	applicable							
Test for overall effect: Z = 1	1.28 (P = 0.20)							
Total (95% CI)	26		25			•	-0.55 [-1.12, 0.	01]
Test for heterogeneity: Chi ²	= 0.01, df = 1 (P	= 0.92), I ² = 0%						
Test for overall effect: Z = 1	1.94 (P = 0.05)							
					-4 -2	0 2	4	
					Favours B	T+SRI Favours BT		

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

20 Compulsive activity checklist (follow-up) Outcome:

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)			1D (fixed) 95% Cl			SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v ER	RP + placebo (1 ye	ear follow-up)								
Cottraux 1990	12	15.50(17.60)	11	24.80(20.80)		_	-			-0.47 [-1.30, 0.36]
Subtotal (95% CI)	12		11							-0.47 [-1.30, 0.36]
Test for heterogeneity: not	applicable						-			
Test for overall effect: Z =	1.10 (P = 0.27)									
					-4	-2	0	2	4	

Favours BT+SRI Favours BT

Favours BT+SRI Favours BT

OCD: combination therapy Review:


Comparison: 01 ERP+ SRI v ERP

Outcome: 21 Target rituals (assessor): time (post-treatment)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl	
01 ERP + Fluvoxamine v ERP	+ placebo (post	treatment)					
Cottraux 1990	16	8.50(7.30)	15	15.60(9.20)	 -	-0.84 [-1.57, -0.10]	
Subtotal (95% CI)	16		15		-	-0.84 [-1.57, -0.10]	
Test for heterogeneity: not a	pplicable				-		
Test for overall effect: $Z = 2$	22 (P = 0.03)						
02 Exposure + Clomipramine	v Exposure + pl	acebo (at 7 weeks)					
Marks 1980	10	2.10(2.10)	10	3.90(2.40)		-0.76 [-1.68, 0.15]	
Subtotal (95% CI)	10		10			-0.76 [-1.68, 0.15]	
Test for heterogeneity: not a	pplicable				-		
Test for overall effect: $Z = 1$.	64 (P = 0.10)						
Total (95% CI)	26		25		•	-0.81 [-1.38, -0.23]	
Test for heterogeneity: Chi² :	0.01, df = 1 (P	= 0.91), I ² = 0%			-		
Test for overall effect: $Z = 2$	75 (P = 0.006)						

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome: 22 Target rituals (assessor): time (follow-up)



Favours BT+SRI Favours BT

Favours BT+SRI Favours BT

Review: OCD: combination therapy

Comparison: 01 ERP+ SRI v ERP

Outcome: 23 Target rituals (assessor): discomfort (post-treatment)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)		SMD (fix 95% 0		SMD (fixed) 95% CI
01 ERP + Fluvoxamine v ER	P + placebo (pos	t treatment)						
Cottraux 1990	16	10.25(8.04)	15	17.00(8.35)				-0.80 [-1.54, -0.07]
Subtotal (95% CI)	16		15			-		-0.80 [-1.54, -0.07]
Test for heterogeneity: not	applicable					-		
Test for overall effect: $Z = 0$	2.14 (P = 0.03)							
02 Exposure + Clomipramin	e v Exposure + pi	lacebo (at 7 weeks)						
Marks 1980	10	2.90(2.00)	10	4.90(1.80)				-1.01 [-1.95, -0.06]
Subtotal (95% CI)	10		10					-1.01 [-1.95, -0.06]
Test for heterogeneity: not	applicable					-		
Test for overall effect: Z = :	2.09 (P = 0.04)							
Total (95% CI)	26		25			•		-0.88 [-1.46, -0.30]
Test for heterogeneity: Chi ²	² = 0.11, df = 1 (P	= 0.74), I ² = 0%				-		
Test for overall effect: Z =	2.97 (P = 0.003)							
					-4	-2 0	2	4
					Fav	vours BT+SRI F	avours BT	

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome: 24 Target rituals (assessor): discomfort (follow-up)

itudy r sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
1 ERP + Fluvoxamine v ERP -	⊦ placebo (6 mo	onths follow-up)				
Cottraux 1990	14	12.21(9.25)	12	13.30(9.80)	— 	-0.11 [-0.88, 0.66]
Subtotal (95% CI)	14		12		•	-0.11 [-0.88, 0.66]
est for heterogeneity: not ap	plicable				7	
est for overall effect: $Z = 0.2$	28 (P = 0.78)					
2 ERP + Fluvoxamine v ERP -	r placebo (1 ye	ear follow-up)				
Cottraux 1990	12	11.50(10.90)	11	11.00(9.10)	— —	0.05 [-0.77, 0.87]
Subtotal (95% CI)	12		11		•	0.05 [-0.77, 0.87]
est for heterogeneity: not ap	plicable				Т	·
est for overall effect: $Z = 0.1$	1 (P = 0.91)					

Review: OCD: combination therapy

Comparison: 01 ERP+ SRI v ERP

25 Target rituals (assessor): duration per day Outcome:

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v ERP + p	placebo (post	treatment)				
Cottraux 1990	16	3.93(2.26)	15	5.40(2.19)	-	-0.64 [-1.37, 0.08]
Subtotal (95% CI)	16		15		•	-0.64 [-1.37, 0.08]
Test for heterogeneity: not appli	licable				-	
Test for overall effect: $Z = 1.74$						
02 ERP + Fluvoxamine v ERP + p	placebo (6 mo	onths follow-up)				
Cottraux 1990	14	4.00(2.80)	12	4.67(2.27)	_ 	-0.25 [-1.03, 0.52]
Subtotal (95% CI)	14		12		•	-0.25 [-1.03, 0.52]
Test for heterogeneity: not appli	licable				٦	
Test for overall effect: $Z = 0.64$	(P = 0.52)					
03 ERP + Fluvoxamine v ERP + p	placebo (1 ve	ar follow-up)				
Cottraux 1990	12	2.70(2.70)	11	3.30(2.70)	_ _ _	-0.21 [-1.04, 0.61]
Subtotal (95% CI)	12		11		•	-0.21 [-1.04, 0.61]
Test for heterogeneity: not appli	licable				7	•
Test for overall effect: Z = 0.51						
				-4	-2 0 2	4

Favours BT+SRI Favours BT

Favours BT+SRI Favours BT

OCD: combination therapy 01 ERP+ SRI v ERP Review:

Comparison:

Outcome: 26 Behavioural avoidance test: discomfort (post treatment)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
	RP + placebo (pos	t treatment)				
Cottraux 1990	16	9.12(6.55)	15	15.61(7.61)	 -	-0.89 [-1.64, -0.15]
Subtotal (95% CI)	16		15		-	-0.89 [-1.64, -0.15]
Test for heterogeneity: not	: applicable				-	
Test for overall effect: Z =	2.35 (P = 0.02)					
02 Exposure + Clomipramin	ne v Exposure + p	lacebo (at 7 weeks)				
Marks 1980	10	15.40(11.90)	10	16.90(10.00)		-0.13 [-1.01, 0.75]
Subtotal (95% CI)	10		10		-	-0.13 [-1.01, 0.75]
est for heterogeneity; not	: applicable				T	
est for overall effect: Z =	0.29 (P = 0.77)					
otal (95% CI)	26		25		•	-0.57 [-1.14, -0.01]
est for heterogeneity: Chi	i ² = 1.69, df = 1 (P	= 0.19), I ² = 40.7%			•	
「est for overall effect: Z =	1.98 (P = 0.05)	**				
Test for overall effect. 2 =	1.50 (1 = 0.00)			-4	-2 0 2	4

OCD: combination therapy Review:

Comparison:


Outcome: 27 Behavioural avoidance test: discomfort (follow-up)

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)			MD (fixed) 95% CI)		SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v EF	RP + placebo (1 ye	ear follow-up)								
Cottraux 1990	12	10.20(9.20)	11	11.50(9.20)		-	_			-0.14 [-0.96, 0.68]
Subtotal (95% CI)	12		11				-			-0.14 [-0.96, 0.68]
Test for heterogeneity: not	applicable						T			,
Test for overall effect: Z =	0.33 (P = 0.74)									
					-4	-2	-	2	4	
					Fa	vours BT+S	RI Fav	ours BT		

Review: OCD: combination therapy

Comparison: 02 ERP + Clomipramine v Clomipramine


01 Leaving the study early Outcome:



OCD: combination therapy Review:

02 ERP + Clomipramine v Clomipramine Comparison:

03 Non-responders (CGI) Outcome:



Favours BT+CMI Favours CMI

Favours BT+CMI Favours CMI

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 02 ERP + Clomipramine v Clomipramine 05 Y-BOCS Comparison:

Outcome:

Study or sub-category	N B	T + Clomipramine Mean (SD)	N	Clomipramine Mean (SD)			(fixed) % Cl		SMD (fixed) 95% CI
Foa 2005	19	10.50(8.20)	27	18.20(7.80)		-			-0.95 [-1.57, -0.33]
Total (95% CI)	19		27			•			-0.95 [-1.57, -0.33]
Test for heterogeneity: no	t applicable								
Test for overall effect: Z =	3.00 (P = 0.003)								
					-4	-2 1	<u> </u>	2	4

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

01 Leaving the study early Outcome:

Study or sub-category	ERP+Fluvoxamine n/N	Anti-ERP+Fluvoxamine n/N	RR (fixed 95% CI	•	RR (fixed) 95% Cl
Cottraux 1990	4/20	7/20	-	-	0.57 [0.20, 1.65]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =	• •	7/20		-	0.57 [0.20, 1.65]
		0.1	0.2 0.5 1	2 5 10	

OCD: combination therapy Review:

03 ERP + Fluvoxamine v Ánti-ERP + Fluvoxamine Comparison: Outcome: 02 Leaving the study early due to adverse effects

Study or sub-category	ERP+Fluvoxamine n/N	Anti-ERP+Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Cottraux 1990	2/20	2/20		1.00 [0.16, 6.42]
Total (95% CI) Test for heterogeneity: not applicate for overall effect: Z = 0.00 (F		2/20		1.00 [0.16, 6.42]
			0.1 0.2 0.5 1 2 5 10 Favours ERP+FLV Favours Anti-ERP+F	

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

03 Global criterion of non-improvement (duration of rituals) Outcome:

Study or sub-category	ERP+Flu∨oxamine n/N	Anti-ERP+Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Post-treatment				
Cottraux 1990	9/20	13/20		0.69 [0.39, 1.24]
Subtotal (95% CI)	9/20	13/20		0.69 [0.39, 1.24]
Test for heterogeneity: not app	olicable		-	•
Test for overall effect: $Z = 1.2$	4 (P = 0.22)			
02.6 months follow-up				
Cottraux 1990	11/20	15/20		0.73 [0.46, 1.17]
Subtotal (95% CI)	11/20	15/20	•	0.73 [0.46, 1.17]
Test for heterogeneity; not app	olicable		-	
Test for overall effect: $Z = 1.2$	9 (P = 0.20)			
03.1 year follow-up				
Cottraux 1990	11/20	14/20		0.79 [0.48, 1.28]
Subtotal (95% CI)	11/20	14/20		0.79 [0.48, 1.28]
Test for heterogeneity; not app				
Test for overall effect: Z = 0.9				

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

04 Hamilton Depression Scale Outcome:

tudy r sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
1 Post treatment							
Cottraux 1990	16	9.12(6.03)	13	10.46(6.98)	=	-0.20 [-0.94, 0.53]	
ubtotal (95% CI)	16		13		•	-0.20 [-0.94, 0.53]	
est for heterogeneity: not a	pplicable				1		
est for overall effect: Z = 0	.54 (P = 0.59)						
2.6 months follow-up							
Cottraux 1990	14	10.71(6.27)	11	11.27(6.02)	=	-0.09 [-0.88, 0.70]	
ubtotal (95% CI)	14		11		•	-0.09 [-0.88, 0.70]	
st for heterogeneity: not a	pplicable						
est for overall effect: Z = 0	.22 (P = 0.83)						
3.1 year follow-up							
Cottraux 1990	12	11.80(7.90)	10	8.50(3.80)		0.50 [-0.36, 1.35]	
ubtotal (95% CI)	12		10		₩	0.50 [-0.36, 1.35]	
est for heterogeneity: not a	pplicable				ľ		
est for overall effect: Z = 1	.14 (P = 0.25)						

Favours ERP + FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 05 Target rituals (assessor): time Comparison:

Outcome:

Study	EF	RP+Fluvoxamine	Ant	i-ERP+Fluvoxamine	SMD (fixed)	SMD (fixed)
or sub-category	ry N Mean (SD) N Mean (SD) 95% CI		95% CI	95% CI		
01 Post treatment						
Cottraux 1990	16	8.50(7.30)	13	12.84(7.78)		-0.56 [-1.31, 0.19]
Subtotal (95% CI)	16		13		-	-0.56 [-1.31, 0.19]
Test for heterogeneity: not a	pplicable				-	
Test for overall effect: $Z = 1$.47 (P = 0.14)					
02 6 months follow-up						
Cottraux 1990	14	10.30(8.70)	11	13.50(3.11)		-0.45 [-1.25, 0.35]
Subtotal (95% CI)	14		11		-	-0.45 [-1.25, 0.35]
Test for heterogeneity: not a	pplicable				-	
Test for overall effect: Z = 1	.10 (P = 0.27)					
03.1 year follow-up						
Cottraux 1990	12	9.70(9.90)	10	11.40(9.40)	- 	-0.17 [-1.01, 0.67]
Subtotal (95% CI)	12		10		-	-0.17 [-1.01, 0.67]
Test for heterogeneity: not a	pplicable				1	
Test for overall effect: $Z = 0$.39 (P = 0.69)					

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison: Outcome: 06 Target rituals (assessor): discomfort

Study or sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Cottraux 1990	16	10.25(8.04)	13	11.30(10.27)	_ _	-0.11 [-0.84, 0.62]
Subtotal (95% CI)	16		13		•	-0.11 [-0.84, 0.62]
Test for heterogeneity: not applicab	le				T	
Test for overall effect: Z = 0.30 (P =	= 0.76)					
02.6 months follow-up						
Cottraux 1990	14	12.21(9.25)	11	13.18(8.50)	— —	-0.11 [-0.90, 0.69]
Subtotal (95% CI)	14		11		•	-0.11 [-0.90, 0.69]
Test for heterogeneity: not applicab	ile				Ī	
Test for overall effect: $Z = 0.26$ (P =	= 0.79)					
03.1 year follow-up						
Cottraux 1990	12	11.50(10.90)	10	9.60(8.60)	_ 	0.18 [-0.66, 1.03]
Subtotal (95% CI)	12		10		-	0.18 [-0.66, 1.03]
Test for heterogeneity: not applicab	ile				T	,
Test for overall effect: Z = 0.43 (P =	= 0.67)					
				-4	-2 0 2	4

Favours ERP+FLV Favours Anti-ERP+FLV

Favours ERP+FLV Favours Anti-ERP+FLV

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 07 Target rituals (assessor): duration per day Comparison: Outcome:

Study or sub-category	N Ef	RP+Fluvoxamine Mean (SD)	Anti- N	ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Cottraux 1990	16	3.93(2.26)	13	4.07(2.56)	_ _	-0.06 [-0.79, 0.68]
Subtotal (95% CI)	16		13		•	-0.06 [-0.79, 0.68]
est for heterogeneity: not a	applicable				T	·
Test for overall effect: Z = 0	.15 (P = 0.88)					
02 6 months follow-up						
Cottraux 1990	14	4.00(2.80)	11	4.09(2.59)		-0.03 [-0.82, 0.76]
Subtotal (95% CI)	14		11		•	-0.03 [-0.82, 0.76]
est for heterogeneity; not a	applicable				T	
est for overall effect: Z = 0	.08 (P = 0.94)					
03.1 year follow-up						
Cottraux 1990	12	2.70(2.70)	10	3.20(3.10)	_ 	-0.17 [-1.01, 0.67]
Subtotal (95% CI)	12		10		-	-0.17 [-1.01, 0.67]
est for heterogeneity; not a	applicable				7	,
Cest for overall effect: $Z = 0$.39 (P = 0.70)					

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 08 Behavioural avoidance test: discomfort Comparison: Outcome:

Study or sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
11 Post treatment						
Cottraux 1990	16	9.12(6.55)	13	11.46(6.75)	-	-0.34 [-1.08, 0.40]
Subtotal (95% CI)	16		13		•	-0.34 [-1.08, 0.40]
est for heterogeneity; not a	oplicable				_	
est for overall effect: $Z = 0$.	91 (P = 0.36)					
12.1 year follow-up						
Cottraux 1990	12	10.20(9.20)	10	10.30(9.40)	_ _	-0.01 [-0.85, 0.83]
Subtotal (95% CI)	12		10		•	-0.01 [-0.85, 0.83]
est for heterogeneity: not ap	oplicable				Т	·
est for overall effect: Z = 0.	02 (P = 0.98)					

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

Outcome: 09 Compulsive activity checklist

Study or sub-category	E N	RP+Fluvoxamine Mean (SD)	Anti N	i-ERP+Fluvoxamine Mean (SD)		SMD (fixed) 95% CI		SMD (fixed) 95% Cl
01 Post treatment								
Cottraux 1990	16	14.56(17.38)	13	21.53(12.56)		-		-0.44 [-1.18, 0.30]
Subtotal (95% CI)	16		13					-0.44 [-1.18, 0.30]
Test for heterogeneity: not a	applicable					-		
Test for overall effect: Z = 1								
02.1 year follow-up								
Cottraux 1990	12	15.50(17.60)	10	20.70(14.30)				-0.31 [-1.15, 0.54]
Subtotal (95% CI)	12		10			•		-0.31 [-1.15, 0.54]
Test for heterogeneity: not a	applicable					_		,
Test for overall effect: Z = 0								
					-4	-2 0	2 4	1

Favours ERP+FLV Favours Anti-ERP+FLV

OCD: combination therapy 04 CT + Fluvoxamine v CT Review:

Comparison: 01 Leaving the study early Outcome:

Study or sub-category	CT + Fluvoxamine n/N	CT n/N		RR (fixed) 95% Cl		RR (fixed) 95% Cl
van Balkom 1998	10/24	6/25		-		1.74 [0.75, 4.03]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1.	•	6/25			-	1.74 [0.75, 4.03]
			0.1 0.2	0.5 1 2	5 10	

Favours CT+FLV Favours CT

Favours CT+FLV Favours CT

OCD: combination therapy 04 CT + Fluvoxamine v CT Review: Comparison:

Outcome: 02 Y-BOCS

Study or sub-category	N C	CT + Fluvoxamine Mean (SD)	N	CT Mean (SD)		SMD (fixed) 95% Cl	SMD (fixed) 95% CI
van Balkom 1998	14	15.60(5.40)	19	13.50(9.70)			0.25 [-0.44, 0.94]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19				0.25 [-0.44, 0.94]
					-1 -0.5	5 Ó O.5 1	

OCD: combination therapy 04 CT + Fluvoxamine v CT 03 Padua Inventory Review: Comparison: Outcome:

Study or sub-category	N C	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
van Balkom 1998	14	43.50(18.40)	19	49.10(23.60)		-0.25 [-0.95, 0.44]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19			-0.25 [-0.95, 0.44]
					-1 -0.5 0 0.5 Favours CT+FLV Favours CT	1

Review: OCD: combination therapy 04 CT + Fluvoxamine v CT 04 Beck Depression Inventory Comparison: Outcome:

Study or sub-category	C N	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
van Balkom 1998	14	10.80(6.60)	19	9.90(7.00)		0.13 [-0.56, 0.82]
Total (95% CI) Test for heterogeneity: not ap Test for overall effect: Z = 0:			19			0.13 [-0.56, 0.82]
					-1 -0.5 0 0.5 1	
					Favours CT+FLV Favours CT	

Review: OCD: combination therapy 04 CT + Fluvoxamine v CT 05 Symptom Checklist-90 Comparison: Outcome:

Study or sub-category	N	CT + Fluvoxamine Mean (SD)	N	CT Mean (SD)		SMD (f 95%	,	SMD (fixed) 95% Cl
van Balkom 1998	14	162.00(42.70)	19	163.40(44.40)				-0.03 [-0.72, 0.66]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19					-0.03 [-0.72, 0.66]
					-1	-0.5	0.5	1

Favours CT+FLV Favours CT

Favours CT+FLV Favours CT

Favours CT+FLV Favours CT

Favours CT+FLV Favours CT

Favours ERP+FLV Favours CT+FLV

OCD: combination therapy Review: Comparison: 04 CT + Fluvoxamine v CT

Outcome: 06 Anxiety Discomfort Scale: patient's ratings

Study or sub-category	N C	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)		SMD (1 95%		SMD (fixed) 95% Cl
van Balkom 1998	14	13.00(4.90)	19	12.50(9.30)				0.06 [-0.63, 0.75]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19					0.06 [-0.63, 0.75]
					-1	-0.5	0.5	1

OCD: combination therapy 04 CT + Fluvoxamine v CT 07 Anxiety Discomfort Scale: therapist's ratings Review: Comparison: Outcome:

Study or sub-category	N	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)			MD (fixed) 95% CI)		MD (fixed) 95% Cl
van Balkom 1998	14	13.60(7.50)	19	13.10(10.20)			-		0.05 [-	0.64, 0.74]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19				-	 -	0.05 [-	0.64, 0.74]
					-1	-0.5	Ó	0.5	1	

Review: OCD: combination therapy Comparison: 04 CT + Fluvoxamine v CT

08 Anxiety Discomfort Scale: assessor's ratings Outcome:

Study or sub-category	N C	T + Fluvoxamine Mean (SD)	N	CT Mean (SD)			MD (fixed) 95% Cl	SMD (fixed) 95% Cl
van Balkom 1998	14	13.80(4.70)	19	12.50(9.50)			-	0.16 [-0.53, 0.85]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			19		,	- 		0.16 [-0.53, 0.85]
					-1	-0.5	0 0.5	1

OCD: combination therapy Review:

Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine

Outcome: 01 Leaving the study early

Study or sub-category	ERP + Fluvoxamine n/N	CT + Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
van Balkom 1998	10/28	10/24	_	0.86 [0.43, 1.70]
Total (95% CI) Test for heterogeneity: not appl Test for overall effect: Z = 0.44		10/24		0.86 [0.43, 1.70]
		0.1	0.2 0.5 1 2 5	10

OCD: combination therapy

05 ERP + Fluvoxamine v CT + Fluvoxamine 02 Y-BOCS Comparison:

Outcome:

Study or sub-category	EF N	RP + Fluvoxamine Mean (SD)	N C	T + Fluvoxamine Mean (SD)		S	SMD (fixed 95% Cl	1)		SMD (fixed) 95% CI
van Balkom 1998	18	12.60(6.60)	14	15.60(5.40)		_	-			-0.48 [-1.19, 0.23]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1			14			-	•			-0.48 [-1.19, 0.23]
Total of Oyol all office. 2 = 1.	.02 (1 = 0.10)				-4	-2 urs ERP+F	0	2 /ours CT+F	4	

Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine 03 Padua Inventory Outcome: ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) Study or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 18 43.20(23.50) 43.50(18.40) -0.01 [-0.71, 0.68] 14 Total (95% CI) 18 14 -0.01 [-0.71, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.04 (P = 0.97) -0.5 0.5 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison: Outcome: 04 Beck Depression Inventory SMD (fixed) SMD (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine Ν 95% CI 95% CI or sub-category Ν Mean (SD) Mean (SD) van Balkom 1998 18 10.10(7.20) 14 10.80(6.60) -0.10 [-0.80, 0.60] Total (95% CI) -0.10 [-0.80, 0.60] 18 14 Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) 0.5 -0.5 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome: 05 Symptom Checklist-90 SMD (fixed) SMD (fixed) ERP + Fluvoxamine CT + Fluvoxamine or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 154.50(51.40) 162.00(42.70) -0.15 [-0.85, 0.55] 18 14 Total (95% CI) 14 -0.15 [-0.85, 0.55] Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67)-0.5 0.5 Favours ERP+FLV Favours CT+FLV OCD: combination therapy Review: Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome 06 Anxiety Discomfort Scale: patient's ratings SMD (fixed) SMD (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine 95% CI 95% CI or sub-category Mean (SD) Mean (SD) van Balkom 1998 18 13.00(4.90) 14 13.00(4.90) 0.00 [-0.70, 0.70] Total (95% CI) 0.00 [-0.70, 0.70] 18 14 Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)-0.5 0.5 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison 07 Anxiety Discomfort Scale: therapist's ratings Outcome: Study ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CL 95% CL van Balkom 1998 18 14.20(10.30) 14 13.60(7.50) 0.06 [-0.64, 0.76] Total (95% CI) 18 14 0.06 [-0.64, 0.76] Test for heterogeneity: not applicable Test for overall effect: Z = 0.18 (P = 0.86)

Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome: 08 Anxiety Discomfort Scale: assessor's ratings ERP + Fluvoxamine SMD (fixed) SMD (fixed) Study CT + Fluvoxamine or sub-category N Mean (SD) N Mean (SD) 95% CI 0.05 [-0.64, 0.75] van Balkom 1998 18 14.20(8.70) 14 13.80(4.70) Total (95% CI) 14 0.05 [-0.64, 0.75] Test for heterogeneity: not applicable Test for overall effect: Z = 0.15 (P = 0.88)

-0.5

Favours ERP+FLV

-0.5

Favours ERP+FLV

Ó

0.5

0.5

Favours CT+FLV

Favours CT+FLV

OCD: combination therapy

Review:

Review: OCD: combination therapy

06 Children: ERP + Fluvoxamine v Fluvoxamine alone Comparison: 01 Non-responder (Y-BOCS reliable change) Outcome:

Study or sub-category	ERP + Fluvoxamine n/N	Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 At 43 weeks				
Neziroglu 2000	0/5	3/5		0.14 [0.01, 2.21]
Subtotal (95% CI)	0/5	3/5		0.14 [0.01, 2.21]
Test for heterogeneity: not	t applicable		_	·
Test for overall effect: Z =	1.39 (P = 0.16)			
02 At 52 weeks				
Neziroglu 2000	0/5	2/5		0.20 [0.01, 3.35]
Subtotal (95% CI)	0/5	2/5		0.20 [0.01, 3.35]
Test for heterogeneity; not	t applicable			•
Test for overall effect: Z =	1.12 (P = 0.26)			
03 At 2 years				
Neziroglu 2000	0/5	2/5		0.20 [0.01, 3.35]
Subtotal (95% CI)	0/5	2/5		0.20 [0.01, 3.35]
Test for heterogeneity: not	t applicable			•
Test for overall effect: Z =	1.12 (P = 0.26)			
		0.00)1 0.01 0.1 1 10 100	1000

Favours ERP+FLV Favours FLV

OCD: combination therapy Review:

Comparison: 06 Children: ERP + Fluvoxamine v Fluvoxamine alone

02 CY-BOCS Outcome:

Study or sub-category	N E	ERP + Fluvoxamine Mean (SD)	N	Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 At 43 weeks Neziroqlu 2000	5	11 6045 645		2 6044 205	_	1 44 1 2 00 0 041
Subtotal (95% CI)	5	-11.60(5.64)	5	-3.60(4.28)		-1.44 [-2.93, 0.04] -1.44 [-2.93, 0.04]
Test for heterogeneity: not applicable						-1.44 [-2.93, 0.04]
Test for overall effect: $Z = 1.91$ (P =	0.06)					
02 At 52 weeks						
Neziroglu 2000	5	-14.00(6.08)	5	-3.40(6.69)		-1.50 [-3.00, 0.00]
Subtotal (95% CI)	- 5		5			-1.50 [-3.00, 0.00]
Test for heterogeneity: not applicable	9				_	
Test for overall effect: $Z = 1.96$ (P =	0.05)					
03 At 2 years						
Neziroglu 2000	5	-20.20(2.17)	5	-9.00(11.42)		-1.23 [-2.65, 0.19]
Subtotal (95% CI)	- 5		5			-1.23 [-2.65, 0.19]
Test for heterogeneity: not applicable	Э				-	
Test for overall effect: $Z = 1.70$ (P =	0.09)					
					-4 -2 0 2	4

Favours ERP+FLV Favours FLV Review: OCD: combination therapy

06 Children: ERP + Fluvoxamine v Fluvoxamine alone 03 NIMH-GOCS Comparison:


Outcome:

Study or sub-category I	EF N	RP + Fluvoxamine Mean (SD)	N	Fluvoxamine Mean (SD)		SMD (fixed) 95% Cl	ı	SMD (fixed) 95% Cl
01 At 43 weeks								
Neziroglu 2000	5	-4.00(1.58)	5	-2.80(2.39)		_		-0.54 [-1.81, 0.74]
ubtotal (95% CI)	5		5			-		-0.54 [-1.81, 0.74]
est for heterogeneity: not applicable	9					7		
est for overall effect: Z = 0.82 (P =								
2 At 52 weeks								
Neziroglu 2000	5	-3.80(2.17)	5	-2.20(2.39)		_		-0.63 [-1.92, 0.66]
ubtotal (95% CI)	5		5			•		-0.63 [-1.92, 0.66]
est for heterogeneity: not applicable	9							•
est for overall effect: Z = 0.96 (P =								
3 At 2 years								
Neziroglu 2000	5	-7.40(2.88)	5	-4.00(4.53)		-		-0.81 [-2.13, 0.51]
ubtotal (95% CI)	5		5			•		-0.81 [-2.13, 0.51]
est for heterogeneity: not applicable	9					1		
est for overall effect: Z = 1.20 (P =	0.23)							
					-10	-5 0	5 10	
					Favours	s ERP+FLV Fav	ours FLV	

OCD: combination therapy Review:

07 Children: CBT + Sertraline v Sertraline Comparison:

01 Leaving the study early Outcome:



Favours CBT+Sertrali Favours Sertraline

Review: OCD: combination therapy

07 Children: CBT + Sertraline v Sertraline Comparison:

Outcome: 02 Leaving the study early due to adverse events

Study or sub-category	CBT + Sertraline n/N	Sertraline n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
POTS 2004	1/28	1/28	•	1.00 [0.07, 15.21]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =	• •	1/28		1.00 [0.07, 15.21]
			0.1 0.2 0.5 1 2 5 10	

Favours CBT+Sertrali Favours Sertraline

Review:

OCD: combination therapy 07 Children: CBT + Sertraline v Sertraline Comparison:

Outcome: 03 CY-BOCS

Study or sub-category	N	CBT + Sertraline Mean (SD)	N	Sertraline Mean (SD)		MD (fixed) 95% Cl	SMD (fixed) 95% Cl
POTS 2004	28	11.20(8.60)	28	16.50(9.10)	-	_	-0.59 [-1.13, -0.05]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 2			28			-	-0.59 [-1.13, -0.05]
					-1 -0.5	0 0.5	1

Favours CBT+Sertrali Favours Sertraline

OCD: combination therapy Review: Comparison: 08 Children: CBT + Sertraline v CBT

Outcome: 01 Leaving the study early

Study or sub-category	CBT + Sertraline n/N	Sertraline n/N		(fixed) 5% Cl	RR (fixed) 95% Cl
POTS 2004	3/28	3/28		-	1.00 [0.22, 4.54]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =	• •	3/28			1.00 [0.22, 4.54]
			0.1 0.2 0.5	1 2 5	10

Favours CBT+Sertrali Favours Sertraline

OCD: combination therapy Review: Comparison: 08 Children: CBT + Sertraline v CBT

Outcome: 02 CY-BOCS

Study or sub-category	N	CBT + Sertraline Mean (SD)	N	Sertraline Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
POTS 2004	28	11.20(8.60)	28	14.00(9.50)		-0.30 [-0.83, 0.22]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			28			-0.30 [-0.83, 0.22]
					-1 -0.5 0 0.5	1


Favours CBT+Sertrali Favours Sertraline

Other medical interventions

Review: OCD: other medical

01 Stereotactic anterior capsulotomy vs cingulotomy 01 CPRS @ 3 months: change score Comparison:

Outcome:



Review: OCD: other medical

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

Outcome: 02 CPRS @ 6 months: change score

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)			(fixed) 5% Cl		SMD (fixed) 95% Cl
Fodstad 1982	2	-13.25(5.30)	2	-11.25(1.06)				_	-0.30 [-2.89, 2.29]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			2					-	-0.30 [-2.89, 2.29]
					-4	-2	0	2	4

Review: OCD: other medical

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

Outcome: 03 CPRS @ 12 months: change score

Fodstad 1982 2 -13.50(2.83) 2 -17.25(6.01)	95% CI
	0.46 [-2.78, 3.70]
Total (95% CI) 2 2 Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78)	0.46 [-2.78, 3.70]

Review: OCD: other medical

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

Outcome: 04 HAM-D @ 3 months; change score

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)		S	MD (fixed) 95% Cl	ı		SMD (fixed) 95% CI
Fodstad 1982	2	-3.00(4.24)	2	-4.00(0.01)			-			0.19 [-2.05, 2.43]
Total (95% CI) Test for heterogeneity: no Test for overall effect: Z =			2							0.19 [-2.05, 2.43]
					-4	-2	ó	2	4	

OCD: other medical Review:

01 Stereotactic anterior capsulotomy vs cingulotomy Comparison:

Outcome: 05 HAM-D @ 6 months: change score

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% Cl
Fodstad 1982	2	-2.00(5.66)	2	-2.00(2.83)			+	_		0.00 [-1.96, 1.96]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			2				+			0.00 [-1.96, 1.96]
					-4	-2	ó	2	4	

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

06 HAM-D @ 12 months: change score Outcome:

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)		SMD (fixe 95% CI		SMD (fixed) 95% Cl
Fodstad 1982	2	-1.50(4.95)	2	-4.50(0.71)				0.48 [-2.89, 3.86]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			2					0.48 [-2.89, 3.86]
					-4	-2 0	2 4	

Favours capsulotomy Favours cingulotomy

Favours capsulotomy Favours cinquiotomy

Favours capsulotomy Favours cingulotomy

Favours capsulotomy Favours cingulotomy

Review: OCD: other medical

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

07 HAM-A @ 3 months; change score Outcome:

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl
Fodstad 1982	2	-4.00(1.41)	2	-11.50(12.02)	-		-		_	0.50 [-2.94, 3.95]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0.			2						- -	0.50 [-2.94, 3.95]
					-4	-2	ó	2	4	

Favours capsulotomy Favours cingulotomy

Favours capsulotomy Favours cingulotomy

Favours capsulotomy Favours cingulotomy

OCD: other medical Review:

Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy

Outcome: 08 HAM-A @ 6 months: change score

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI
Fodstad 1982	2	-3.00(2.83)	2	-6.00(5.66)	-	0.38 [-2.54, 3.31]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			2			0.38 [-2.54, 3.31]

Review: OCD: other medical

01 Stereotactic anterior capsulotomy vs cingulotomy 09 HAM-A @ 12 months; change score Comparison:

Outcome:

Study or sub-category	N	Capsulotomy Mean (SD)	N	Cingulotomy Mean (SD)) (fixed) 5% Cl			SMD (fixed) 95% Cl
Fodstad 1982	2	-2.50(3.54)	2	-7.50(7.78)			-		_	0.47 [-2.84, 3.79]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0.			2						-	0.47 [-2.84, 3.79]
					-4	-2	Ó	ż	4	

OCD: other medical Review:

Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo


Outcome: 01 Adverse effects

Study or sub-category	Active RTMS n/N	Placebo RTMS n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Alonso 2001	1/10	0/8		2.45 [0.11, 53.25]
Total (95% CI) Total events: 1 (Active RTM Test for heterogeneity: not a Test for overall effect: Z = 0	applicable	8		2.45 [0.11, 53.25]
			0.01 0.1 1 10 100)
			Favours active RTMS Favours placebo RTM	MS

Review: OCD: other medical

Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo

Outcome: 02 Non-responders (Y-BOCS 40%)



Favours active RTMS Favours placebo RTMS

Review: OCD: other medical Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo Outcome: 03 Y-BOCS; change score Active RTMS Placebo RTMS SMD (fixed) SMD (fixed) Study orsub-category N Mean (SD) Ν 95% CI 95% CI Mean (SD) Alonso 2001 10 -3.40(8.24) -0.25(3.92) -0.45 [-1.39, 0.50] 8 Total (95% CI) 10 -0.45 [-1.39, 0.50] Test for heterogeneity: not applicable Test for overall effect: Z = 0.93 (P = 0.35) Favours active RTMS Favours placebo RTMS Review: OCD: other medical Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo 04 HAM-D: change score Active RTMS Placebo RTMS SMD (fixed) SMD (fixed) Study or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Alonso 2001 10 -0.30(3.95) 0.25(1.16) -0.17 [-1.10, 0.76] Total (95% CI) -0.17 [-1.10, 0.76] 10 Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72) Favours active RTMS Favours placebo RTMS OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome: 01 Y-BOCS @ post-treatment SMD (fixed) SMD (fixed) Right Left or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal 17.00(4.86) 6 16.67(12.31) 0.03 [-1.10, 1.16] Subtotal (95% CI) 0.03 [-1.10, 1.16] Test for heterogeneity: not applicable Test for overall effect: Z = 0.06 (P = 0.96) -2 Favours right Favours left OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left 02 BDI @ post-treatment SMD (fixed) Study Right Left SMD (fixed) Mean (SD) Mean (SD) 95% CI 95% CI or sub-category 01 Right prefrontal v Left prefrontal 0.48 [-0.67, 1.64] Sachdev 2001 14.17(8.91) 6 9.67(8.26) Subtotal (95% CI) 0.48 [-0.67, 1.64] Test for heterogeneity: not applicable Test for overall effect: Z = 0.82 (P = 0.41) Favours right Favours left Review: OCD: other medical Comparison 03 Repetitive transcranial magnetic stimulation; right vs left 03 MADRS @ post-treatment Outcome: Study Right Left SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CL 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 15.33(10.35) 6.00(7.51) 0.95 [-0.27, 2.18] Subtotal (95% CI) 0.95 [-0.27, 2.18] Test for heterogeneity: not applicable Test for overall effect: Z = 1.53 (P = 0.13) Favours right Favours left OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome: 04 STAI-S @ post-treatment SMD (fixed) SMD (fixed) Study Right Left N Mean (SD) Ν Mean (SD) 95% CI or sub-category 01 Right prefrontal v Left prefrontal Sachdev 2001 6 0.04 [-1.10. 1.17] 6 45.50(9.67) 45.00(15.02) Subtotal (95% CI) 0.04 [-1.10, 1.17] Test for heterogeneity: not applicable Test for overall effect: Z = 0.06 (P = 0.95)

Favours right Favours left

Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome: 05 Y-BOCS @ 1-month follow-up SMD (fixed) SMD (fixed) Study Right Left orsub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 12.00(3.94) 6 16.50(8.31) -0.64 [-1.81, 0.54] Subtotal (95% CI) -0.64 [-1.81, 0.54] Test for heterogeneity: not applicable Test for overall effect: Z = 1.07 (P = 0.29) Favours right Favours left OCD: other medical Review: Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome: 06 BDI @ 1-month follow-up SMD (fixed) SMD (fixed) Study Right Left Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category Ν 01 Right prefrontal v Left prefrontal Sachdev 2001 11.60(14.64) 6 10.83(7.78) 0.06 [-1.07, 1.19] Subtotal (95% CI) 0.06 [-1.07, 1.19] Test for heterogeneity: not applicable Test for overall effect: Z = 0.10 (P = 0.92) Favours right Favours left Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left 07 MADRS @ 1-month follow-up Outcome: SMD (fixed) SMD (fixed) Right Left or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal 12.20(8.81) 6.83(5.71) 0.67 [-0.51, 1.85] Subtotal (95% CI) 0.67 [-0.51, 1.85] Test for heterogeneity: not applicable Test for overall effect: Z = 1.11 (P = 0.27) -2 Favours right Favours left Review: OCD: other medical 03 Repetitive transcranial magnetic stimulation: right vs left Comparison: Outcome: 08 STAI-S @ 1-month follow-up SMD (fixed) SMD (fixed) Study Right Left or sub-category Mean (SD) Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal -0.05 [-1.18, 1.08] Sachdev 2001 44.50(18.96) 6 45.33(12.72) Subtotal (95% CI) -0.05 [-1.18, 1.08] Test for heterogeneity: not applicable Test for overall effect: Z = 0.08 (P = 0.93) Favours right Favours left Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left 09 Non-responders (Y-BOCS 40%) @ 1-month follow-up Outcome: Right RR (fixed) RR (fixed) Study Left or sub-category nNn/N 95% CI 95% CI 01 Right prefrontal v Left prefrontal 1.00 [0.20, 4.95] 1.00 [0.20, 4.95] Sachdev 2001 2/6 2/6 Subtotal (95% CI) Total events: 2 (Right), 2 (Left) Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)

0.2

0.5

Favours right Favours left

5

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 01 Adverse effects

Study or sub-category	Treatment 1 n/N	Treatment 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Plasma exchange vs plac	cebo			
Perlmutter 1999	7/10	2/10		3.50 [0.95, 12.90]
Subtotal (95% CI)	10	10	-	3.50 [0.95, 12.90]
Total events: 7 (Treatment 1)), 2 (Treatment 2)		-	·
Test for heterogeneity; not a	applicable			
Test for overall effect: Z = 1				
02 IV immunoglobulin vs plac	cebo			
Perlmutter 1999	6/10	2/10	 	3.00 [0.79, 11.44]
Subtotal (95% CI)	10	10		3.00 [0.79, 11.44]
Total events: 6 (Treatment 1)), 2 (Treatment 2)			
Test for heterogeneity; not a				
Test for overall effect: Z = 1				
03 Plasma exchange vs IV ir	mmunoglobulin			
Perlmutter 1999	7/10	6/10	-	1.17 [0.61, 2.23]
Subtotal (95% CI)	10	10	-	1.17 [0.61, 2.23]
Total events: 7 (Treatment 1)), 6 (Treatment 2)		Γ	·
Test for heterogeneity: not a				
Test for overall effect: Z = 0				
		0.01	0.1 1 10	100
		Faur	ours Treatment 1 Favours Treatme	ent 2
		ravu	ous realment i lavours frealme	an a

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 02 Leaving study early

Study or sub-category	Treatment 1 n/N	Treatment 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 Plasma exchange vs placebo)			
Perlmutter 1999	0/10	0/10		Not estimable
Subtotal (95% CI)	0	0		Not estimable
Total events: 0 (Treatment 1), 0	(Treatment 2)			
Test for heterogeneity: not applie	cable			
Test for overall effect: not applic	cable			
02 IV immunoglobulin vs placebo)			
Perlmutter 1999	1/10	0/10		— 3.00 [0.14, 65.90]
Subtotal (95% CI)	10	10		3.00 [0.14, 65.90]
Total events: 1 (Treatment 1), 0	(Treatment 2)		- -	
Test for heterogeneity: not appli	cable			
Test for overall effect: $Z = 0.70$	(P = 0.49)			
03 Plasma exchange vs IV immu	ınoglobulin			
Perlmutter 1999	0/10	1/10		0.33 [0.02, 7.32]
Subtotal (95% CI)	10	10		0.33 [0.02, 7.32]
Total events: 0 (Treatment 1), 1	(Treatment 2)		_	
Test for heterogeneity: not applie	cable			
Test for overall effect: $Z = 0.70$	(P = 0.49)			
		0.01	0.1 1 10	100
		Fav	ours Treatment 1 Favours Trea	itment 2

Review:

04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 03 Y-BOCS* Comparison:

Outcome:

Study or sub-category N	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Plasma exchange vs placebo						
Perlmutter 1999	5	18.20(6.10)	7	29.71(3.55)		-2.24 [-3.83, -0.66]
Subtotal (95% CI)	5		7			-2.24 [-3.83, -0.66]
est for heterogeneity; not applicable	,					
est for overall effect: $Z = 2.77$ (P = 0	0.006)					
02 IV immunoglobulin vs placebo						
Perlmutter 1999	6	17.83(9.68)	7	29.71(3.55)		-1.57 [-2.88, -0.26]
ubtotal (95% CI)	6		7		-	-1.57 [-2.88, -0.26]
est for heterogeneity: not applicable						
est for overall effect: $Z = 2.35$ (P = 0	0.02)					
3 Plasma exchange vs IV immunoglo	bulin					
Perlmutter 1999	5	18.20(6.10)	6	17.83(9.68)	 _	0.04 [-1.15, 1.23]
Subtotal (95% CI)	5		6		-	0.04 [-1.15, 1.23]
est for heterogeneity: not applicable	,				Т	
est for overall effect: $Z = 0.07$ (P = 0	0.95)					
					-4 -2 0 2	4

Favours Treatment 1 Favours Treatment 2

Review:

OCD: other medical
04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
04 NIMH-Global Severity* Comparison:

Outcome:

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
	ebo					
Perlmutter 1999	5	6.33(2.30)	7	8.29(0.76)		-1.15 [-2.43, 0.13]
Subtotal (95% CI)	5		7		-	-1.15 [-2.43, 0.13]
Fest for heterogeneity: not a	pplicable				_	
Test for overall effect: $Z = 1$.	77 (P = 0.08)					
02 IV immunoglobulin vs plac	ebo					
Perlmutter 1999	6	6.33(1.97)	7	8.29(0.76)		-1.26 [-2.50, -0.03]
Subtotal (95% CI)	6		7		-	-1.26 [-2.50, -0.03]
est for heterogeneity; not a	pplicable				_	
est for overall effect: $Z = 2$.	00 (P = 0.04)					
3 Plasma exchange vs IV im	munoglobulin					
Perlmutter 1999	5	6.33(2.30)	6	6.33(1.97)	 _	0.00 [-1.19, 1.19]
Subtotal (95% CI)	5		6			0.00 [-1.19, 1.19]
est for heterogeneity; not a	pplicable					
est for overall effect: Z = 0.	•					

Favours Treatment 1 Favours Treatment 2

Favours Treatment 1 Favours Treatment 2

Review:

04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 05 CGI-Symptom Severity* Comparison:

Outcome:

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Plasma exchange vs place	ebo					
Perlmutter 1999	5	3.60(1.14)	7	4.86(0.48)		-1.43 [-2.78, -0.09]
Subtotal (95% CI)	5		7			-1.43 [-2.78, -0.09]
Test for heterogeneity: not ap	plicable					
Fest for overall effect: $Z = 2.0$	09 (P = 0.04)					
02 IV immunoglobulin vs place	ebo					
Perlmutter 1999	6	3.92(1.11)	7	4.86(0.48)		-1.06 [-2.25, 0.14]
Subtotal (95% CI)	6		7		-	-1.06 [-2.25, 0.14]
Fest for heterogeneity: not ap	plicable				-	
est for overall effect: $Z = 1$.	73 (P = 0.08)					
03 Plasma exchange vs IV im	munoglobulin					
Perlmutter 1999	5	3.60(1.14)	6	3.92(1.11)		-0.26 [-1.45, 0.93]
Subtotal (95% CI)	5		6			-0.26 [-1.45, 0.93]
Test for heterogeneity: not ap	plicable				7	
Test for overall effect: Z = 0.						

Review:

04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) Comparison:

Outcome: 06 Global Assessment Scale*

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
01 Plasma exchange vs placebo							
Perlmutter 1999	5	-63.40(12.36)	7	-54.86(4.30)		-0.93 [-2.16, 0.31]	
Subtotal (95% CI)	5		7			-0.93 [-2.16, 0.31]	
Test for heterogeneity: not applicab	le					,	
Test for overall effect: Z = 1.47 (P =	= 0.14)						
02 IV immunoglobulin vs placebo							
Perlmutter 1999	6	-62.83(10.69)	7	-54.86(4.30)		-0.94 [-2.11, 0.23]	
Subtotal (95% CI)	6		7			-0.94 [-2.11, 0.23]	
Test for heterogeneity: not applicab	ile				-		
Test for overall effect: $Z = 1.57$ (P =	= 0.12)						
03 Plasma exchange vs IV immuno	alobulin						
Perlmutter 1999	5	-63.40(12.36)	6	-62.83(10.69)	 _	-0.05 [-1.23, 1.14]	
Subtotal (95% CI)	5		6			-0.05 [-1.23, 1.14]	
Test for heterogeneity: not applicab	ile				T	,	
Test for overall effect: Z = 0.08 (P =							
					-4 -2 0 2	4	

Favours Treatment 1 Favours Treatment 2

Review:

OCD: other medical
04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) Comparison:

Outcome:

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl	
D1 Plasma exchange vs placeb	0						
Perlmutter 1999	5	4.20(2.28)	7	7.00(1.41)		-1.43 [-2.77, -0.09]	
ubtotal (95% CI)	5		7			-1.43 [-2.77, -0.09]	
est for heterogeneity: not appl	icable					•	
est for overall effect: Z = 2.09	(P = 0.04)						
02 IV immunoglobulin vs placeb	0						
Perlmutter 1999	6	5.33(1.37)	7	7.00(1.41)		-1.12 [-2.32, 0.09]	
ubtotal (95% CI)	6		7			-1.12 [-2.32, 0.09]	
est for heterogeneity: not appl	icable						
est for overall effect: $Z = 1.81$	(P = 0.07)						
3 Plasma exchange vs IV imm	unoglobulin						
Perlmutter 1999	5	4.20(2.28)	6	5.33(1.37)		-0.56 [-1.79, 0.66]	
ubtotal (95% CI)	5		6			-0.56 [-1.79, 0.66]	
est for heterogeneity: not appl	icable						
est for overall effect: Z = 0.90	(P = 0.37)						

Favours Treatment 1 Favours Treatment 2

Favours Treatment 1 Favours Treatment 2

Review: OCD: other medical 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 08 NIMH-Depression*


Comparison: Outcome:

Study or sub-category	•		Treatment 2 N Mean (SD)		SMD (fixed) 95% CI	SMD (fixed) 95% Cl	
01 Plasma exchange vs plac	ebo						
Perlmutter 1999	5	3.60(2.19)	7	7.57(2.30)		-1.62 [-3.02, -0.23]	
ubtotal (95% CI)	5		7			-1.62 [-3.02, -0.23]	
est for heterogeneity; not a	pplicable						
est for overall effect: Z = 2							
)2 IV immunoglobulin vs plac	ebo						
Perlmutter 1999	6	4.83(2.14)	7	7.57(2.30)		-1.14 [-2.35, 0.07]	
Subtotal (95% CI)	6		7			-1.14 [-2.35, 0.07]	
est for heterogeneity; not a	pplicable				-		
est for overall effect: Z = 1	.85 (P = 0.06)						
)3 Plasma exchange vs IV ir	nmunoglobulin						
Perlmutter 1999	5	3.62(0.19)	6	4.83(2.14)		-0.69 [-1.93, 0.55]	
Subtotal (95% CI)	5		6			-0.69 [-1.93, 0.55]	
est for heterogeneity; not a	pplicable					,	
est for overall effect: Z = 1							

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 09 NIMH-OC*



Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 01 Leaving study early

Study or sub-category	Plasma exchange n/N	IV immunoglobulin n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Perlmutter 1999	2/10	0/9		4.55 [0.25, 83.70]
Total (95% CI) Total events: 2 (Plasma exch Test for heterogeneity: not a Test for overall effect: Z = 1	• •	9	-	4.55 [0.25, 83.70]
		0.01	01 1 10 1	+ nn

Favours plasma exch. Favours IV immu.

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 02 Y-BOCS*


Study or sub-category	N F	Plasma exchange Mean (SD)	N IV	' immunoglobulin Mean (SD)			(fixed) % Cl		SMD (fixed) 95% CI
Perlmutter 1999	5	10.50(8.27)	6	12.00(2.45)		-			-0.24 [-1.43, 0.96]
Total (95% CI) Test for heterogeneity: not Test for overall effect: Z =			6						-0.24 [-1.43, 0.96]
					-4	-2	ö	2	4

Favours plasma exch. Favours IV immu.

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 03 Global Assessment Scale*



Favours plasma exch. Favours IV immu.